



RESOURCE AND PATIENT MANAGEMENT SYSTEM

Clinical Reporting System

(BGP)

CRS Clinical Performance Measure Logic Manual for FY 2012 Clinical Measures

Version 12.1
May 2012

Office of Information Technology (OIT)
Division of Information Resource Management
Albuquerque, New Mexico

Table of Contents

| | | |
|------------|---|----------|
| 1.0 | Introduction..... | 1 |
| 2.0 | Performance Measure Logic..... | 2 |
| 2.1 | Performance Measure Logic Basics | 2 |
| 2.1.1 | CRS Denominator Definitions..... | 2 |
| 2.1.2 | Performance Measure Logic Example..... | 12 |
| 2.1.3 | Age Ranges..... | 14 |
| 2.1.4 | Standard Health Care Codes..... | 15 |
| 2.2 | Diabetes Related Measure Topics..... | 16 |
| 2.2.1 | Diabetes Prevalence | 16 |
| 2.2.2 | Diabetes Comprehensive Care..... | 19 |
| 2.2.3 | Diabetes: Glycemic Control | 24 |
| 2.2.4 | Diabetes: Blood Pressure Control | 29 |
| 2.2.5 | Diabetes: LDL Assessment | 33 |
| 2.2.6 | Diabetes: Nephropathy Assessment | 37 |
| 2.2.7 | Diabetic Retinopathy | 41 |
| 2.2.8 | RAS Antagonist Use in Diabetic Patients | 45 |
| 2.2.9 | Diabetes: Access to Dental Services | 50 |
| 2.3 | Dental Measure Topics..... | 53 |
| 2.3.1 | Access to Dental Services | 53 |
| 2.3.2 | Dental Sealants | 56 |
| 2.3.3 | Topical Fluoride | 59 |
| 2.4 | Immunization Measure Topics..... | 61 |
| 2.4.1 | Influenza | 61 |
| 2.4.2 | Adult Immunizations | 66 |
| 2.4.3 | Childhood Immunizations | 70 |
| 2.4.4 | Adolescent Immunizations..... | 82 |
| 2.5 | Childhood Diseases Group..... | 90 |
| 2.5.1 | Appropriate Treatment for Children with Upper Respiratory Infection . | 90 |
| 2.5.2 | Appropriate Testing for Children with Pharyngitis..... | 93 |
| 2.6 | Cancer Related Measure Topics | 95 |
| 2.6.1 | Cancer Screening: Pap Smear Rates..... | 95 |
| 2.6.2 | Cancer Screening: Mammogram Rates | 99 |
| 2.6.3 | Colorectal Cancer Screening..... | 103 |
| 2.6.4 | Comprehensive Cancer Screening..... | 107 |
| 2.6.5 | Tobacco Use and Exposure Assessment..... | 112 |
| 2.6.6 | Tobacco Cessation..... | 118 |
| 2.7 | Behavioral Health Related Performance Measure Topics | 124 |
| 2.7.1 | Alcohol Screening (FAS Prevention) | 124 |
| 2.7.2 | Alcohol Screening and Brief Intervention (ASBI) in the ER | 128 |
| 2.7.3 | Intimate Partner (Domestic) Violence Screening | 132 |

| | | |
|---------|--|-----|
| 2.7.4 | Depression Screening | 135 |
| 2.7.5 | Antidepressant Medication Management | 140 |
| 2.8 | Cardiovascular Disease Related Measure Topics | 146 |
| 2.8.1 | Obesity Assessment | 146 |
| 2.8.2 | Childhood Weight Control | 151 |
| 2.8.3 | Nutrition and Exercise Education for At Risk Patients | 154 |
| 2.8.4 | Physical Activity Assessment | 158 |
| 2.8.5 | Comprehensive Health Screening | 161 |
| 2.8.6 | Cardiovascular Disease and Cholesterol Screening | 168 |
| 2.8.7 | Cardiovascular Disease and Blood Pressure Control | 171 |
| 2.8.8 | Controlling High Blood Pressure | 174 |
| 2.8.9 | Comprehensive CVD-Related Assessment | 178 |
| 2.8.10 | Appropriate Medication Therapy after a Heart Attack | 185 |
| 2.8.11 | Persistence of Appropriate Medication Therapy after a Heart Attack | 196 |
| 2.8.12 | Appropriate Medication Therapy in High Risk Patients | 208 |
| 2.8.13 | Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge | 219 |
| 2.8.14 | Cholesterol Management for Patients with Cardiovascular Conditions | 222 |
| 2.8.15 | Heart Failure and Evaluation of LVS Function | 225 |
| 2.9 | STD-Related Measure Topics | 228 |
| 2.9.1 | HIV Screening | 228 |
| 2.9.2 | HIV Quality of Care | 233 |
| 2.9.3 | Hepatitis C Screening | 235 |
| 2.9.4 | Chlamydia Screening | 237 |
| 2.9.5 | Sexually Transmitted Infection Screening | 239 |
| 2.10 | Other Clinical Measures Topics | 247 |
| 2.10.1 | Osteoporosis Management | 247 |
| 2.10.2 | Osteoporosis Screening in Women | 250 |
| 2.10.3 | Rheumatoid Arthritis Medication Monitoring | 252 |
| 2.10.4 | Osteoarthritis Medication Monitoring | 257 |
| 2.10.5 | Asthma | 261 |
| 2.10.6 | Asthma Assessments | 264 |
| 2.10.7 | Asthma Quality of Care | 269 |
| 2.10.8 | Medication Therapy for Persons with Asthma | 274 |
| 2.10.9 | Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation | 280 |
| 2.10.10 | Chronic Kidney Disease Assessment | 282 |
| 2.10.11 | Prediabetes/Metabolic Syndrome | 284 |
| 2.10.12 | Proportion of Days Covered by Medication Therapy | 292 |
| 2.10.13 | Medications Education | 297 |
| 2.10.14 | Medication Therapy Management Services | 299 |
| 2.10.15 | Self Management (Confidence) | 301 |
| 2.10.16 | Public Health Nursing | 302 |

| | |
|---|------------|
| 2.10.17 Breastfeeding Rates | 306 |
| 2.10.18 Use of High-Risk Medications in the Elderly | 309 |
| 2.10.19 Functional Status Assessment in Elders | 314 |
| 2.10.20 Fall Risk Assessment in Elders | 317 |
| 2.10.21 Palliative Care | 319 |
| 2.10.22 Annual Wellness Visit | 322 |
| 2.10.23 Goal Setting..... | 324 |
| Contact Information | 326 |

Preface

The Government Performance and Results Act (GPRA) requires federal agencies to report annually on how the agency measured up against the performance targets set in its annual Plan. The Indian Health Service (IHS) GPRA report includes measures for clinical prevention and treatment, quality of care, infrastructure, and administrative efficiency functions.

The IHS Clinical Reporting System (CRS) is a Resource and Patient Management System (RPMS) software application designed for national reporting as well as Area Office and local monitoring of clinical GPRA and developmental measures. CRS was first released for Fiscal Year (FY) 2002 performance measures (as GPRA+) and is based on a design by the Aberdeen Area (GPRA2000).

This manual contains the FY 2012 clinical performance measure definitions and logic for the CRS 2012 Version 12.0 software. CRS is the reporting tool used by the IHS Office of Planning and Evaluation to collect and report clinical performance results annually to the Department of Health and Human Services and to Congress.

Each year, an updated version of CRS software is released to reflect changes in the logic descriptions of the different denominators and numerators. Additional performance measures may also be added. Local facilities can run reports as often as they want to and can also use CRS to transmit data to their Area. The Area Office can use CRS to produce an aggregated Area report for either annual GPRA or Area Director Performance reports.

CRS produces reports on demand from local RPMS databases for both GPRA and developmental clinical measures that are based on RPMS data, thus eliminating the need for manual chart audits for evaluating and reporting clinical measures.

To produce reports with comparable data across every facility, the GPRA measures definitions was “translated” into programming code with the assistance of clinical subject matter experts. CRS uses predefined taxonomies to find data items in the RPMS Patient Care Component (PCC) to determine if a patient meets the performance measure criteria. Taxonomies contain groups of codes (e.g., diagnoses or procedures) or site-specific terms. Each performance measure has one or more defined denominators and numerators.

Administrative and clinical users can produce reports for selected measures at any time to:

- Identify potential data issues in their RPMS, i.e., missing or incorrect data.

- Monitor their site's performance against past national performance and upcoming agency goals.
- Identify specific areas where the facility is not meeting the measure in order to initiate business process or other changes.
- Quickly measure impact of process changes on performance measures.
- Identify areas meeting or exceeding measures to provide lessons learned.

Users of the RPMS CRS include:

- Area Office and site quality improvement staff
- Compliance Officers
- GPRA coordinators
- Clinical staff, such as physicians, nurses, nurse practitioners, and other providers
- Area Office directors
- Any staff involved with quality assurance initiatives
- Staff who run various CRS reports

1.0 Introduction

This manual provides information on the performance measure logic used by the Clinical Reporting System (CRS) Version 12.1 Selected Measures (Local) Report (Fiscal Year [FY] 2012 Clinical Performance Measures). For information on system setup, available reports and steps for running the reports, and performing Area Office functions, refer to the CRS Version 12.1 User Manual.

2.0 Performance Measure Logic

This section provides the following information for each performance measure topic:

- For Government Performance and Results Act (GPRA) measures, the measure description is provided as stated in the Indian Health Service (IHS) Annual Performance Report to Congress
- Definitions of all denominators and numerators for each performance measure topic
- Detailed description of the logic for the denominator and numerator, including specific codes, fields, taxonomies, and/or values searched
- Key changes to logic from the previous year, if any
- Description of which patients and information are contained on the patient list
- Performance measure source and past IHS performance, if any, and IHS or Healthy People (HP) 2020 targets for the performance measure
- Report examples
- Patient list examples

Note: All report examples and patient list examples used in this section were produced from “scrubbed” demonstration databases and do not represent individual patient data.

2.1 Performance Measure Logic Basics

2.1.1 CRS Denominator Definitions

Each performance measure topic has one or more define denominators and numerators. The denominator is the total population that is being reviewed for a specific measure. For the National GPRA & Program Assessment Rating Tool (PART) Report, only one denominator for each topic is reported. These denominators are pre-defined, based on the Active Clinical Population definition. For the Selected Measures reports for local use (CRS Version 12.1 User Manual, Section 5.12), multiple denominators may be reported to provide a complete picture of clinical performance. There are also additional options available to further refine denominator definitions.

2.1.1.1 Denominator Definitions for National GPRA Reporting

The Active Clinical population is the denominator definition used as the basis for *most* GPRA measures. This denominator was developed in FY 2003 specifically for clinical performance measures because it is more representative of the active clinical population.

Note: There are facilities that do not offer direct care. Patients in these facilities receive only Contract Health Services (CHS) and therefore do not meet the requirements of the Active Clinical population. A new site parameter, Contract Health Site Only, was added for these facilities in FY2006.

Prior to FY 2003, the GPRA User Population denominator definition was used for national reporting, similar to the agency's IHS User Population definition.

The *Active Clinical* population for the National GPRA & PART Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the Resource and Patient Management System (RPMS) Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past three years. At least one visit must be to one of the following core medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 01 | General |
| 06 | Diabetic |
| 10 | GYN |
| 12 | Immunization |
| 13 | Internal Medicine |
| 20 | Pediatrics |
| 24 | Well Child |
| 28 | Family Practice |
| 57 | EPSDT |
| 70 | Women's Health |
| 80 | Urgent Care |
| 89 | Evening |

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

| Clinic Code | Clinic Description |
|-------------|-------------------------------|
| 02 | Cardiac |
| 03 | Chest And TB |
| 05 | Dermatology |
| 07 | ENT |
| 08 | Family Planning |
| 16 | Obstetrics |
| 19 | Orthopedic |
| 23 | Surgical |
| 25 | Other |
| 26 | High Risk |
| 27 | General Preventive |
| 31 | Hypertension |
| 32 | Postpartum |
| 37 | Neurology |
| 38 | Rheumatology |
| 49 | Nephrology |
| 50 | Chronic Disease |
| 69 | Endocrinology |
| 75 | Urology |
| 81 | Men's Health Screening |
| 85 | Teen Clinic |
| 88 | Sports Medicine |
| B8 | Gastroenterology - Hepatology |
| B9 | Oncology - Hematology |
| C3 | Colposcopy |

- Patient must be alive on the last day of the report period.
- Patient must be American Indian/Alaska Native (AI/AN) (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

The *Active Clinical Plus Behavioral Health Population* for National GPRA & PART Reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past three years. At least one visit must be to one of the following core medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 01 | General |
| 06 | Diabetic |
| 10 | GYN |
| 12 | Immunization |
| 13 | Internal Medicine |
| 20 | Pediatrics |
| 24 | Well Child |
| 28 | Family Practice |
| 57 | EPSDT |
| 70 | Women's Health |
| 80 | Urgent Care |
| 89 | Evening |

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 02 | Cardiac |
| 03 | Chest And TB |
| 05 | Dermatology |
| 07 | ENT |
| 08 | Family Planning |
| 14 | Mental Health |
| 16 | Obstetrics |
| 19 | Orthopedic |
| 23 | Surgical |
| 25 | Other |
| 26 | High Risk |

| Clinic Code | Clinic Description |
|-------------|-------------------------------|
| 27 | General Preventive |
| 31 | Hypertension |
| 32 | Postpartum |
| 37 | Neurology |
| 38 | Rheumatology |
| 43 | Alcohol & Substance Abuse |
| 48 | Medical Social Services |
| 49 | Nephrology |
| 50 | Chronic Disease |
| 69 | Endocrinology |
| 75 | Urology |
| 81 | Men's Health Screening |
| 85 | Teen Clinic |
| 88 | Sports Medicine |
| B8 | Gastroenterology – Hepatology |
| B9 | Oncology – Hematology |
| C3 | Colposcopy |
| C4 | Behavioral Health |
| C9 | Telebehavioral Health |

- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy that is specified by the user.

The *Active Clinical CHS Population* for National GPRA & PART Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two CHS visits in the three years prior to the end of the report period.
- Patient must be alive on the last day of the report period.

- Patient must be AI/AN (defined as Beneficiary 01). This item is entered and updated during the patient registration process.
- User must reside in a community included in the site's official GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy that is specified by the user.

The *Active Clinical Behavioral Health Population* for National GPRA & PART Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two behavioral health visits in the three years prior to the end of the report period.
- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This item is entered and updated during the patient registration process.
- User must reside in a community included in the site's official GPRA community taxonomy, defined as all communities of residence in the Urban Outreach & Referral catchment area specified in the community taxonomy that is specified by the user.

The *GPRA User Population* for the National GPRA & PART Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

Note: The GPRA User Population definition is similar, but not identical, to the definition used by IHS headquarters (HQ) for annual user population statistics. GPRA “visits” are not required to be workload reportable as defined by IHS HQ.

2.1.1.2 Denominator Definitions for Selected Measures Reports

In addition to the National GPRA & PART Report, CRS provides Selected Measures reports intended for local facility use for specific public health and/or performance improvement initiatives (CRS Version 12.0 User Manual, Section 5.12). Multiple denominators and numerators will be reported for each measure (e.g., *both* Active Clinical and GPRA User Population). Users have additional options to define the denominators as explained below.

The Active Clinical Population for Selected Measures (Local) Reports is defined as follows:

- Patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past three years. At least one visit must be to one of the following core medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 01 | General |
| 06 | Diabetic |
| 10 | GYN |
| 12 | Immunization |
| 13 | Internal Medicine |
| 20 | Pediatrics |
| 24 | Well Child |
| 28 | Family Practice |
| 57 | EPSDT |
| 70 | Women's Health |
| 80 | Urgent Care |
| 89 | Evening |

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

| Clinic Code | Clinic Description |
|-------------|-------------------------------|
| 02 | Cardiac |
| 03 | Chest And TB |
| 05 | Dermatology |
| 07 | ENT |
| 08 | Family Planning |
| 16 | Obstetrics |
| 19 | Orthopedic |
| 23 | Surgical |
| 25 | Other |
| 26 | High Risk |
| 27 | General Preventive |
| 31 | Hypertension |
| 32 | Postpartum |
| 37 | Neurology |
| 38 | Rheumatology |
| 49 | Nephrology |
| 50 | Chronic Disease |
| 69 | Endocrinology |
| 75 | Urology |
| 81 | Men's Health Screening |
| 85 | Teen Clinic |
| 88 | Sports Medicine |
| B8 | Gastroenterology - Hepatology |
| B9 | Oncology - Hematology |
| C3 | Colposcopy |

- Patient must be alive on the last day of the Report period.
- User defines population type: AI/AN patients only, non AI/AN, or both. This data item is entered and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The *Active Clinical Plus Behavioral Health Population* for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past three years. At least one visit must be to one of the following core medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 01 | General |
| 06 | Diabetic |
| 10 | GYN |
| 12 | Immunization |
| 13 | Internal Medicine |
| 20 | Pediatrics |
| 24 | Well Child |
| 28 | Family Practice |
| 57 | EPSDT |
| 70 | Women's Health |
| 80 | Urgent Care |
| 89 | Evening |

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

| Clinic Code | Clinic Description |
|-------------|--------------------|
| 02 | Cardiac |
| 03 | Chest And TB |
| 05 | Dermatology |
| 07 | ENT |
| 08 | Family Planning |
| 14 | Mental Health |
| 16 | Obstetrics |
| 19 | Orthopedic |
| 23 | Surgical |
| 25 | Other |
| 26 | High Risk |

| Clinic Code | Clinic Description |
|-------------|-------------------------------|
| 27 | General Preventive |
| 31 | Hypertension |
| 38 | Rheumatology |
| 43 | Alcohol & Substance Abuse |
| 48 | Medical Social Services |
| 49 | Nephrology |
| 50 | Chronic Disease |
| 69 | Endocrinology |
| 75 | Urology |
| 81 | Men's Health Screening |
| 85 | Teen Clinic |
| 88 | Sports Medicine |
| B8 | Gastroenterology – Hepatology |
| B9 | Oncology – Hematology |
| C3 | Colposcopy |

- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both. This data item is typed and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patients (patient panel); or all patients, regardless of community of residence.

The *Active Clinical CHS Population* for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two CHS visits in the three years prior to the end of the Report Period.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The *Active Clinical Behavioral Health Population* for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two behavioral health visits in the three years prior to the end of the Report Period.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The *User Population* for Selected Measures (Local) reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be excluded from the denominator automatically.
- Patient must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

2.1.2 Performance Measure Logic Example

Cancer Screening: Pap Smear Rates: During FY 2012, achieve the tentative target rate of 59.5% for the proportion of female patients ages 21 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous three years.

For CRS, the GPRA measure definition is defined as:

- Denominator (total number of patients evaluated): Active Clinical female patients ages 21 through 64, excluding those with documented history of hysterectomy. (The clinical owner of the measure has determined based on current medical guidelines that “eligible” women are defined as ages 21–64.)
- Numerator (those from the denominator who meet the criteria for the measure): patients with documented Pap smear in past three years or refusal in past year.

For the programmer, the Pap Smear measure is described in terms of the following logic:

1. Begin with the Active Clinical population definition.
 - Exclude any patients with the name of “DEMO, PATIENT.”
 - Exclude any patient records that are included in the RPMS Demo/Test Patient Search Template.
 - Exclude any patients with a date of death in the Patient Registration file.
 - Exclude any patients who do *not* have value 01 (AI/AN) in the Beneficiary field in Patient Registration file.
 - Exclude any patients whose Community of Residence is not included in the site’s defined GPRA Community Taxonomy for this report.
 - For the remaining patients, search visit files for the three years prior to the selected report end date; exclude any patients whose visits do not meet the “two medical clinics” definition; *or*, for facilities with the CHS-Only site parameter set to Yes, exclude any patients who do not have two CHS visits in the past three years.
2. From these patients, identify the subset that are female and that are at least age 21 on the first day of the current report period and less than age 65 on the last day of the report period.
3. Exclude patients with documented hysterectomy by searching the V Procedure file for procedure codes 68.4 through 68.8 or V CPT for CPT codes 51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200 through 58294, 58548, 58550 through 58554, 58570 through 58573, 58951, 58953 through 58954, 58956, 59135 or V POV 618.5, V88.01, V88.03 or Women's Health procedure called Hysterectomy any time before the end of the report period.
4. For these patients (the denominator), check for a Pap smear in the past three years in the following order:

- a. Check V Lab for a lab test called Pap Smear and for any site-populated pap smear lab test documented in the BGP PAP SMEAR TAX taxonomy; *or*
- b. Check V Lab for any LOINC code listed in the predefined BGP PAP LOINC CODES taxonomy (see the *CRS Technical Manual* for specific codes); *or*
- c. Check the Purpose of Visit file (V POV) for: a diagnosis of: V67.01 Follow-up Vaginal Pap Smear, V76.2-Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10–16, 795.19; *or*
- d. Check V Procedures for a procedure of 91.46; *or*
- e. Check V CPT for the following CPT codes: 88141 through 88167, 88174 through 88175, G0123, G0124, G0141, G0143 through G0145, G0147, G0148, P3000, P3001, Q0091; *or*
- f. Check the Women's Health Tracking package for documentation of a procedure called Pap Smear and where the result does *not* have "ERROR/DISREGARD".

If a visit with any of the specified codes is found, the patient is considered to have met the measure, and the program checks the next patient.

2.1.3 Age Ranges

Unless otherwise noted, for the purposes of CRS reports, the age of a patient is calculated at the beginning of the report period. For example, for a report period of July 1, 2011 through June 30, 2012, Jane Doe is defined as age 74 if her birth date is June 10, 1937, even though she becomes age 75 during the report period.

2.1.4 Standard Health Care Codes

2.1.4.1 Current Procedural Terminology Codes

One of several code sets used by the healthcare industry to standardize data, and allow for comparison and analysis. Current Procedural Terminology (CPT) was developed and is updated annually by the American Medical Association, and is widely used in producing bills for services rendered to patients. CPTs include codes for diagnostic and therapeutic procedures, and specify information that differentiates the codes based on cost. CPT codes are the most widely accepted nomenclature in the United States for reporting physician procedures and services for federal and private insurance third-party reimbursement. CRS searches for CPT and other codes as specified in the logic definition to determine if a patient meets a denominator or numerator definition.

2.1.4.2 International Classification of Disease Codes

One of several code sets used by the healthcare industry to standardize data. The International Classification of Disease (ICD) is an international diagnostic coding scheme. In addition to diseases, ICD also includes several families of terms for medical-specialty diagnoses, health status, disablements, procedure, and reasons for contact with healthcare providers. IHS currently uses ICD, Ninth Revision (ICD-9) for coding. CRS searches for ICD and other codes as specified in the logic definition, to determine if a patient meets a denominator or numerator definition.

2.1.4.3 Logical Observation Identifiers Names and Codes

Logical Observation Identifiers Names and Codes (LOINC®). A standard coding system originally initiated for laboratory values, the system is being extended to include non-laboratory observations (electrocardiograms, vital signs, etc.). Standard code sets are used to define individual tests and mitigate variations in local terminologies for laboratory and other healthcare procedures, for example, Glucose or Glucose Test. IHS began integrating LOINC values into RPMS in several pilot sites in 2002.

Refer to the CRS Version 12.1 Technical Guide for a list of specific LOINC codes included in each LOINC taxonomy.

2.2 Diabetes Related Measure Topics

2.2.1 Diabetes Prevalence

Denominators

All *User Population patients*. Broken down by gender and age groups (less than (<)15, 15 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, greater than (>)64 years).

Numerators

Anyone diagnosed with Diabetes *at any time* before the end of the Report Period.

Anyone diagnosed with Diabetes *during* the Report Period.

Logic Description

Age is calculated at the beginning of the Report Period.

Diabetes definition: At least one diagnosis of 250.00 through 250.93 recorded in V POV file.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of diabetic patients with most recent diagnosis.

Measure Source

HP 2010 5–2, 5–3

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 12.8% |
| IHS FY 2010 Performance | 12.0% |
| IHS FY 2009 Performance | 12.0% |
| IHS FY 2008 Performance | 12.0% |
| IHS FY 2007 Performance | 11.0% |
| IHS FY 2006 Performance | 11.0% |
| IHS FY 2005 Performance | 11.0% |

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2004 Performance | 10.0% |

DU

November 25, 2012

Page 1

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Diabetes Prevalence

Denominator(s):

- All User Population patients. Broken down by gender and by age groups: < 15, 15-19, 20-24, 25-34, 35-44, 45-54, 55-64, > 64.

Numerator(s):

- Anyone diagnosed with Diabetes at any time before the end of the Report Period.

- Anyone diagnosed with Diabetes during the Report Period.

Logic:

Age is calculated at the beginning of the Report Period. Diabetes diagnosis is defined as at least one diagnosis 250.00-250.93 recorded in the V POV file.

Performance Measure Description:

Continue tracking (i.e., data collection and analyses) Area age-specific diabetes prevalence rates to identify trends in the age-specific prevalence of diabetes (as a surrogate marker for diabetes incidence) for the AI/AN population.

Past Performance and/or Target:

IHS Performance: FY 2011 - 12.8%, FY 2010 - 12%, FY 2009 - 12%, FY 2008 - 12%, FY 2007 - 11%, FY 2006 - 11%, FY 2005 - 11%, FY 2004 - 10%

Source:

HP 2010 5-2, 5-3

Diabetes Prevalence

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|---------------------------|---------------|-----|----------------|-----|--------------------|-------------|-----|-----------------|
| # User Pop | 2,896 | | 2,456 | | | 2,346 | | |
| # w/ any DM DX | 265 | 9.2 | 243 | 9.9 | -0.7 | 197 | 8.4 | +0.8 |
| # w/ DM DX w/in past year | 173 | 6.0 | 146 | 5.9 | +0.0 | 100 | 4.3 | +1.7 |
| # Male User Pop | 1,368 | | 1,152 | | | 1,109 | | |
| # w/ any DM DX | 114 | 8.3 | 104 | 9.0 | -0.7 | 72 | 6.5 | +1.8 |
| # w/DM DX | | | | | | | | |

| | | | | | | | | |
|-------------------|-------|-----|-------|------|------|-------|------|------|
| w/in past year | 82 | 6.0 | 78 | 6.8 | -0.8 | 48 | 4.3 | +1.7 |
| # Female User Pop | 1,528 | | 1,304 | | | 1,237 | | |
| # w/ any DM DX | 151 | 9.9 | 139 | 10.7 | -0.8 | 125 | 10.1 | -0.2 |
| # w/ DM DX | | | | | | | | |
| w/in past year | 91 | 6.0 | 68 | 5.2 | +0.7 | 52 | 4.2 | +1.8 |

Figure 2-1: Sample Summary Report, Diabetes Prevalence Topic

| | | | | | | | | |
|--|-------------------|-------|-------|-------|-------|-------|-------|---------|
| DU | November 25, 2012 | | | | | | | Page 2 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Diabetes Prevalence (con't) | | | | | | | | |
| TOTAL USER POPULATION | | | | | | | | |
| Age Distribution | | | | | | | | |
| | <15 | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-64 | >64 yrs |
| CURRENT REPORT PERIOD | | | | | | | | |
| Total # User Pop | 730 | 239 | 261 | 403 | 389 | 390 | 262 | 222 |
| # w/ DM DX ever | 1 | 3 | 7 | 37 | 57 | 67 | 50 | 43 |
| % w/ DM DX ever | 0.1 | 1.3 | 2.7 | 9.2 | 14.7 | 17.2 | 19.1 | 19.4 |
| | | | | | | | | |
| # w/DM DX in past yr | 0 | 2 | 3 | 14 | 42 | 49 | 34 | 29 |
| % w/DM DX in past yr | 0.0 | 0.8 | 1.1 | 3.5 | 10.8 | 12.6 | 13.0 | 13.1 |
| PREVIOUS YEAR PERIOD | | | | | | | | |
| Total # User Pop | 711 | 227 | 243 | 352 | 316 | 277 | 181 | 149 |
| # w/ DM DX ever | 3 | 4 | 9 | 31 | 54 | 57 | 45 | 40 |
| % w/ DM DX ever | 0.4 | 1.8 | 3.7 | 8.8 | 17.1 | 20.6 | 24.9 | 26.8 |
| | | | | | | | | |
| # w/DM DX in past yr | 1 | 3 | 3 | 9 | 33 | 37 | 31 | 29 |
| % w/DM DX in past yr | 0.1 | 1.3 | 1.2 | 2.6 | 10.4 | 13.4 | 17.1 | 19.5 |
| CHANGE FROM PREV YR % | | | | | | | | |
| w/ DM DX ever | -0.3 | -0.5 | -1.0 | +0.4 | -2.4 | -3.4 | -5.8 | -7.5 |
| w/DM DX in past yr | -0.1 | -0.5 | -0.1 | +0.9 | +0.4 | -0.8 | -4.1 | -6.4 |
| BASELINE REPORT PERIOD | | | | | | | | |
| Total # User Pop | 787 | 208 | 217 | 329 | 293 | 228 | 141 | 143 |
| # w/ DM DX ever | 2 | 4 | 12 | 20 | 38 | 46 | 31 | 44 |
| % w/ DM DX ever | 0.3 | 1.9 | 5.5 | 6.1 | 13.0 | 20.2 | 22.0 | 30.8 |
| | | | | | | | | |
| # w/DM DX in past yr | 2 | 1 | 3 | 7 | 18 | 21 | 20 | 28 |
| % w/DM DX in past yr | 0.3 | 0.5 | 1.4 | 2.1 | 6.1 | 9.2 | 14.2 | 19.6 |
| CHANGE FROM BASE YR % | | | | | | | | |
| w/ DM DX ever | -0.1 | -0.7 | -2.8 | +3.1 | +1.7 | -3.0 | -2.9 | -11.4 |
| w/DM DX in past yr | -0.3 | +0.4 | -0.2 | +1.3 | +4.7 | +3.4 | -1.2 | -6.5 |

Figure 2-2: Sample Age Breakdown Page, Diabetes Prevalence Topic

| DU | November 25, 2012 | Page 1 |
|--|---------------------|---------|
| *** IHS 2012 Clinical Performance Measure Patient List *** DEMO INDIAN HOSPITAL Report Period: Jan 01, 2012 to Dec 31, 2012 Entire Patient List | | |
| ----- UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient ----- Diabetes Prevalence: List of diabetic patients with most recent diagnosis ----- | | |
| PATIENT NAME DENOMINATOR | HRN NUMERATOR | SEX AGE |
| PATIENT1,DEBORAH | 000001 COMMUNITY #1 | F 20 |
| UP | 02/01/12 POV | 250.00 |
| PATIENT2,TARA | 000002 COMMUNITY #1 | F 21 |
| UP | 05/24/12 POV | 250.00 |
| PATIENT3,BOBBIE | 000003 COMMUNITY #1 | F 28 |
| UP | 03/30/12 POV | 250.00 |
| PATIENT4,WINONA | 000004 COMMUNITY #1 | F 37 |
| UP | 04/30/12 POV | 250.00 |
| PATIENT5,NADINE | 000005 COMMUNITY #1 | F 44 |
| UP | 03/19/12 POV | 250.00 |
| PATIENT6,RUTH | 000006 COMMUNITY #1 | F 44 |
| UP | 03/19/12 POV | 250.00 |

Figure 2-3: Sample Patient List, Diabetes Prevalence, Patients with Diabetes Diagnosis

2.2.2 Diabetes Comprehensive Care

Denominators

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two diabetes mellitus- (DM-) related visits ever.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

Numerators

Patients with hemoglobin A1c documented during the Report Period, regardless of result

Patients with blood pressure (BP) documented during the Report Period

Patients with controlled BP, defined as less than ($<$) 130/80, i.e., the mean systolic value is less than 130 and the mean diastolic value is less than 80

Patients with low-density lipoprotein (LDL) completed during the Report Period, regardless of result

Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the Report Period *or* with the evidence of diagnosis and/or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period

Patients receiving a qualified retinal evaluation during the Report Period

Note: This numerator does *not* include refusals.

Patients with diabetic foot exam during the Report Period

Note: This numerator does *not* include refusals.

Patients with comprehensive diabetes care (Documented A1c *and* Blood Pressure *and* LDL *and* Nephropathy Assessment *and* Retinal Exam *and* Diabetic Foot Exam).

Logic Description

Diabetes definition: First Purpose of Visit (POV) 250.00 through 250.93 recorded in the POV file prior to the Report Period.

A1c definition: Searches for most recent A1c test with a result during the Report Period. If none found, CRS searches for the most recent A1c test without a result. A1c defined as: CPT 83036, 83037, 3044F through 3046F, 3047F (old code); LOINC taxonomy; or site-populated taxonomy DM AUDIT HGB A1C TAX.

BP documented definition: Having a minimum of two BPs documented on non-Emergency Room (ER) visits during the Report Period.

CRS uses mean of last three BPs documented on non-ER visits during the Report Period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) BPs and dividing by three (or two).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on a non-ER visit during the Report Period.

Controlled BP definition: CRS uses a mean, as described above. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from BP measurements, it will search for the most recent of any of the following CPT codes documented on non-ER visits during the Report Period: BP Documented: 0001F or 2000F; *or* Systolic 3074F, 3075F, or 3077F *with* Diastolic: 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combination represents BP less than (<) 130/80 and will be included in the Controlled BP numerator: CPT 3074F *and* 3078F. All other combinations *will not* be included in the Controlled BP numerator.

LDL definition: Finds last test done during the Report Period; defined as CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F; LOINC taxonomy; site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX.

Nephropathy assessment definition: (1) Estimated GFR with result during the report period, defined as any of the following: (A) Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or (B) LOINC taxonomy, *and* (2) Quantitative Urinary Protein Assessment during the Report Period, defined as any of the following: (A) CPT 82042, 82043, or 84156; (B) LOINC taxonomy; or (C) site-populated taxonomy BGP QUANT URINE PROTEIN.

| |
|---|
| <p>Note: Be sure and check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values.</p> |
|---|

(3) ESRD diagnosis/treatment defined as any of the following ever: (A) V CPT 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), or S9339; (B) V POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.*; (C) V Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6*.

Qualified retinal evaluation definition: (1) diabetic retinal exam or (2) other eye exam. The following methods are qualifying for this measure: (1) dilated retinal evaluation by an optometrist or ophthalmologist, or (2) seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist, or (3) any photographic method formally validated to seven standard fields (ETDRS).

- *Diabetic Retinal Exam:* Any of the following during the Report Period: (1) Exam Code 03 Diabetic Eye Exam (dilated retinal examination or formally validated* ETDRS photographic equivalent), (2) CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging formally validated* to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.
- *Other Eye Exam:* (1) Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or formally validated* teleophthalmology retinal evaluation clinics or (2) non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order: Clinic Codes A2 (Diabetic Retinopathy)**, 17, 18; Provider Code 24, 79, 08; CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014; Procedure 95.02.

*Validation study properly powered and controlled against the ETDRS gold standard.

**Validated photographic (teleophthalmology) retinal surveillance.

Diabetic foot exam definition: (1) Exam Code 28 Diabetic Foot Exam, Complete; (2) non-DNKA visit with a podiatrist (Provider Codes 33, 84 or 25), (3) non-DNKA visit to Podiatry Clinic (Clinic Code 65), or (4) CPT 2028F.

Bilateral foot amputation definition: CPT 27290.50 through 27295.50, 27590.50 through 27592.50, 27598.50, 27880.50 through 27882.50 (50 modifier indicates bilateral)

Unilateral foot amputation definition: Must have 2 separate occurrences for either CPT or Procedure codes on 2 different dates of service: (1) CPT 27290 through 27295, 27590 through 27592, 27598, 27880 through 27882, or (2) ICD Procedure codes 84.10, 84.13 through 84.19.

Key Logic Changes from CRS Version 12.0

1. Deleted POV code V72.0 from Other Eye Exam definition.
2. Deleted Clinic Code 64 from Other Eye Exam definition.

3. Added codes 50384-7 and 69405-9 to LOINC taxonomy for Estimated GFR.
4. Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.
5. Added codes 13991-5, 2888-6, 40857-5, 50209-6, 51190-7, 53229-1, 53525-2 to LOINC taxonomy for Quantitative Urine Protein.

Patient List Description

List of diabetic patients with documented tests, if any.

Measure Source

Foot Exam: HP 2020 D-9

Measure Past Performance and Long-Term Targets

| Target | Percent |
|----------------------------|---------|
| HP 2020 goal for foot exam | 74.8% |

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|--------|----------|
| DU | November 25, 2012 | | | | | | Page 9 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Diabetes Comprehensive Care | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Diabetic Pts | 144 | | 97 | | | 87 | | |
| # w/Comp Diabetes Care | 10 | 6.9 | 1 | 1.0 | +5.9 | 0 | 0.0 | +6.9 |
| # w/A1c done w/ or w/o result | 92 | 63.9 | 70 | 72.2 | -8.3 | 52 | 59.8 | +4.1 |
| # w/ BPs documented | 120 | 83.3 | 78 | 80.4 | +2.9 | 74 | 85.1 | -1.7 |
| # w/Controlled BP <130/80 | 28 | 19.4 | 20 | 20.6 | -1.2 | 13 | 14.9 | +4.5 |
| # w/ LDL done | 78 | 54.2 | 46 | 47.4 | +6.7 | 23 | 26.4 | +27.7 |
| # w/ est GFR & quant UP assmt or w/ESRD | 53 | 36.8 | 11 | 11.3 | +25.5 | 6 | 6.9 | +29.9 |
| # w/Retinal Evaluation -No Refusals | 54 | 37.5 | 39 | 40.2 | -2.7 | 44 | 50.6 | -13.1 |
| Active Diabetic Pts w/o Hx of Bilateral Amputation | 137 | | 97 | | | 87 | | |

| | | | | | | | | |
|------------------------|----|------|----|------|------|----|------|------|
| # w/Diabetic Foot Exam | | | | | | | | |
| -No Refusals | 20 | 14.6 | 18 | 18.6 | -4.0 | 16 | 18.4 | -3.8 |

Figure 2-4: Sample Summary Report, Diabetes Comprehensive Care Topic

***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT *****

DU

November 25, 2012

Page 11

*** IHS 2012 Clinical Performance Measure Patient List ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Entire Patient List

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetes Comprehensive Care: List of diabetic patients with documented tests,
if any.

| PATIENT NAME | HRN | COMMUNITY | SEX AGE |
|--|--|--------------|---------|
| DENOMINATOR | NUMERATOR | | |
| ----- | | | |
| PATIENT1,DEBORAH | 000001 | COMMUNITY #1 | F 45 |
| AD | A1c: 02/28/12 6.6; BPs: 133/82 UNC; LDL: 10/28/12 119; | | |
| EYE: 01/07/12 C1 18 | | | |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F 51 |
| AD | BP: <130/80; BPs: 118/61; ESRD: 03/03/12 90951; FOOT | | |
| AMPUTATION | | | |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F 52 |
| AD | A1c: 04/09/12 6.5; BPs: 138/66 UNC; GFR: 04/09/12 & | | |
| QUANT UP: 03/31/12 QUANT URINE PROTEIN; EYE: 03/30/12 C1 18; FOOT EXAM: 01/07/12 | | | |
| C1 65 | | | |

Figure 2-5: Sample Patient List, Diabetes Comprehensive Care

2.2.3 Diabetes: Glycemic Control

GPRA Measure Description, Poor Glycemic Control

During FY 2012, achieve the target rate of 18.6% for the proportion of patients with diagnosed diabetes who have poor glycemic control (defined as A1c greater than (>) 9.5).

GPRA Measure Description, Ideal Glycemic Control

During FY 2012, achieve the target rate of 32.7% for the proportion of patients with diagnosed diabetes who have ideal glycemic control (defined as A1c less than (<) 7).

Denominators

All User Population patients diagnosed with diabetes prior to the report period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever; (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than five.

Numerators

Number of patients with a Hemoglobin A1c documented during the Report Period, regardless of result.

Poor Control: Total of Poor and Very Poor Control: Patients with A1c greater than (>) 9.5. (GPRA Numerator)

Very Poor Control: Patients with A1c equal to or greater than (\geq) 12.

Poor Control: Patients with A1c greater than (>) 9.5 and less than (<) 12.

Fair Control: Patients with A1c equal to or greater than (\geq) 8 and less than or equal to (\leq) 9.5.

Good Control: Patients with A1c equal to or greater than (\geq) 7 and less than (<) 8.

Ideal Control: Patients with A1c less than (<) 7. (GPRA Numerator)

Without Result: Patients with A1c documented but no value.

Logic Description

Diabetes definition: First Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report Period.

Hemoglobin A1c definition: Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result. Without result is defined as A1c documented but with no value.

CRS uses the following definitions:

| Subject Defined | CPT Codes | LOINC Codes | Taxonomy |
|--|--|-------------|-------------------------|
| Creatinine (for Active Adult Diabetic denominator) | CPT codes are not included since they do not store the result, which is used in this topic | Yes | DM AUDIT CREATININE TAX |
| Hemoglobin A1c | 83036, 83037, 3044F-3046F, 3047F (old code) Note: CPT 3044F represents A1c less than(<)7 and will be included in the Ideal Control numerator. | Yes | DM AUDIT HGB A1C TAX |

In the CPT Codes column, specific LOINC codes used CRS are located in the *CRS Technical Manual*.

Key Logic Changes from CRS Version 12.0

Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.

Patient List Description

List of diabetic patients with most recent A1c value, if any.

Measure Source

HEDIS; HP 2020 D-11, D-5

Measure Past Performance and Long-Term Targets

Hemoglobin A1c Documented

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 83.0% |
| IHS FY 2010 Performance | 82.0% |
| IHS FY 2009 Performance | 80.0% |
| IHS FY 2008 Performance | 79.0% |
| IHS FY 2007 Performance | 79.0% |
| IHS FY 2006 Performance | 79.0% |
| IHS FY 2005 Performance | 78.0% |
| IHS FY 2004 Performance | 77.0% |
| IHS FY 2003 Performance | 75.0% |
| IHS FY 2002 Performance | 73.0% |
| HP 2020 Goal | 71.1% |

Poor Glycemic Control

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 19.1% |
| IHS FY 2010 Performance | 18.0% |
| IHS FY 2009 Performance | 18.0% |
| IHS FY 2008 Performance | 17.0% |
| IHS FY 2007 Performance | 16.0% |
| IHS FY 2006 Performance | 16.0% |
| IHS FY 2005 Performance | 15.0% |
| IHS FY 2004 Performance | 17.0% |
| IHS FY 2003 Performance | 17.0% |
| IHS FY 2002 Performance | 18.0% |

Ideal Glycemic Control

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 31.9% |
| IHS FY 2010 Performance | 32.0% |
| IHS FY 2009 Performance | 31.0% |
| IHS FY 2008 Performance | 32.0% |
| IHS FY 2007 Performance | 31.0% |
| IHS FY 2006 Performance | 31.0% |
| IHS FY 2005 Performance | 30.0% |
| IHS FY 2004 Performance | 27.0% |
| IHS FY 2003 Performance | 28.0% |
| IHS FY 2002 Performance | 25.0% |
| <i>HP 2020 Goal</i> | <i>58.9%</i> |

| | | |
|--|-------------------|---|
| DU | November 25, 2012 | Page 11 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |
| Diabetes: Glycemic Control | | |
| REPORT PERIOD | % | PREV YR PERIOD % CHG from BASE % CHG from |
| | | PREV YR % PERIOD BASE % |
| User Pop w/ DM DX | | |

| | | | | | | | | |
|-----------------------------------|-----|------|-----|------|-------|-----|------|-------|
| prior to report end date | 229 | | 202 | | | 180 | | |
| # w/A1c done w/ or w/o result | 95 | 41.5 | 72 | 35.6 | +5.8 | 53 | 29.4 | +12.0 |
| # w/A1c =>12 | 3 | 1.3 | 1 | 0.5 | +0.8 | 3 | 1.7 | -0.4 |
| # w/A1c >9.5 and <12 | 15 | 6.6 | 3 | 1.5 | +5.1 | 8 | 4.4 | +2.1 |
| # w/A1c =>8 and =<9.5 | 12 | 5.2 | 19 | 9.4 | -4.2 | 10 | 5.6 | -0.3 |
| # w/A1c=>7 and <8 | 13 | 5.7 | 16 | 7.9 | -2.2 | 7 | 3.9 | +1.8 |
| # w/A1c <7 | 38 | 16.6 | 33 | 16.3 | +0.3 | 23 | 12.8 | +3.8 |
| # w/A1c w/o Result | 14 | 6.1 | 0 | 0.0 | +6.1 | 2 | 1.1 | +5.0 |
| Active Diabetic Pts (GPRA) | 144 | | 97 | | | 87 | | |
| # w/A1c done w/ or w/o result | 92 | 63.9 | 70 | 72.2 | -8.3 | 52 | 59.8 | +4.1 |
| # w/A1c > 9.5 (GPRA) | 18 | 12.5 | 4 | 4.1 | +8.4 | 11 | 12.6 | -0.1 |
| # w/A1c =>12 | 3 | 2.1 | 1 | 1.0 | +1.1 | 3 | 3.4 | -1.4 |
| # w/A1c >9.5 and < 12 | 15 | 10.4 | 3 | 3.1 | +7.3 | 8 | 9.2 | +1.2 |
| # w/A1c =>8 and =<9.5 | 12 | 8.3 | 19 | 19.6 | -11.3 | 10 | 11.5 | -3.2 |
| # w/A1c=>7 and <8 | 13 | 9.0 | 16 | 16.5 | -7.5 | 7 | 8.0 | +1.0 |
| # w/A1c <7 (GPRA) | 35 | 24.3 | 31 | 32.0 | -7.7 | 22 | 25.3 | -1.0 |
| # w/A1c w/o Result | 14 | 9.7 | 0 | 0.0 | +9.7 | 2 | 2.3 | +7.4 |
| Active Adult Diabetic Patients | 102 | | 75 | | | 63 | | |
| # w/A1c done w/ or w/o result | 71 | 69.6 | 61 | 81.3 | -11.7 | 46 | 73.0 | -3.4 |
| # w/A1c =>12 | 3 | 2.9 | 1 | 1.3 | +1.6 | 3 | 4.8 | -1.8 |
| # w/A1c >9.5 and <12 | 13 | 12.7 | 2 | 2.7 | +10.1 | 7 | 11.1 | +1.6 |
| # w/A1c =>8 and =<9.5 | 11 | 10.8 | 18 | 24.0 | -13.2 | 8 | 12.7 | -1.9 |
| # w/A1c =>7 and <8 | 10 | 9.8 | 12 | 16.0 | -6.2 | 6 | 9.5 | +0.3 |
| # w/A1c <7 | 28 | 27.5 | 28 | 37.3 | -9.9 | 22 | 34.9 | -7.5 |
| # w/A1c w/o Result | 6 | 5.9 | 0 | 0.0 | +5.9 | 0 | 0.0 | +5.9 |

Figure 2-6: Sample Report, Diabetes: Glycemic Control Topic

| |
|--|
| ***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT ***** |
| DU November 25, 2012 Page 16 |
| *** IHS 2012 Clinical Performance Measure Patient List *** |
| DEMO INDIAN HOSPITAL |

| Report Period: Jan 01, 2012 to Dec 31, 2012 Entire Patient List | | | | |
|--|--------|------------------------|------|-----|
| ----- | | | | |
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Diabetes: Glycemic Control: List of diabetic patients with most recent Alc value, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,DEBORA | 000001 | COMMUNITY #1 | F | 45 |
| UP,AD,AAD | | 03/28/12 Alc: | 6.6 | |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F | 51 |
| UP,AD,AAD | | 02/20/12 Alc: | 12.4 | |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F | 52 |
| UP,AD,AAD | | 04/09/12 Alc: | 6.5 | |
| PATIENT4,WINONA | 000004 | COMMUNITY #1 | F | 53 |
| UP | | | | |
| PATIENT5,NADINE | 000005 | COMMUNITY #1 | F | 61 |
| UP,AD,AAD | | 02/01/12 Alc: | 6.5 | |
| PATIENT6,RUTH | 000006 | COMMUNITY #1 | F | 64 |
| UP | | | | |

Figure 2-7: Sample Patient List, Diabetes: Glycemic Control

2.2.4 Diabetes: Blood Pressure Control

GPRA Measure Description

During FY 2012, achieve the target rate of 38.7% for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as less than (<)130/80).

Denominators

All User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM-related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than five.

Numerators

Patients with BP documented during the report period.

Patients with controlled BP, defined as less than (<) 130/80, i.e., the mean systolic value is less than 130 and the mean diastolic value is less than 80 (GPRA Numerator).

Patients with BP that is not controlled.

Logic Description

Diabetes definition: First DM POV 250.00 through 250.93 recorded in the V POV file prior to the Report Period.

BP documented definition: CRS uses mean of last three BPs documented on non-ER visits during the Report Period. If three BPs are not available, uses mean of the last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F-3080F or POV V81.1 documented on a non-ER visit during the Report Period.

Controlled BP definition: CRS uses a mean, as described above where BP is less than (<)130/80. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented on non-ER visits during the Report Period: BP Documented: CPT 0001F or 2000F or POV V81.1; *or* Systolic: CPT 3074F, 3075F or 3077F *with* Diastolic: CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do *not* have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combination represents BP less than (<)130/80 and will be included in the Controlled BP numerator: CPT 3074F *and* 3078F. All other combinations will *not* be included in the Controlled BP numerator.

CRS uses the following definition:

| Subject Defined | CPT Codes | LOINC Codes | Taxonomy |
|--|--|-------------|----------------------------|
| Creatinine (for Active Adult Diabetic denominator) | CPT codes are not included since they do not store the result, which is used in this topic | Yes | DM AUDIT CREATININE TAX |

In the LOINC Codes column, specific LOINC codes by CRS are location in the *CRS Technical Manual*.

Key Logic Changes from CRS Version 12.0

Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.

Patient List Description

List of diabetic patients with BP value, if any.

Measure Source

HP 2020 D-7

Measure Past Performance and Long-Term Targets

Controlled BP

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 37.8% |
| IHS FY 2010 Performance | 38.0% |
| IHS FY 2009 Performance | 37.0% |
| IHS FY 2008 Performance | 38.0% |
| IHS FY 2007 Performance | 39.0% |
| IHS FY 2006 Performance | 37.0% |
| IHS FY 2005 Performance | 37.0% |
| IHS FY 2004 Performance | 35.0% |
| IHS FY 2003 Performance | 37.0% |
| IHS FY 2002 Performance | 36.1% |
| <i>HP 2020 Goal</i> | <i>57.0%</i> |

BP Assessed

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 87.9% |
| IHS FY 2010 Performance | 89.0% |

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2009 Performance | 88.0% |
| IHS FY 2008 Performance | 89.0% |
| IHS FY 2005 Performance | 89.0% |

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|---------|----------|--|
| DU | November 25, 2012 | | | | | | Page 13 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Diabetes: Blood Pressure Control | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| User Pop w/ DM DX prior to report period | 229 | | 202 | | | 180 | | | |
| # w/ BPs Documented | 132 | 57.6 | 88 | 43.6 | +14.1 | 84 | 46.7 | +11.0 | |
| # w/controlled BP < 130/80 | 32 | 14.0 | 24 | 11.9 | +2.1 | 18 | 10.0 | +4.0 | |
| # w/Not controlled BP | 100 | 43.7 | 64 | 31.7 | +12.0 | 66 | 36.7 | +7.0 | |
| Active Diabetic Pts (GPRA) | 144 | | 97 | | | 87 | | | |
| # w/ BPs Documented | 120 | 83.3 | 78 | 80.4 | +2.9 | 74 | 85.1 | -1.7 | |
| # w/Controlled BP < 130/80 (GPRA) | 28 | 19.4 | 20 | 20.6 | -1.2 | 13 | 14.9 | +4.5 | |
| # w/Not controlled BP | 92 | 63.9 | 58 | 59.8 | +4.1 | 61 | 70.1 | -6.2 | |
| Active Adult Diabetic Patients | 102 | | 75 | | | 63 | | | |
| # w/ BPs Documented | 82 | 80.4 | 61 | 81.3 | -0.9 | 56 | 88.9 | -8.5 | |
| # w/Controlled BP < 130/80 | 20 | 19.6 | 14 | 18.7 | +0.9 | 8 | 12.7 | +6.9 | |
| # w/Not controlled BP | 62 | 60.8 | 47 | 62.7 | -1.9 | 48 | 76.2 | -15.4 | |

Figure 2-8: Sample Report, Diabetes: Blood Pressure Control Topic

| | | | | | | | | | |
|--|-------------------|--|--|--|--|--|---------|--|--|
| ***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT ***** | | | | | | | | | |
| DU | November 25, 2012 | | | | | | Page 23 | | |
| *** IHS 2012 Clinical Performance Measure Patient List *** | | | | | | | | | |

| DEMO INDIAN HOSPITAL Report Period: Jan 01, 2012 to Dec 31, 2012 Entire Patient List | | | | | |
|---|--------|---------------------------------|-----|-----|--|
| ----- UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient ----- Diabetes: Blood Pressure Control: List of diabetic patients with BP value, if any. ----- | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1,DEBORAH UP,AD,AAD | 000001 | COMMUNITY #1 133/82 UNC | F | 45 | |
| PATIENT2,TARA UP,AD,AAD | 000002 | COMMUNITY #1 3074F/3080F UNC | F | 51 | |
| PATIENT3,BOBBIE UP,AD,AAD | 000003 | COMMUNITY #1 138/66 UNC | F | 52 | |
| PATIENT4,WINONA UP | 000004 | COMMUNITY #1 | F | 53 | |
| PATIENT5,NADINE UP,AD,AAD | 000005 | COMMUNITY #1 159/86 UNC | F | 61 | |
| PATIENT6,RUTH UP | 000006 | COMMUNITY #1 139/74 UNC | F | 64 | |

Figure 2-9: Sample Patient List, Diabetes: Blood Pressure Control

2.2.5 Diabetes: LDL Assessment

GPRA Measure Description

During FY 2012, achieve the target rate of 70.3% for the proportion of patients with diagnosed diabetes who are assessed for dyslipidemia (LDL cholesterol).

Denominators

All User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than five.

Numerators

Patients with LDL completed during the Report Period, regardless of result. (GPRA Numerator)

Patients with *LDL results* less than (<) 130.

- a. Patients with LDL results less than or equal to (<=) 100
- b. Patients with LDL results 101–129

Logic Description

Diabetes definition: First DM POV 250.00 through 250.93 recorded in the V POV file prior to the Report Period.

LDL definition: Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

CRS uses the following to define the tests:

| Subject Defined | CPT Codes | LOINC Codes. | Taxonomy |
|--|--|--------------|--|
| Creatinine (for Active Adult Diabetic denominator) | CPT codes are not included since they do not store the result, which is used in this topic | Yes | DM AUDIT CREATININE TAX |
| LDL Done | 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F | Yes | DM AUDIT LDL CHOLESTEROL TAX |
| LDL less than (<)130 | 3048F, 3049F | | Tests in above taxonomy with LDL less than (<)130 |
| LDL equal to or less than (<=)100 | 3048F | | Tests in above taxonomy with LDL equal to or less than (<=)100 |

In the LOINC Codes column, specific LOINC codes used by CRS are located in the *CRS Technical Manual*.

Key Logic Changes from CRS Version 12.0

1. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.
2. Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.

Patient List Description

List of diabetic patients with documented LDL cholesterol test, if any.

Measure Source

HP 2010 12–15

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 68.7% |
| IHS FY 2010 Performance | 67.0% |
| IHS FY 2009 Performance | 65.0% |
| IHS FY 2008 Performance | 63.0% |
| IHS FY 2007 Performance | 61.0% |
| IHS FY 2006 Performance | 60.0% |
| IHS FY 2005 Performance | 53.0% |
| IHS FY 2004 Performance | 53.0% |
| IHS FY 2003 Performance | 47.5% |
| IHS FY 2002 Performance | 43.7% |

DU

November 25, 2012

Page 15

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Diabetes: LDL Assessment

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|----------------------------|---------------|------|----------------|------|--------------------|-------------|------|-----------------|
| # w/ LDL done | 84 | 36.7 | 48 | 23.8 | +12.9 | 23 | 12.8 | +23.9 |
| # w/LDL <130 | 58 | 25.3 | 40 | 19.8 | +5.5 | 15 | 8.3 | +17.0 |
| A. # w/LDL =<100 | 37 | 16.2 | 31 | 15.3 | +0.8 | 8 | 4.4 | +11.7 |
| B. # w/LDL 101-129 | 17 | 7.4 | 9 | 4.5 | +3.0 | 7 | 3.9 | +3.5 |
| Active Diabetic Pts (GPRA) | 144 | | 97 | | | 87 | | |

| | | | | | | | | |
|--------------------------------|-----|------|----|------|------|----|------|-------|
| # w/ LDL done (GPRA) | 78 | 54.2 | 46 | 47.4 | +6.7 | 23 | 26.4 | +27.7 |
| # w/LDL <130 | 54 | 37.5 | 38 | 39.2 | -1.7 | 15 | 17.2 | +20.3 |
| A. # w/LDL =<100 | 35 | 24.3 | 30 | 30.9 | -6.6 | 8 | 9.2 | +15.1 |
| B. # w/LDL 101-129 | 15 | 10.4 | 8 | 8.2 | +2.2 | 7 | 8.0 | +2.4 |
| Active Adult Diabetic Patients | 102 | | 75 | | | 63 | | |
| # w/ LDL done | 60 | 58.8 | 43 | 57.3 | +1.5 | 21 | 33.3 | +25.5 |
| # w/LDL <130 | 41 | 40.2 | 35 | 46.7 | -6.5 | 13 | 20.6 | +19.6 |
| A. # w/LDL =<100 | 26 | 25.5 | 26 | 34.7 | -9.2 | 8 | 12.7 | +12.8 |
| B. # w/LDL 101-129 | 12 | 11.8 | 9 | 12.0 | -0.2 | 5 | 7.9 | +3.8 |

Figure 2-10: Sample Report, Diabetes: LDL Assessment

***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT *****

DU

November 25, 2012

Page 30

*** IHS 2012 Clinical Performance Measure Patient List ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Entire Patient List

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetes: LDL Assessment: List of diabetic patients with documented LDL
cholesterol test, if any

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|-----------|---------|
| PATIENT1,DEBORAH | 000001 | COMMUNITY #1 | F | 45 |
| UP,AD,AAD | | LDL: 03/28/12 | | 119 |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F | 51 |
| UP,AD,AAD | | LDL: 02/20/12 | | 86 |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F | 52 |
| UP,AD,AAD | | | | |
| PATIENT4,WINONA | 000004 | COMMUNITY #1 | F | 53 |
| UP | | | | |
| PATIENT5,NADINE | 000005 | COMMUNITY #1 | F | 61 |
| UP,AD,AAD | | LDL: 02/06/12 | CPT 3048F | LDL<100 |
| PATIENT6,RUTH | 000006 | COMMUNITY #1 | F | 64 |
| UP | | LDL: 05/21/12 | | 107 |

Figure 2-11: Sample Patient List, Diabetes: LDL Assessment

2.2.6 Diabetes: Nephropathy Assessment

GPRA Measure Description

During FY 2012, achieve the target rate of 57.8% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

Denominators

All User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are aged 19 or older at the beginning of the Report Period; (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever; (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than five.

Numerator

Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the Report Period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the Report Period. (GPRA Numerator)

Logic Description

Diabetes definition: First DM Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report period.

Nephropathy assessment definition:

- Estimated GFR with result during the Report Period and Quantitative Urinary Protein Assessment during the Report Period, *or*
- ESRD diagnosis/treatment defined as any diagnosis ever.

CRS uses the following to define the tests/diagnoses:

| Subject Defined | CPT Codes | LOINC Codes | Taxonomy |
|--|--|-------------|---|
| Creatinine (for Active Adult Diabetic Denominator) | CPT codes are not included since they do not store the result, which is used in this topic | Yes | DM AUDIT CREATININE TAX |
| Estimated GFR | | Yes | BGP GPRA ESTIMATED GFR TAX |
| Quantitative Urinary Protein Assessment | CPT: 82042 through 82043, 84156 | Yes | BGP QUANT URINE PROTEIN TAX Note: Be sure and check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values |
| End Stage Renal Disease | V CPT: 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), or S9339 V POV: 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56* V Procedure: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6* | | |

In the LOINC Codes column, specific LOINC codes used by CRS are located in the *CRS Technical Manual*.

Key Logic Changes from CRS Version 12.0

1. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.

2. Added codes 50384-7 and 69405-9 to LOINC taxonomy for Estimated GFR.
3. Added codes 13991-5, 2888-6, 40857-5, 50209-6, 51190-7, 53229-1, 53525-2 to LOINC taxonomy for Quantitative Urine Protein.

Patient List Description

List of diabetic patients with nephropathy assessment, if any.

Measure Source

HP 2010 5–11

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|--|---------|
| IHS FY 2011 Performance | 56.5% |
| IHS FY 2010 Performance | 55.0% |
| IHS FY 2009 Performance | 50.0% |
| IHS FY 2008 Performance | 50.0% |
| IHS FY 2007 Performance (new baseline established; revised standards of care resulted in revised measure definition) | 40.0% |
| IHS FY 2006 Performance (measure definition was different from current definition) | 55.0% |
| IHS FY 2005 Performance (measure definition was different from current definition) | 47.0% |
| IHS FY 2004 Performance (measure definition was different from current definition) | 42.0% |
| IHS FY 2003 Performance (measure definition was different from current definition) | 37.5% |
| IHS FY 2002 Performance (measure definition was different from current definition) | 35.0% |

| | | | | | | | | |
|--|-------------------|---|---------|---|-----------|---------|---|----------|
| DU | November 25, 2012 | | | | | Page 17 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Diabetes: Nephropathy Assessment | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| User Pop w/ DM DX prior | | | | | | | | |
| to Report Period | 229 | | 202 | | | 180 | | |

| | | | | | | | | |
|--|-----|------|----|------|-------|----|-----|-------|
| # w/ est GFR & quant UP assmt or w/ESRD | 55 | 24.0 | 16 | 7.9 | +16.1 | 8 | 4.4 | +19.6 |
| Active Diabetic Pts (GPRA) | 144 | | 97 | | | 87 | | |
| # w/ est GFR & quant UP assmt or w/ESRD (GPRA) | 53 | 36.8 | 11 | 11.3 | +25.5 | 6 | 6.9 | +29.9 |
| Active Adult Diabetic Patients | 102 | | 75 | | | 63 | | |
| # w/ est GFR & quant UP assmt or w/ESRD | 41 | 40.2 | 6 | 8.0 | +32.2 | 4 | 6.3 | +33.8 |

Figure 2-12: Sample Report, Diabetes: Nephropathy Assessment

***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT *****

DU

November 25, 2012

Page 37

*** IHS 2012 Clinical Performance Measure Patient List ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Entire Patient List

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetes: Nephropathy Assessment: List of diabetic patients with nephropathy
assessment, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-------------------------------|---|------------------------|-----|-----|
| ----- | | | | |
| PATIENT1,DEBORAH UP,AD,AAD | 000001 | COMMUNITY #1 | F | 45 |
| PATIENT2,TARA UP,AD,AAD | 000002 | COMMUNITY #1 | F | 51 |
| PATIENT3,BOBBIE UP,AD,AAD | 000003 | COMMUNITY #1 | F | 52 |
| | GFR: 09/09/12 & QUANT UP: 03/31/12 QUANT URINE PROTEIN | | | |
| PATIENT4,WINONA UP | 000004 | COMMUNITY #1 | F | 53 |
| PATIENT5,NADINE UP,AD,AAD | 000005 | COMMUNITY #1 | F | 61 |
| | ESRD: 03/03/12 CPT 90967 | | | |
| PATIENT6,RUTH UP | 000006 | COMMUNITY #1 | F | 64 |
| PATIENT7,DANIELLE UP | 000007 | COMMUNITY #1 | F | 79 |
| | ESRD: 11/01/12 POV V56.8 | | | |

Figure 2-13: Sample Patient List, Diabetes: Nephropathy Assessment

2.2.7 Diabetic Retinopathy

GPRA Measure Description

During FY 2012, achieve the target rate of 54.8% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

Denominators

All User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than five.

Numerators

Patients receiving a qualified retinal evaluation during the Report Period.

Note: This numerator does not include refusals. (GPRA Numerator)

- a. Patients receiving diabetic retinal exam during the Report Period
- b. Patients receiving other eye exams during the Report Period
- c. Patients who refused a diabetic retinal exam during the Report Period.

Logic Description

Diabetes definition: First DM Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report Period.

Serum creatinine definition (used with Active Adult Diabetic denominator): Site-populated taxonomy DM AUDIT CREATININE TAX; or LOINC taxonomy (NOTE: CPT codes are not included since they do not store the result, which is used in this topic.).

Qualified retinal evaluation definition: (1) Diabetic retinal exam or (2) other eye exam, as shown below. The following methods are qualifying for this measure:

- Dilated retinal evaluation by an optometrist or ophthalmologist

- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist
- Any photographic method validated to seven standard fields (ETDRS).

CRS searches in the following order for:

Diabetic Retinal Exam (any of the following during the report period)

| Exam | CPT Codes | Other Codes |
|-----------------------|--|---|
| Diabetic Retinal Exam | 2022F, 2024F, 2026F, S0620, S0621, S3000 | VExam: 03 (dilated retinal examination or formally validated* photographic equivalent) |

Other Eye Exam (any of the following during the report period)

| Exam | CPT Codes | Other Codes |
|---|---|--|
| Non-Did Not Keep Appointment (DNKA) visit to ophthalmology or optometry or formally validated* tele-ophthalmology retinal evaluation clinics | | Clinic codes: A2 (Diabetic Retinopathy)**, 17, 18 |
| Non-DNKA visit to an optometrist or ophthalmologist | 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014 | Provider Codes: 24, 79, 08 Procedure: 95.02 |
| Refusal of a diabetic retinal exam. Refusals are only counted if the patient did not have a diabetic retinal exam or other eye exam. If a patient had both a diabetic retinal exam/other eye exam and a refusal, only the diabetic retinal exam/other eye exam will be counted. | | Refusals Exam: 03 |

*Validation study properly powered and controlled against the ETDRS gold standard.

**Validated photographic (teleophthalmology) retinal surveillance.

Key Logic Changes from CRS Version 12.0

1. Deleted POV code V72.0 from Other Eye Exam definition.
2. Deleted Clinic Code 64 from Other Eye Exam definition.
3. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.

Patient List Description

List of diabetic patients with qualified retinal evaluation or refusal, if any.

Measure Source

HP 2020 D-10

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|--|
| IHS FY 2011 Performance | 54.8% (National rate) |
| IHS FY 2010 Performance | 53.0% (National rate) |
| IHS FY 2009 Performance | 51.0% (National rate) |
| IHS FY 2008 Performance | 50.0% (National rate) |
| IHS FY 2007 Performance | 49.0% (National rate) |
| IHS FY 2006 Performance | 49.0% (National Rate) 52.0% (Designated Sites Rate) |
| IHS FY 2005 Performance | 50.0% (National Rate) 50.0% (Designated Sites Rate) |
| IHS FY 2004 Performance | 47.0% (National Rate) 55.0% (Designated Sites Rate) |
| IHS FY 2003 Performance | 49.0% |
| IHS FY 2002 Performance | 49.0% |
| HP 2020 Goal | 58.7% |

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|---------|----------|--|
| DU | November 25, 2012 | | | | | | Page 19 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Diabetic Retinopathy | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| User Pop w/ DM DX prior to report period | 229 | | 202 | | | 180 | | | |
| # w/Retinal Evaluation | | | | | | | | | |
| -No Refusals | 65 | 28.4 | 47 | 23.3 | +5.1 | 54 | 30.0 | -1.6 | |
| A. # w/ DM Retinal exam | 7 | 3.1 | 6 | 3.0 | +0.1 | 6 | 3.3 | -0.3 | |
| B. # w/Other Eye Exams | 58 | 25.3 | 41 | 20.3 | +5.0 | 48 | 26.7 | -1.3 | |
| # w/Retinal Exam Refusal | 3 | 1.3 | 0 | 0.0 | +1.3 | 0 | 0.0 | +1.3 | |

| | | | | | | | | |
|--------------------------------|-----|------|----|------|------|----|------|-------|
| Active Diabetic Pts (GPRA) | 117 | | 95 | | 87 | | | |
| # w/Retinal Evaluation | | | | | | | | |
| -No Refusals (GPRA) | 54 | 44.6 | 39 | 41.1 | +3.6 | 44 | 50.6 | -5.9 |
| A. # w/ DM Retinal exam | 7 | 5.8 | 6 | 6.3 | -0.5 | 6 | 6.9 | -1.1 |
| B. # w/Other Eye Exams | 47 | 38.8 | 33 | 34.7 | +4.1 | 38 | 43.7 | -4.8 |
| # w/Retinal Exam Refusal | 3 | 2.5 | 0 | 0.0 | +2.5 | 0 | 0.0 | +2.5 |
| Active Diabetic Pts (GPRA) | 144 | | 97 | | | 87 | | |
| # w/Retinal Evaluation | | | | | | | | |
| -No Refusals (GPRA) | 54 | 37.5 | 39 | 40.2 | -2.7 | 44 | 50.6 | -13.1 |
| A. # w/ DM Retinal exam | 7 | 4.9 | 6 | 6.2 | -1.3 | 6 | 6.9 | -2.0 |
| B. # w/Other Eye Exams | 47 | 32.6 | 33 | 34.0 | -1.4 | 38 | 43.7 | -11.0 |
| # w/Retinal Exam Refusal | 3 | 2.1 | 0 | 0.0 | +2.1 | 0 | 0.0 | +2.1 |
| Active Adult Diabetic Patients | 102 | | 75 | | | 63 | | |
| # w/Retinal Evaluation | | | | | | | | |
| -No Refusals | 39 | 38.2 | 32 | 42.7 | -4.4 | 39 | 61.9 | -23.7 |
| A. # w/ DM Retinal exam | 6 | 5.9 | 4 | 5.3 | +0.5 | 6 | 9.5 | -3.6 |
| B. # w/Other Eye Exams | 33 | 32.4 | 28 | 37.3 | -5.0 | 33 | 52.4 | -20.0 |
| # w/Retinal Exam Refusal | 2 | 2.0 | 0 | 0.0 | +2.0 | 0 | 0.0 | +2.0 |

Figure 2-14: Sample Report, Diabetic Retinopathy

```

***** CONFIDENTIAL PATIENT INFORMATION, COVERED BY THE PRIVACY ACT *****
DU                                     November 25, 2012                                     Page 50

***   IHS 2012 Clinical Performance Measure Patient List   ***
      DEMO INDIAN HOSPITAL
      Report Period: Jan 01, 2012 to Dec 31, 2012
      Entire Patient List

-----

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetic Retinopathy: List of diabetic patients with qualified retinal
evaluation or refusal, if any.

PATIENT NAME          HRN      COMMUNITY      SEX AGE
DENOMINATOR          NUMERATOR

```

| | | | | |
|------------------|--------|----------------------|---|----|
| PATIENT1,DEBORAH | 000001 | COMMUNITY #1 | F | 45 |
| UP,AD,AAD | | 01/07/12 C1 18 | | |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F | 51 |
| UP,AD,AAD | | | | |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F | 52 |
| UP,AD,AAD | | 06/30/12 C1 18 | | |
| PATIENT4,WINONA | 000004 | COMMUNITY #1 | F | 53 |
| UP | | | | |
| PATIENT5,NADINE | 000005 | COMMUNITY #1 | F | 61 |
| UP,AD,AAD | | 05/22/12 Refused | | |
| PATIENT6,RUTH | 000006 | COMMUNITY #1 | F | 64 |
| UP | | | | |
| PATIENT7,JONELLE | 000007 | COMMUNITY #1 | F | 69 |
| UP,AD,AAD | | 03/29/12 Diab Eye Ex | | |

Figure 2-15: Sample Patient List, Diabetic Retinopathy

2.2.8 RAS Antagonist Use in Diabetic Patients

Denominator

Active Diabetic patients with HTN, defined as all Active Clinical patients diagnosed with diabetes and hypertension prior to the Report Period, AND at least two visits during the Report Period, AND 2 DM-related visits ever.

Numerators

Patients not receiving a RAS Antagonist medication during the Report Period.

- a. Patients with contraindication/previous adverse reaction to RAS Antagonist therapy.

Logic Description

Diabetes definition: First Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report Period.

Hypertension definition: Diagnosis (POV or problem list) 401.* prior to the Report Period, and at least one hypertension POV during the Report Period.

RAS Antagonist Numerator Logic

Renin Angiotensin System (RAS) Antagonist medication codes defined with medication taxonomy BGP PQA RASA MEDS.

ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Enalapril-Felodipine, Fosinopril-hydrochlorothiazide, Lisinopril-hydrochlorothiazide, Moexipril-hydrochlorothiazide, Quinapril-hydrochlorothiazide, Trandolapril-verapamil).

ARB medications are: Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan).

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Irbesartan-hydrochlorothiazide, Losartan-hydrochlorothiazide, Olmesartan-amlodipine-hydrochlorothiazide, Olmesartan-hydrochlorothiazide, Telmisartan-amlodipine, Telmisartan-hydrochlorothiazide, Valsartan-hydrochlorothiazide).

Direct Renin Inhibitor medications are: Direct Renin Inhibitors (Aliskiren).

Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-hydrochlorothiazide, Aliskiren-hydrochlorothiazide, Aliskiren-valsartan).

CRS uses the following codes to define contraindications to ACE inhibitors/ARBs.

| Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|-----------|---|
| Pregnancy | | POV or Problem List: At least two visits during the Report Period with 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53, 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, |

| Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|--|--|
| | | 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09), where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. |
| | Abortion: Any of the following: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267 | Abortion: Any of the following POVs: 635*, 636*, or 637* Procedures: 69.01, 69.51, 74.91, 96.49 |
| | Miscarriage: Any of the following: 59812, 59820, 59821, 59830 | Miscarriage: Any of the following POVs: 630, 631, 632, 633*, or 634* |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI (not medically indicated) refusal for any RAS Antagonist at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documentated allergies to RAS Antagonists.

Adverse Drug Reaction/Allergy to RAS Antagonists

| ICD and Other Codes |
|---|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): “ace inhibitor”, “ACEI”, “Angiotensin Receptor Blocker” or “ARB” |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: “ace i*”, “ACEI”, “Angiotensin Receptor Blocker” or “ARB” |

Key Logic Changes from CRS Version 12.0

1. Renamed topic to RAS Antagonist Use in Diabetic Patients.
2. Added RAS Antagonist medications to logic.
3. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
4. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).

Patient List Description

List of diabetic patients with hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

Measure Source

PQA (Pharmacy Quality Alliance)

Measure Past Performance and Long-Term Targets

None

| | | |
|--|-------------------|------------------------------------|
| DU | November 25, 2012 | Page 24 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |
| RAS Antagonist Use in Diabetic Patients | | |
| REPORT | % | PREV YR % CHG from BASE % CHG from |

| | PERIOD | | PERIOD | | PREV YR % PERIOD | | BASE % | |
|--|--------|------|--------|------|------------------|---|--------|-------|
| Active Diabetic Pts w/ HTN | 76 | | 57 | | 54 | | | |
| # w/ no RAS Antagonist Rx or w/contra/ ADR | 21 | 27.6 | 9 | 15.8 | +11.8 | 6 | 11.1 | +16.5 |
| A. # w/contra/ADR w/ % of Total | 13 | 61.9 | 2 | 22.2 | +39.7 | 2 | 33.3 | +28.6 |

Figure 2-16: Sample Report, ACEI/ARB Use in Diabetic Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

ACEI/ARB Use in Diabetic Patients: List of diabetic patients with hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
|-----------------------------|--------|--|-----|-----|------------------------|
| PATIENT1,DEBORAH AD | 000001 | COMMUNITY #1 ACEI/ARB Contra pregnant | F | 20 | |
| PATIENT2,TARA AD | 000002 | COMMUNITY #1 06/05/12 | F | 44 | |
| PATIENT3,BOBBIE AD | 000003 | COMMUNITY #1 01/29/12 | F | 45 | |
| PATIENT4,WINONA AD | 000004 | COMMUNITY #1 ACEI/ARB Allergy: 05/05/12 | F | 57 | ADR POV 995.2 + E942.6 |
| PATIENT5,NADINE AD | 000005 | COMMUNITY #1 | F | 57 | |
| PATIENT6,RUTH AD | 000006 | COMMUNITY #1 09/22/12 | F | 61 | |
| PATIENT7,JONELLE AD | 000007 | COMMUNITY #1 06/01/12 ACEI/ARB Contra | M | 25 | POV 425.1 |

Figure 2-17: Sample Patient List: ACEI/ARB Use in Diabetic Patients

2.2.9 Diabetes: Access to Dental Services

Denominator

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever.

Numerators

Patients with documented dental visit during the Report Period.

Note: This numerator does *not* include refusals.

Patients with documented dental exam refusal during the Report Period.

Logic Description

Diabetes definition: First DM Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report period.

Dental visit definition: For non-CHS dental visits, searches for V Dental ADA codes 0000 or 0190; VExam 30; or POV V72.2. For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

Refusal definition: Non-CHS dental visit with refusal of ADA Code 0000 or 0190, or refusal of Exam 30. Refusals are only counted if the patient did not have a documented dental visit.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of diabetic patients with documented dental visit or refusal, if any.

Measure Source

HP 2020 D-8

Measure Past Performance and Long-Term Targets:

| Past Performance | Percent |
|-------------------------|---------|
| IHS FY 2005 Performance | 39.0% |
| IHS FY 2004 Performance | 37.0% |
| IHS FY 2003 Performance | 36.0% |
| IHS FY 2002 Performance | 36.0% |
| HP 2020 Goal | 61.2% |

Performance Improvement Tip

If your facility's dental services are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

| | | |
|--|-------------------|---------|
| DU | November 25, 2012 | Page 26 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |

| ----- | | | | | | | | | |
|--|--------|------|---------|------|-----------|--------|------|----------|--|
| Diabetes: Access to Dental Services | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Diabetic Pts | 144 | | 97 | | | 87 | | | |
| # w/dental visit in past yr-No Refusals | 17 | 11.8 | 20 | 20.6 | -8.8 | 18 | 20.7 | -8.9 | |
| # w/dental exam refusal | 4 | 2.8 | 0 | 0.0 | +2.8 | 0 | 0.0 | +2.8 | |

Figure 2-18: Sample Report, Diabetes and Dental Access

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|----------------------|-----|------|--|
| Diabetes: Access to Dental Services: List of diabetic patients and documented dental visit or refusal, if any. | | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE | |
| DENOMINATOR | | NUMERATOR | | | |
| ----- | | | | | |
| PATIENT1,DEBORAH | 000001 | COMMUNITY #1 | F | 45 | |
| AD | | 03/03/12 Refused ADA | | 0000 | |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F | 51 | |
| AD | | | | | |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F | 52 | |
| AD | | 01/06/12 ADA | | 0190 | |
| PATIENT4,NADINE | 000004 | COMMUNITY #1 | F | 61 | |
| AD | | | | | |
| PATIENT5,SHERRY | 000005 | COMMUNITY #1 | F | 68 | |
| AD | | | | | |
| PATIENT6,JONELLE | 000006 | COMMUNITY #1 | F | 69 | |
| AD | | 03/29/12 ADA | | 0000 | |

Figure 2-19: Sample Patient List, Diabetes and Dental Access

2.3 Dental Measure Topics

2.3.1 Access to Dental Services

GPRA Measure Description

During FY 2012, achieve the target rate of 26.9% for the proportion of patients who receive dental services.

Denominators

All patients in the *User Population*. Broken down by age groups (0 through 5, 6 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)74). (GPRA Denominator)

Numerators

Patients with documented dental visit during the Report Period.

Note: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented dental exam refusal during the Report Period.

Logic Description

Dental visit definition: For non-CHS dental visits, searches for V Dental ADA codes 0000 or 0190; VExam 30; or POV V72.2. For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

Refusal definition: Non-CHS dental visit with refusal of ADA Code 0000 or 0190, or refusal of Exam 30. Refusals are only counted if the patient did not have a documented dental visit.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with documented dental visit or refusal and date.

Measure Source

HP 2020 OH-7

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 26.9% |
| IHS FY 2010 Performance | 25.0% |
| IHS FY 2009 Performance | 25.0% |
| IHS FY 2008 Performance | 25.0% |
| IHS FY 2007 Performance | 25.0% |
| IHS FY 2006 Performance | 23.0% |
| IHS FY 2005 Performance | 24.0% |
| IHS FY 2004 Performance | 24.0% |
| IHS FY 2003 Performance | 25.0% |
| IHS FY 2002 Performance | 24.9% |
| <i>HP 2020 Goal</i> | <i>49.0%</i> |

Performance Improvement Tip

If your facility's dental services are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

| | | | | | | | | |
|--|-------------------|-----|---------|-----|-----------|--------|---------|----------|
| DU | November 25, 2012 | | | | | | Page 28 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Access to Dental Services | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| # User Pop (GPRA) | 2,896 | | 2,456 | | | 2,346 | | |
| # w/dental visit in past yr-No Refusals (GPRA) | 252 | 8.7 | 201 | 8.2 | +0.5 | 207 | 8.8 | -0.1 |
| # w/dental exam refusal | 6 | 0.2 | 0 | 0.0 | +0.2 | 0 | 0.0 | +0.2 |

Figure 2-20: Sample Report, Access to Dental Services

| | | |
|-----|--|---------|
| DU | November 25, 2012 | Page 29 |
| *** | IHS 2012 Selected Measures with Community Specified Report | *** |
| | DEMO INDIAN HOSPITAL | |
| | Report Period: Jan 01, 2012 to Dec 31, 2012 | |
| | Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | |
| | Baseline Period: Jan 01, 2000 to Dec 31, 2000 | |

| | | | | | | | |
|--|------|------|-------|-------|-------|-------|---------|
| ----- | | | | | | | |
| Access to Dental Services (con't) | | | | | | | |
| TOTAL USER POPULATION | | | | | | | |
| Age Distribution | | | | | | | |
| | 0-5 | 6-21 | 22-34 | 35-44 | 45-54 | 55-74 | >74 yrs |
| CURRENT REPORT PERIOD | | | | | | | |
| Total # User Pop | 355 | 759 | 577 | 407 | 397 | 411 | 81 |
| # w/dental visit in past yr-No Refusals (GPRA) | 25 | 71 | 63 | 35 | 32 | 25 | 1 |
| % w/dental visit in past yr-No Refusals (GPRA) | 7.0 | 9.4 | 10.9 | 8.6 | 8.1 | 6.1 | 1.2 |
| # w/dental exam refusal | 0 | 1 | 0 | 0 | 2 | 3 | 0 |
| % w/dental exam refusal | 0.0 | 0.1 | 0.0 | 0.0 | 0.5 | 0.7 | 0.0 |
| PREVIOUS YEAR PERIOD | | | | | | | |
| Total # User Pop | 361 | 704 | 517 | 332 | 284 | 292 | 56 |
| # w/dental visit in past yr-No Refusals (GPRA) | 19 | 59 | 46 | 24 | 24 | 25 | 4 |
| % w/dental visit in past yr-No Refusals (GPRA) | 5.3 | 8.4 | 8.9 | 7.2 | 8.5 | 8.6 | 7.1 |
| # w/dental exam refusal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| % w/dental exam refusal | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CHANGE FROM PREV YR % | | | | | | | |
| w/dental visit in past yr-No Refusals (GPRA) | +1.8 | +1.0 | +2.0 | +1.4 | -0.4 | -2.5 | -5.9 |
| w/dental exam refusal | +0.0 | +0.1 | +0.0 | +0.0 | +0.5 | +0.7 | +0.0 |
| BASELINE REPORT PERIOD | | | | | | | |
| Total # User Pop | 363 | 728 | 455 | 293 | 228 | 236 | 52 |
| # w/dental visit in past yr-No Refusals (GPRA) | 17 | 70 | 39 | 31 | 27 | 20 | 3 |
| % w/dental visit in past yr-No Refusals (GPRA) | 4.7 | 9.6 | 8.6 | 10.6 | 11.8 | 8.5 | 5.8 |
| # w/dental exam refusal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| % w/dental exam refusal | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CHANGE FROM BASE YR % | | | | | | | |
| w/dental visit in past yr-No Refusals (GPRA) | +2.4 | -0.3 | +2.3 | -2.0 | -3.8 | -2.4 | -4.5 |
| w/dental exam refusal | +0.0 | +0.1 | +0.0 | +0.0 | +0.5 | +0.7 | +0.0 |

Figure 2-21: Sample Age Breakdown Report, Access to Dental Services

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Access to Dental Service: List of patients with documented dental visit or refusal and date. (con't)

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|------|-----|
| PATIENT10,JOHN | 000010 | COMMUNITY #1 | M | 17 |
| UP | | 01/03/12 ADA | 0190 | |
| PATIENT11,HOWARD | 000011 | COMMUNITY #1 | M | 25 |
| UP | | 01/24/12 ADA | 0000 | |
| PATIENT12,JAMES | 000012 | COMMUNITY #1 | M | 31 |
| UP | | 02/19/12 ADA | 0000 | |
| PATIENT13,STEVEN | 000013 | COMMUNITY #1 | M | 32 |
| UP | | 01/24/12 ADA | 0000 | |
| PATIENT14,EDWARD | 000014 | COMMUNITY #1 | M | 32 |
| UP | | 06/10/12 ADA | 0000 | |
| PATIENT15,DAVID | 000015 | COMMUNITY #1 | M | 33 |
| UP | | 04/10/12 ADA | 0190 | |

Figure 2-22: Sample Patient List, Access to Dental Services

2.3.2 Dental Sealants

GPRA Measure Description

During FY 2012, achieve the target count of 276,893 sealants placed in American Indian and Alaska Native patients.

Denominator

No denominator. This measure is a total count only, not a percentage.

Numerators

For patients meeting the *User Population* definition, the total number of dental sealants during the report period.

Note: This numerator does not include refusals. (GPRA Numerator).

- a. Dental sealants in patients less than (<)12 years.
- b. Dental sealants in patients 12 through 18 years.
- c. Dental sealants in patients greater than (>)18 years.

Age breakouts are based on Healthy People 2010 age groups for dental sealants.

Logic Description

Age of the patient is calculated at the beginning of the report period.

Sealants definition: V Dental ADA Code 1351 or V CPT Code D1351. Only two sealants per tooth will be counted during the Report Period. Each tooth is identified by the data element Operative Site in RPMS. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

Refusal definition: Refusal of ADA Code 1351 or refusal of CPT Code D1351. Refusals are only counted if a patient did not have a sealant during the Report Period. If a patient had both a sealant and a refusal, only the sealant will be counted. If a patient has multiple refusals, only one refusal will be counted.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients who received or refused dental sealants during Report Period.

Measure Source

HP 2010 21–8

Measure Past Performance and Long-Term Targets:

| Performance | # of Sealants |
|-------------------------|--------------------|
| IHS FY 2011 Performance | 276,893 |
| IHS FY 2010 Performance | 275,459 |
| IHS FY 2009 Performance | 257,067 |
| IHS FY 2008 Performance | 241,207 |
| IHS FY 2007 Performance | 245,449 |
| IHS FY 2006 Performance | 246,645 |
| IHS FY 2005 Performance | 249,882 |
| IHS FY 2004 Performance | 230,295 287,158 |
| IHS FY 2003 Performance | 232,182 |
| IHS FY 2002 Performance | 227,945 |
| IHS FY 2001 Performance | 212,612 |

For the IHS FY 2004 Performance, # of Sealants, please note this was reported by the National Patient Information Reporting System (NPIRS).

Performance Improvement Tip

If your facility's dental visits are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

| | | | | | |
|--|-------------------|-------------------|---------------------|----------------|------------------|
| DU | November 25, 2012 | | | | Page 30 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | |
| DEMO INDIAN HOSPITAL | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | |
| ----- | | | | | |
| Dental Sealants | | | | | |
| | REPORT PERIOD | PREV YR PERIOD | CHG from PREV YR | BASE PERIOD | CHG from BASE |
| Total # of Sealants | | | | | |
| Documented (GPRA) | 50 | 61 | -11 | 81 | -31 |
| A. # Dental Sealants documented pts | | | | | |
| <12 yrs | 35 | 26 | +9 | 40 | -5 |
| B. # Dental Sealants documented pts | | | | | |
| 12-18 yrs | 13 | 34 | -21 | 40 | -27 |
| C. # Dental Sealants documented pts >18 yrs | 2 | 1 | +1 | 1 | +1 |
| # refusals | 3 | 0 | +3 | 0 | +3 |

Figure 2-23: Sample Report, Dental Sealants

| | | | | |
|--|--------|--|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Dental Sealants: List of patients who received or refused dental sealants during Report period. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT20,GEORGE | 000020 | COMMUNITY #1 | M | 5 |
| UP | | 4 sealants: 03/28/12 ADA 1351 (1); 03/28/12 ADA 1351 (1); 03/28/12 ADA 1351 (1); 03/28/12 ADA 1351 (1) | | |
| PATIENT21,CODY | 000021 | COMMUNITY #1 | M | 7 |
| UP | | 0 sealants: 03/03/12 Refused ADA 1351 | | |
| PATIENT50,DAWN | 000050 | COMMUNITY #2 | F | 4 |
| UP | | 3 sealants: 04/15/12 ADA 1351 (1); 05/19/12 ADA 1351 (1); 05/19/12 ADA 1351 (1) | | |
| PATIENT51,JOY | 000051 | COMMUNITY #2 | F | 6 |

| | |
|-------------------|------------------------------------|
| UP | 2 sealants: 03/17/12 ADA 1351 (2) |
| PATIENT52, DONALD | 000052 COMMUNITY #2 M 8 |
| UP | 1 sealants: 02/02/12 CPT D1351 (1) |

Figure 2-24: Sample Patient List, Dental Sealants

2.3.3 Topical Fluoride

GPRA Measure Description

During FY 2012, achieve the target count of 161,461 AI/AN patients who receive at least one topical fluoride application.

Denominator

No denominator. This measure is a total count only, not a percentage.

Numerators

For patients meeting the *User Population* definition, the total number of patients with at least one topical fluoride treatment during the Report Period.

Note: This numerator does *not* include refusals. (GPRA Numerator)

For patients meeting the *User Population* definition, the total number of patients with a documented topical fluoride application refusal in past year.

For patients meeting the *User Population* definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

For patients meeting the *User Population* definition, the total number of documented topical fluoride application refusals during past year.

Logic Description

Topical fluoride application definition: (1) V Dental ADA Codes 1201 (old code), 1203, 1204, 1205 (old code), 1206, or 5986; (2) V CPT Codes D1201 (old code), D1203, D1204, D1205 (old code), D1206, or D5986; 3) V POV V07.31. A maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

Refusal definition: Refusal of ADA Code 1201 (old code), 1203, 1204, 1205 (old code), 1206 or 5986, or refusal of CPT Code D1201 (old code), D1203, D1204, D1205 (old code), D1206, or D5986. Refusals are only counted if a patient did not have a topical fluoride application during the Report Period. If a patient had both an application and a refusal, only the application will be counted. If a patient has multiple refusals, only one refusal will be counted.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients who received or refused at least one topical fluoride application during Report Period.

Measure Source

Not Available

Measure Past Performance and Long-Term Targets:

| Performance | Number of Patients |
|-------------------------|--------------------|
| IHS FY 2011 Performance | 161,461 |
| IHS FY 2010 Performance | 145,181 |
| IHS FY 2009 Performance | 136,794 |
| IHS FY 2008 Performance | 120,754 |
| IHS FY 2007 Performance | 107,934 |
| IHS FY 2006 Performance | 95,439 |
| IHS FY 2005 Performance | 85,318 |
| IHS FY 2005 Performance | 113,324 |

For the IHS FY 2005 Performance, Number of Patients (113,324) is the number of applications.

Performance Improvement Tip

If your facility's dental visits are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

| | | |
|--|-------------------|---------|
| DU | November 25, 2012 | Page 33 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |

| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | |
|---|------------------|-------------------|---------------------|----------------|------------------|
| ----- | | | | | |
| Topical Fluoride | | | | | |
| | REPORT PERIOD | PREV YR PERIOD | CHG from PREV YR | BASE PERIOD | CHG from BASE |
| Total # of patients w/At Least 1 Topical Fluoride App -No Refusals (GPRA) | 45 | 26 | +19 | 15 | +30 |
| # Patients w/Refusals | 7 | 0 | +7 | 0 | +7 |
| Total # of Topical Fluoride Applications | 50 | 26 | +24 | 15 | +35 |
| # Refusals | 7 | 0 | +7 | 0 | +7 |

Figure 2-25: Sample Report, Topical Fluoride

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|------------------------|-----|----------|-----------------------------|
| Topical Fluoride: List of patients who received or refused at least one topical fluoride application during Report period. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT20,GEORGE | 000020 | COMMUNITY #1 | M | 5 | |
| UP | | 1 topical fluoride: | | 06/18/12 | CPT D5986 |
| PATIENT21,RYAN | 000021 | COMMUNITY #1 | M | 8 | |
| UP | | 0 topical fluoride: | | 03/03/12 | Refused ADA 1201 |
| PATIENT22,MICHAEL | 000022 | COMMUNITY #1 | M | 9 | |
| UP | | 0 topical fluoride: | | 03/03/12 | Refused CPT D1203 |
| PATIENT23,MARTY | 000023 | COMMUNITY #1 | M | 15 | |
| UP | | 2 topical fluoride: | | 01/07/12 | ADA 1204; 08/27/12 ADA 1204 |

Figure 2-26: Sample Patient List, Topical Fluoride

2.4 Immunization Measure Topics

2.4.1 Influenza

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 63.4% for the proportion of non-institutionalized adults aged 65 years and older who receive an influenza immunization.

Denominators

All *Active Clinical patients*. Broken down by age groups.

- a. Active Clinical patients *younger than age 18*.
- b. Active Clinical patients *ages 18 through 49*.
- c. Active Clinical patients *ages 18 through 49 and considered high risk for influenza*.
- d. Active Clinical patients *ages 50 through 64*.
- e. Active Clinical patients *ages 65 and older*. (GPRA Denominator)

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever.

All *User Population patients*. Broken down by age groups.

- a. User Population patients *younger than age 18*.
- b. User Population patients *ages 18 through 49*.
- c. User Population patients *ages 18 through 49 and considered high risk for influenza*.
- d. User Population patients *ages 50 through 64*.
- e. User Population patients *ages 65 and older*.

Numerators

Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

Note: The only refusals included in this numerator are not medically indicated (NMI) refusals. (GPRA Numerator)

- a. Patients with a contraindication or a documented NMI refusal.

Patients with documented influenza refusal during the report period.

Logic Description

Age of the patient is calculated at the beginning of the report period.

Diabetes: First DM POV 250.00 through 250.93 recorded in the V POV file prior to the Report period.

Influenza definition: Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

| Immunization | CPT Codes | ICD and Other Codes |
|-------------------|--|---|
| Influenza vaccine | 90654-90662, 90724 (old code), G0008, G8108 (old code) | Immunization (CVX) Codes: 88-Influenza Virus Vaccine, NOS; 15 Inf Virus Vac SV; 16 Inf Virus Vac WV; 111 Inf Virus Vac Intranasal; 135 Inf High Dose Seasonal; 140 Inf Virus Vac SV Preservative Free; 141 Inf Virus Vac SV; 144 Inf Virus Vac SV Intradermal POV: V04.8 (old code), V04.81 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142 ICD Procedure Code: 99.52 |

2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.
3. **Refusal:** Any of the following during the Report Period: (A) Immunization codes 88, 111, 135, 140, 141, 144, 15, or 16, as documented in PCC Refusal File (i.e., REF), (B) CPT codes 90654 through 90662, 90724 (old code), G0008, G8108 (old code) as documented in PCC Refusal File (i.e., REF) or (C) Immunization Package as contraindication of "Patient Refusal."
4. **High Risk for Influenza:** Persons considered high risk for influenza are defined as those who have 2 or more visits in the past 3 years with a POV or Problem diagnosis of any of the following: HIV Infection (042, 042.0 through 044.9 (old codes)); Diabetes (250.00 through 250.93); Rheumatic Heart Disease (393.-398.99); Hypertensive Heart Disease (402.00 through 402.91); Hypertensive Heart/Renal Disease (404.00 through 404.93); Ischemic Heart Disease (410.00-414.9); Pulmonary Heart Disease (415.0 through 416.9); Other Endocardial Heart Disease (424.0 through 424.9); Cardiomyopathy (425.0 through 425.9); Congestive Heart Failure (428.0 through 428.9, 429.2); Chronic Bronchitis (491.0 through 491.9); Emphysema (492.0 through 492.8); Asthma (493.00 through 493.91); Bronchiectasis, CLD, COPD (494.0 through 496.); Pneumoconioses (500 through 505); Chronic Liver Disease (571.0 through 571.9); Nephrotic Syndrome (581.0 through 581.9); Renal Failure (585.6, 585.9); Transplant (996.80-996.89); Kidney Transplant (V42.0-V42.89); Chemotherapy (V58.1); Chemotherapy follow-up (V67.2).

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with Influenza code or refusal, if any.

Measure Source

HP 2020 IID-12.7

Measure Past Performance and Long-Term Targets for Patients => 65 Vaccine Rate:

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 63.4% |
| IHS FY 2010 Performance | 62.0% |
| IHS FY 2009 Performance | 59.0% |
| IHS FY 2008 Performance | 62.0% |
| IHS FY 2007 Performance | 59.0% |
| IHS FY 2006 Performance | 58.0% |
| IHS FY 2005 Performance | 59.0% |
| IHS FY 2004 Performance | 54.0% |
| IHS FY 2003 Performance | 51.0% |
| IHS FY 2002 Performance | 51.4% |
| <i>HP 2020 Goal</i> | <i>90.0%</i> |

Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in Influenza Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

| | | | | | | | |
|--|-------------------|---|---------|---|-----------|--------|---------|
| DU | November 25, 2012 | | | | | | Page 35 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Influenza | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | BASE % |
| Active Clinical Pts | 1,554 | | 1,209 | | | 1,101 | |

| | | | | | | | | |
|---|-----|------|-----|------|------|-----|------|-------|
| Total # w/Flu vaccine/ contra/NMI Refusal | 194 | 12.5 | 115 | 9.5 | +3.0 | 49 | 4.5 | +8.0 |
| A. # w/ Contraind/ NMI Ref | | | | | | | | |
| w/ % of Total IZ | 12 | 6.2 | 2 | 1.7 | +4.4 | 0 | 0.0 | +6.2 |
| # w/ Influenza Refusal | 17 | 1.1 | 6 | 0.5 | +0.6 | 0 | 0.0 | +1.1 |
| Active Clinical Pts <18 | 442 | | 416 | | | 435 | | |
| Total # w/Flu vaccine/ contra/NMI Refusal | 54 | 12.2 | 21 | 5.0 | +7.2 | 6 | 1.4 | +10.8 |
| A. # w/ Contraind/ NMI Ref | | | | | | | | |
| w/ % of Total IZ | 3 | 5.6 | 0 | 0.0 | +5.6 | 0 | 0.0 | +5.6 |
| # w/ Influenza Refusal | 6 | 1.4 | 0 | 0.0 | +1.4 | 0 | 0.0 | +1.4 |
| Active Clinical Pts 18-49 | 752 | | 572 | | | 486 | | |
| Total # w/Flu vaccine/ contra/NMI Refusal | 48 | 6.4 | 33 | 5.8 | +0.6 | 14 | 2.9 | +3.5 |
| A. # w/ Contraind/ NMI Ref | | | | | | | | |
| w/ % of Total IZ | 3 | 6.3 | 2 | 6.1 | +0.2 | 0 | 0.0 | +6.3 |
| # w/ Influenza Refusal | 3 | 0.4 | 0 | 0.0 | +0.4 | 0 | 0.0 | +0.4 |
| Active Clinical Pts 18-49 high risk | 166 | | 109 | | | 69 | | |
| Total # w/Flu vaccine/ contra/NMI Refusal | 25 | 15.1 | 25 | 22.9 | -7.9 | 7 | 10.1 | +4.9 |
| A. # w/ Contraind/ NMI Ref | | | | | | | | |
| w/ % of Total IZ | 3 | 12.0 | 1 | 4.0 | +8.0 | 0 | 0.0 | +12.0 |
| # w/ Influenza Refusal | 3 | 1.8 | 0 | 0.0 | +1.8 | 0 | 0.0 | +1.8 |
| Active Clinical Patients ages 50-64 | 244 | | 157 | | | 115 | | |
| Total # w/Flu vaccine/contra/ NMI Refusal | 59 | 24.2 | 37 | 23.6 | +0.6 | 14 | 12.2 | +12.0 |
| A. # w/ Contraind/ NMI Ref w/ % of | | | | | | | | |
| Total IZ | 5 | 8.5 | 0 | 0.0 | +8.5 | 0 | 0.0 | +8.5 |
| # w/Influenza Refusal | 3 | 1.2 | 5 | 3.2 | -2.0 | 0 | 0.0 | +1.2 |

Figure 2-27: Sample Report, Adult Immunizations: Influenza

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Influenza: List of patients with Influenza code or refusal, if any.

| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
|--------------|-----|-----------|-----|-----|
|--------------|-----|-----------|-----|-----|

| DENOMINATOR | NUMERATOR |
|--------------------------------|--|
| PATIENT1,DEBORAH AD | 000001 COMMUNITY #1 F 15 01/28/12 Imm 88 |
| PATIENT2,CRYSTAL UP,AC | 000002 COMMUNITY #1 F 24 |
| PATIENT3,DEMETRIA UP,AC, HR | 000003 COMMUNITY #1 F 35 02/25/12 Imm 140 |
| PATIENT4,JADE UP | 000004 COMMUNITY #1 F 50 |
| PATIENT5,MARIE UP,AC,AD,HR | 000005 COMMUNITY #1 F 65 01/21/12 NMI Refusal |

Figure 2-28: Sample Patient List, Adult Immunization: Influenza

2.4.2 Adult Immunizations

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 87.5% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

Denominators

Active Clinical patients ages 65 or older. (GPRA Denominator)

Active Clinical patients ages 18 through 64 and considered high risk for pneumococcal.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever.

Active Clinical patients ages 18 through 64.

All User Population patients ages 65 and older at beginning of Report Period.

User Population patients ages 18 through 64 and considered high risk for pneumococcal.

User Population patients ages 18 through 64.

Numerators

Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the Report Period.

Note: The only refusals included in this numerator are NMI refusals. (GPRA Numerator)

- a. Patients with a contraindication or a documented NMI refusal.

Patients with documented Pneumococcal refusal during the Report Period.

Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumovax after the age of 65 or a dose of pneumovax in the past 5 years.

Note: The only refusals included in this numerator are NMI refusals. (GPRA Numerator)

Patients who have received 1 dose of Tdap ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals. (GPRA Numerator)

Patients who have received 1 dose of Tdap/Td in the past 10 years, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals. (GPRA Numerator)

Logic Description

Age of the patient is calculated at the beginning of the Report period.

Diabetes definition: First DM POV 250.00250.93 recorded in the V POV file prior to the Report period.

Pneumococcal Immunization definition: Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Pneumococcal immunization:** Any of the codes in the table below.

| Immunization | CPT Codes | ICD and Other Codes |
|----------------------|--|--|
| Pneumococcal Vaccine | 90669, 90670, 90732, G0009, G8115 (old code) | Immunization (CVX) Codes: 33 – Pneumococcal Polysaccharide Vaccine; 100 – Pneumococcal Conjugate Vaccine; 109 – Pneumo NOS; 133 – Pneumo Conjugate POV: V06.6; V03.82 V Procedure: 99.55 |

2. **Pneumococcal Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.

3. **Pneumococcal Refusal:** Any of the following during the Report Period: (A) Immunization codes 33, 100, 109, or 133, as documented in PCC Refusal File (i.e., REF), (B) CPT codes 90669, 90670, 90732, G0009, G8115 (old code) as documented in PCC Refusal File (i.e. REF) or (C) Immunization Package as contraindication of "Patient Refusal."
4. **High Risk for Pneumococcal:** Persons considered high risk for pneumococcal are defined as those who have 2 or more visits in the past 3 years with a POV or Problem diagnosis of any of the following: HIV Infection (042, 042.0 through 043.9 (old codes), 044.9 (old code)); Diabetes (250.00 through 250.93); Chronic alcoholism (303.90, 303.91); Congestive Heart Failure (428.0-428.9, 429.2); Emphysema (492.0 through 492.8); Asthma (493.00 through 493.91); Bronchiectasis, CLD, COPD (494. Through 496.); Pneumoconioses (501.through 505.); Chronic Liver Disease (571.0 through 571.9); Nephrotic Syndrome (581.0-581.9); Renal Failure (585.6, 585.9); Injury to spleen (865.00 through 865.19); Transplant (996.80-996.89); Kidney Transplant (V42.0 through V42.89); Chemotherapy (V58.1); Chemotherapy follow-up (V67.2).

Tdap/Td Immunization definition: Any of the following documented during the applicable time frame.

1. **Tdap/Td immunization:** Any of the codes in the table below.

| Immunization | CPT Codes | ICD and Other Codes |
|--------------|--------------|--|
| Tdap Vaccine | 90715 | Immunization (CVX) Codes: 115 – Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed |
| Td Vaccine | 90714, 90718 | Immunization (CVX) Codes: 9 – Tetanus and diphtheria toxoids, adsorbed, for adult use 113 – Tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use POV: V06.5 |

2. **Tdap/Td Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients equal to or greater than (\geq) 18 yrs or DM DX with IZ, evidence of disease, contraindication, or refusal, if any.

Measure Source

HP 2020 IID-13.1

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|--|--------------|
| IHS FY 2011 Performance | 85.5% |
| IHS FY 2010 Performance | 84.0% |
| IHS FY 2009 Performance | 82.0% |
| IHS FY 2008 Performance | 82.0% |
| IHS FY 2007 Performance | 79.0% |
| IHS FY 2006 Performance | 74.0% |
| IHS FY 2005 Performance | 69.0% |
| IHS FY 2004 Performance | 69.0% |
| IHS FY 2003 Performance | 65.0% |
| IHS FY 2002 Performance | 64.0% |
| <i>HP 2020 Goal for % of patients => 65</i> | <i>90.0%</i> |

Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in Pneumo Vax Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|---------|----------|
| DU | November 25, 2012 | | | | | | Page 41 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Adult Immunizations | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts ages 65 & older (GPRA) | 116 | | 64 | | | 65 | | |
| Total # w/Pneumovax/ contra/NMI Refusal (GPRA) | 50 | 43.1 | 44 | 68.8 | -25.6 | 37 | 56.9 | -13.8 |
| A. # w/ Contraind/ NMI Ref w/ % of | | | | | | | | |
| Total IZ | 4 | 8.0 | 2 | 4.5 | +3.5 | 0 | 0.0 | +8.0 |
| # w/Pneumovax Refusal | 3 | 2.6 | 0 | 0.0 | +2.6 | 0 | 0.0 | +2.6 |
| Active Clinical Pts | | | | | | | | |

| | | | | | | | | |
|------------------------------|-----|------|-----|------|-------|-----|------|-------|
| 18-64 high risk | 222 | | 164 | | | 105 | | |
| Total # w/Pneumovax/ contra/ | | | | | | | | |
| NMI Refusal | 55 | 24.8 | 47 | 28.7 | -3.9 | 39 | 37.1 | -12.4 |
| A. # w/ Contra/ NMI Ref | | | | | | | | |
| w/ % of Total IZ | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # w/ Pneumovax | | | | | | | | |
| Refusal | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| Active Diabetic Pts | 144 | | 97 | | | 87 | | |
| Total # w/up to date | | | | | | | | |
| Pneumovax/contra/NMI | | | | | | | | |
| Refusal | 56 | 38.9 | 49 | 50.5 | -11.6 | 46 | 52.9 | -14.0 |
| A. # w/ Contraind/ NMI | | | | | | | | |
| Ref w/ % of | | | | | | | | |
| Total IZ | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # w/Pneumovax | | | | | | | | |
| Refusal | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |

Figure 2-29: Sample Report, Adult Immunization: Pneumovax

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Adult Immunizations: List of patients =>18 yrs or DM DX with IZ, evidence of disease, contraindication, or refusal, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|---------|---------------------------|
| PATIENT1,DEBORAH | 000001 | COMMUNITY #1 | F | 18 |
| UP,AC,HR | | TDAP/TD: 12/22/11 | Imm 9 | (past 10 yrs) |
| PATIENT2,TARA | 000002 | COMMUNITY #1 | F | 27 |
| UP,AC | | TDAP: 03/03/12 | Imm 115 | (ever); TDAP/TD: 03/03/12 |
| PATIENT3,BOBBIE | 000003 | COMMUNITY #1 | F | 41 |
| UP,AC | | | | |
| PATIENT4,NADINE | 000004 | COMMUNITY #1 | F | 55 |
| UP,AC,HR,AD | | Pneumo: 03/27/10 | Imm 33 | (ever) (up-to-date); |
| TDAP/TD: 03/27/10 | | Imm 9 | | (past 10 yrs) |
| PATIENT5,SHERRY | 000005 | COMMUNITY #1 | F | 68 |
| UP,AC,HR | | Pneumo: 02/03/12 | Refused | CPT 90669 |

Figure 2-30: Sample Patient List, Adult Immunization: Pneumovax

2.4.3 Childhood Immunizations

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 77.8% for the proportion of American Indian/Alaska Native children ages 19 through 35 months who have received the recommended immunizations.

Denominators

Active Clinical patients ages 19 through 35 months at end of Report Period.

User Population patients ages 19 through 35 months at end of Report Period.

User Population patients active in the Immunization Package who are 19 through 35 months at end of Report Period. (GPRA Denominator)

Note: Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Numerators

Patients who have received the 4:3:1:3:3 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received the 4:3:1:3:3:1 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received the 4:3:1:3:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals. (GPRA Numerator)

Patients who have received four doses of DTaP ever, including contraindications.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received three doses of Polio ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received one dose of MMR ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received three doses of HiB ever, including contraindications.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received three doses of Hepatitis B vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received one dose of Varicella ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received four doses of Pneumococcal conjugate vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received two doses of Hepatitis A vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received two or three doses of Rotavirus vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received two doses of Influenza vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

For each of the above numerators, the following subnumerators are included:

- a. Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal

Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program

Immunization Program Numerator: Patients who have received the 4:3:1:3:3 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B), *not* including refusals, contraindications, and patients with evidence of disease.

Immunization Program Numerator: Patients who have received the 4:3:1:3:3:1 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, and 1 Varicella), *not* including refusals, contraindications, and patients with evidence of disease.

Immunization Program Numerator: Patients who have received the 4:3:1:3:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), *not* including refusals, contraindications, and patients with evidence of disease.

Logic Description

Age definition: Age of the patient is calculated at the beginning of the Report Period. Therefore the age range will be adjusted to 7 through 23 months, which makes the patient between the ages of 19 through 35 months at the end of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

Active Immunization Package Patients denominator definition: Same as User Pop definition except includes only patients flagged as active in the Immunization Package.

Note: Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Dosage and types of immunization definitions:

- Four doses of DTaP: (1) four DTaP/DTP/Tdap; (2) one DTaP/DTP/Tdap and three DT/td; (3) one DTaP/DTP/Tdap and three each of Diphtheria and Tetanus; (4) four DT and four Acellular Pertussis; (5) four Td and four Acellular Pertussis; or (6) four each of Diphtheria, Tetanus, and Acellular Pertussis.
- Three doses of Polio: (1) v OPV; (2) three IPV; or (3) combination of OPV and IPV totaling 3 doses.
- One dose of MMR: (1) MMR; (2) one M/R and one Mumps; (3) one R/M and one Measles; or (4) one each of Measles, Mumps, and Rubella.
- Three doses of Hep B
- Three doses of HIB
- One dose of Varicella
- Four doses of Pneumococcal
- Two doses of Hepatitis A
- Two or three doses of Rotavirus, depending on the vaccine administered
- Two doses of Influenza

Except for the Immunization Program Numerators, NMI refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only.

Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g. 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all two doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator.
- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate NMI refusal for the Measles and Mumps immunizations.
- For immunizations where required number of doses is >1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.

- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period.)
- To be counted in subnumerator A, a patient must meet the numerator definition *and* have a REF refusal in PCC or a Parent or Patient Refusal in the IZ program for any of the immunizations in the numerator. For example, if a patient refused Rubella only but had immunizations for Measles and Mumps, the patient would be included in subnumerator A.

For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, all conditions shown below must be met:

- Each immunization must be refused and documented separately. For example, if a patient has an REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.
- Where the required number of doses is greater than (>)1, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the 4 DTaP numerator, only one refusal is necessary to be counted in the refusal numerator.

Childhood immunization refusals are defined as Parent/Patient Refusal in Immunization package or PCC Refusal type REF or NMI for IZ codes:

| Immunization | Immunization Codes for Refusals | CPT Codes for Refusals |
|---------------------------|---|--|
| DTaP | 20, 50, 106, 107, 110, 120, 130, 132, 146 | 90696, 90698, 90700, 90721, 90723 |
| DTP | 1, 22, 102 | 90701, 90711 (old code), 90720 |
| Tdap | 115 | 90715 |
| DT (Diphtheria & Tetanus) | 28 | 90702 |
| Td (Tetanus & Diphtheria) | 9, 113 | 90714, 90718 |
| Tetanus | 35, 112 | 90703 |
| Acellular Pertussis | 11 | |
| OPV | 2, 89 | 90712 |
| IPV | 10, 89, 110, 120, 130, 132, 146 | 90696, 90698, 90711 (old code), 90713, 90723 |
| MMR | 3, 94 | 90707, 90710; M/R: 90708 |
| M/R (Measles/ Rubella) | 4 | |
| R/M (Rubella/ Mumps) | 38 | 90709 (old code) |
| Measles | 5 | 90705 |
| Mumps | 7 | 90704 |

| Immunization | Immunization Codes for Refusals | CPT Codes for Refusals |
|---------------------|---|---|
| Rubella | 6 | 90706 |
| HiB | 17, 22, 46-49, 50, 51, 102, 120, 132, 146 | 90645-90648, 90698, 90720-90721, 90737 (old code), 90748 |
| Hepatitis B | 8, 42-45, 51, 102, 104, 110, 132, 146 | 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code) |
| Varicella | 21, 94 | 90710, 90716 |
| Pneumococcal | 33, 100, 109, 133 | 90669, 90670, 90732, G0009, G8115 (old code) |
| Hepatitis A | 1, 52, 83, 84, 85, 104 | 90632-90634, 90636, 90730 (old code) |
| Rotavirus | 74, 116, 119, 122 | 90680 |
| Influenza | 15, 16, 88, 111, 135, 140, 141 | 90654-90658, 90659 (old code), 90660-90662, 90724 (old code), G0008, G8108 (old code) |

Childhood immunizations are defined in the following ways:

| Immunization | CPT Codes | ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, V Procedure, Evidence of Disease, Contraindication or Refusal Codes |
|---------------------------|-----------------------------------|--|
| DTaP | 90696, 90698, 90700, 90721, 90723 | Immunization (CVX) Codes: 20, 50, 106, 107, 110, 120, 130, 132, 146 POV: V06.1 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| DTP | 90701, 90711 (old code), 90720 | Immunization (CVX) Codes: 1, 22, 102 POV: V06.1, V06.2, V06.3 V Procedure: 99.39 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Tdap | 90715 | Immunization (CVX) Codes: 115 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| DT (Diphtheria & Tetanus) | 90702 | Immunization (CVX) Codes: 28 POV: V06.5 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Td (Tetanus & Diphtheria) | 90714, 90718 | Immunization (CVX) Codes: 9, 113 POV: V06.5 Contraindications: Immunization Package contraindication of "Anaphylaxis." |

| Immunization | CPT Codes | ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, V Procedure, Evidence of Disease, Contraindication or Refusal Codes |
|-----------------------|--|--|
| Diphtheria | 90719 | POV: V03.5 V Procedure: 99.36 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Tetanus | 90703 | Immunization (CVX) Codes: 35, 112 POV: V03.7 V Procedure: 99.38 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Acellular Pertussis | | Immunization (CVX) Codes: 11 POV: V03.6 V Procedure: 99.37 (old code) Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| OPV | 90712 | Immunization (CVX) Codes: 2, 89 Contraindications: POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208 or Immunization Package contraindication of "Anaphylaxis." |
| IPV | 90696, 90698, 90711 (old code), 90713, 90723 | Immunization (CVX) Codes: 10, 89, 110, 120, 130, 132, 146 POV: V04.0, V06.3 V Procedure: 99.41 Evidence of Disease: POV or PCC Problem List (active or inactive) 730.70-730.79 Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Neomycin Allergy." |
| MMR | 90707, 90710 | Immunization (CVX) Codes: 3, 94 POV: V06.4 V Procedure: 99.48 Contraindications: POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," "Immune Deficient," or "Neomycin Allergy." |
| M/R (Measles/Rubella) | 90708 | Immunization (CVX) Codes: 4 Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| R/M (Rubella/Mumps) | 90709 (old code) | Immunization (CVX) Codes: 38 Contraindications: Immunization Package contraindication of "Anaphylaxis" |

| Immunization | CPT Codes | ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, V Procedure, Evidence of Disease, Contraindication or Refusal Codes |
|---------------------|---|---|
| Measles | 90705 | Immunization (CVX) Codes: 5 POV: V04.2 V Procedure: 99.45 Evidence of Disease: POV or PCC Problem List (active or inactive) 055* Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| Mumps | 90704 | Immunization (CVX) Codes: 7 POV: V04.6 V Procedure: 99.46 Evidence of Disease: POV or PCC Problem List (active or inactive) 072* Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| Rubella | 90706 | Immunization (CVX) Codes: 6 POV: V04.3 V Procedure: 99.47 Evidence of Disease: POV or PCC Problem List (active or inactive) 056*, 771.0 Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| HiB | 90645-90648, 90698, 90720-90721, 90737 (old code), 90748 | Immunization (CVX) Codes: 17, 22, 46-49, 50, 51, 102, 120, 132, 146 POV: V03.81 Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| Hepatitis B | 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, (old code) Q3023 (old code) | Immunization (CVX) Codes: 8, 42-45, 51, 102, 104, 110, 132, 146 Evidence of Disease: POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3 Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| Varicella | 90710, 90716 | Immunization (CVX) Codes: 21, 94 POV: V05.4 Evidence of Disease: 1) POV or PCC Problem List (active or inactive) 052*, 053* or 2) 2) Immunization Package contraindication of "Hx of Chicken Pox" or "Immune." Contraindications: POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," "Immune Deficient," or "Neomycin Allergy." |
| Pneumococcal | 90669, 90670, 90732, G0009, G8115 (old code) | Immunization (CVX) Codes: 33, 100, 109, 133 POV: V06.6; V03.82 Contraindications: Immunization Package contraindication of "Anaphylaxis" |

| Immunization | CPT Codes | ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, V Procedure, Evidence of Disease, Contraindication or Refusal Codes |
|---------------------------|---|---|
| Hepatitis A | 90632-90634, 90636, 90730 (old code) | Immunization (CVX) Codes: 31, 52, 83, 84, 85, 104 Evidence of Disease: POV or PCC Problem List (active or inactive) 070.0, 070.1 Contraindications: Immunization Package contraindication of "Anaphylaxis" |
| Rotavirus – 2-dose series | 90681 | Immunization (CVX) Codes: 119 Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency" |
| Rotavirus – 3-dose series | 90680 | Immunization (CVX) Codes: 74, 116, 122 POV: V05.8 Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency" |
| Influenza | 90654-90658, 90659 (old code), 90660-90662, 90724 (old code), G0008, G8108 (old code) | Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144 POV: V04.8 (old code), V04.81, V06.6 V Procedure: 99.52 Contraindications: Immunization Package contraindication of "Egg Allergy" or "Anaphylaxis" |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients 19 through 35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had two DTaP, no IZ will be listed for DTaP.

Note 1: Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7 through 23 months.

Note 2: The order of the display for the immunizations is: 4 Dtap/Dtp;3 IPV/OPV;MMR;3 HIB;3 HEP;Vari;4 PNEUMO. A blank value in the Numerator column means the patient didn't meet the requirements for any of the immunizations. Another example is "MMR; vari;4 PNEUMO," which means the patient did not have 4 Dtap/Dtp, 3 IPV/OPV, 3 HIB and 3 Hep B immunizations.

Measure Source

CDC; HP 2020 IID-7, IID-8; HEDIS

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|--|---------|
| IHS FY 2011 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months) | 75.9% |
| IHS FY 2010 GPRA Performance Active Immunization Package 4:3:1:3:3:1 (rate for children age 19 through 35 months) | 79.0% |
| IHS FY 2009 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months) | 79.0% |
| IHS FY 2008 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months) | 78.0% |
| <i>IHS FY 2008 Non-GPRA Performance Active Clinical 4:3:1:3:3 (rate for children age 19 through 35 months)</i> | 68.0% |
| IHS FY 2007 GPRA Performance Active Immunization Package 4:3:1:3:3(rate for children age 19 through 35 months) | 78.0% |
| IHS FY 2006 Performance (rate for children age 19 through 35 months) | 80.0% |
| IHS FY 2005 Performance (rate for children age 19 through 35 months) | 75.0% |
| IHS FY 2004 Performance(baseline rate for children age 19 through 35 months) | 72.0% |
| IHS FY 2004 Performance(rate for children age 3 through 27 months) | 81.0% |
| IHS FY 2003 Performance(rate for children age 3 through 27 months) | 80.0% |
| IHS FY 2002 Performance(rate for children age 3 through 27 months) | 80.0% |
| <i>HP 2020 goal for % of children age 19 through 35 months with 4:3:1:3:3:4 vaccines</i> | 80.0% |
| <i>HP 2020 goal for % of children age 19 through 35 months with each individual vaccine</i> | 90.0% |

For the IHS FY 2006 Performance (rate for children 19 through 35 months), the Percent (80.0) please consider: All 2002 through 2006 rates reported on this table were reported by the Immunization Program from the quarterly immunization reports. Effective in 2007, CRS reports the rate and not the Immunization Program. The CRS rate is reported using the CRS Active Immunization Package denominator.

Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM

- Providers should document refusals; write “Refused” in appropriate vaccine order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

| | | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|---------|----------|--|
| DU | November 25, 2012 | | | | | | Page 51 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 20000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Childhood Immunizations | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical Pts | | | | | | | | | |
| 19-35 months | 56 | | 39 | | | 55 | | | |
| | | | | | | | | | |
| # w/ 43133 combo | | | | | | | | | |
| or w/ Dx/ Contraind/ | | | | | | | | | |
| NMI Refusal | 11 | 19.6 | 3 | 7.7 | +12.0 | 6 | 10.9 | +8.7 | |
| A. # w/ Dx/Contraind/NMI | | | | | | | | | |
| Ref w/ % of | | | | | | | | | |
| Total 43133 | 1 | 9.1 | 0 | 0.0 | +9.1 | 0 | 0.0 | +9.1 | |
| # w/ 43133 | | | | | | | | | |
| refusal | 2 | 3.6 | 0 | 0.0 | +3.6 | 0 | 0.0 | +3.6 | |
| | | | | | | | | | |
| # w/ 431331 combo | | | | | | | | | |
| or w/ Dx/ Contraind/ | | | | | | | | | |
| NMI Refusal | 9 | 16.1 | 3 | 7.7 | +8.4 | 5 | 9.1 | +7.0 | |
| A. # w/ Dx/Contraind/NMI | | | | | | | | | |
| Ref w/ % of | | | | | | | | | |
| Total 431331 | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 | |
| # w/ 431331 | | | | | | | | | |
| Refusal | 1 | 1.8 | 0 | 0.0 | +1.8 | 0 | 0.0 | +1.8 | |
| | | | | | | | | | |
| # w/ 4313314 combo | | | | | | | | | |
| or w/Dx/Contraind/ | | | | | | | | | |
| NMI Refusal | 3 | 5.4 | 0 | 0.0 | +5.4 | 0 | 0.0 | +5.4 | |
| A. # w/ Dx/Contraind/NMI | | | | | | | | | |
| Ref w/ % of | | | | | | | | | |
| Total 4313314 | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 | |
| # w/ 4313314 | | | | | | | | | |
| Refusal | 2 | 3.6 | 0 | 0.0 | +3.6 | 0 | 0.0 | +3.6 | |
| | | | | | | | | | |
| # w/ 4 doses DTaP | | | | | | | | | |
| or w/ Contraind/ | | | | | | | | | |
| NMI Refusal | 16 | 28.6 | 3 | 7.7 | +20.9 | 9 | 16.4 | +12.2 | |
| A. # w/ Contraind/NMI | | | | | | | | | |
| Ref w/ % of | | | | | | | | | |
| Total DTaP | 1 | 6.3 | 0 | 0.0 | +6.3 | 0 | 0.0 | +6.3 | |
| # w/ DTaP Refusal | 6 | 10.7 | 0 | 0.0 | +10.7 | 0 | 0.0 | +10.7 | |

Figure 2-31: Sample Report, Childhood Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Childhood Immunizations: List of patients 19-35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP. NOTE: Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7-23 months.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|----------------------------------|--------|---|-----|-----|
| PATIENT1, ANDREA UP, AC, IMM | 000001 | COMMUNITY #1 4 DTaP/DTP; 3 Polio; MMR; 3 Hib; 3 Hep B; Vari; 2 Influenza | F | 0 |
| PATIENT2, HEATHER UP, AC, IMM | 000002 | COMMUNITY #1 NMI DTaP/DTP; NMI Polio; 2 Hep A; 2 Influenza | F | 1 |
| PATIENT3, TONYA UP | 000003 | COMMUNITY #1 | F | 1 |
| PATIENT4, JAMES UP, AC, IMM | 000004 | COMMUNITY #1 3 Polio; MMR; 3 Hep B; Vari; NMI Rota | M | 0 |
| PATIENT5, SCOTT UP, AC, IMM | 000005 | COMMUNITY #1 3 Hib; 2 Hep A; 3 Rota; 2 Influenza | M | 0 |

Figure 2-32: Sample Patient List, Childhood Immunizations

2.4.4 Adolescent Immunizations

Denominators

Active Clinical patients age 13. Broken down by gender where noted.

Active Clinical patients ages 13 through 17. Broken down by gender where noted.

Numerators

Patients who have received the 2:3:1 combination (i.e., two MMR, three Hepatitis B, one Varicella), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patient who have received the 1:3:2:1 combination (i.e., one Td/Tdap, three Hepatitis B, two MMR, one Varicella), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received the 1:1:3 combination (i.e., one Td/Tdap, one meningococcal, three HPV), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Note: This numerator is broken down by gender.

Patient who have received the 1:1 combination (i.e., one Td/Tdap, one meningococcal), including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received one dose of Tdap/Td ever, including contraindications and evidence of disease.

- a. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
- b. Patients who have received one dose of Tdap ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received two doses of MMR ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received three doses of Hepatitis B ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received one dose of Varicella ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received one dose of meningococcal ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Patients who have received three doses of HPV ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

Note: This numerator is broken down by gender.

For each of the above numerators, the following subnumerators are included:

- a. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.

Logic Description

Age definition: Age of the patient is calculated at the beginning of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within ten days of each other will be considered as the same immunization.

Dosage and types of immunization definitions:

- One dose of Td or Tdap
- Two doses of MMR: (1) two MMRs; (2) two M/R and two Mumps; (3) two R/M and two Measles; or (4) two each of Measles, Mumps, and Rubella
- Three doses of Hep B *or* two doses *if* documented with CPT 90743
- One dose of Varicella
- One dose of Meningococcal
- Three doses of HPV

Not Medically Indicated (NMI) refusals, evidence of disease and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only.

Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate refusal for the Measles and Mumps immunizations.
- For immunizations where required number of doses is greater than (>)1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period).
- To be counted in subnumerator A, a patient must have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in subnumerator A.

For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, all conditions shown below must be met:

- Each immunization must be refused and documented separately. For example, if a patient has an REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.
- Where the required number of doses is greater than (>)1, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the 4 DTaP numerator, only one refusal is necessary to be counted in the refusal numerator.

Adolescent immunizations are defined in the following ways:

| Immunization | CPT Codes | ICD and Other Codes |
|-----------------------|--------------|---|
| MMR | 90707, 90710 | Immunization codes: 3, 94 POV: V06.4 V Procedure: 99.48 Contraindications: POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," "Immune Deficient," or "Neomycin Allergy." Refusals: Immunization codes 3, 94; CPT codes 90707, 90710 |
| M/R (Measles/Rubella) | 90708 | Immunization code: 4 Refusals: Immunization code 4; CPT code 90708 Contraindications: Immunization Package contraindication of "Anaphylaxis." |

| Immunization | CPT Codes | ICD and Other Codes |
|-------------------------|---|--|
| R/M (Rubella/ Mumps) | 90709 (old code) | Immunization code: 38 Refusals: Immunization code 38; CPT code 90709 (old code) Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Measles | 90705 | Immunization code: 5 POV: V04.2 V Procedure: 99.45 Evidence of Disease: POV or PCC Problem List (active or inactive) 055* Refusals: Immunization code 5; CPT code 90705 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Mumps | 90704 | Immunization code: 7 POV: V04.6 V Procedure: 99.46 Evidence of Disease: POV or PCC Problem List (active or inactive) 072* Refusals: Immunization code 7; CPT code 90704 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Rubella | 90706 | Immunization code: 6 POV: V04.3 V Procedure: 99.47 Evidence of Disease: POV or PCC Problem List (active or inactive) 056*, 771.0 Refusals: Immunization code 6; CPT code 90706 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Hepatitis B | 90736, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, Q3023 | Immunization codes: 8, 42-45, 51, 102, 104, 110, 132, 146 Evidence of Disease: POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3 Refusals: Immunization codes 8, 42-45, 51, 102, 104, 110, 132, 146; CPT codes 90736, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, Q3023 Contraindications: Immunization Package contraindication of "Anaphylaxis." |

| Immunization | CPT Codes | ICD and Other Codes |
|---------------------|------------------|---|
| Varicella | 90710, 90716 | Immunization codes: 21, 94 POV: V05.4 Evidence of Disease: 1) POV or PCC Problem List (active or inactive) 052*, 053*; or 2) Immunization Package contraindication of "Hx of Chicken Pox" or "Immune." Refusals: Immunization codes 21, 94; CPT codes 90710, 90716 Contraindications: POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," "Immune Deficient," or "Neomycin Allergy." |
| Tdap | 90715 | Immunization code: 115 Refusals: Immunization code 115; CPT code 90715 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Td | 90714, 90718 | Immunization codes: 9, 113 POV: V06.5 Refusals: Immunization codes 9, 113; CPT codes 90714, 90718 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| Meningococcal | 90733, 90734 | Immunization codes: 32, 108, 114, 136, 147 Refusals: Immunization codes 32, 108, 114, 136, 147; CPT codes 90733, 90734 Contraindications: Immunization Package contraindication of "Anaphylaxis." |
| HPV | 90649, 90650 | Immunization codes: 62, 118, 137 Refusals: Immunization codes 62, 118, 137; CPT codes 90649, 90650 Contraindications: Immunization Package contraindication of "Anaphylaxis." |

Key Logic Changes from CRS Version 12.0

1. Added CVX code 147 to meningococcal and refusal definitions.
2. Added new measures for 1:1:3 (one Td/Tdap, one meningococcal, three HPV) and 1:1 (one Td/Tdap, one meningococcal).
3. Changed HPV measures to include males.

Patient List Description

List of patients 13 through 17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had two Hep B, no IZ will be listed for Hep B.

Note: An absent value in the Numerator column means the patient did not meet the requirements for any of the immunizations. An example for a female patient age 13 with a value of “;2 MMR” which means the patient did not have one Td/Tdap, three Hepatitis B, one Varicella, one Meningococcal, and three HPV immunizations.

Measure Source

HEDIS, HP 2020 IID-11

Measure Past Performance and Long-Term Targets:

| Target | Percent |
|---|---------|
| HP 2020 goal for each individual IZ: Tdap, Meningococcal, HPV | 80.0% |
| HP 2020 goal for each individual IZ: varicella | 90.0% |

Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in appropriate vaccine Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

| | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|---------|----------|
| DU | November 25, 2012 | | | | | | Page 66 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Adolescent Immunizations | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical patients | | | | | | | | |
| age 13 | 20 | | 17 | | | 28 | | |
| # w/2:3:1 Combo or w/ | | | | | | | | |
| Dx/Contraind/ | | | | | | | | |
| NMI Refusal | 2 | 10.0 | 0 | 0.0 | +10.0 | 0 | 0.0 | +10.0 |
| A. # w/ Dx/ Contraind/ | | | | | | | | |
| NMI Ref w/ % of Total | | | | | | | | |
| 2:3:1 | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # w/ 2:3:1 | | | | | | | | |
| Refusal | 4 | 20.0 | 0 | 0.0 | +20.0 | 0 | 0.0 | +20.0 |

| | | | | | | | | |
|--|----|-------|----|-----|--------|----|-----|--------|
| # w/1:3:2:1 Combo or w/ Dx/Contraind/ NMI Refusal | 1 | 5.0 | 0 | 0.0 | +5.0 | 0 | 0.0 | +5.0 |
| A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:3:2:1 | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # w/ 1:3:2:1 Refusal | 4 | 20.0 | 0 | 0.0 | +20.0 | 0 | 0.0 | +20.0 |
| # w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal | 2 | 10.0 | 0 | 0.0 | +10.0 | 0 | 0.0 | +10.0 |
| A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3 | 1 | 50.0 | 0 | 0.0 | +50.0 | 0 | 0.0 | +50.0 |
| # w/ 1:1:3 Refusal | 1 | 5.0 | 0 | 0.0 | +5.0 | 0 | 0.0 | +5.0 |
| Male Active Clinical Pts age 13 | 8 | | 12 | | | 15 | | |
| # w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal | 1 | 12.5 | 0 | 0.0 | +12.5 | 0 | 0.0 | +12.5 |
| A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3 | 1 | 100.0 | 0 | 0.0 | +100.0 | 0 | 0.0 | +100.0 |
| # w/ 1:1:3 Refusal | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| Female Active Clinical Pts age 13 | 12 | | 6 | | | 13 | | |
| # w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal | 1 | 8.3 | 0 | 0.0 | +8.3 | 0 | 0.0 | +8.3 |
| A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3 | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # w/ 1:1:3 Refusal | 1 | 8.3 | 0 | 0.0 | +8.3 | 0 | 0.0 | +8.3 |

Figure 2-33: Sample Report, Adolescent Immunizations

| | | | | |
|--|-----------|--------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Adolescent Immunizations: List of patients 13-17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 Hep B, no IZ will be listed for Hep B. | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
| DENOMINATOR | NUMERATOR | | | |
| ----- | | | | |
| PATIENT1,LINDA | 000001 | COMMUNITY #3 | F | 13 |

| | |
|---------------------|--|
| AC | 2 MMR; 2 Hep B + 90743 |
| PATIENT2, SHERRY | 000002 COMMUNITY #3 F 13 |
| AC | NMI Tdap; NMI MMR; NMI Hep B; NMI Vari |
| PATIENT22, JESSICA | 000022 COMMUNITY #4 F 13 |
| AC | Ref MMR; 3 Hep B; Evid Vari |
| PATIENT23, SAMANTHA | 000023 COMMUNITY #4 F 13 |
| AC | Td; 3 Hep B; NMI Meningococcal |
| PATIENT24, NINA | 000024 COMMUNITY #4 F 13 |
| AC | Contra MMR; Contra Vari |
| PATIENT25, RHONDA | 000025 COMMUNITY #4 F 13 |
| AC | Td; 3 HPV |

Figure 2-34: Sample Patient List, Adolescent Immunizations

2.5 Childhood Diseases Group

2.5.1 Appropriate Treatment for Children with Upper Respiratory Infection

Denominators

Active Clinical patients who were ages three months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first six months of the report period.

User Population patients who were ages three months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first six months of the report period.

Numerator

Patients who were *not* prescribed an antibiotic on or within three days after diagnosis. In this measure, appropriate treatment is *not* to receive an antibiotic.

Logic Description

Age is calculated as follows: Children three months as of six months (182 days) of the year prior to the Report Period to 18 years as of the first six months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

1. Patient's diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit. Upper Respiratory Infection defined as POV 460 or 465.*. Outpatient visit defined as Service Category A, S, or O.

2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
3. Patient's visit must only have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
5. The patient did not have an active prescription for antibiotics as of the URI visit date. "Active" prescription defined as:

Rx Days Supply greater than or equal to (\geq) (URI Visit Date–Prescription Date)

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or V Procedure 99.21. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceftibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol.) Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

Updated 6 months to be 182 days.

Patient List Description

List of patients three months to 18 years of age with upper respiratory infection, with antibiotic prescription, if any.

Measure Source

HEDIS

Measure Past Performance and Long-Term Targets

None

DU

November 25, 2012

Page 72

*** IHS 2012 Selected Measures with Community Specified Report ***

| DEMO INDIAN HOSPITAL | | | | | | | | |
|---|------------------|------|-------------------|------|-----------------------|----------------|------|--------------------|
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Appropriate Treatment for Children with Upper Respiratory Infection (con't) | | | | | | | | |
| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
| Active Clinical 3 months-18 yrs w/Upper Respiratory Infection | 38 | | 36 | | | 30 | | |
| # w/o Antibiotic Rx | 37 | 97.4 | 35 | 97.2 | +0.1 | 27 | 90.0 | +7.4 |
| User Pop 3 months-18 yrs w/Upper Respiratory Infection | 43 | | 38 | | | 35 | | |
| # w/o Antibiotic Rx | 42 | 97.7 | 37 | 97.4 | +0.3 | 32 | 91.4 | +6.2 |

Figure 2-35: Sample Report, Appropriate Treatment for Children with Upper Respiratory Infection

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
|--|--------|--|-----|-----|
| Appropriate Treatment for Children with Upper Respiratory Infection: List of patients 3 months to 18 years with upper respiratory infection, with antibiotic prescription, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1, PAMELA | 000001 | COMMUNITY #3 | F | 3 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT2, ALICIA | 000002 | COMMUNITY #3 | F | 7 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT3, JAMES | 000003 | COMMUNITY #3 | M | 0 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT4, HENRY | 000004 | COMMUNITY #3 | M | 12 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT25, HEATHER | 000025 | COMMUNITY #4 | F | 7 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT26, DYLAN | 000026 | COMMUNITY #4 | M | 3 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT27, CODY | 000027 | COMMUNITY #4 | M | 4 |
| UP, AC | | MEETS MEASURE | | |
| PATIENT28, KAREN | 000028 | COMMUNITY #5 | F | 0 |
| UP, AC | | antibiotic injection: 01/06/12 DOES NOT MEET MEASURE | | |

Figure 2-36: Sample Patient List, Appropriate Treatment for Children with Upper Respiratory Infection

2.5.2 Appropriate Testing for Children with Pharyngitis

Denominators

Active Clinical patients who were ages 2 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period six months (182 days) prior to the Report Period through the first six months of the Report Period.

User Population patients who were ages 2 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period six months (182 days) prior to the Report Period through the first six months of the Report Period.

Numerator

Patients who received a Group A strep test.

Logic Description

Age is calculated as follows: Children two years as of six months (182 days) of the year prior to the Report Period to 18 years as of the first six months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

1. Patient's diagnosis of pharyngitis must have occurred at an outpatient visit. Pharyngitis defined as POV 462, 463, or 034.0. Outpatient visit defined as Service Category A, S, or O.
2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with pharyngitis diagnosis.
3. Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.
4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
5. The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. "Active" prescription defined as:
6. Rx Days Supply greater than or equal to (\geq) (URI Visit Date - Prescription Date)
7. The patient filled a prescription for antibiotics on or within three days after the pharyngitis visit.

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or V Procedure 99.21. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Cefibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol.) Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, a patient must have received a Group A Streptococcus test within the seven-day period beginning three days prior through three days after the Pharyngitis visit date.

Group A Streptococcus test defined as: CPT 87430 (by enzyme immunoassay), 87650-87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test); site-populated taxonomy BGP GROUP A STREP TESTS; and LOINC taxonomy.

Key Logic Changes from CRS Version 12.0

1. Updated 6 months to be 182 days.
2. Added code 68954-7 to LOINC taxonomy for Group A Strep Test.

Patient List Description

List of patients 2 through 18 years of age with pharyngitis and a Group A Strep test, if any.

Measure Source

HEDIS

Measure Past Performance and Long-Term Targets

None

| | | | | | | |
|--|-------------------|---------|---|----------|---------|------------|
| DU | November 25, 2012 | | | | Page 75 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | |
| ----- | | | | | | |
| Appropriate Testing for Children with Pharyngitis (con't) | | | | | | |
| REPORT | % | PREV YR | % | CHG from | BASE | % CHG from |

| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
|---|--------|------|--------|------|-----------|--------|------|--------|
| Active Clinical 2-18 yrs w/ Pharyngitis and Antibiotic Rx | 10 | | 5 | | | 8 | | |
| # w/Group A Strep Test | 9 | 90.0 | 3 | 60.0 | +30.0 | 2 | 25.0 | +65.0 |
| User Pop 2-18 yrs w/ Pharyngitis and Antibiotic Rx | 11 | | 7 | | | 10 | | |
| # w/Group A Strep Test | 9 | 81.8 | 4 | 57.1 | +24.7 | 2 | 20.0 | +61.8 |

Figure 2-37: Sample Report, Appropriate Testing for Children with Pharyngitis

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
|--|--------|--------------------------------|-----|-------------------------|
| Appropriate Testing for Children with Pharyngitis: List of patients 2-18 years with pharyngitis and a Group A Strep test, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| PATIENT1,MICHAEL UP,AC | 000001 | COMMUNITY #1 03/19/12 RAPID | M | 9 ANTIGEN (STREP A) |
| PATIENT2,JOSEPH UP,AC | 000002 | COMMUNITY #1 05/01/12 RAPID | M | 12 ANTIGEN (STREP A) |
| PATIENT3,LESTER UP | 000003 | COMMUNITY #1 | M | 13 |
| PATIENT24,MONICA UP,AC | 000024 | COMMUNITY #2 01/23/12 RAPID | F | 5 ANTIGEN (STREP A) |
| PATIENT25,MICHAEL JAMES UP,AC | 000025 | COMMUNITY #2 03/12/12 RAPID | M | 7 ANTIGEN (STREP A) |

Figure 2-38: Sample Patient List, Appropriate Testing for Children with Pharyngitis

2.6 Cancer Related Measure Topics

2.6.1 Cancer Screening: Pap Smear Rates

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 59.5% for the proportion of female patients ages 21 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous three years.

Denominators

Female Active Clinical patients ages 21 through 64 without documented history of Hysterectomy. (GPRA Denominator)

Female User Population patients ages 21 through 64 without a documented history of Hysterectomy.

Numerators

Patients with a Pap smear documented in the past three years.

Note: This numerator does *not* include refusals. (GPRA Denominator)

Patients with documented Pap smear refusal in past year.

Logic Description

Age of the patient is calculated at the beginning of the report period. Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|--|--|-------------|----------|
| Hysterectomy | 51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135 | V Procedure: 68.4-68.8 V POV: 618.5, V88.01, V88.03 Women's Health: Procedure called Hysterectomy. | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|------------------------|--|--|-------------|-------------------|
| Pap Smear | 88141-88167, 88174-88175, G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 | V Lab: PAP SMEAR POV: V67.01 Follow-up Vaginal Pap Smear V76.2 Screen Mal Neop-Cervix V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only) V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients 795.0*, 795.10-16, 795.19 V Procedure: 91.46 Women's Health: Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD" | Yes | BGP PAP SMEAR TAX |
| Refusal (in past year) | Refusal of codes: 88141-88167, 88174-88175, G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 | Refusals: Lab Test Value Pap Smear | | |

Key Logic Changes from CRS Version 12.0

Added code 49034-2 to LOINC taxonomy for Pap Smear.

Patient List Description

List of women 21 through 64 with documented Pap Smear or refusal, if any.

Measure Source

HP 2020 C-15

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 58.1% |
| IHS FY 2010 Performance | 59.0% |
| IHS FY 2009 Performance | 59.0% |
| IHS FY 2008 Performance | 59.0% |
| IHS FY 2007 Performance | 59.0% |
| IHS FY 2006 Performance | 59.0% |
| IHS FY 2005 Performance | 60.0% |
| IHS FY 2004 Performance | 58.0% |
| IHS FY 2003 Performance | 61.0% |
| IHS FY 2002 Performance | 62.0% |
| <i>HP 2020 Goal</i> | <i>93.0%</i> |

Performance Improvement Tips

- Providers should ask about and record off-site tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should document refusals; write “Refused” in Pap Order box on PCC form. Data entry mnemonic: REF (Lab Test Value, Date Refused).

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|---------|----------|
| DU | November 25, 2012 | | | | | | Page 77 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Cancer Screening: Pap Smear Rates (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Female Active Clinical | | | | | | | | |
| 21-64 yrs (GPRA) | 500 | | 377 | | | 320 | | |
| # w/Pap Smear recorded | | | | | | | | |
| w/in 3 years-No Refusals | | | | | | | | |
| (GPRA) | 202 | 40.4 | 179 | 47.5 | -7.1 | 147 | 45.9 | -5.5 |
| # w/ Pap Smear | | | | | | | | |
| Refusal | 8 | 1.6 | 0 | 0.0 | +1.6 | 0 | 0.0 | +1.6 |
| # Female User Pop | | | | | | | | |
| 21-64 years | 833 | | 699 | | | 614 | | |
| # w/Pap Smear recorded | | | | | | | | |
| w/in 3 years | | | | | | | | |
| -No Refusals | 220 | 26.4 | 196 | 28.0 | -1.6 | 159 | 25.9 | +0.5 |
| # w/ Pap Smear | | | | | | | | |

| | | | | | | | | |
|---------|---|-----|---|-----|------|---|-----|------|
| Refusal | 8 | 1.0 | 0 | 0.0 | +1.0 | 0 | 0.0 | +1.0 |
|---------|---|-----|---|-----|------|---|-----|------|

Figure 2-39: Sample Report, Cancer Screening: Pap Smear Rates

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|------------------------|-----|--------|--|
| Cancer Screening: Pap Smear Rates: List of women 21-64 with documented Pap smear or refusal, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT1,EVELYN | 000001 | COMMUNITY #1 | F | 21 | |
| UP | | 05/05/11 POV | | 795.06 | |
| PATIENT2,MICHELLE | 000002 | COMMUNITY #1 | F | 22 | |
| UP,AC | | 05/31/12 Lab | | | |
| PATIENT3,KAITLYN | 000003 | COMMUNITY #1 | F | 22 | |
| UP,AC | | 04/03/12 POV | | V67.01 | |
| PATIENT4,BRITNEY | 000004 | COMMUNITY #1 | F | 22 | |
| UP,AC | | 01/10/12 POV | | V72.3 | |
| PATIENT5,KATY | 000005 | COMMUNITY #1 | F | 22 | |
| UP,AC | | 05/08/11 CPT | | 88150 | |

Figure 2-40: Sample Patient List, Cancer Screening: Pap Smear rates

2.6.2 Cancer Screening: Mammogram Rates

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 51.7% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last two years.

Denominators

Female Active Clinical patients ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRA Denominator)

Female Active Clinical patients ages 42 and older without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

Female User Population patients ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

Female User Population patients ages 42 and older without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRA Developmental Denominator)

Numerators

All patients who had a Mammogram documented in the past two years.

Note: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented mammogram refusal in the past year

Logic Description

Age of the patient is calculated at the beginning of the Report Period. For all denominators, patients must be at least the minimum age as of the beginning of the Report Period. For the 52 through 64 denominators, the patients must be less than 65 years of age as of the end of the Report Period.

| Subject Defined | CPT Codes | ICD and Other Codes |
|------------------------|--|--|
| Bilateral Mastectomy | 19300.50-19307.50 or old code 19180, 19200, 19220 OR 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) OR 19240, with modifier of 50 or 09950 | V Procedure: 85.42, 85.44, 85.46, 85.48 |
| Unilateral Mastectomy | Must have 2 separate occurrences on 2 different dates of service. 19300-19307, or old codes 19180, 19200, 19220, 19240 | Must have 2 separate occurrences on 2 different dates of service. 85.41, 85.43, 85.45, 85.47 |
| Mammogram | V Rad or VCPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202 | POV: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast V Procedure: 87.36-87.37 Women's Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD" |
| Refusal (in past year) | V Rad Mammogram for CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202 | |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of women 42+ with mammogram/refusal, if any.

Measure Source

HP 2020 C-17

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 49.8% |
| IHS FY 2010 Performance | 48.0% |
| IHS FY 2009 Performance | 45.0% |
| IHS FY 2008 Performance | 45.0% |
| IHS FY 2007 Performance | 43.0% |
| IHS FY 2006 Performance | 41.0% |
| IHS FY 2005 Performance | 41.0% |
| IHS FY 2004 Performance | 40.0% |
| IHS FY 2003 Performance | 40.0% |
| IHS FY 2002 Performance | 42.0% |
| <i>HP 2020 Goal</i> | <i>81.1%</i> |

Performance Improvement Tips

- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should document refusals; write “Refused” in Mammogram Order box on PCC form. Data entry mnemonic: REF (Mammogram, Procedure (CPT) Code, Date Refused).

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|------|----------|--|
| DU | November 25, 2012 | | | | | | | Page 79 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Cancer Screening: Mammogram Rates (con't) | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Female Active Clinical | | | | | | | | | |
| 52-64 (GPRA) | 97 | | 60 | | | 47 | | | |
| # w/Mammogram recorded w/in | | | | | | | | | |
| 2 years-No Refusals | | | | | | | | | |
| (GPRA) | 31 | 32.0 | 22 | 36.7 | -4.7 | 22 | 46.8 | -14.8 | |

| | | | | | | | | |
|---|-----|------|-----|------|-------|-----|------|-------|
| # w/ Mammogram Refusal | 7 | 7.2 | 0 | 0.0 | +7.2 | 0 | 0.0 | +7.2 |
| # Female Active Clinical 42+ (GPRA Dev.) | 293 | | 188 | | | 163 | | |
| # w/Mammogram recorded w/in 2 years-No Refusals (GPRA Dev.) | 63 | 21.5 | 62 | 33.0 | -11.5 | 54 | 33.1 | -11.6 |
| # w/ Mammogram Refusal | 9 | 3.1 | 0 | 0.0 | +3.1 | 0 | 0.0 | +3.1 |
| # Female User Pop 52-64 | 175 | | 122 | | | 102 | | |
| # w/Mammogram recorded w/in 2 years-No Refusals | 34 | 19.4 | 26 | 21.3 | -1.9 | 23 | 22.5 | -3.1 |
| # w/ Mammogram Refusal | 7 | 4.0 | 0 | 0.0 | +4.0 | 0 | 0.0 | +4.0 |
| # Female User Pop 42+ | 513 | | 380 | | | 333 | | |
| # w/Mammogram recorded w/in 2 years-No Refusals | 67 | 13.1 | 69 | 18.2 | -5.1 | 58 | 17.4 | -4.4 |
| # w/ Mammogram Refusal | 9 | 1.8 | 0 | 0.0 | +1.8 | 0 | 0.0 | +1.8 |

Figure 2-41: Sample Report, Cancer Screening: Mammogram rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Cancer Screening: Mammogram Rates: List of women 42+ with mammogram/refusal, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|------------------------------|--------|--|-----|-----|
| PATIENT1,CARLA UP,AC | 000001 | COMMUNITY #1 10/01/11 CPT 77052 | F | 43 |
| PATIENT2,CRYSTAL UP | 000002 | COMMUNITY #1 | F | 42 |
| PATIENT3,ALEXA UP,AC | 000003 | COMMUNITY #1 04/24/11 CPT 76090 | F | 45 |
| PATIENT4,HANNAH UP | 000004 | COMMUNITY #1 | F | 42 |
| PATIENT5,MARTHA UP | 000005 | COMMUNITY #1 | F | 43 |
| PATIENT6,TARA UP,AC | 000006 | COMMUNITY #1 01/15/12 Refused CPT G0206 | F | 44 |
| PATIENT7,CAROL LYNN UP,AC | 000007 | COMMUNITY #1 03/05/12 RAD 76092 | F | 44 |
| PATIENT8,MARY ANN UP,AC | 000008 | COMMUNITY #1 | F | 52 |

| | |
|-----------------------------|--|
| PATIENT9, BARBARA UP, AC | 000009 COMMUNITY #1 F 52 04/22/12 CPT 77057 |
|-----------------------------|--|

Figure 2-42: Sample Patient List, Cancer Screening: Mammogram rates

2.6.3 Colorectal Cancer Screening

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 43.2% for the proportion of clinically appropriate patients ages 51 through 80 who have received colorectal screening.

Denominators

All *Active Clinical patients* ages 51 through 80 without a documented diagnosis of colorectal cancer or total colectomy. Broken down by gender. (GPRA Denominator)

All *User Population patients* ages 51 through 80 without any documented diagnosis of colorectal cancer or total colectomy.

Numerators

Patients who have had any CRC screening, defined as any of the following: (1) Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report period; (2) flexible sigmoidoscopy or double contrast barium enema in the past five years; or (3) colonoscopy in the past 10 years.

| |
|---|
| <p>Note: This numerator does <i>not</i> include refusals. (GPRA Numerator)</p> |
|---|

Patients with documented CRC screening refusal in the past year.

Patients with FOBT or FIT during the Report Period.

Patients with a flexible sigmoidoscopy or double contrast barium enema in the past five years or a colonoscopy in the past 10 years.

Patients with a flexible sigmoidoscopy in the past five years or a colonoscopy in the past 10 years.

Patients with a flexible sigmoidoscopy and double contrast barium enema in the past five years or a colonoscopy in the past 10 years.

Logic Description

Age is calculated at the beginning of the Report Period.

Denominator Exclusions

Any diagnosis ever of one of the following:

1. **Colorectal Cancer:** POV: 153.*, 154.0, 154.1, 197.5, V10.05; CPT G0213–G0215 (old codes), G0231 (old code).
2. **Total Colectomy:** CPT 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210 through 44212; V Procedure 45.8 (old code).

Colorectal cancer screening definition: The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

Colorectal Cancer Screening (CRS looks for the most recent of any of the following during timeframes specified in numerator section above)

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|--|---|-------------|--------------------|
| Fecal Occult Blood lab test (FOBT) or Fecal Immuno-chemical Test (FIT) | 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code) | | Yes | BGP GPRA FOB TESTS |
| Flexible Sigmoidoscopy | 45330-45345, G0104 | V Procedure: 45.24 | | |
| Double contrast barium enema | VRad 74280, G0106, G0120 | | | |
| Colonoscopy | 44388 through 44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121 | V POV: V76.51 Colon screening V Procedure: 45.22, 45.23, 45.25, 45.42, 45.43 | | |

Refusal definition: Any of the following in the past year:

| Subject Defined | CPT Codes | ICD and Other Codes | Taxonomy |
|-----------------|---|--|-------------------------------|
| Refusals | FOBT or FIT: 82270, 82274, 89205 (old code), G0107 (old code), G0328, or G0394 (old code) Flexible Sigmoidoscopy: 45330-45345, G0104 DCBE: 74280, G0106, G0120 Colonoscopy: 44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121 | Flexible Sigmoidoscopy V Procedure: 45.24, 45.42 Colonoscopy V Procedure: 45.22, 45.23, 45.25, 45.42, 45.43 | V Lab Fecal Occult Blood Test |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients 51 through 80 with CRC screening or refusal, if any.

Measure Source

HEDIS, HP 2020 C-16

Measure Past Performance and Long-Term Targets:

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 41.7% |
| IHS FY 2010 Performance | 37.0% |
| IHS FY 2009 Performance | 33.0% |
| IHS FY 2008 Performance | 29.0% |
| IHS FY 2007 Performance | 26.0% |
| IHS FY 2006 Performance | 22.0% |
| <i>HP 2020 Goal</i> | <i>70.5%</i> |

Performance Improvement Tip

Providers should ask about and record off-site historical tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy). Providers should also enter as a refusal if the patient refuses the colorectal cancer screening. Refusals may be entered with the data entry mnemonic of REF (refusal).

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|---------|------|----------|--|
| DU | November 25, 2012 | | | | | Page 82 | | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Colorectal Cancer Screening (con't) | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| AC Pts 51-80 w/o colorectal cancer or total colectomy (GPRA) | 316 | | 195 | | | 152 | | | |
| # w/ CRC screening -No Refusals (GPRA) | 64 | 20.3 | 49 | 25.1 | -4.9 | 28 | 18.4 | +1.8 | |
| # w/ CRC Screening Refusal | 10 | 3.2 | 0 | 0.0 | +3.2 | 0 | 0.0 | +3.2 | |
| # w/FOBT/FIT during Report period | 12 | 3.8 | 11 | 5.6 | -1.8 | 0 | 0.0 | +3.8 | |
| # w/Flex Sig, DCBE, or Colonoscopy | 55 | 17.4 | 40 | 20.5 | -3.1 | 28 | 18.4 | -1.0 | |
| # w/Flex Sig or Colonoscopy | 49 | 15.5 | 31 | 15.9 | -0.4 | 20 | 13.2 | +2.3 | |
| # w/Flex Sig & DCBE or Colonoscopy | 46 | 14.6 | 29 | 14.9 | -0.3 | 18 | 11.8 | +2.7 | |
| Male Active Clinical 51-80 | 151 | | 93 | | | 65 | | | |
| # w/ CRC screening -No Refusals | 27 | 17.9 | 18 | 19.4 | -1.5 | 9 | 13.8 | +4.0 | |
| # w/ CRC Screening Refusal | 5 | 3.3 | 0 | 0.0 | +3.3 | 0 | 0.0 | +3.3 | |
| # w/FOBT/FIT during Report period | 7 | 4.6 | 3 | 3.2 | +1.4 | 0 | 0.0 | +4.6 | |
| # w/Flex Sig, DCBE, or Colonoscopy | 22 | 14.6 | 15 | 16.1 | -1.6 | 9 | 13.8 | +0.7 | |
| # w/Flex Sig or Colonoscopy | 20 | 13.2 | 14 | 15.1 | -1.8 | 8 | 12.3 | +0.9 | |
| # w/Flex Sig & DCBE or Colonoscopy | 20 | 13.2 | 14 | 15.1 | -1.8 | 8 | 12.3 | +0.9 | |

Figure 2-43: Sample Report, Colorectal Cancer Screening

| | | | | |
|--|-----|-----------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Colorectal Cancer Screening: List of patients 51-80 with CRC screening or refusal, if any. | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
| DENOMINATOR | | NUMERATOR | | |
| ----- | | | | |

| | | | | |
|---------------------|--------|----------------|------------|-----|
| PATIENT1,DANIELLE | 000001 | COMMUNITY #1 | F | 51 |
| UP | | FOB: 08/19/12 | CPT G0107 | |
| PATIENT2,MARIE | 000002 | COMMUNITY #1 | F | 51 |
| UP,AC | | COLO: 02/12/12 | Refused | CPT |
| PATIENT3,MARY ANN | 000003 | COMMUNITY #1 | F | 52 |
| UP,AC | | | | |
| PATIENT4,BOBBIE | 000004 | COMMUNITY #1 | F | 52 |
| UP,AC | | BE: 01/25/12 | RAD 74280 | |
| PATIENT5,WINONA | 000005 | COMMUNITY #1 | F | 53 |
| UP,AC | | | | |
| PATIENT6,DARLENE | 000006 | COMMUNITY #1 | F | 54 |
| UP,AC | | SIG: 04/07/09 | | |
| 45.24; BE: 03/31/10 | | RAD 74280 | | |
| PATIENT7,JOYCE | 000007 | COMMUNITY #1 | F | 57 |
| UP,AC | | COLO: 07/07/12 | POV V76.51 | |

Figure 2-44: Sample Patient List, Colorectal Cancer Screening

2.6.4 Comprehensive Cancer Screening

GPRA Measure Description

Increase the proportion of patients ages 21 through 80 who received a comprehensive cancer screening.

Denominators

Active Clinical patients ages 21 through 80 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening. (GPRA Developmental Denominator)

- Active Clinical female patients* ages 21 through 80.
- Active Clinical male patients* ages 51 through 80.

Numerators

Patients who have had all screenings for which they are eligible.

Note: This numerator does *not* include refusals. (GPRA Developmental Numerator)

- Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
- Male patients with colorectal cancer screening.

Logic Description

Age is calculated at the beginning of the Report Period.

Cervical Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 21 through 64 and not have a documented history of hysterectomy. Patients must be at least 21 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Pap Smear documented in the past three years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|--|---|-------------|-------------------|
| Hysterectomy | 51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135 | V Procedure: 68.4-68.8 V POV: 618.5, V88.01, V88.03 Women's Health: Procedure called Hysterectomy. | | |
| Pap Smear | 88141-88167, 88174-88175, G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 | V Lab: PAP SMEAR POV: V67.01 Follow-up Vaginal Pap Smear V76.2 Screen Mal Neop-Cervix V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only) V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients 795.0*, 795.10-16, 795.19 V Procedure: 91.46 Women's Health: Procedure called Pap Smear | Yes | BGP PAP SMEAR TAX |

Breast Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies. Patients must be at least age 52 as of the beginning of the Report Period and must be less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Mammogram documented in the past two years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

| Subject Defined | CPT Codes | ICD and Other Codes |
|-----------------------|--|---|
| Bilateral Mastectomy | 19300.50-19307.50 or old code 19180, 19200, 19220 OR 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) OR 19240, with modifier of 50 or 09950 | V Procedure: 85.42, 85.44, 85.46, 85.48 |
| Unilateral Mastectomy | Must have 2 separate occurrences on 2 different dates of service. 19300-19307, or old codes 19180, 19200, 19220, 19240 | Must have 2 separate occurrences on 2 different dates of service. 85.41, 85.43, 85.45, 85.47 |
| Mammogram | V Rad or VCPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202 | POV: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast V Procedure: 87.36-87.37 Women's Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD". |

Colorectal cancer screening definition: To be eligible for this screening, patients must be Active Clinical ages 51 through 80 and not have a documented history ever of colorectal cancer or total colectomy. To be counted as having the screening, patients must have had any of the following: (1) FOBT or FIT during the Report Period; (2) flexible sigmoidoscopy or double contrast barium enema in the past 5 years; or (3) colonoscopy in the past 10 years.

The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|---|---|-------------|--------------------|
| Colorectal Cancer | G0213 through G0215, G0231 | V POV: 153.*, 154.0, 154.1, 197.5, V10.05 | | |
| Total Colectomy | 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210-44212 | V Procedure: 45.8 (old code) | | |
| Fecal Occult Blood lab test (FOBT) or Fecal Immuno-chemical Test (FIT) | 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code) | | Yes | BGP GPRA FOB TESTS |
| Flexible Sigmoidoscopy | 45330 through 45345, G0104 | V Procedure: 45.24 | | |
| Double contrast barium enema | VRad 74280, G0106, G0120 | | | |
| Colonoscopy | 44388 through 44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121 | V POV: V76.51 Colon screening V Procedure: 45.22, 45.23, 45.25, 45.42, 45.43 | | |

Key Logic Changes from CRS Version 12.0

Added code 49034-2 to LOINC taxonomy for Pap Smear.

Patient List Description

List of patients 21 through 80 with comprehensive cancer screening, if any.

Measure Source

Not Available

Measure Past Performance and Long-Term Targets

None

Performance Improvement Tip

- Providers should ask about and record off-site Pap tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.

- Providers should ask about and record off-site historical colorectal cancer tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy).

DU

November 25, 2012

Page 87

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Comprehensive Cancer Screening

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|---|------------------|------|-------------------|------|-----------------------|----------------|------|--------------------|
| Active Clinical 21-80 (GPRA Dev.) | 721 | | 509 | | | 424 | | |
| # w/ Comprehensive Cancer Screening-No Refusals (GPRA Dev.) | 226 | 31.3 | 195 | 38.3 | -7.0 | 153 | 36.1 | -4.7 |
| A. Female 21-80 | 570 | | 416 | | | 359 | | |
| A. # Female w/all Screens | 199 | 34.9 | 177 | 42.5 | -7.6 | 144 | 40.1 | -5.2 |
| B. Male 51-80 | 151 | | 93 | | | 65 | | |
| B. # Male w/CRC Screen | 27 | 17.9 | 18 | 19.4 | -1.5 | 9 | 13.8 | +4.0 |

Figure 2-45: Sample Report, Comprehensive Cancer Screening

| | | | | | |
|--|--------|----------------|-----|--------|--|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
| Comprehensive Cancer Screening: List of patients 21-80 with comprehensive cancer screening, if any. | | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE | |
| DENOMINATOR | | NUMERATOR | | | |
| ----- | | | | | |
| PATIENT1,DANIELLE | 000001 | COMMUNITY #1 | F | 21 | |
| AC,PAP | | PAP: 05/05/11 | POV | 795.0 | |
| PATIENT2,MARIE | 000002 | COMMUNITY #1 | F | 51 | |
| AC,PAP | | | | | |
| PATIENT3,MARY ANN | 000003 | COMMUNITY #1 | F | 52 | |
| AC,MAM | | MAM: 07/06/11 | CPT | 77055 | |
| PATIENT4,BOBBIE | 000004 | COMMUNITY #1 | F | 53 | |
| AC,PAP,MAM,CRCS | | CRCS: 07/20/12 | POV | V76.51 | |
| PATIENT5,WINONA | 000005 | COMMUNITY #1 | F | 57 | |
| AC,PAP,MAM,CRCS | | MAM: 10/01/11 | CPT | 77052 | |

| | | | | |
|-----------------|--------|----------------|------|-------|
| PATIENT6 ,HARRY | 000006 | COMMUNITY #1 | M | 56 |
| AC,CRCS | | CRCS: 04/07/08 | Proc | 45.24 |
| PATIENT7 ,LARRY | 000007 | COMMUNITY #1 | M | 57 |
| AC,CRCS | | | | |
| PATIENT8 ,BARRY | 000008 | COMMUNITY #1 | M | 63 |
| AC,CRCS | | CRCS: 02/18/12 | CPT | 45330 |

Figure 2-46: Sample Patient List, Comprehensive Cancer Screening

2.6.5 Tobacco Use and Exposure Assessment

Denominators

Active Clinical patients ages five and older. Broken down by gender and age groups (5 through 13, 14 through 17, 18 through 24, 25 through 44, 45 through 64, and 65 and older), based on HP 2010 age groups.

All pregnant female User Population patients with no documented miscarriage or abortion.

All User Population patients ages five and older. Broken down by gender.

Numerators

Patients who have been screened for tobacco use during the Report Period.

Patients identified as current tobacco users during the Report Period, both smokers and smokeless users.

- a. Patients identified as current smokers during the Report Period.
- b. Patients identified as current smokeless tobacco users during the Report Period.

Patients identified as exposed to environmental tobacco smoke (ETS) (second-hand smoke) during the Report Period.

Logic Description

Ages are calculated at beginning of Report Period.

For screening, an additional eight months is included for patients who were pregnant during the Report Period but who had their tobacco assessment prior to that.

CRS uses the following codes to define the denominators and numerators:

| Subject Defined | CPT Codes | ICD and Other Codes |
|---|-----------------------------------|---|
| <p>Pregnancy (At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.) An additional 8 months is included for patients who were pregnant during the Report period but who had their tobacco assessment prior to that.</p> | | <p>V POV: 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53, 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09</p> |
| <p>Miscarriage (after second pregnancy POV in past 20 months)</p> | <p>59812, 59820, 59821, 59830</p> | <p>V POV: 630, 631, 632, 633*, 634*</p> |

| Subject Defined | CPT Codes | ICD and Other Codes |
|---|--|--|
| Abortion (after second pregnancy POV in past 20 months) | 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267 | V POV: 635*, 636* 637* Procedure: 69.01, 69.51, 74.91, 96.49 |
| Screened for Tobacco Use (time frame for pregnant patients is past 20 months) | D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8453 (old code), G8455-G8457 (old codes), G8402 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed) | V POV or current Active Problem List: 305.1, 305.1* (old codes), 649.00-649.04, V15.82 Patient Education codes: "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), or G8453 (old code) Dental code: 1320 |
| Tobacco Users (time frame for pregnant patients is past 20 months) | 99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code) | V POV or current Active Problem List: 305.1, 305.10-305.12 (old codes), or 649.00-649.04 Dental code: 1320 |
| Current Smokers (time frame for pregnant patients is past 20 months) | 99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), G8455 (old code), G8402 (old code), G8453 (old code) | V POV or current Active Problem List: 305.1, 305.10-305.12 (old codes), or 649.00-649.04 Dental code: 1320 |
| Current Smokeless (time frame for pregnant patients is past 20 months) | 1035F (Current Smokeless Tobacco User), G8456 (old code) | |

For numerator definitions, all existing national Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS-CHEWING/DIP), and TOBACCO (EXPOSURE) Health Factors are listed below with the numerator to which they apply.

| Health Factor | Numerator |
|--------------------------------|---|
| Ceremonial | Screened (does NOT count as Smoker) |
| Cessation-Smokeless | Screened; Tobacco Users; Smokeless User |
| Cessation-Smoker | Screened; Tobacco Users; Smoker |
| Current Smokeless | Screened; Tobacco Users; Smokeless User |
| Current Smoker | Screened; Tobacco Users; Smoker |
| Current Smoker, status unknown | Screened; Tobacco Users; Smoker |
| Current smoker, every day | Screened; Tobacco Users; Smoker |
| Current smoker, some day | Screened; Tobacco Users; Smoker |

| Health Factor | Numerator |
|---|---|
| Non-Tobacco User | Screened |
| Previous Smokeless | Screened |
| Previous (Former) Smokeless | Screened |
| Previous Smoker | Screened |
| Previous (Former) Smoker | Screened |
| Smoke Free Home | Screened |
| Smoker In Home | Screened; ETS |
| Current Smoker & Smokeless | Screened; Tobacco Users; Smoker; Smokeless User |
| Exposure To Environmental Tobacco Smoke | Screened; ETS |

Key Logic Changes from CRS Version 12.0

1. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
2. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).

Patient List Description

List of patients five and older with documented tobacco screening, if any.

Measure Source

HP 2020 TU-1.1 Cigarette smoking 18 and older; TU-1.2 Smokeless tobacco use 18 and older; TU-11 Exposure to ETS-nonsmokers three and older

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------------------|---------|
| IHS FY 2011 Performance (Screening) | 62.0% |
| IHS FY 2010 Performance (Screening) | 60.0% |
| IHS FY 2009 Performance (Screening) | 57.0% |
| IHS FY 2008 Performance (Screening) | 54.0% |
| IHS FY 2005 Performance (Screening) | 34.0% |
| IHS FY 2004 Performance (Screening) | 27.0% |

| Performance | Percent |
|---|---------|
| IHS FY 2008 Performance (Tobacco Users) | 29.0% |
| HP 2020 Goals: TU-1.1 (Cigarette smoking 18 and older): 12%; TU-1.2 (Smokeless tobacco use 18 and older): 0.3%; TU-11 (Exposure to ETS-non smokers 18 and older): 68% | |

| | | | | | | | | | |
|--|---------|-------------------|----------|---------|--------|-----------|--------|---------|----------|
| DU | | November 25, 2012 | | | | | | Page 90 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Tobacco Use and Exposure Assessment (con't) | | | | | | | | | |
| | | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| % | PREV YR | % | CHG from | BASE | % | CHG from | | | |
| | | PERIOD | PERIOD | PERIOD | PERIOD | PREV YR % | PERIOD | BASE % | |
| # Active Clinical Pts | | | | | | | | | |
| => 5 | | 1,357 | | 1,031 | | | 911 | | |
| # w/Tobacco | | | | | | | | | |
| Screening | | 624 | 46.0 | 426 | 41.3 | +4.7 | 328 | 36.0 | +10.0 |
| # Tobacco Users w/ % of | | | | | | | | | |
| Total Screened | | 294 | 47.1 | 165 | 38.7 | +8.4 | 130 | 39.6 | +7.5 |
| A. # Smokers w/ % of | | | | | | | | | |
| Total Tobacco Users | | 277 | 94.2 | 164 | 99.4 | -5.2 | 130 | 100.0 | -5.8 |
| B. # Smokeless Tobacco | | | | | | | | | |
| Users w/ % of Total | | | | | | | | | |
| Tobacco Users | | 29 | 9.9 | 5 | 3.0 | +6.8 | 3 | 2.3 | +7.6 |
| # exposed to ETS/ | | | | | | | | | |
| smoker in home w/ % of | | | | | | | | | |
| Total Screened | | 4 | 0.6 | 2 | 0.5 | +0.2 | 1 | 0.3 | +0.3 |
| # Male Active Clinical | | | | | | | | | |
| ages => 5 | | 570 | | 430 | | | 374 | | |
| # w/Tobacco | | | | | | | | | |
| Screening | | 230 | 40.4 | 152 | 35.3 | +5.0 | 128 | 34.2 | +6.1 |
| # Tobacco Users w/ % of | | | | | | | | | |
| Total Screened | | 136 | 59.1 | 69 | 45.4 | +13.7 | 59 | 46.1 | +13.0 |
| A. # Smokers w/ % of | | | | | | | | | |
| Total Tobacco Users | | 124 | 91.2 | 69 | 100.0 | -8.8 | 59 | 100.0 | -8.8 |
| B. # Smokeless Tobacco | | | | | | | | | |
| Users w/ % of Total | | | | | | | | | |
| Tobacco Users | | 22 | 16.2 | 2 | 2.9 | +13.3 | 3 | 5.1 | +11.1 |
| # exposed to ETS/ | | | | | | | | | |
| smoker in home w/ % of | | | | | | | | | |
| Total Screened | | 1 | 0.4 | 0 | 0.0 | +0.4 | 1 | 0.8 | -0.3 |
| # Female Active Clinical | | | | | | | | | |
| ages => 5 | | 787 | | 601 | | | 537 | | |
| # w/Tobacco | | | | | | | | | |
| Screening | | 394 | 50.1 | 274 | 45.6 | +4.5 | 200 | 37.2 | +12.8 |
| # Tobacco Users w/ % of | | | | | | | | | |
| Total Screened | | 158 | 40.1 | 96 | 35.0 | +5.1 | 71 | 35.5 | +4.6 |
| A. # Smokers w/ % of | | | | | | | | | |
| Total Tobacco Users | | 153 | 96.8 | 95 | 99.0 | -2.1 | 71 | 100.0 | -3.2 |

| | | | | | | | | |
|---|---|-----|---|-----|------|---|-----|------|
| B. # Smokeless Tobacco | | | | | | | | |
| Users w/ % of Total | | | | | | | | |
| Tobacco Users | 7 | 4.4 | 3 | 3.1 | +1.3 | 0 | 0.0 | +4.4 |
| # exposed to ETS/ smoker in home w/ % of | | | | | | | | |
| Total Screened | 3 | 0.8 | 2 | 0.7 | +0.0 | 0 | 0.0 | +0.8 |

Figure 2-47: Sample Report, Tobacco Use Assessment Tobacco Use and Exposure Assessment

| | | | | | | |
|--|----------------------------------|-------|-------|-------|-------|--------------|
| DU | November 25, 2012 | | | | | Page 95 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | |
| ----- | | | | | | |
| Tobacco Use and Exposure Assessment (con't) | | | | | | |
| | TOTAL ACTIVE CLINICAL POPULATION | | | | | |
| | Age Distribution | | | | | |
| | 5-13 | 14-17 | 18-24 | 25-44 | 45-64 | 65 and older |
| CURRENT REPORT PERIOD | | | | | | |
| # Active Clinical | 171 | 74 | 177 | 448 | 371 | 116 |
| # w/Tobacco Screening | 10 | 19 | 102 | 243 | 199 | 51 |
| % w/Tobacco Screening | 5.8 | 25.7 | 57.6 | 54.2 | 53.6 | 44.0 |
| | | | | | | |
| # Tobacco Users | 3 | 8 | 46 | 118 | 104 | 15 |
| % Tobacco Users w/ % of | | | | | | |
| Total Screened | 30.0 | 42.1 | 45.1 | 48.6 | 52.3 | 29.4 |
| | | | | | | |
| # Smokers | 2 | 8 | 43 | 108 | 102 | 14 |
| % Smokers w/ % of | | | | | | |
| Total Tobacco Users | 66.7 | 100.0 | 93.5 | 91.5 | 98.1 | 93.3 |
| | | | | | | |
| # Smokeless | 1 | 0 | 3 | 15 | 8 | 2 |
| % Smokeless w/ % of | | | | | | |
| Total Tobacco Users | 33.3 | 0.0 | 6.5 | 12.7 | 7.7 | 13.3 |
| | | | | | | |
| # ETS/Smk Home | 0 | 0 | 0 | 3 | 1 | 0 |
| % ETS/Smk Home w/ % of | | | | | | |
| Total Screened | 0.0 | 0.0 | 0.0 | 1.2 | 0.5 | 0.0 |
| PREVIOUS YEAR PERIOD | | | | | | |
| # Active Clinical | 176 | 62 | 168 | 323 | 238 | 64 |
| # w/Tobacco Screening | 11 | 14 | 87 | 147 | 128 | 39 |
| % w/Tobacco Screening | 6.3 | 22.6 | 51.8 | 45.5 | 53.8 | 60.9 |
| | | | | | | |
| # Tobacco Users | 0 | 5 | 41 | 60 | 50 | 9 |
| % Tobacco Users w/ % of | | | | | | |
| Total Screened | 0.0 | 35.7 | 47.1 | 40.8 | 39.1 | 23.1 |
| | | | | | | |
| # Smokers | 0 | 5 | 40 | 60 | 50 | 9 |
| % Smokers w/ % of | | | | | | |
| Total Tobacco Users | 0.0 | 100.0 | 97.6 | 100.0 | 100.0 | 100.0 |
| | | | | | | |
| # Smokeless | 0 | 0 | 1 | 3 | 1 | 0 |

| | | | | | | |
|--|-------|------|------|------|-------|-------|
| % Smokeless w/ % of Total Tobacco Users | 0.0 | 0.0 | 2.4 | 5.0 | 2.0 | 0.0 |
| # ETS/Smk Home | 0 | 0 | 0 | 2 | 0 | 0 |
| % ETS/Smk Home w/ % of Total Screened | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 | 0.0 |
| CHANGE FROM PREV YR % | | | | | | |
| # w/Tobacco Screening | -0.4 | +3.1 | +5.8 | +8.7 | -0.1 | -17.0 |
| Tobacco Users | +30.0 | +6.4 | -2.0 | +7.7 | +13.2 | +6.3 |
| Smokers | +66.7 | +0.0 | -4.1 | -8.5 | -1.9 | -6.7 |
| Smokeless | +33.3 | +0.0 | +4.1 | +7.7 | +5.7 | +13.3 |
| ETS | +0.0 | +0.0 | +0.0 | -0.1 | +0.5 | +0.0 |

Figure 2-48: Sample Age Breakdown Report, Tobacco Use Assessment

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
|--|--------|--|-----|-----|
| Tobacco Use and Exposure Assessment: List of patients 5 and older with documented tobacco screening, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| PATIENT1,CHESTER | 000001 | COMMUNITY #1 | M | 7 |
| UP,AC | | 01/10/12 SCREEN | | |
| PATIENT2,JUAN | 000002 | COMMUNITY #1 | M | 19 |
| UP | | | | |
| PATIENT3,BEN | 000003 | COMMUNITY #1 | M | 22 |
| UP | | | | |
| PATIENT4,MARY | 000004 | COMMUNITY #1 | F | 35 |
| UP,AC,PREG | | 04/10/12 SCREEN, 04/10/12 USER, 04/10/12 SMOKELESS | | |
| PATIENT5,HARRY B | 000005 | COMMUNITY #1 | M | 13 |
| UP | | 03/15/12 SCREEN | | |
| PATIENT6,EMERSON | 000006 | COMMUNITY #1 | M | 15 |
| UP,AC | | 05/21/12 SCREEN, 05/21/11 USER, 05/21/12 SMOKER, | | |
| 05/21/12 ETS | | | | |
| PATIENT7,EUGENE JAY | 000007 | COMMUNITY #1 | M | 29 |
| UP | | | | |
| PATIENT8,ROGER | 000008 | COMMUNITY #1 | M | 31 |
| UP,AC | | 01/21/12 SCREEN, 01/21/12 USER, 01/21/12 SMOKER | | |
| PATIENT9,ANDREW | 000009 | COMMUNITY #1 | M | 42 |
| UP | | | | |

Figure 2-49: Sample Patient List, Tobacco Use Assessment

2.6.6 Tobacco Cessation

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 30.0% for the proportion of tobacco-using patients who receive tobacco cessation intervention.

Denominators

Active Clinical patients identified as *current tobacco users* prior to the Report Period. Broken down by gender and age groups (less than (<)12, 12 through 17, 18 and older). (GPRA Denominator)

User Population patients identified as *current tobacco users* prior to the report period. Broken down by gender.

Numerators

Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid during the Report Period.

Note: This numerator does *not* include refusals. (GPRA Numerator)

Patients who refused tobacco cessation counseling during the Report Period.

Patients identified during the Report Period as having quit their tobacco use.

Patients who have received tobacco cessation counseling, received a prescription for a smoking cessation aid, or who quit their tobacco use during the Report Period.

Note: This numerator does *not* include refusals.

Logic Description

Age is calculated at the beginning of the Report Period.

| Subject Defined | ICD and Other Codes |
|---|--|
| Tobacco Users (documented prior to the Report Period) | <p>Tobacco Health Factors (looks at the last documented health factor in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS–CHEWING/DIP) categories): Current Smoker, Current Smokeless, Current Smoker and Smokeless, Cessation-Smoker, Cessation-Smokeless, Current Smoker, status unknown, Current smoker, every day, or Current smoker, some day</p> <p>CPT code (looks at the last documented): 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code) or G8453 (old code)</p> <p>V POV or current Active Problem List (looks at the last documented): 305.1, 305.10-305.12 (old codes), or 649.00-649.04</p> |

| Subject Defined | ICD and Other Codes |
|--|---|
| Tobacco Cessation Counseling (documented during the Report Period) | Patient education codes containing: "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 (old code) or G8453 (old code) Dental code: 1320 Clinic code: 94 (tobacco cessation clinic) CPT code: D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 (old code) or G8453 (old code) |
| Prescription for Tobacco Cessation Aid (documented during the Report Period) | Taxonomy: Medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy Medication Name: Any medication with name containing "NICOTINE PATCH", "NICOTINE POLACRILEX", "NICOTINE INHALER", or "NICOTINE NASAL SPRAY" CPT Code: 4001F |
| Quit Tobacco User (documented during the Report Period) | V POV or current Active Problem List: 305.13 Tobacco use in remission (old code) or V15.82 Health Factors documented during the Report Period (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (Former) Smoker, Previous (Former) Smokeless. |

Tobacco Cessation Counseling Refusal Definition

Documented refusal of patient education code containing "TO-", "-TO", or "-SHS" or CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 (old code) or G8453 (old code). Refusals will only be counted if a patient did not receive counseling or a prescription for tobacco cessation aid.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

Measure Source

Smoking Cessation Attempts: HP 2020 TU-4; Smoking Cessation Counseling: HP 2020 TU-10

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 29.4% |

| Performance | Percent |
|---|--------------|
| IHS FY 2010 Performance | 25.0% |
| IHS FY 2009 Performance | 24.0% |
| IHS FY 2008 Performance | 21.0% |
| IHS FY 2007 Performance | 16.0% |
| IHS FY 2006 Performance | 12.0% |
| <i>HP 2020 goal for increasing smoking cessation attempts for adult smokers</i> | <i>80.0%</i> |

| | | | | | | | | | |
|---|-------------------|------|---------|------|-----------|--------|------|----------|--|
| DU | November 25, 2012 | | | | | | | Page 101 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Tobacco Cessation (con't) | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical Tobacco Users (GPRA) | 301 | | 236 | | | 182 | | | |
| # w/tobacco cessation counseling or Rx for cessation-No Refusals (GPRA) | 54 | 17.9 | 46 | 19.5 | -1.6 | 48 | 26.4 | -8.4 | |
| # w/refusal of counseling | 8 | 2.7 | 0 | 0.0 | +2.7 | 0 | 0.0 | +2.7 | |
| # who quit | 13 | 4.3 | 3 | 1.3 | +3.0 | 1 | 0.5 | +3.8 | |
| # w/ cessation counseling, cessation aid, or quit -No Refusals | 66 | 21.9 | 48 | 20.3 | +1.6 | 49 | 26.9 | -5.0 | |
| Male Active Clinical Tobacco Users | 140 | | 117 | | | 94 | | | |
| # w/tobacco cessation counseling or RX for cessation-No Refusals | 29 | 20.7 | 20 | 17.1 | +3.6 | 25 | 26.6 | -5.9 | |
| # w/refusal of counseling | 2 | 1.4 | 0 | 0.0 | +1.4 | 0 | 0.0 | +1.4 | |
| # who quit | 5 | 3.6 | 1 | 0.9 | +2.7 | 1 | 1.1 | +2.5 | |
| # w/ cessation counseling, cessation aid, or quit -No Refusals | 34 | 24.3 | 21 | 17.9 | +6.3 | 26 | 27.7 | -3.4 | |
| Female Active Clinical Tobacco Users | 161 | | 119 | | | 88 | | | |
| # w/tobacco cessation counseling or RX for cessation-No Refusals | 25 | 15.5 | 26 | 21.8 | -6.3 | 23 | 26.1 | -10.6 | |
| # w/refusal of | | | | | | | | | |

| | | | | | | | | |
|--|----|------|----|------|------|----|------|------|
| counseling | 6 | 3.7 | 0 | 0.0 | +3.7 | 0 | 0.0 | +3.7 |
| # who quit | 8 | 5.0 | 2 | 1.7 | +3.3 | 0 | 0.0 | +5.0 |
| # w/ cessation counseling, cessation aid, or quit | | | | | | | | |
| -No Refusals | 32 | 19.9 | 27 | 22.7 | -2.8 | 23 | 26.1 | -6.3 |

Figure 2-50: Sample Report, Tobacco Cessation

| | | | |
|---|-----|-------|------|
| Tobacco Cessation (con't) | | | |
| ACTIVE CLINICAL TOBACCO USERS | | | |
| Age Distribution | | | |
| | <12 | 12-17 | =>18 |
| CURRENT REPORT PERIOD | | | |
| Active Clin Tobacco Users | 0 | 6 | 295 |
| # w/tobacco cessation counseling or Rx for cessation aid | | | |
| -No Refusals | 0 | 0 | 54 |
| % w/ tobacco cessation counseling or Rx for cessation aid | | | |
| -No Refusals | 0.0 | 0.0 | 18.3 |
| # w/refusal of counseling | 0 | 0 | 8 |
| % w/refusal of counseling | 0.0 | 0.0 | 2.7 |
| # who quit | 0 | 1 | 12 |
| % who quit | 0.0 | 16.7 | 4.1 |
| # w/tobacco cessation counseling, or Rx for cessation aid or quit | | | |
| -No Refusals | 0 | 1 | 65 |
| % w/ tobacco cessation counseling, or Rx for cessation aid or quit | | | |
| -No Refusals | 0.0 | 16.7 | 22. |
| PREVIOUS YEAR PERIOD | | | |
| Active Clin Tobacco Users | 1 | 4 | 231 |
| # w/tobacco cessation counseling or Rx for cessation aid | | | |
| -No Refusals | 0 | 0 | 46 |
| % w/tobacco cessation counseling or Rx for cessation aid | | | |
| -No Refusals | 0.0 | 0.0 | 19.9 |
| # w/refusal of counseling | 0 | 0 | 0 |
| % w/refusal of counseling | 0.0 | 0.0 | 0.0 |
| # who quit | 0 | 0 | 3 |
| % who quit | 0.0 | 0.0 | 1.3 |

| | | | |
|--|------|-------|------|
| # w/tobacco cessation counseling, Rx for cessation aid or quit | | | |
| -No Refusals | 0 | 0 | 48 |
| % w/ tobacco cessation counseling, Rx for cessation aid or quit | | | |
| -No Refusals | 0.0 | 0.0 | 20.8 |
| CHANGE FROM PREV YR % | | | |
| w/tobacco cessation counseling or Rx for cessation aid | | | |
| -No Refusals | +0.0 | +0.0 | -1.6 |
| w/refusal of counseling | +0.0 | +0.0 | +2.7 |
| who quit | +0.0 | +16.7 | +2.8 |
| w/tobacco cessation counseling, Rx for cessation aid or quit | | | |
| -No Refusals | +0.0 | +16.7 | +1.3 |

Figure 2-51: Sample Age Breakdown Report, Tobacco Cessation

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Tobacco Cessation: List of tobacco users with tobacco cessation intervention,
 if any, or who have quit tobacco use.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|---|-----|-----|
| PATIENT1,BRITNEY UP,AC | 000001 | COMMUNITY #1 COUNSEL/RX: 06/10/12 CPT G0375 | F | 22 |
| PATIENT2,LORETTA UP,AC | 000002 | COMMUNITY #1 COUNSEL/RX: 01/13/12 305.1-DP | F | 22 |
| PATIENT3,HALEY UP,AC | 000003 | COMMUNITY #1 COUNSEL/RX: 02/19/12 TO-LA | F | 25 |
| PATIENT4,ANGEL UP,AC | 000004 | COMMUNITY #1 COUNSEL/RX: 03/05/12 CPT 4000F | F | 30 |
| PATIENT5,JOYCE UP,AC | 000005 | COMMUNITY #1 QUIT: PREVIOUS (FORMER) SMOKER 05/31/12 | F | 31 |
| PATIENT6,ESTHER UP,AC | 000006 | COMMUNITY #1 COUNSEL/RX: 03/05/12 CESSATION MED - NICOTINE 14MG TRANSDERMAL PATCH | F | 32 |
| PATIENT7,SARAH UP,AC | 000007 | COMMUNITY #1 | F | 33 |
| PATIENT8,PAULA UP,AC | 000008 | COMMUNITY #1 COUNSEL/RX: 03/17/12 TO-QT | F | 34 |

Figure 2-52: Sample Patient List Tobacco Cessation

2.7 Behavioral Health Related Performance Measure Topics

2.7.1 Alcohol Screening (FAS Prevention)

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 58.7% for the proportion of female patients ages 15 to 44 who receive screening for alcohol use.

Denominators

Female Active Clinical patients ages 15 to 44. (GPRA Denominator)

Female User Population patients ages 15 to 44.

Numerators

Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, or received alcohol-related patient education during the report period.

Note: This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with alcohol screening during the report period.
- b. Patients with alcohol-related diagnosis or procedure during the report period
- c. Patients with alcohol-related patient education during the report period.
- d. Patients with documented alcohol screening refusal in past year.

Logic Description

Ages are calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

| Subject Defined | ICD and Other Codes |
|-------------------|---|
| Alcohol Screening | PCC Exam Code: 35 CPT code: 99408, 99409, G0396, G0397, H0049, H0050, 3016F Any CAGE Health Factor V POV: V11.3 (history of alcoholism), V79.1 (screening for alcoholism) BHS Problem Code: 29.1 (Screening for Alcoholism) V Measurement in PCC or BHS: AUDT, AUDC, or CRFT |

| Subject Defined | ICD and Other Codes |
|---------------------------|--|
| Alcohol-related Diagnosis | V POV, Current PCC or BHS Problem List: 303.*, 305.0*, 291.*, 357.5* BHS POV: 10, 27, 29 |
| Alcohol-related Procedure | V Procedure: 94.46, 94.53, 94.61-94.63, 94.67-94.69 |
| Alcohol-related Education | Patient Education codes: "AOD-" or "-AOD", "CD-" or "-CD" (old codes), or containing V11.3, V79.1, 303.*, 305.0*, 291.* 357.5*, 99408, 99409, G0396, G0397, H0049, or H0050, or 3016F |

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

Refusal definition: Refusal of PCC Exam Code 35 in the past year

Recommended Brief Screening Tool

Single Alcohol Screening Question (SASQ) (below).

For Women:

When was the last time you had more than four drinks in one day?

For Men:

When was the last time you had more than five drinks in one day?

Any time in the past three months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

Alcohol Health Factors

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

1. Have you ever felt the need to **C**ut down on your drinking?
2. Have people **A**nnoyed you by criticizing your drinking?
3. Have you ever felt bad or **G**uilty about your drinking?
4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?
5. Based on how many YES answers are received, document Health Factor:
 - HF-CAGE 0/4 (all "No" answers)

- HF-CAGE 1/4
- HF-CAGE 2/4
- HF-CAGE 3/4
- HF-CAGE 4/4

Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: # of drinks daily

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of female patients with documented alcohol screening or refusal, if any.

Measure Source

HP 2010 16–17a

Measure Past Performance and Long-term Targets

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 57.8% |
| IHS FY 2010 Performance | 55.0% |
| IHS FY 2009 Performance | 52.0% |
| IHS FY 2008 Performance | 47.0% |
| IHS FY 2007 Performance | 41.0% |
| IHS FY 2006 Performance | 28.0% |
| IHS FY 2005 Performance | 11.0% |
| IHS FY 2004 Performance | 7.0% |

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 114 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |
| Alcohol Screening (FAS Prevention) | | |
| | REPORT | % |
| | PERIOD | |
| | PREV YR | % |
| | PERIOD | |
| | CHG from | BASE |
| | PREV YR | % |
| | PERIOD | |
| | CHG from | BASE |
| | BASE | % |
| Female Active Clinical | | |

| | | | | | | | | |
|---|-----|------|-----|-----|-------|-----|-----|-------|
| ages 15-44 (GPRA) | 434 | | 348 | | | 304 | | |
| # w/ alcohol screening/ Dx/Proc/Pt Ed | | | | | | | | |
| -No Refusals (GPRA) | 50 | 11.5 | 2 | 0.6 | +10.9 | 1 | 0.3 | +11.2 |
| A. # w/alcohol screening | 43 | 9.9 | 1 | 0.3 | +9.6 | 0 | 0.0 | +9.9 |
| B. # w/alcohol related Dx or procedure | 3 | 0.7 | 1 | 0.3 | +0.4 | 1 | 0.3 | +0.4 |
| C. # w/alcohol related patient education | 10 | 2.3 | 0 | 0.0 | +2.3 | 0 | 0.0 | +2.3 |
| # w/alcohol screening refusal | 3 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| Female User Population ages 15-44 | 725 | | 636 | | | 588 | | |
| # w/ alcohol screening/Dx/ Proc/Pt Ed | | | | | | | | |
| -No Refusals | 54 | 7.4 | 2 | 0.3 | +7.1 | 2 | 0.3 | +7.1 |
| A. # w/alcohol screening | 46 | 6.3 | 1 | 0.2 | +6.2 | 0 | 0.0 | +6.3 |
| B. # w/alcohol related Dx or procedure | 4 | 0.6 | 1 | 0.2 | +0.4 | 2 | 0.3 | +0.2 |
| C. # w/alcohol related patient education | 11 | 1.5 | 0 | 0.0 | +1.5 | 0 | 0.0 | +1.5 |
| # w/alcohol screening refusal | 3 | 0.4 | 0 | 0.0 | +0.4 | 0 | 0.0 | +0.4 |

Figure 2-53: Sample Report, Alcohol Screening (FAS Prevention)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Alcohol Screening (FAS Prevention): List of female patients with documented alcohol screening or refusal, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|--------------------------------|-----|-----|
| PATIENT1,CHRISTINE S | 000001 | COMMUNITY #1 | F | 15 |
| UP | | | | |
| PATIENT2,RITA A | 000002 | COMMUNITY #1 | F | 15 |
| UP,AC | | SCREEN: 03/06/12 | | |
| POV V11.3 | | | | |
| PATIENT3,DIANE L | 000003 | COMMUNITY #1 | F | 15 |
| UP | | SCREEN: 02/02/12 Refused Ex 35 | | |
| PATIENT4,ALICIA | 000004 | COMMUNITY #1 | F | 15 |
| UP,AC | | | | |
| PATIENT5,MELISSA | 000005 | COMMUNITY #1 | F | 16 |
| UP,AC | | PT ED: 02/13/12 99408-P | | |
| PATIENT6,LISA MARIE | 000006 | COMMUNITY #1 | F | 16 |
| UP,AC | | SCREEN: 10/13/12 HF CAGE 1/4 | | |
| PATIENT7,RUTH NELLIE | 000007 | COMMUNITY #1 | F | 16 |
| UP | | | | |
| PATIENT8,ALISHA DAWN | 000008 | COMMUNITY #1 | F | 16 |

UP, AC

SCREEN: 03/03/12 CPT 3016F

Figure 2-54: Sample Patient List, Alcohol Screening (FAS Prevention)

2.7.2 Alcohol Screening and Brief Intervention (ASBI) in the ER

Denominators

Number of visits for *Active Clinical Plus BH patients* age 15 through 34 seen in the ER for injury during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *Active Clinical Plus BH patients* age 15 through 34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *User Population patients* age 15 through 34 seen in the ER for injury during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *User Population patients* age 15 through 34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Numerators

Number of visits where patients were screened in the ER for hazardous alcohol use.

- a. Number of visits where patients were screened positive.

Number of visits where patients were provided a brief negotiated interview (BNI) at or within seven days of the ER visit.

- a. Number of visits where patients were provided a BNI at the ER visit.
- b. Number of visits where patients were provided a BNI not at the ER visit but within 7 days of the ER visit.

Logic Description

Age of the patient is calculated as of the beginning of the Report Period.

Emergency room visit definition: Clinic Code 30.

Multiple visits definition: If a patient has multiple ER visits for injury during the Report Period, each visit will be counted in the denominator. For the screening numerator, each ER visit with injury at which the patient was screened for hazardous alcohol use will be counted. For the positive alcohol use screen numerator, each ER visit with injury at which the patient screened positive for hazardous alcohol use will be counted. For the BNI numerators, each visit where the patient was either provided a BNI at the ER or within seven days of the ER visit will be counted. An example of this logic is shown below.

| ER Visit w/Injury | Denom Count | Scrn Num | Pos Scrn Num Count | BNI Num Count |
|--|----------------|-------------|-----------------------|------------------|
| ***** | | | | |
| John Doe, 07/17/09, Screened Positive at ER, BNI at ER | | | | |
| John Doe, 09/01/09, Screened Positive at ER, No BNI | | | | |
| John Doe, 11/15/09, No Screen | | | | |
| ***** | | | | |
| COUNTS: | 3 | 2 | 2 | 1 |

CRS uses the following codes:

| Subject Defined | ICD and Other Codes |
|---|---|
| Injury | V POV (primary or secondary): 800.0–999.9 or E800.0–E989. |
| ER Screening for Hazardous Alcohol Use | <p><i>Any conducted during an ER visit:</i></p> <p>PCC Exam Code: 35</p> <p>Any Alcohol Health Factor (i.e., CAGE)</p> <p>V POV: V79.1 Screening for Alcoholism</p> <p>CPT: G0396, G0397, H0049, 99408, 99409, 3016F</p> <p>V Measurement in PCC: AUDT, AUDC, or CRFT</p> |
| Positive Screen for Hazardous Alcohol Use | <p><i>Any of the following for the screening conducted during an ER visit:</i></p> <p>PCC Exam Code: 35 Alcohol Screening result of “Positive”</p> <p>Health Factor: CAGE result of 1/4, 2/4, 3/4 or 4/4</p> <p>CPT: G0396, G0397, 99408, 99409</p> <p>V Measurement Result in PCC: AUDT result of equal to or greater than (=>) 8, AUDC result of equal to or greater than (=>) 4 for men and equal to or greater than (=>) 3 for women, CRFT result of 2-6</p> |
| BNI | <p><i>Any of the following documented at the ER visit or within seven days of the ER visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:</i></p> <p>CPT: G0396, G0397, H0050, 99408, 99409</p> <p>Patient Education Code: AOD-BNI or containing G0396, G0397, H0050, 99408, or 99409</p> |

Recommended Brief Screening Tool

SASQ (below).

For Women:

When was the last time you had more than four drinks in one day?

For Men:

When was the last time you had more than five drinks in one day?

Any time in the past three months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

Alcohol Health Factors

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

1. Have you ever felt the need to **C**ut down on your drinking?
2. Have people **A**nnoyed you by criticizing your drinking?
3. Have you ever felt bad or **G**uilty about your drinking?
4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?

Based on how many YES answers are received, document Health Factor:

- HF-CAGE 0/4 (all No answers)
- HF-CAGE 1/4
- HF-CAGE 2/4
- HF-CAGE 3/4
- HF-CAGE 4/4

Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: number of drinks daily

Key Logic Changes from CRS Version 12.0

Changed denominator to Active Clinical Plus Behavioral Health.

Patient List Description

List of visits for patients seen in the ER for an injury, with screening for hazardous alcohol use, results of screen and BNI, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 117 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Alcohol Screening and Brief Intervention (ASBI) in the ER | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| # ER Injury Visits for AC+BH Pts 15-34 | 34 | | 34 | | | 32 | | | |
| # Visits w/ ER Hazardous Alcohol Screening | 20 | 58.8 | 0 | 0.0 | +58.8 | 0 | 0.0 | +58.8 | |
| A. # Visits w/Positive Screen | 15 | 44.1 | 0 | 0.0 | +44.1 | 0 | 0.0 | +44.1 | |
| # ER Injury Visits for Male AC+BH Pts 15-34 | 13 | | 19 | | | 20 | | | |
| # Visits w/ ER Hazardous Alcohol Screening | 8 | 61.5 | 0 | 0.0 | +61.5 | 0 | 0.0 | +61.5 | |
| A. # Visits w/Positive Screen | 5 | 38.5 | 0 | 0.0 | +38.5 | 0 | 0.0 | +38.5 | |
| # ER Injury Visits for Female AC+BH Pts 15-34 | 21 | | 15 | | | 12 | | | |
| # Visits w/ ER Hazardous Alcohol Screening | 12 | 57.1 | 0 | 0.0 | +57.1 | 0 | 0.0 | +57.1 | |
| A. # Visits w/Positive Screen | 10 | 47.6 | 0 | 0.0 | +47.6 | 0 | 0.0 | +47.6 | |
| # of ER Injury Visits for AC+BH Pts 15-24 | 18 | | 16 | | | 21 | | | |
| # Visits w/ ER Hazardous Alcohol Screening | 11 | 61.1 | 0 | 0.0 | +61.1 | 0 | 0.0 | +61.1 | |
| A. # Visits w/Positive Screen | 9 | 50.0 | 0 | 0.0 | +50.0 | 0 | 0.0 | +50.0 | |
| # ER Injury Visit for | | | | | | | | | |

| | | | |
|---|--------|-------------|-------------|
| AC+BH Pts 25-34 | 16 | 18 | 11 |
| # Visits w/ ER Hazardous Alcohol Screening | 9 56.3 | 0 0.0 +56.3 | 0 0.0 +56.3 |
| A. # Visits w/Positive Screen | 6 37.5 | 0 0.0 +37.5 | 0 0.0 +37.5 |

Figure 2-55: Sample Report, Alcohol Screening and Brief Intervention (ASBI) in the ER

| | | | | |
|--|-------------|------------------------|---------------|------------------------------|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Alcohol Screening and Brief Intervention (ASBI) in the ER: List of visits for patients seen in the ER for an injury, with screening for hazardous alcohol use, results of screen and BNI, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,DARLENE S | 000001 | COMMUNITY #1 | F | 33 |
| UP,AC+BH | ER 1) | 02/02/12 | POV 816.02, | SCREEN: Neg/No Res CPT 3016F |
| PATIENT2,RITA A | 000002 | COMMUNITY #1 | F | 33 |
| UP,AC+BH | ER 1) | 07/12/12 | POV 875.0, | SCREEN: Pos Ex 35, BNI: No |
| PATIENT3,DIANE L | 000003 | COMMUNITY #1 | F | 15 |
| UP,AC+BH | ER 1) | 09/08/12 | POV 815.00, | SCREEN: None |
| PATIENT4,ALICIA | 000004 | COMMUNITY #1 | F | 18 |
| UP | ER 1) | 04/20/12 | POV 959.7, | SCREEN: Neg/No Res CPT H0049 |
| PATIENT5,MELISSA | 000005 | COMMUNITY #1 | F | 16 |
| UP,AC+BH | | | | |
| PATIENT6,LISA MARIE | 000006 | COMMUNITY #1 | F | 20 |
| UP | ER 1) | 12/16/12 | POV 873.42, | SCREEN: None; ER 2) 12/18/12 |
| | POV 800.10, | SCREEN: Pos Ex 35, | BNI: 12/18/12 | Yes ER AOD-BNI |

Figure 2-56: Sample Patient List, Alcohol Screening and Brief Intervention (ASBI) in the ER

2.7.3 Intimate Partner (Domestic) Violence Screening

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 55.3% for the proportion of female patients ages 15 to 40 who receive screening for domestic violence.

Denominators

Female Active Clinical patients ages 13 and older.

Female Active Clinical patients ages 15 through 40. (GPRA Denominator)

Female User Population patients ages 13 and older.

Numerators

Patients screened for intimate partner (domestic) violence at any time during the Report Period.

Note: This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with documented IPV/DV exam
- b. Patients with IPV/DV related diagnosis
- c. Patients provided with education or counseling about IPV/DV
- d. Patients with documented refusal in past year of an IPV/DV exam or IPV/DV-related education.

Logic Description

Age of the patient is calculated at the beginning of the report period. CRS uses the following codes to define numerators.

| Subject Defined | CPT Codes | ICD and Other Codes |
|-------------------|-----------|--|
| IPV/DV Screening | | V Exam: Code 34 BHS Exam: IPV/DV |
| IPV/DV Diagnosis | | V POV or current PCC or BHS Problem List: 995.80-995.83, 995.85, V15.41, V15.42, V15.49 BHS POV: 43.*, 44.* |
| IPV/DV Education | | Patient education codes: "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, or V15.49 |
| IPV/DV Counseling | | V POV: V61.11 |
| Refusals | | V Exam: Code 34 BHS IPV/DV exam Patient education codes containing "DV-" or "-DV" |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of female patients 13 and older with documented IPV/DV screening or refusal, if any.

Measure Source

HP 2010 15–34

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 55.3% |
| IHS FY 2010 Performance | 53.0% |
| IHS FY 2009 Performance | 48.0% |
| IHS FY 2008 Performance | 42.0% |
| IHS FY 2007 Performance | 36.0% |
| IHS FY 2006 Performance | 28.0% |
| IHS FY 2005 Performance | 13.0% |
| IHS FY 2004 Performance | 4.0% |

| | | | | | | | | | |
|--|-------------------|-----|---------|-----|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 128 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Intimate Partner (Domestic) Violence Screening (con't) | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| # Female Active | | | | | | | | | |
| Clinical ages | | | | | | | | | |
| 13 and older | 712 | | 519 | | | 460 | | | |
| # w/IPV/DV | | | | | | | | | |
| Screening | | | | | | | | | |
| -No Refusals | 13 | 1.8 | 1 | 0.2 | +1.6 | 0 | 0.0 | +1.8 | |
| A. # w/documented | | | | | | | | | |
| IPV/DV exam | 8 | 1.1 | 0 | 0.0 | +1.1 | 0 | 0.0 | +1.1 | |
| B. # w/ IPV/DV related | | | | | | | | | |
| diagnosis | 4 | 0.6 | 0 | 0.0 | +0.6 | 0 | 0.0 | +0.6 | |
| C. # provided DV | | | | | | | | | |
| education | 4 | 0.6 | 1 | 0.2 | +0.4 | 0 | 0.0 | +0.6 | |
| # w/ IPV/DV | | | | | | | | | |
| refusal | 3 | 0.4 | 0 | 0.0 | +0.4 | 0 | 0.0 | +0.4 | |
| # Female Active | | | | | | | | | |
| Clinical ages 15-40 | | | | | | | | | |
| (GPRA) | 380 | | 311 | | | 267 | | | |
| # w/IPV/DV screening | | | | | | | | | |
| -No Refusals | | | | | | | | | |
| (GPRA) | 11 | 2.9 | 1 | 0.3 | +2.6 | 0 | 0.0 | +2.9 | |
| A. # w/ documented | | | | | | | | | |
| IPV/DV exam | 6 | 1.6 | 0 | 0.0 | +1.6 | 0 | 0.0 | +1.6 | |
| B. # w/ IPV/DV related | | | | | | | | | |
| diagnosis | 3 | 0.8 | 0 | 0.0 | +0.8 | 0 | 0.0 | +0.8 | |
| C. # provided DV | | | | | | | | | |
| education | 4 | 1.1 | 1 | 0.3 | +0.7 | 0 | 0.0 | +1.1 | |

| | | | | | | | | |
|-----------------------------------|-------|-----|-------|-----|------|-----|-----|------|
| # w/ IPV/DV refusal | 2 | 0.5 | 0 | 0.0 | +0.5 | 0 | 0.0 | +0.5 |
| # Female User Pop 13 and older | 1,218 | | 1,005 | | | 917 | | |
| # w/IPV/DV Screening -No Refusals | 13 | 1.1 | 1 | 0.1 | +1.0 | 1 | 0.1 | +1.0 |
| A. # w/ documented IPV/DV exam | 8 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| B. # w/ IPV/DV related diagnosis | 4 | 0.3 | 0 | 0.0 | +0.3 | 1 | 0.1 | +0.2 |
| C. # provided DV education | 4 | 0.3 | 1 | 0.1 | +0.2 | 0 | 0.0 | +0.3 |
| # w/ IPV/DV refusal | 3 | 0.2 | 0 | 0.0 | +0.2 | 0 | 0.0 | +0.2 |

Figure 2-57: Sample Report, Intimate Partner (Domestic) Violence Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Intimate Partner (Domestic) Violence Screening: List of female patients 13 and older with documented IPV/DV screening or refusal, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|-----|-----|
| PATIENT1,ELVIRA | 000001 | COMMUNITY #1 | F | 13 |
| UP | | 03/18/12 Refused Ex | | 34 |
| PATIENT2,SHARON KAY | 000002 | COMMUNITY #1 | F | 14 |
| UP | | | | |
| PATIENT3,KRISTINA | 000003 | COMMUNITY #1 | F | 15 |
| UP | | | | |
| PATIENT4,RITA | 000004 | COMMUNITY #1 | F | 15 |
| UP,AC | | EXAM: 05/06/12 Ex | | 34 |
| PATIENT5,DIANE LOUISE | 000005 | COMMUNITY #1 | F | 15 |
| UP | | EXAM: 02/24/12 Ex | | 34 |
| PATIENT6,ALICE LILA | 000006 | COMMUNITY #1 | F | 15 |
| UP,AC | | | | |

Figure 2-58: Sample Patient List, Intimate Partner (Domestic) Violence Screening

2.7.4 Depression Screening

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 56.5% for the proportion of adults ages 18 and older who receive annual screening for depression.

Denominators

Active Clinical patients ages 18 and older. Broken down by gender. (GPRA Denominator)

- a. *Active Clinical patients* ages 65 and older. Broken down by gender.

User Population patients ages 18 and older. Broken down by gender.

- b. *User Population patients* ages 65 and older. Broken down by gender.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever. Broken down by gender.

Active IHD patients, defined as all Active Clinical patients diagnosed with ischemic heart disease (IHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two IHD-related visits ever. Broken down by gender.

Numerators

Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

Note: This numerator does not include refusals. (GPRA Numerator)

- a. Patients screened for depression during the Report Period.
- b. Patients with a diagnosis of a mood disorder during the Report Period.
- c. Patients with documented depression screening refusal in past year.
- d. Patients with depression-related education or refusal of education in past year.

Note: Depression-related patient education does not count toward the GPRA numerator and is included as a separate numerator only.

Logic Description

Age is calculated at beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | ICD and Other Codes |
|------------------------|--|
| Diabetes | V POV: 250.00–250.93 |
| Ischemic Heart Disease | V POV: 410.0–412.*, 414.0–414.9, 429.2 |

| Subject Defined | ICD and Other Codes |
|--|--|
| Depression Screening | V Exam: Exam Code 36 V POV: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) V Measurement in PCC or BHS: PHQ2 or PHQ9 |
| Mood Disorders | At least 2 visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. V POV: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 BHS POV: 14, 15 |
| Depression-related Patient Education (does not count toward GPRA numerator) | <i>Documented education of any of the following during the Report Period:</i> Patient education codes: containing "DEP-" (depression), 296.2* or 296.3*, "BH-" (behavioral and social health), 290319, 995.5*, or 995.80–995.85, "SB-" (suicidal behavior) or 300.9, or "PDEP-" (postpartum depression) or 648.44. |
| Screening Refusals | V Exam: Exam Code 36, in past year |
| Refusal of Depression-related Patient Education (does not count toward GPRA numerator) | <i>Documented refusal of any of the following during the Report Period:</i> Patient education codes: containing "DEP-" (depression), "BH-" (behavioral and social health), "SB-" (suicidal behavior), or "PDEP-" (postpartum depression). |

Recommended Brief Screening Tool

A sample of a Patient Health Questionnaire (PHQ-2 Scaled Version) appears below.

Over the past two weeks, how often have you been bothered by any of the following problems?

1. Little interest or pleasure in doing things
 - Not at all Value: 0
 - Several days Value: 1
 - More than half the days Value: 2
 - Nearly every day Value: 3
2. Feeling down, depressed, or hopeless
 - Not at all Value: 0
 - Several days Value: 1
 - More than half the days Value: 2

- Nearly every day Value: 3

Total Possible PHQ-2 Score: Range: 0–6

0–2: Negative

3–6: Positive; further evaluation indicated

Provider should note the screening tool used was the PHQ-2 Scaled in the COMMENT section of the Exam Code.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with documented depression screening or refusal/diagnosed with mood disorder, if any.

Measure Source

USPSTF (US Preventive Services Task Force), HP 2010 developmental indicator 18 through 6.

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|---------|
| IHS FY 2011 Performance | 56.5% |
| IHS FY 2010 Performance | 52.0% |
| IHS FY 2009 Performance | 44.0% |
| IHS FY 2008 Performance | 35.0% |
| IHS FY 2007 Performance | 24.0% |
| IHS FY 2006 Performance | 15.0% |

| | | | | | | | |
|--|-------------------|---|---------|---|----------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 130 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Depression Screening (con't) | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % |
| | PERIOD | | PERIOD | | PREV YR | % PERIOD | CHG from |
| | | | | | | | BASE % |
| Active Clinical Pts | | | | | | | |
| =>18 (GPRA) | 1,112 | | 793 | | | 666 | |
| # w/Depression screening | | | | | | | |

| | | | | | | | | |
|---|-----|-----|-----|-----|------|-----|-----|------|
| or Mood Disorder DX-No Refusals (GPRA) | 81 | 7.3 | 42 | 5.3 | +2.0 | 17 | 2.6 | +4.7 |
| A. # screened for depression | 39 | 3.5 | 0 | 0.0 | +3.5 | 0 | 0.0 | +3.5 |
| B. # w/mood disorder DX | 43 | 3.9 | 42 | 5.3 | -1.4 | 17 | 2.6 | +1.3 |
| # w/depression screening refusal | 5 | 0.4 | 0 | 0.0 | +0.4 | 0 | 0.0 | +0.4 |
| # w/depression education or refusal | 11 | 1.0 | 3 | 0.4 | +0.6 | 0 | 0.0 | +1.0 |
| Male Active Clinical Pts >=18 | 448 | | 308 | | | 250 | | |
| # w/ Depression screening or Mood Disorder DX-No Refusals | 25 | 5.6 | 7 | 2.3 | +3.3 | 1 | 0.4 | +5.2 |
| A. # screened for depression | 14 | 3.1 | 0 | 0.0 | +3.1 | 0 | 0.0 | +3.1 |
| B. # w/Mood Disorder DX | 11 | 2.5 | 7 | 2.3 | +0.2 | 1 | 0.4 | +2.1 |
| # with depression screening refusal | 3 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| # w/depression education or refusal | 3 | 0.7 | 1 | 0.3 | +0.3 | 0 | 0.0 | +0.7 |
| Female Active Clinical Pts >=18 | 664 | | 485 | | | 416 | | |
| # w/ Depression screening or Mood Disorder DX-No Refusals | 56 | 8.4 | 35 | 7.2 | +1.2 | 16 | 3.8 | +4.6 |
| A. # screened for depression | 25 | 3.8 | 0 | 0.0 | +3.8 | 0 | 0.0 | +3.8 |
| B. # w/Mood Disorder DX | 32 | 4.8 | 35 | 7.2 | -2.4 | 16 | 3.8 | +1.0 |
| # with depression screening refusal | 2 | 0.3 | 0 | 0.0 | +0.3 | 0 | 0.0 | +0.3 |
| # w/depression education or refusal | 8 | 1.2 | 2 | 0.4 | +0.8 | 0 | 0.0 | +1.2 |
| A. Active Clinical Pts => 65 | 116 | | 64 | | | 65 | | |
| # w/ Depression screening or Mood Disorder DX-No Refusals | 9 | 7.8 | 6 | 9.4 | -1.6 | 2 | 3.1 | +4.7 |
| A. # screened for depression | 3 | 2.6 | 0 | 0.0 | +2.6 | 0 | 0.0 | +2.6 |
| B. # w/mood disorder DX | 6 | 5.2 | 6 | 9.4 | -4.2 | 2 | 3.1 | +2.1 |
| # with depression screening refusal | 1 | 0.9 | 0 | 0.0 | +0.9 | 0 | 0.0 | +0.9 |
| # w/depression education or refusal | 2 | 1.7 | 2 | 3.1 | -1.4 | 0 | 0.0 | +1.7 |

Figure 2-59: Sample Report, Depression Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Depression Screening: List of patients with documented depression screening or refusal/diagnosed with mood disorder, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|--|--------|--|-----|-----|
| PATIENT55, LORETTA LYNN UP | 000055 | COMMUNITY #1 | F | 78 |
| PATIENT56, TINA MARIE UP, AC, AD, IHD | 000056 | COMMUNITY #1 SCREEN: 05/22/12 Meas PHQ9 | F | 78 |
| PATIENT57, DANIELLE UP, AC | 000057 | COMMUNITY #1 PT ED: 02/06/12 296.20-DP | F | 79 |
| PATIENT58, LESLIE ANN UP, AC | 000058 | COMMUNITY #1 SCREEN: 04/15/12 POV V79.0 | F | 80 |
| PATIENT59, DONNA SUE UP, AC | 000059 | COMMUNITY #1 SCREEN: 01/15/12 POV V79.0 | F | 86 |
| PATIENT60, TAYLOR OLIVIA UP, AC | 000060 | COMMUNITY #1 | F | 87 |
| PATIENT61, DENNIS GERALD UP | 000061 | COMMUNITY #1 PT ED: 02/01/12 296.20-DP | M | 18 |
| PATIENT62, JOSHUA DALE UP, AC | 000062 | COMMUNITY #1 | M | 18 |

Figure 2-60: Sample Patient List, Depression Screening

2.7.5 Antidepressant Medication Management

Denominators

As of the 120th day of the Report Period, *Active Clinical Plus BH patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

As of the 120th day of the Report Period, *User Population patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

Numerators

Optimal Practitioner Contacts: Patients with at least three mental health visits with a non-mental health or mental health provider within 12 weeks (84 days) after diagnosis, two of which must be face-to-face visits and one of which must be with a prescribing provider.

Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).

Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).

Logic Description

Age is calculated at the beginning of the report period. To be included in the denominator, patient must meet *both* of the following conditions:

1. One of the following from the 121st day of the year prior to the Report Period to the 120th day of the Report Period:
 - a. One visit in any setting with major depression DX (see list of codes below) as primary POV.
 - b. Two outpatient visits occurring on different dates of service with secondary POV of major depression.
 - c. An inpatient visit with secondary POV of major depression.

For example, if Report Period is July 1, 2011 through June 30, 2012, the patient must have one of the three scenarios above during 11/1/2010 through 10/29/2011.

Major depression is defined as POV 296.2*, 296.3*, 298.0, 300.4, 309.1, 311. The Index Episode Start Date is date of the patient's earliest visit during this period. For inpatient visits, the discharge date will be used.

2. Filled a prescription for an antidepressant medication (see list of medications below) within 30 days before the Index Episode Start Date or 14 days on or after that date. In V Medication, Date Discontinued must not be equal to the prescription (i.e., visit) date. The Index Prescription Date is the date of the earliest prescription for antidepressant medication filled during that time period.

Denominator Exclusions

1. Patients who have had any diagnosis of depression within the previous 120 days (four months) of the Index Episode Start Date. The POVs to be checked for prior depressive episodes is more comprehensive and include the following: POV 296.2*-296.9*, 298.0, 300.4, 309.0, 309.1, 309.28, 311, or
2. Patients who had a new or refill prescription for antidepressant medication (see the list of medications below) within 90 days (3 months) prior to the Index Prescription Date are excluded as they do not represent new treatment episodes, or

3. Patients who had an acute mental health or substance abuse inpatient stay during the 245 days after the Index Episode Start Date treatment period. Acute mental health stays are defined as Service Category of H and primary POV 290*, 293* through 302*, 306* through 316*. Substance abuse inpatient stays are defined as Service Category of H and primary POV 291* through 292*, 303* through 305* or primary POV 960* through 979* and secondary POV of 291* through 292*, 303* through 305*.

Optimal Practitioner Contacts Numerator

Patient must have one of the following:

1. Three face-to-face follow-up outpatient, non-ER visits (clinic code not equal to 30) or intermediate treatment with either a non-mental-health or mental health provider within 84 days after the Index Episode Start Date, *or*...
2. Two face-to-face outpatient, non-ER visits (clinic code not equal to 30) and one telephone visit (Service Category T), with either a non-mental-health or mental health provider within 84 days after the Index Episode Start Date.

For either option, one of the visits must be to a prescribing provider, defined as Provider Codes 00, 08, 11, 16 through 18, 21, 24 through 25, 30, 33, 41, 44 through 45, 47, 49, 64, 67 through 68, 70 through 83, 85 through 86, A1, A9, or B1 through B6.

Note: If patient was diagnosed with two secondary diagnoses of depression, the second visit may be counted toward the numerator.

Outpatient mental health provider visits are defined as BHS or PCC visit with primary provider code of 06, 12, 19, 48, 49, 50, 62, 63, 81, or 92 through 96, *and*:

- a. (1) Service category A, S, or O, and (2A) CPT 90801, 90802, 90804 through 90819, 90821 through 90824, 90826 through 90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90871 (old code), 90875, 90876, 99384 through 99387, 99394 through 99397, 99401 through 99404, G0155, G0176, G0177, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013–H2020, M0064, S9484, S9485 or (2B) POV 290*, 293*–302*, 306*–316, or
- b. (1) Service category of A, S, or O and (2A) Location of Encounter = Home (as designated in Site Parameters) or (2B) Clinic Code = 11, or
- c. Service category of T.

Outpatient non-mental-health provider visits are defined as BHS or PCC visits with:

- a. (1) Service category A, S, or O, a (2) CPT 90801, 90802, 90804 through 90819, 90821 through 90824, 90826–90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90871 (old code), 90875, 90876, G0155, G0176, G0177, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013 through H2020, M0064, S9484, S9485, or...
- b. (1) Service category A, S, O, or T or (2) Location of Encounter = Home (as designated in Site Parameters) or (3A) clinic code 11 and (3B) POV 290*, 293* through 302*, 306* through 316*, or...
- c. (1) Service category A, S, or O, and (2) CPT 99384 through 99387, 99394 through 99397, 99401 through 99404 and (3) POV 290*, 293* through 302*, 306* through 316*.

Effective Acute Phase Treatment Numerator

For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114-day time frame, the patient is not included in the numerator.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Example of Patient Included in Numerator:

- First RX is Index Rx Date: 11/1/2011, # Days Prescribed=30
- Rx covers patient through 12/1/2011
- Second RX: 12/15/2011, # Days Prescribed=30
- Gap #1 = (12/15/2011-12/1/2011) = 14 days
- Rx covers patient through 1/14/2012
- Third RX: 1/10/2012, # Days Prescribed=30
- No gap days
- Rx covers patient through 2/13/2012
- Index Rx Date 11/1/2011 + 114 days = 2/23/2012

- Patient's 84th treatment day occurs on 2/7/2012, which is less than or equal to (\leq) 2/23/2012 and # gap days of 14 is less than 30

Example of Patient Not Included in Numerator:

- First Rx is Index Rx Date: 11/1/2011, # Days Prescribed=30
- Rx covers patient through 12/1/2011
- Second Rx: 12/15/2011, # Days Prescribed=30
- Gap #1 = (12/15/2011-12/1/2011) = 14 days
- Rx covers patient through 1/14/2012
- Third Rx: 2/01/2012, # Days Prescribed=30
- Gap #2 = (2/01/2012 through 1/14/2012) = 18, total # gap days = 32, so patient is not included in the numerator

Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see list of medications below) filled within 231 days of the Index Prescription Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Prescription Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231 day time frame, the patient is not included in the numerator.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Antidepressant medications defined with medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS. (Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinephrine reuptake inhibitors (SNRI), and other antidepressants.) Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

Changed denominator to Active Clinical Plus Behavioral Health.

Patient List Description

List of patients with new depression DX and optimal practitioner contact (OPC), acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

Measure Source

HEDIS, HP 2010 18-9b

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 141 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Antidepressant Medication Management (con't) | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| AC+BH Pts =>18 w/new depression DX and antidepressant meds | | | | | | | | | |
| | 17 | | 6 | | | 2 | | | |
| # w/3 outpt mental health visits within 12 weeks | | | | | | | | | |
| | 5 | 29.4 | 1 | 16.7 | +12.7 | 0 | 0.0 | +29.4 | |
| # w/12 week treatment meds | | | | | | | | | |
| | 9 | 52.9 | 4 | 66.7 | -13.7 | 0 | 0.0 | +52.9 | |
| # w/180 day treatment meds | | | | | | | | | |
| | 4 | 23.5 | 3 | 50.0 | -26.5 | 0 | 0.0 | +23.5 | |
| User Pop Pts =>18 w/new depression DX and antidepressant meds | | | | | | | | | |
| | 18 | | 7 | | | 3 | | | |
| # w/3 outpt mental health visits within 12 weeks | | | | | | | | | |
| | 5 | 27.8 | 1 | 14.3 | +13.5 | 0 | 0.0 | +27.8 | |
| # w/12 week treatment meds | | | | | | | | | |
| | 9 | 50.0 | 4 | 57.1 | -7.1 | 0 | 0.0 | +50.0 | |
| # w/180 day treatment meds | | | | | | | | | |
| | 4 | 22.2 | 3 | 42.9 | -20.6 | 0 | 0.0 | +22.2 | |

Figure 2-61: Sample Report, Antidepressant Medication Management

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

| Antidepressant Medication Management: List of patients with new depression DX and optimal practitioner contact (OPC), acute phase treatment (APT) and continuation phase treatment (CONPT), if any. | | | | |
|---|--------|---|-----|-----|
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| PATIENT1,MICHELLE D UP,AC+BH CONPT: DAYS=60, GAP=1 | 000001 | COMMUNITY #1 IESD: 06/06/11; NOT OPC; NOT APT: DAYS=60, GAP=1; NOT | F | 22 |
| PATIENT2,PAULA KAY UP,AC+BH CONPT | 000002 | COMMUNITY #1 IESD: 10/29/11; NOT OPC; NOT APT: DAYS=68, GAP=28; | F | 34 |
| PATIENT3,RHONDA SUE UP CONPT: DAYS=74, GAP=0 | 000003 | COMMUNITY #1 IESD: 04/21/12; NOT OPC; NOT APT: DAYS=74, GAP=0; NOT | F | 35 |
| PATIENT4,KATHLEEN UP,AC+BH | 000004 | COMMUNITY #1 IESD: 11/15/11; NOT OPC; APT; CONPT | F | 38 |

Figure 2-62: Sample Patient List, Antidepressant Medication Management

2.8 Cardiovascular Disease Related Measure Topics

2.8.1 Obesity Assessment

Denominators

Active Clinical patients ages 2 through 74. Broken down by gender and age groups (2 through 5, 6 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74).

All User Population patients ages 2 through 74. Broken down by gender.

Numerators

Patients for whom a Body Mass Index (BMI) could be calculated.

Note: This numerator does *not* include refusals.

1. For those with a BMI calculated, those considered overweight but not obese using BMI and standard tables
2. For those with a BMI calculated, those considered obese using BMI and standard tables
3. Total of overweight and obese

Patients with documented refusal in past year.

Logic Description

Age is calculated at beginning of the Report Period.

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2-18, definitions are based on standard tables. Refusals include REF, NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with current BMI, if any.

Measure Source

HP 2020: NWS-9 Obesity in Adults 20+, NWS-10.1 (Obesity in Children 2-5), NWS-10.2 Overweight or Obesity in Children 6-11, NWS-10.3 Overweight or Obesity in Adolescents 12-19, NWS-10.4 Overweight or Obesity in Children 2-19

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|---|---------|
| Assessed as Obese—IHS FY 2011 Performance | 46.9% |
| Assessed as Obese—IHS FY 2010 Performance | 47.0% |
| Assessed as Obese—IHS FY 2009 Performance | 47.0% |
| Assessed as Obese—IHS FY 2008 Performance | 46.0% |
| BMI Measured—IHS FY 2011 Performance | 78.0% |
| BMI Measured—IHS FY 2010 Performance | 76.0% |
| BMI Measured—IHS FY 2009 Performance | 75.0% |
| BMI Measured—IHS FY 2008 Performance | 74.0% |

| Performance | Percent |
|---|---------|
| BMI Measured– FY 2005 Performance | 64.0% |
| BMI Measured–IHS FY 2004 Performance | 60.0% |
| HP 2020 Goal: Obesity in Adults 20+ (NWS-9) | 30.6% |
| HP 2020 Goal: Overweight or Obesity in Children 2–5 (NWS-10.1) | 9.6% |
| HP 2020 Goal: Overweight or Obesity in Children 6–11 (NWS-10.2) | 15.7% |
| HP 2020 Goal: Overweight or Obesity in Adolescents 12–19 (NWS-10.3) | 16.1% |
| HP 2020 Goal: Overweight or Obesity in Children 2–19 (NWS-10.4) | 14.6% |

Performance Improvement Tips

1. A Body Mass Index report can be run from your PCC Management Reports menu. This report can be run for all patients or for a specific template of patients that has been pre-defined with a QMan search. The BMI report will provide you with patient height, weight, date weight taken, BMI and NHANES percentile.
2. Recent guidelines indicate that height for adults must be taken at least once every five years, rather than once after age 18. Your BMI rates may be lower than anticipated because of height data that is over five years old.
3. If height and weight measurements are being recorded as cm/kg vs. in/lbs ensure providers are *noting* they are cm/kg *and* that data entry is entering the measurements correctly in PCC, as shown below.
 - Use mnemonics of CHT and KWT (vs. HT and WT), or
 - Add “c” after height value and “k” after weight value (e.g. 100c, 50k)

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 143 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Obesity Assessment (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts | | | | | | | | |
| ages 2-74 | 1,400 | | 1,096 | | | 982 | | |
| # w/BMI calculated | | | | | | | | |
| -No Refusals | 880 | 62.9 | 824 | 75.2 | -12.3 | 712 | 72.5 | -9.6 |
| A. # Overweight w/ | | | | | | | | |
| % of Total BMI | 242 | 27.5 | 237 | 28.8 | -1.3 | 191 | 26.8 | +0.7 |
| B. # Obese w/ | | | | | | | | |
| % of Total BMI | 372 | 42.3 | 339 | 41.1 | +1.1 | 267 | 37.5 | +4.8 |

| | | | | | | | | |
|--|-----|------|-----|------|-------|-----|------|-------|
| C. # Overweight/Obese w/ % of Total BMI | 614 | 69.8 | 576 | 69.9 | -0.1 | 458 | 64.3 | +5.4 |
| # w/BMI refusal (No BMI) | 4 | 0.3 | 0 | 0.0 | +0.3 | 0 | 0.0 | +0.3 |
| Male Active Clinical Pts 2-74 | 595 | | 465 | | | 410 | | |
| # w/BMI calculated -No Refusals | 341 | 57.3 | 331 | 71.2 | -13.9 | 283 | 69.0 | -11.7 |
| A. # Overweight w/ % of Total BMI | 103 | 30.2 | 98 | 29.6 | +0.6 | 73 | 25.8 | +4.4 |
| B. # Obese w/ % of Total BMI | 155 | 45.5 | 141 | 42.6 | +2.9 | 117 | 41.3 | +4.1 |
| C. #Overweight/Obese w/ % of Total BMI | 258 | 75.7 | 239 | 72.2 | +3.5 | 190 | 67.1 | +8.5 |
| # w/BMI refusal (no BMI) | 2 | 0.3 | 0 | 0.0 | +0.3 | 0 | 0.0 | +0.3 |
| Female Active Clinical Pts 2-74 | 805 | | 631 | | | 572 | | |
| # w/BMI calculated -No Refusals | 539 | 67.0 | 493 | 78.1 | -11.2 | 429 | 75.0 | -8.0 |
| A. # Overweight w/ % of Total BMI | 139 | 25.8 | 139 | 28.2 | -2.4 | 118 | 27.5 | -1.7 |
| B. # Obese w/ % of Total BMI | 217 | 40.3 | 198 | 40.2 | +0.1 | 150 | 35.0 | +5.3 |
| C. #Overweight/Obese w/ % of Total BMI | 356 | 66.0 | 337 | 68.4 | -2.3 | 268 | 62.5 | +3.6 |
| # w/BMI refusal (No BMI) | 2 | 0.2 | 0 | 0.0 | +0.2 | 0 | 0.0 | +0.2 |

Figure 2-63: Sample Report, Obesity Assessment

| | | | | | | | | |
|-----------------------------------|----------------------------------|------|-------|-------|-------|-------|-------|-------|
| Obesity Assessment (con't) | | | | | | | | |
| | TOTAL ACTIVE CLINICAL POPULATION | | | | | | | |
| | Age Distribution | | | | | | | |
| | 2-5 | 6-11 | 12-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-74 |
| CURRENT REPORT PERIOD | | | | | | | | |
| Total # Active Clin | 109 | 112 | 157 | 133 | 233 | 215 | 216 | 225 |
| # w/BMI calculated | | | | | | | | |
| -No Refusals | 52 | 44 | 89 | 117 | 183 | 146 | 128 | 121 |
| % w/BMI calculated | | | | | | | | |
| -No Refusals | 47.7 | 39.3 | 56.7 | 88.0 | 78.5 | 67.9 | 59.3 | 53.8 |
| # A. Overweight | 9 | 10 | 21 | 33 | 44 | 39 | 38 | 48 |
| % A. Overweight w/ % Total BMI | 17.3 | 22.7 | 23.6 | 28.2 | 24.0 | 26.7 | 29.7 | 39.7 |
| # B. Obese | 7 | 13 | 28 | 39 | 86 | 86 | 61 | 52 |
| % B. Obese w/ % of Total BMI | 13.5 | 29.5 | 31.5 | 33.3 | 47.0 | 58.9 | 47.7 | 43.0 |
| # C. Overweight or Obese | 16 | 23 | 49 | 72 | 130 | 125 | 99 | 100 |

| | | | | | | | | |
|--|-------|------|------|------|-------|-------|-------|-------|
| % C. Overweight or Obese w/ % Total BMI | 30.8 | 52.3 | 55.1 | 61.5 | 71.0 | 85.6 | 77.3 | 82.6 |
| # w/BMI refusal (No BMI) | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| % w/BMI refusal (No BMI) | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.8 | 0.8 |
| PREVIOUS YEAR PERIOD | | | | | | | | |
| Total # Active Clin | 111 | 120 | 137 | 128 | 172 | 151 | 140 | 137 |
| # w/BMI calculated | | | | | | | | |
| -No Refusals | 49 | 56 | 88 | 114 | 155 | 129 | 113 | 120 |
| % w/BMI calculated | | | | | | | | |
| -No Refusals | 44.1 | 46.7 | 64.2 | 89.1 | 90.1 | 85.4 | 80.7 | 87.6 |
| # A. Overweight | 7 | 11 | 20 | 38 | 47 | 33 | 36 | 45 |
| % A. Overweight w/ % Total BMI | 14.3 | 19.6 | 22.7 | 33.3 | 30.3 | 25.6 | 31.9 | 37.5 |
| # B. Obese | 14 | 14 | 26 | 35 | 65 | 77 | 56 | 52 |
| % B. Obese w/ % of Total BMI | 28.6 | 25.0 | 29.5 | 30.7 | 41.9 | 59.7 | 49.6 | 43.3 |
| # C. Overweight or Obese | 21 | 25 | 46 | 73 | 112 | 110 | 92 | 97 |
| % C. Overweight or Obese w/ % Total BMI | 42.9 | 44.6 | 52.3 | 64.0 | 72.3 | 85.3 | 81.4 | 80.8 |
| # w/BMI refusal (No BMI) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| % w/BMI refusal (No BMI) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CHANGE FROM PREV YR % | | | | | | | | |
| w/BMI calculated | | | | | | | | |
| -No Refusals | +3.6 | -7.4 | -7.5 | -1.1 | -11.6 | -17.5 | -21.5 | -33.8 |
| A. Overweight | +3.0 | +3.1 | +0.9 | -5.1 | -6.3 | +1.1 | -2.2 | +2.2 |
| B. Obese | -15.1 | +4.5 | +1.9 | +2.6 | +5.1 | -0.8 | -1.9 | -0.4 |
| C. Overweight or Obese | -12.1 | +7.6 | +2.8 | -2.5 | -1.2 | +0.3 | -4.1 | +1.8 |
| w/BMI refusal (No BMI) | +1.9 | +0.0 | +0.0 | +0.0 | +0.0 | +0.7 | +0.8 | +0.8 |

Figure 2-64: Sample Report, Age Breakout, Obesity Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Obesity Assessment: List of patients with current BMI, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------------------|-----|-----|
| PATIENT1,PAMELA UP,AC | 000001 | COMMUNITY #1 16.03 | F | 3 |
| PATIENT2,GLENDA UP,AC | 000002 | COMMUNITY #1 17.49 | F | 3 |
| PATIENT3,SHIRLEY UP | 000003 | COMMUNITY #1 | F | 5 |
| PATIENT4,MARY ANNE UP,AC | 000004 | COMMUNITY #1 Refused | F | 5 |
| PATIENT5,JACKIE UP | 000005 | COMMUNITY #1 | F | 9 |
| PATIENT6,ZINNIA UP | 000006 | COMMUNITY #1 29.41 [OVERWEIGHT] | F | 15 |
| PATIENT7,MARY RYAN UP,AC | 000007 | COMMUNITY #1 33.69 [OBESE] | F | 15 |

Figure 2-65: Sample Patient List, Obesity Assessment

2.8.2 Childhood Weight Control

GPRA Description

During FY 2012, achieve the tentative long-term target rate of 24% for the proportion of children with a BMI of 95% or higher.

Denominators

Active Clinical patients aged 2 through 5 for whom a BMI could be calculated.
 Broken down by gender and age groups (2, 3, 4, 5).

Numerators

Patients with BMI in the 85th to 94th percentile.

Patients with a BMI at or above the 95th percentile.

Patients with a BMI at or above the 85th percentile.

Logic Description

BMI calculation definition: All patients for whom a BMI could be calculated and who are between the ages of two and five at the beginning of the Report Period and who do not turn age six during the Report Period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be two years of age at the beginning of the time period, but is three years old at the time of the most current BMI found. That patient will fall into the age three group. CRS looks for the most recent BMI in the Report Period. CRS calculates BMI at the time the report is run using NHANES II. A height and weight must be taken on the same day any time during the Report Period. The BMI values for this measure are reported differently than in Obesity Assessment since this age group is children ages 2 through 5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

Patients whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

BMI Standard Reference Data

| Low-High Ages | Sex | BMI >= (OVERWT) | BMI >= (OBESE) | Data Check Limits BMI > | Data Check Limits BMI < |
|---------------|--------|-----------------|----------------|-------------------------|-------------------------|
| 2-2 | MALE | 17.7 | 18.7 | 36.8 | 7.2 |
| 2-2 | FEMALE | 17.5 | 18.6 | 37.0 | 7.1 |
| 3-3 | MALE | 17.1 | 18.0 | 35.6 | 7.1 |
| 3-3 | FEMALE | 17.0 | 18.1 | 35.4 | 6.8 |
| 4-4 | MALE | 16.8 | 17.8 | 36.2 | 7.0 |
| 4-4 | FEMALE | 16.7 | 18.1 | 36.0 | 6.9 |
| 5-5 | MALE | 16.9 | 18.1 | 36.0 | 6.9 |
| 5-5 | FEMALE | 16.9 | 18.5 | 39.2 | 6.8 |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients ages 2 through 5, with current BMI.

Measure Source

CDC, National Center for Health Statistics, HP 2020 NWS-10.1

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|-------------|
| IHS FY 2011 Performance | 24.1% |
| IHS FY 2010 Performance | 25.0% |
| IHS FY 2009 Performance | 25.0% |
| IHS FY 2008 Performance | 24.0% |
| IHS FY 2007 Performance | 24.0% |
| IHS FY 2006 Performance | 24.0% |
| <i>HP 2020 Goal</i> | <i>9.6%</i> |

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 156 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Childhood Weight Control (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts | | | | | | | | |
| 2-5 w/BMI | 44 | | 39 | | | 40 | | |
| # w/BMI 85-94% | 7 | 15.9 | 5 | 12.8 | +3.1 | 10 | 25.0 | -9.1 |
| # w/BMI =>95% | 5 | 11.4 | 9 | 23.1 | -11.7 | 5 | 12.5 | -1.1 |
| # w/BMI =>85% | 12 | 27.3 | 14 | 35.9 | -8.6 | 15 | 37.5 | -10.2 |
| Active Clinical Pts | | | | | | | | |
| Age 2 | 2 | | 8 | | | 5 | | |
| # w/BMI 85-94% | 1 | 50.0 | 0 | 0.0 | +50.0 | 1 | 20.0 | +30.0 |
| # w/BMI =>95% | 0 | 0.0 | 2 | 25.0 | -25.0 | 0 | 0.0 | +0.0 |
| # w/BMI =>85% | 1 | 50.0 | 2 | 25.0 | +25.0 | 1 | 20.0 | +30.0 |
| Active Clinical Pts | | | | | | | | |
| Age 3 | 23 | | 15 | | | 8 | | |
| # w/BMI 85-94% | 2 | 8.7 | 2 | 13.3 | -4.6 | 3 | 37.5 | -28.8 |
| # w/BMI =>95% | 3 | 13.0 | 3 | 20.0 | -7.0 | 2 | 25.0 | -12.0 |
| # w/BMI =>85% | 5 | 21.7 | 5 | 33.3 | -11.6 | 5 | 62.5 | -40.8 |
| Active Clinical Pts | | | | | | | | |
| Age 4 | 12 | | 10 | | | 17 | | |
| # w/BMI 85-94% | 1 | 8.3 | 2 | 20.0 | -11.7 | 3 | 17.6 | -9.3 |
| # w/BMI =>95% | 1 | 8.3 | 2 | 20.0 | -11.7 | 2 | 11.8 | -3.4 |
| # w/BMI =>85% | 2 | 16.7 | 4 | 40.0 | -23.3 | 5 | 29.4 | -12.7 |
| Active Clinical Pts | | | | | | | | |
| Age 5 | 7 | | 6 | | | 10 | | |

| | | | | | | | | |
|----------------|---|------|---|------|-------|---|------|-------|
| # w/BMI 85-94% | 3 | 42.9 | 1 | 16.7 | +26.2 | 3 | 30.0 | +12.9 |
| # w/BMI =>95% | 1 | 14.3 | 2 | 33.3 | -19.0 | 1 | 10.0 | +4.3 |
| # w/BMI =>85% | 4 | 57.1 | 3 | 50.0 | +7.1 | 4 | 40.0 | +17.1 |

Figure 2-66: Sample Report, Childhood Weight Control

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Childhood Weight Control: List of patients ages 2-5, with current BMI.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|-------------------------|-----|--------------------|
| PATIENT1,MELISSA ANN | 000001 | COMMUNITY #1 | F | 4 |
| AC | | Age at BMI: 4; 08/20/12 | | 16.03 |
| PATIENT2,RANDY | 000002 | COMMUNITY #1 | M | 2 |
| AC | | Age at BMI: 2; 05/06/12 | | 17.96 [OVERWEIGHT] |
| PATIENT3,PAUL BARRY | 000003 | COMMUNITY #1 | M | 2 |
| AC | | Age at BMI: 2; 08/05/12 | | 19.87 [OBESE] |
| PATIENT4,TYLER | 000004 | COMMUNITY #1 | M | 4 |
| AC | | Age at BMI: 4; 02/19/12 | | 15.67 |
| PATIENT5,SAMUEL III | 000005 | COMMUNITY #1 | M | 5 |
| AC | | Age at BMI: 5; 11/29/12 | | 19.07 [OBESE] |
| PATIENT21,JOSEPHINE | 000021 | COMMUNITY #2 | F | 4 |
| AC | | Age at BMI: 4; 05/30/12 | | 15.71 |

Figure 2-67: Sample Patient List, Childhood Weight Control

2.8.3 Nutrition and Exercise Education for At Risk Patients

Denominators

Active Clinical patients ages six and older considered overweight (including obese). Broken down by gender.

- Active Clinical patients ages 6 and older *considered obese*. Broken down by gender and age groups (6 through 11, 12 through 19, 20 through 39, 40 through 59, 60 years plus).

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of the Report Period, *and* at least two visits in the past year, *and* two diabetes-related visits ever.

Numerators

Patients provided with medical nutrition therapy during the Report Period.

Patients provided specific nutrition education during the Report Period.

Patients provided specific exercise education during the Report Period.

Patients provided with other related exercise and nutrition (lifestyle) education.

Logic Description

Age of the patient is calculated at beginning of Report Period.

Diabetes: First DM Purpose of Visit 250.00 through 250.93 recorded in the V POV file prior to the Report period.

Overweight: Ages 19 and older, BMI equal to or greater than (\geq) 25. Overweight is defined as including both obese and overweight categories calculated by BMI.

Obese: Ages 19 and older, BMI equal to or greater than (\geq) 30. For ages 18 and under, the definition is based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report Period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years; not required to be recorded on same day.

CRS uses any of the following codes to define the numerators.

| Subject Defined | CPT Codes | ICD and Other Codes |
|--|----------------------------|---|
| Medical nutrition therapy | 97802-97804, G0270, G0271 | Primary or secondary provider codes: 07, 29 Clinic codes: 67 (dietary) or 36 (WIC) |
| Nutrition education | | V POV: V65.3 dietary surveillance and counseling Patient education codes: ending “-N” (nutrition), “-MNT” (medical nutrition therapy), (or old code “-DT” (diet)) or containing V65.3, 97802-97804, G0270, or G0271. |
| Exercise education | | V POV: V65.41 exercise counseling Patient education codes: ending “-EX” (exercise) or containing V65.41. |
| Related exercise and nutrition education | S9449, S9451, S9452, S9470 | Patient education codes: ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01, S9449, S9451, S9452, or S9470. |

Key Logic Changes from CRS Version 12.0

Added CPT codes S9449, S9451, S9452, S9470 to Related Exercise and Nutrition Education definition.

Patient List Description

A list of at risk patients with education, if any.

Measure Source

HP 2010 19–17

Measure Past Performance and Long-Term Targets for Diabetic Education

| Performance | Percent |
|--------------|---------|
| HP 1997 data | 42.0% |

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 160 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Nutrition and Exercise Education for At Risk Patient | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| # Overweight Active Clinical patients =>6 | 598 | | 555 | | | 442 | | | |
| # w/medical nutrition therapy | 44 | 7.4 | 23 | 4.1 | +3.2 | 27 | 6.1 | +1.2 | |
| # specific nutrition education provided | 83 | 13.9 | 79 | 14.2 | -0.4 | 78 | 17.6 | -3.8 | |
| # w/exercise educ | 34 | 5.7 | 28 | 5.0 | +0.6 | 35 | 7.9 | -2.2 | |
| # w/ other exec or nutrition educ | 75 | 12.5 | 59 | 10.6 | +1.9 | 24 | 5.4 | +7.1 | |
| # Male Overweight Active Clinical pts =>6 | 251 | | 230 | | | 182 | | | |
| # w/medical nutrition therapy | 18 | 7.2 | 8 | 3.5 | +3.7 | 10 | 5.5 | +1.7 | |
| # specific nutrition education provided | 36 | 14.3 | 32 | 13.9 | +0.4 | 28 | 15.4 | -1.0 | |
| # w/exercise educ | 16 | 6.4 | 12 | 5.2 | +1.2 | 16 | 8.8 | -2.4 | |
| # w/ other exec or nutrition educ | 41 | 16.3 | 22 | 9.6 | +6.8 | 11 | 6.0 | +10.3 | |
| # Female Overweight Active Clinical pts =>6 | 347 | | 325 | | | 260 | | | |
| # w/medical nutrition therapy | 26 | 7.5 | 15 | 4.6 | +2.9 | 17 | 6.5 | +1.0 | |
| # specific nutrition education provided | 47 | 13.5 | 47 | 14.5 | -0.9 | 50 | 19.2 | -5.7 | |

| | | | | | | | | |
|--------------------------------------|----|-----|----|------|------|----|-----|------|
| # w/exercise educ | 18 | 5.2 | 16 | 4.9 | +0.3 | 19 | 7.3 | -2.1 |
| # w/ other exec or nutrition educ | 34 | 9.8 | 37 | 11.4 | -1.6 | 13 | 5.0 | +4.8 |

Figure 2-68: Sample Report, Nutrition and Exercise Education for At Risk Patients

| Nutrition and Exercise Education for At Risk Patient (con't) | | | | | |
|--|------|-------|-------|-------|------|
| TOTAL OBESE ACTIVE CLINICAL POPULATION | | | | | |
| Age Distribution | | | | | |
| # Obese Active Clinical | 6-11 | 12-19 | 20-39 | 40-59 | =>60 |
| CURRENT REPORT PERIOD | | | | | |
| # Obese Active Clinical | 13 | 28 | 167 | 125 | 32 |
| # w/medical nutrition therapy | 0 | 2 | 15 | 10 | 3 |
| % w/medical nutrition therapy | 0.0 | 7.1 | 9.0 | 8.0 | 9.4 |
| # # w/specific nutrition education provided | 0 | 3 | 22 | 28 | 7 |
| % # w/specific nutrition education provided | 0.0 | 10.7 | 13.2 | 22.4 | 21.9 |
| # w/exercise educ | 0 | 1 | 8 | 14 | 5 |
| % w/exercise educ | 0.0 | 3.6 | 4.8 | 11.2 | 15.6 |
| # w/other exec or nutrition educ | 0 | 3 | 18 | 16 | 7 |
| % w/other exec or nutrition educ | 0.0 | 10.7 | 10.8 | 12.8 | 21.9 |
| PREVIOUS YEAR PERIOD | | | | | |
| # Obese Active Clinical | 14 | 26 | 137 | 116 | 32 |
| # w/medical nutrition therapy | 0 | 3 | 8 | 3 | 2 |
| % w/medical nutrition therapy | 0.0 | 11.5 | 5.8 | 2.6 | 6.3 |
| # # w/specific nutrition education provided | 0 | 2 | 19 | 22 | 7 |
| % # w/specific nutrition education provided | 0.0 | 7.7 | 13.9 | 19.0 | 21.9 |
| # w/exercise educ | 0 | 0 | 4 | 14 | 4 |
| % w/exercise educ | 0.0 | 0.0 | 2.9 | 12.1 | 12.5 |
| # w/other exec or nutrition educ | 0 | 2 | 13 | 23 | 3 |
| % w/other exec or nutrition educ | 0.0 | 7.7 | 9.5 | 19.8 | 9.4 |
| CHANGE FROM PREV YR % | | | | | |
| medical nutrition therapy | +0.0 | -4.4 | +3.1 | +5.4 | +3.1 |
| Spec nutr ed | +0.0 | +3.0 | -0.7 | +3.4 | +0.0 |
| w/exercise educ | +0.0 | +3.6 | +1.9 | -0.9 | +3.1 |
| w/other exec or | | | | | |

| | | | | | |
|----------------|------|------|------|------|-------|
| nutrition educ | +0.0 | +3.0 | +1.3 | -7.0 | +12.5 |
|----------------|------|------|------|------|-------|

Figure 2-69: Sample Age Breakout Report, Nutrition and Exercise Education for At Risk Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Nutrition and Exercise Education for At Risk Patients: List of at risk patients, with education if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|-----------------------------|-----------|
| ----- | | | | |
| PATIENT1,SANDRA KAY | 000001 | COMMUNITY #1 | F | 21 |
| AC-OW,AC-OB | | LIFE: 05/15/12 | TO-LA | |
| PATIENT2,CAITLYN | 000002 | COMMUNITY #1 | F | 22 |
| AC-OW | | NUTR: 03/15/12 | UTI-N SN | |
| PATIENT3,BRITNEY | 000003 | COMMUNITY #1 | F | 22 |
| AC-OW,AC-OB | | MNT: 03/04/12 | Prv | 29 |
| PATIENT4,LORETTA | 000004 | COMMUNITY #1 | F | 22 |
| AC-OW,AC-OB | | NUTR: 05/07/12 | HTN-N SN; EXER ED: 05/07/12 | HTN-EX |
| PATIENT5,HALEY | 000005 | COMMUNITY #1 | F | 25 |
| AC-OW,AC-OB | | | | |
| PATIENT6,BRITTANY | 000006 | COMMUNITY #1 | F | 25 |
| AC-OW,AC-OB | | EXER ED: 01/15/12 | 278.00-EX; LIFE: 01/15/12 | 278.00-EX |

Figure 2-70: Sample Patient List, Nutrition, and Exercise Education for At Risk Patients

2.8.4 Physical Activity Assessment

Denominators

Active Clinical patients ages 5 and older. Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

User Population patients ages 5 and older. Broken down by gender.

Numerator 1 (User Population Patients assessed for physical activity during the Report Period). Broken down by gender.

Numerators

Patients assessed for physical activity during the Report Period.

Patients from Numerator 1 who have received exercise education following their physical activity assessment.

Logic Description

Age of the patient is calculated at beginning of Report Period.

CRS uses any of the following codes to define the numerators.

| Subject Defined | ICD and Other Codes |
|------------------------------|---|
| Physical Activity Assessment | Health Factors: Any health factor for category Activity Level documented during the Report Period. |
| Exercise education | V POV: V65.41 exercise counseling Patient education codes: ending “-EX” (exercise) or containing V65.41. |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with physical activity assessment and any exercise education.

| | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 171 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Physical Activity Assessment | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts | | | | | | | | |
| 5 and older | 1,357 | | 1,031 | | | 911 | | |
| # w/ physical activity | | | | | | | | |
| assessment | 19 | 1.4 | 0 | 0.0 | +1.4 | 0 | 0.0 | +1.4 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 4 | 21.1 | 0 | 0.0 | +21.1 | 0 | 0.0 | +21.1 |
| Male Active Clinical | | | | | | | | |
| =>5 | 570 | | 430 | | | 374 | | |
| # w/ physical activity | | | | | | | | |

| | | | | | | | | |
|---------------------------|-------|------|-------|-----|-------|-------|-----|-------|
| assessment | 7 | 1.2 | 0 | 0.0 | +1.2 | 0 | 0.0 | +1.2 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 1 | 14.3 | 0 | 0.0 | +14.3 | 0 | 0.0 | +14.3 |
| Female Active Clinical | | | | | | | | |
| =>5 | 787 | | 601 | | | 537 | | |
| # w/ physical activity | | | | | | | | |
| assessment | 12 | 1.5 | 0 | 0.0 | +1.5 | 0 | 0.0 | +1.5 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 3 | 25.0 | 0 | 0.0 | +25.0 | 0 | 0.0 | +25.0 |
| User Pop ages | | | | | | | | |
| 5 and older | 2,592 | | 2,142 | | | 2,025 | | |
| # w/ physical activity | | | | | | | | |
| assessment | 19 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 4 | 21.1 | 0 | 0.0 | +21.1 | 0 | 0.0 | +21.1 |
| Male User Pop Pts | | | | | | | | |
| =>5 | 1,211 | | 988 | | | 945 | | |
| # w/ physical activity | | | | | | | | |
| assessment | 7 | 0.6 | 0 | 0.0 | +0.6 | 0 | 0.0 | +0.6 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 1 | 14.3 | 0 | 0.0 | +14.3 | 0 | 0.0 | +14.3 |
| Female User Pop Pts | | | | | | | | |
| =>5 | 1,381 | | 1,154 | | | 1,080 | | |
| # w/ physical activity | | | | | | | | |
| assessment | 12 | 0.9 | 0 | 0.0 | +0.9 | 0 | 0.0 | +0.9 |
| # w/ exercise educ | | | | | | | | |
| w/ % of physical activity | | | | | | | | |
| assessment | 3 | 25.0 | 0 | 0.0 | +25.0 | 0 | 0.0 | +25.0 |

Figure 2-71: Sample Report, Physical Activity Assessment

| | | | | | | | | |
|--------------------------------------|----------------------------------|-------|-------|-------|-------|-------|-------|---------|
| Physical Activity Assessment (con't) | | | | | | | | |
| | TOTAL ACTIVE CLINICAL5 AND OLDER | | | | | | | |
| | Age Distribution | | | | | | | |
| | 5-11 | 12-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-74 | >74 yrs |
| CURRENT REPORT PERIOD | | | | | | | | |
| Total # AC Pts =>5 | 132 | 157 | 133 | 233 | 215 | 216 | 225 | 46 |
| # w/ physical activity | | | | | | | | |
| assessment | 2 | 6 | 3 | 1 | 2 | 0 | 3 | 2 |
| % w/ physical activity | | | | | | | | |
| assessment | 1.5 | 3.8 | 2.3 | 0.4 | 0.9 | 0.0 | 1.3 | 4.3 |
| # w/ exercise educ w/ | | | | | | | | |
| % of physical activity | | | | | | | | |

| | | | | | | | | |
|---|-------|-------|-------|------|------|------|------|------|
| assessment | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| % w/ exercise educ w/ % of physical activity assessment | 50.0 | 33.3 | 33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PREVIOUS YEAR PERIOD | | | | | | | | |
| Total # AC Pts =>5 | 141 | 137 | 128 | 172 | 151 | 140 | 137 | 25 |
| # w/ physical activity assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| % w/ physical activity assessment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| # w/ exercise educ w/ % of physical activity assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| % w/ exercise educ w/ % of physical activity assessment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CHANGE FROM PREV YR % | | | | | | | | |
| # w/ physical activity assessment | +1.5 | +3.8 | +2.3 | +0.4 | +0.9 | +0.0 | +1.3 | +4.3 |
| w/ exercise educ w/ % of physical activity assessment | +50.0 | +33.3 | +33.3 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |

Figure 2-72: Sample Age Breakout Report, Physical Activity Assessment

| | | | | |
|--|--------|------------------------|---------------------------------------|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Physical Activity Assessment: List of patients with physical activity assessment and any exercise education. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,MISTY DAWN UP,AC | 000001 | COMMUNITY #1 | F | 5 |
| | | PHYS ACT: 08/08/12 | VERY ACTIVE; EXER ED: 08/08/12 OBS-EX | |
| PATIENT2,RITA ANN UP,AC | 000002 | COMMUNITY #1 | F | 15 |
| | | PHYS ACT: 03/06/12 | SOME ACTIVITY; EXER ED: 03/06/12 | |
| TO-EX | | | | |
| PATIENT3,RHONDA SUE UP,AC | 000003 | COMMUNITY #1 | F | 22 |
| | | PHYS ACT: 04/02/12 | ACTIVE; EXER ED: 04/02/12 V65.41 | |
| PATIENT4,MARY UP,AC | 000004 | COMMUNITY #1 | F | 28 |
| | | PHYS ACT: 12/12/12 | SOME ACTIVITY; | |
| PATIENT5,JOSEPH HENRY UP,AC | 000005 | COMMUNITY #1 | M | 12 |
| | | PHYS ACT: 08/02/12 | SOME ACTIVITY; | |
| PATIENT6,BOB UP,AC | 000006 | COMMUNITY #1 | M | 17 |
| | | PHYS ACT: 05/05/12 | INACTIVE; EXER ED: 05/05/12 OBS-EX | |

Figure 2-73: Sample Patient List, Physical Activity Assessment

2.8.5 Comprehensive Health Screening

Denominators

Active Clinical patients ages 2 and older.

Active Clinical patients ages 12 to 75.

Active Clinical patients ages 18 and older.

Female Active Clinical patients ages 15 through 40.

Active Clinical patients ages 5 and older.

Active Clinical patients ages 2 through 74.

Active Clinical patients ages 20 and over.

Active Clinical patients ages 5 and older.

Numerators

ALL Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and Intimate Partner Violence/Domestic Violence (IPV/DV) screening, BMI calculated, and tobacco use, BP, and physical activity assessed.

Note: This does *not* include refusals.

Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and BP assessed.

Note: This does *not* include physical activity assessment and does *not* include refusals.

Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

Note: This numerator does *not* include refusals or alcohol-related patient education.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

Note: This numerator does *not* include refusals.

IPV/DV Screening: Patients screened for IPV/DV at any time during the Report Period.

Note: This numerator does *not* include refusals.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report period.

BMI Available: Patients for whom a BMI could be calculated.

Note: This numerator does *not* include refusals.

BP Assessed: Patients with BP value documented at least twice in prior two years.

Physical Activity Assessed: Patients assessed for physical activity during the Report Period.

Logic Description

Age of the patient is calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

| Subject Defined | ICD and Other Codes |
|---------------------------|---|
| Alcohol Screening | PCC Exam Code: 35 CPT code: 99408, 99409, G0396, G0397, H0049, H0050, 3016F Any CAGE Health Factor V POV: V11.3 (history of alcoholism), V79.1 (screening for alcoholism) BHS Problem Code: 29.1 (Screening for Alcoholism) V Measurement in PCC or BHS: AUDT, AUDC, or CRFT |
| Alcohol-related Diagnosis | V POV, Current PCC or BHS Problem List: 303.*, 305.0*, 291.*, 357.5* BHS POV: 10, 27, 29 |
| Alcohol-related Procedure | V Procedure: 94.46, 94.53, 94.61-94.63, 94.67-94.69 |

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

Depression screening definition: CRS uses the following codes to define the numerator.

| Subject Defined | ICD and Other Codes |
|----------------------|--|
| Depression Screening | V Exam: Exam Code 36 V POV: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) V Measurement in PCC or BHS: PHQ2 or PHQ9 |
| Mood Disorders | At least two visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. V POV: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 BHS POV: 14, 15 |

IPV/DV screening definition: CRS uses the following codes to define the numerator.

| Subject Defined | ICD and Other Codes |
|-------------------|--|
| IPV/DV Screening | V Exam: Code 34 BHS Exam: IPV/DV |
| IPV/DV Diagnosis | V POV or current PCC or BHS Problem List: 995.80-995.83, 995.85, V15.41, V15.42, V15.49 BHS POV: 43.*, 44.* |
| IPV/DV Education | Patient education codes: "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, or V15.49 |
| IPV/DV Counseling | V POV: V61.11 |

Tobacco screening definition: CRS uses the following codes to define the numerator.

| Subject Defined | CPT Codes | ICD and Other Codes |
|--------------------------|--|--|
| Screened for Tobacco Use | D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed) | V POV or current Active Problem List: 305.1, 305.1* (old codes), 649.00-649.04, V15.82 Patient Education codes: "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), or G8453 (old code) Dental code: 1320 Health Factor categories: Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE) |

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day.

Blood pressure definition: CRS uses mean of last three Blood Pressures documented on non-ER visits in the past two years. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on a non-ER visit during the Report Period.

Physical Activity Assessment definition: CRS uses the following codes to define the numerator.

| Subject Defined | ICD and Other Codes |
|------------------------------|---|
| Physical Activity Assessment | Health Factors: Any health factor for category Activity Level documented during the Report Period. |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with assessments received, if any.

| | | | | | | | | | |
|--|-------------------|-----|---------|-----|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 181 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Comprehensive Health Screening | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical ages | | | | | | | | | |
| 2 and older | 1,446 | | 1,121 | | | 1,007 | | | |
| # w/ Comprehensive Health | | | | | | | | | |
| Screening-No | | | | | | | | | |
| Refusals | 56 | 3.9 | 39 | 3.5 | +0.4 | 40 | 4.0 | -0.1 | |
| # w/ Comprehensive Health | | | | | | | | | |
| Screening-No Refusals | | | | | | | | | |
| or Phys Activity | 67 | 4.6 | 46 | 4.1 | +0.5 | 53 | 5.3 | -0.6 | |
| Active Clinical | | | | | | | | | |
| ages 12-75 | 1,180 | | 867 | | | 753 | | | |
| # w/ alcohol screening/ | | | | | | | | | |
| Dx/Proc/-No Refusals | | | | | | | | | |
| or Pt Ed | 95 | 8.1 | 12 | 1.4 | +6.7 | 3 | 0.4 | +7.7 | |
| Active Clinical | | | | | | | | | |
| => 18 | 1,112 | | 793 | | | 666 | | | |
| # w/ Depression screening | | | | | | | | | |
| or Mood Disorder Dx- | | | | | | | | | |
| No Refusals | 81 | 7.3 | 42 | 5.3 | +2.0 | 17 | 2.6 | +4.7 | |
| # Female Active | | | | | | | | | |
| Clinical ages 15-40 | 380 | | 311 | | | 267 | | | |
| # w/IPV/DV screening- | | | | | | | | | |
| No Refusals | 11 | 2.9 | 1 | 0.3 | +2.6 | 0 | 0.0 | +2.9 | |
| # Active Clinical | | | | | | | | | |
| Pts =>5 | 1,357 | | 1,031 | | | 911 | | | |

| | | | | | | | | |
|--|-------|------|-------|------|-------|-----|------|-------|
| # w/Tobacco Screening | 624 | 46.0 | 426 | 41.3 | +4.7 | 328 | 36.0 | +10.0 |
| Active Clinical Pts 2-74 | 1,400 | | 1,096 | | | 982 | | |
| # w/BMI calculated-No Refusals | 880 | 62.9 | 824 | 75.2 | -12.3 | 712 | 72.5 | -9.6 |
| Active Clinical Patients ages 20 and older | 1,068 | | 753 | | | 640 | | |
| # w/ BPs documented w/in 2 yrs | 643 | 60.2 | 557 | 74.0 | -13.8 | 478 | 74.7 | -14.5 |
| Active Clinical Pts 5 and older | 1,357 | | 1,031 | | | 911 | | |
| # w/ physical activity assessment | 19 | 1.4 | 0 | 0.0 | +1.4 | 0 | 0.0 | +1.4 |

Figure 2-74: Sample Report, Comprehensive Health Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Comprehensive Health Screening: List of patients with assessments received, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|--|--------|------------------------|-----|-----|
| PATIENT1,SANDRA KAY AC | 000001 | COMMUNITY #1 | F | 15 |
| 03/06/12 Ex 34; TOB: 09/05/12 NEVER SMOKED; BMI: 17.49; PHYS ACT: 03/06/12 SOME ACTIVITY | | | | |
| PATIENT2,CAITLYN AC | 000002 | COMMUNITY #1 | F | 16 |
| PATIENT3,BRITNEY AC | 000003 | COMMUNITY #1 | F | 16 |
| PATIENT4,LORETTA AC | 000004 | COMMUNITY #1 | F | 17 |
| PATIENT5,HALEY AC | 000005 | COMMUNITY #1 | F | 18 |
| PATIENT6,BRITTANY AC | 000006 | COMMUNITY #1 | F | 19 |
| STATUS UNKNOWN; BMI: 21.01 | | | | |

Figure 2-75: Sample Patient List, Comprehensive Health Screening

2.8.6 Cardiovascular Disease and Cholesterol Screening

Denominators

Active Clinical patients ages 23 and older. Broken down by gender.

User Population patients ages 23 and older. Broken down by gender.

Active IHD patients, defined as all Active Clinical patients diagnosed with ischemic heart disease (IHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two IHD-related visits ever. Broken down by gender.

Numerators

Patients with documented blood total cholesterol screening any time in the past five years.

- a. Patients with high total cholesterol levels, defined as equal to or greater than (\geq) 240

Patients with LDL completed in the past five years, regardless of result.

- a. Patients with LDL less than or equal to (\leq) 100
- b. Patients with LDL 101 through 130
- c. Patients with LDL 131 through 160
- d. Patients with LDL greater than ($>$) 160

Logic Description

Age is calculated at the beginning of the Report Period.

CRS uses the following codes to define the IHD denominator.

| Subject Defined | ICD and Other Codes |
|------------------------|--|
| Ischemic Heart Disease | V POV: 410.0-412.*, 414.0-414.9, 429.2 |

Total Cholesterol definition: Searches for most recent cholesterol test with a result during the Report Period. If more than one cholesterol test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If a cholesterol test with a result is not found, CRS searches for the most recent cholesterol test without a result.

LDL Cholesterol definition: Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

CRS uses the following codes to define LDL and total cholesterol.

| Subject Defined | CPT Codes | LOINC Codes | Taxonomy |
|-------------------|---|-------------|------------------------------|
| LDL | 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F For numerator LDL equal to or less than (\leq)100, CPT 3048F will count as meeting the measure. | Yes | DM AUDIT LDL CHOLESTEROL TAX |
| Total Cholesterol | 82465 | Yes | DM AUDIT CHOLESTEROL TAX |

Key Logic Changes from CRS Version 12.0

- Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.
- Added code 9342-7 to LOINC taxonomy for Total Cholesterol.

Patient List Description

List of patients with cholesterol or LDL value, if any.

Measure Source

HP 2020 HDS-6, HDS-7

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|---|--------------|
| IHS FY 2006 Performance (blood total cholesterol screening) | 48.0% |
| IHS FY 2005 Performance (blood total cholesterol screening) | 43.0% |
| HP 1998 baseline | 67.0% |
| <i>HP 2020 goal for adults who have had blood cholesterol checked (HDS-6)</i> | <i>82.1%</i> |
| <i>HP 2020 goal for adults with high cholesterol (HDS-7)</i> | <i>13.5%</i> |

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 185 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |

| Cardiovascular Disease and Cholesterol Screening | | | | | | | | | |
|---|---------------|------|----------------|------|--------------------|-------------|------|-----------------|--|
| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % | |
| Active Clinical Pts => 23 | 986 | | 676 | | | 569 | | | |
| # w/ Total Cholesterol screen w/in 5 yrs | 248 | 25.2 | 217 | 32.1 | -6.9 | 201 | 35.3 | -10.2 | |
| A. # w/ High Chol =>240 w/ % of Total Chol Screen | 21 | 8.5 | 23 | 10.6 | -2.1 | 28 | 13.9 | -5.5 | |
| # w/LDL done in past 5 yrs | 251 | 25.5 | 185 | 27.4 | -1.9 | 114 | 20.0 | +5.4 | |
| A. # w/LDL =<100 w/ % of Total LDL Screen | 108 | 43.0 | 95 | 51.4 | -8.3 | 46 | 40.4 | +2.7 | |
| B. # w/LDL 101-130 w/ % of Total LDL Screen | 73 | 29.1 | 44 | 23.8 | +5.3 | 35 | 30.7 | -1.6 | |
| C. # w/LDL 131-160 w/ % of Total LDL Screen | 25 | 10.0 | 25 | 13.5 | -3.6 | 13 | 11.4 | -1.4 | |
| D. # w/LDL >160 w/ % of Total LDL Screen | 15 | 6.0 | 9 | 4.9 | +1.1 | 10 | 8.8 | -2.8 | |
| Male Active Clinical Pts =>23 | 408 | | 272 | | | 220 | | | |
| # w/ Total Cholesterol screen w/in 5 yrs | 106 | 26.0 | 97 | 35.7 | -9.7 | 85 | 38.6 | -12.7 | |
| A. # w/ High Chol =>240 w/ % of Total Chol Screen | 11 | 10.4 | 14 | 14.4 | -4.1 | 8 | 9.4 | +1.0 | |
| # w/LDL done in past 5 yrs | 115 | 28.2 | 91 | 33.5 | -5.3 | 59 | 26.8 | +1.4 | |
| A. # w/LDL =<100 w/ % of Total LDL Screen | 53 | 46.1 | 45 | 49.5 | -3.4 | 23 | 39.0 | +7.1 | |
| B. # w/LDL 101-130 w/ % of Total LDL Screen | 25 | 21.7 | 18 | 19.8 | +2.0 | 18 | 30.5 | -8.8 | |
| C. # w/LDL 131-160 w/ % of Total LDL Screen | 8 | 7.0 | 12 | 13.2 | -6.2 | 5 | 8.5 | -1.5 | |
| D. # w/LDL >160 w/ % of Total LDL Screen | 10 | 8.7 | 8 | 8.8 | -0.1 | 4 | 6.8 | +1.9 | |

Figure 2-76: Sample Report, CVD and Cholesterol Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

| Cardiovascular Disease and Cholesterol Screening: List of patients with cholesterol or LDL value if any. | | | | | |
|--|--------|------------------------|-----|-----|--|
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT100,JASON AARON UP,AC | 000100 | COMMUNITY #1 | M | 46 | |
| PATIENT101,JOHN THOMAS UP | 000101 | COMMUNITY #1 | M | 47 | |
| PATIENT102,DAKOTA CHEY UP | 000102 | COMMUNITY #1 | M | 47 | |
| PATIENT103,TRAVIS CLINT UP | 000103 | COMMUNITY #1 | M | 47 | |
| PATIENT104,TRACY MITCHE UP,AC,IHD | 000104 | COMMUNITY #1 | M | 47 | |
| PATIENT105,RUSSELL DALE UP | 000105 | COMMUNITY #1 | M | 48 | |
| PATIENT106,CURTIS DWAYN UP,AC | 000106 | COMMUNITY #1 | M | 49 | |
| PATIENT107,RONALD UP,AC | 000107 | COMMUNITY #1 | M | 49 | |
| | | | | | |

Figure 2-77: Sample Patient List, CVD and Cholesterol Screening

2.8.7 Cardiovascular Disease and Blood Pressure Control

Denominators

All *Active Clinical patients* ages 20 and over. Broken down by gender.

All *User Population patients* ages 20 and older. Broken down by gender.

Active IHD patients, defined as all Active Clinical patients diagnosed with IHD prior to the Report Period, *and* at least two visits during the Report Period, *and* two IHD-related visits ever. Broken down by gender.

Numerators

Patients with Blood Pressure value documented at least twice in prior two years.

- Patients with normal BP, defined as < 120/80, i.e., the mean systolic value is less than (<) 120 *and* the mean diastolic value is less than (<) 80.
- Patients with Pre Hypertension I BP, defined as equal to or greater than (=>) 120/80 and less than (<) 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 *and* the mean diastolic value is equal to 80.
- Patients with Pre Hypertension II BP, defined as equal to or greater than (=>) 130/80 and less than (<) 140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 *and* the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.

- d. Patients with Stage 1 Hypertension BP, defined as equal to or greater than (\geq) 140/90 and less than ($<$) 160/100, i.e., the mean systolic value is equal to or greater than (\geq) 140 and less than ($<$) 160 *and* the mean diastolic value is equal to or greater than (\geq) 90 and less than ($<$) 100.
- e. Patients with Stage 2 Hypertension BP, defined as equal to or greater than (\geq) 160/100, i.e., the mean systolic value is equal to or greater than (\geq) 160 *and* the mean diastolic value is equal to or greater than (\geq) 100.

Logic Description

Age of the patient is calculated at beginning of the Report Period.

Blood pressure definition: CRS uses mean of last three Blood Pressures documented on non-ER visits in the past two years. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on a non-ER visit during the Report Period.

CRS uses the following codes to define the IHD numerator.

| Subject Defined | ICD and Other Codes |
|------------------------|--|
| Ischemic Heart Disease | V POV: 410.0-412.*, 414.0-414.9, 429.2 |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of Patients equal to or greater than (\geq) 20 or who have IHD with BP value, if any.

Measure Source

HP 2020 HDS-5

Measure Past Performance and Long-Term Targets

| Measure | Percent |
|---|---------|
| HP 2020 goal for adults with high blood pressure (140/90) | 26.9% |

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 196 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Cardiovascular Disease and Blood Pressure Control | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical Patients | | | | | | | | | |
| ages 20 and older | 1,068 | | 753 | | | 640 | | | |
| # w/ BPs documented | | | | | | | | | |
| w/in 2 yrs | 643 | 60.2 | 557 | 74.0 | -13.8 | 478 | 74.7 | -14.5 | |
| A. # w/Normal BP w/ % | | | | | | | | | |
| of Total Screened | 128 | 19.9 | 134 | 24.1 | -4.2 | 121 | 25.3 | -5.4 | |
| B. # w/Pre HTN I BP w/ % | | | | | | | | | |
| of Total Screened | 107 | 16.6 | 115 | 20.6 | -4.0 | 83 | 17.4 | -0.7 | |
| C. # w/Pre HTN II BP w/ % | | | | | | | | | |
| of Total Screened | 148 | 23.0 | 114 | 20.5 | +2.6 | 105 | 22.0 | +1.1 | |
| D. # w/Stage 1 HTN BP w/ % | | | | | | | | | |
| of Total Screened | 173 | 26.9 | 150 | 26.9 | +0.0 | 130 | 27.2 | -0.3 | |
| E. # w/Stage 2 HTN BP w/ % | | | | | | | | | |
| of Total Screened | 37 | 5.8 | 39 | 7.0 | -1.2 | 39 | 8.2 | -2.4 | |
| Male Active Clinical Patients | | | | | | | | | |
| ages 20 and older | 432 | | 293 | | | 241 | | | |
| # w/ BPs documented | | | | | | | | | |
| w/in 2 yrs | 231 | 53.5 | 203 | 69.3 | -15.8 | 177 | 73.4 | -20.0 | |
| A. # w/Normal BP w/ % | | | | | | | | | |
| of Total Screened | 8 | 3.5 | 23 | 11.3 | -7.9 | 22 | 12.4 | -9.0 | |
| B. # w/Pre HTN I BP w/ % | | | | | | | | | |
| of Total Screened | 27 | 11.7 | 37 | 18.2 | -6.5 | 22 | 12.4 | -0.7 | |
| C. # w/Pre HTN II BP w/ % | | | | | | | | | |
| of Total Screened | 64 | 27.7 | 46 | 22.7 | +5.0 | 45 | 25.4 | +2.3 | |
| D. # w/Stage 1 HTN BP w/ % | | | | | | | | | |
| of Total Screened | 89 | 38.5 | 79 | 38.9 | -0.4 | 63 | 35.6 | +2.9 | |
| E. # w/Stage 2 HTN BP w/ % | | | | | | | | | |
| of Total Screened | 16 | 6.9 | 17 | 8.4 | -1.4 | 25 | 14.1 | -7.2 | |
| Female Active Clinical Patients | | | | | | | | | |
| ages 20 and older | 636 | | 460 | | | 399 | | | |
| # w/ BPs documented | | | | | | | | | |
| w/in 2 yrs | 412 | 64.8 | 354 | 77.0 | -12.2 | 301 | 75.4 | -10.7 | |
| A. # w/Normal BP w/ % | | | | | | | | | |
| of Total Screened | 120 | 29.1 | 111 | 31.4 | -2.2 | 99 | 32.9 | -3.8 | |

| | | | | | | | | |
|---|----|------|----|------|------|----|------|------|
| B. # w/Pre HTN I BP w/ % of Total Screened | 80 | 19.4 | 78 | 22.0 | -2.6 | 61 | 20.3 | -0.8 |
| C. # w/Pre HTN II BP w/ % of Total Screened | 84 | 20.4 | 68 | 19.2 | +1.2 | 60 | 19.9 | +0.5 |
| D. # w/Stage 1 HTN BP w/ % of Total Screened | 84 | 20.4 | 71 | 20.1 | +0.3 | 67 | 22.3 | -1.9 |
| E. # w/Stage 2 HTN BP w/ % of Total Screened | 21 | 5.1 | 22 | 6.2 | -1.1 | 14 | 4.7 | +0.4 |

Figure 2-78: Sample Report, CVD and Blood Pressure Control

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|----------------------------------|-----|-----|--|
| Cardiovascular Disease and Blood Pressure Control: List of Patients => 20 or who have IHD with BP value, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1,SANDRA KAY UP,AC | 000001 | COMMUNITY #1 | F | 21 | |
| PATIENT2,EVELYN UP | 000002 | COMMUNITY #1 /3080F | F | 21 | |
| PATIENT3,MICHELLE UP,AC | 000003 | COMMUNITY #1 125/67 PRE HTN 1 | F | 22 | |
| PATIENT4,CAITLYN UP,AC,IHD | 000004 | COMMUNITY #1 131/67 PRE HTN 2 | F | 22 | |
| PATIENT5,BRITNEY JANE UP,AC | 000005 | COMMUNITY #1 102/56 NORMAL | F | 22 | |
| PATIENT6,KATHRYN ANNE UP,AC | 000006 | COMMUNITY #1 161/90 STG 2 HTN | F | 22 | |
| PATIENT7,RHONDA UP,AC | 000007 | COMMUNITY #1 153/85 STG 1 HTN | F | 22 | |

Figure 2-79: Sample Patient List, CVD and Blood Pressure Control

2.8.8 Controlling High Blood Pressure

Denominator

Active Clinical patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD. Broken down by gender and age groups (18 through 45 and 46 through 85).

Numerators

Number of patients with Blood Pressure value documented during the Report Period.

- f. Patients with *normal blood pressure*, defined as less than (<) 120/80; that is, the mean systolic value is less than (<) 120 *and* the mean diastolic value is less than (<) 80.

- g. Patients with *Pre Hypertension I BP*, defined as equal to or greater than (\Rightarrow) 120/80 and less than ($<$) 130/80, that is, the mean systolic value is equal to or greater than (\Rightarrow) 120 and less than ($<$) 130 *and* the mean diastolic value is equal to 80.
- h. Patients with *Pre Hypertension II BP*, defined as equal to or greater than (\Rightarrow) 130/80 and less than ($<$) 140/90; that is, the mean systolic value is equal to or greater than (\Rightarrow) 130 and less than ($<$) 140 *and* the mean diastolic value is equal to or greater than (\Rightarrow) 80 and less than ($<$) 90.
- i. Patients with *Stage 1 Hypertension Blood Pressure (BP)*, defined as equal to or greater than (\Rightarrow) 140/90 and less than ($<$) 160/100; that is, the mean systolic value is equal to or greater than (\Rightarrow) 140 and less than ($<$) 160 *and* the mean diastolic value is equal to or greater than (\Rightarrow) 90 and less than ($<$) 100.
- j. Patients with *Stage 2 Hypertension BP*, defined as equal to or greater than (\Rightarrow) 160/100; that is, the mean systolic value is equal to or greater than (\Rightarrow) 160 *and* the mean diastolic value is equal to or greater than (\Rightarrow) 100.

Logic Description

Age of the patient is calculated at beginning of the Report Period.

Blood pressure definition: CRS uses mean of last three BPs documented on non-ER visits during the Report Period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on non-ER visit during the Report Period.

CRS uses the following codes to define ESRD and hypertension.

| Subject Defined | CPT Codes | ICD and Other Codes |
|-----------------|---|---|
| ESRD | 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), or S9339 | V POV: 585.5, 585.6, V42.0, V45.1, (old code), V45.11, V45.12, or V56.* V Procedure: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6* |
| Hypertension | | V POV or Problem List Prior to the Report Period and at Least One Hypertension POV during Report Period: 401.* |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with hypertension and BP value, if any.

Measure Source

HP 2020 HDS-5, HDS-12

Measure Past Performance and Long-Term Targets

| Measure | Percent |
|--|---------|
| <i>HP 2020 goal for adults with high blood pressure (140/90)</i> | 26.9% |
| <i>HP 2020 goal for adults with high blood pressure and whose blood pressure is controlled</i> | 61.2% |

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 200 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |
| Controlling High Blood Pressure | | |

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|---|------------------|------|-------------------|------|-----------------------|----------------|------|--------------------|
| Active Clinical Pts | | | | | | | | |
| 18-85 w/HTN dx | 108 | | 101 | | | 91 | | |
| # w/ BPs documented | 96 | 88.9 | 92 | 91.1 | -2.2 | 85 | 93.4 | -4.5 |
| A. # w/Normal BP w/ % of Total Screened | 5 | 5.2 | 6 | 6.5 | -1.3 | 3 | 3.5 | +1.7 |
| B. # w/Pre HTN I BP w/ % of Total Screened | 8 | 8.3 | 13 | 14.1 | -5.8 | 8 | 9.4 | -1.1 |
| C. # w/Pre HTN II BP w/ % of Total Screened | 23 | 24.0 | 17 | 18.5 | +5.5 | 19 | 22.4 | +1.6 |
| D. # w/Stage 1 HTN BP w/ % of Total Screened | 36 | 37.5 | 41 | 44.6 | -7.1 | 42 | 49.4 | -11.9 |
| E. # w/Stage 2 HTN BP w/ % of Total Screened | 10 | 10.4 | 15 | 16.3 | -5.9 | 13 | 15.3 | -4.9 |
| A. Active Clinical Pts | | | | | | | | |
| 18-45 w/HTN dx | 23 | | 19 | | | 13 | | |
| # w/ BPs documented | 17 | 73.9 | 16 | 84.2 | -10.3 | 11 | 84.6 | -10.7 |
| A. # w/Normal BP w/ % of Total Screened | 2 | 11.8 | 2 | 12.5 | -0.7 | 0 | 0.0 | +11.8 |
| B. # w/Pre HTN I BP w/ % of Total Screened | 1 | 5.9 | 1 | 6.3 | -0.4 | 1 | 9.1 | -3.2 |
| C. # w/Pre HTN II BP w/ % of Total Screened | 3 | 17.6 | 2 | 12.5 | +5.1 | 2 | 18.2 | -0.5 |
| D. # w/Stage 1 HTN BP w/ % of Total Screened | 7 | 41.2 | 6 | 37.5 | +3.7 | 7 | 63.6 | -22.5 |
| E. # w/Stage 2 HTN BP w/ % of Total Screened | 2 | 11.8 | 5 | 31.3 | -19.5 | 1 | 9.1 | +2.7 |
| B. Active Clinical Pts | | | | | | | | |
| 46-85 w/HTN dx | 85 | | 82 | | | 78 | | |
| # w/ BPs documented | 79 | 92.9 | 76 | 92.7 | +0.3 | 74 | 94.9 | -1.9 |
| A. # w/Normal BP w/ % of Total Screened | 3 | 3.8 | 4 | 5.3 | -1.5 | 3 | 4.1 | -0.3 |
| B. # w/Pre HTN I BP w/ % of Total Screened | 7 | 8.9 | 12 | 15.8 | -6.9 | 7 | 9.5 | -0.6 |
| C. # w/Pre HTN II BP w/ % of Total Screened | 20 | 25.3 | 15 | 19.7 | +5.6 | 17 | 23.0 | +2.3 |
| D. # w/Stage 1 HTN BP w/ % of Total Screened | 29 | 36.7 | 35 | 46.1 | -9.3 | 35 | 47.3 | -10.6 |
| E. # w/Stage 2 HTN BP w/ % of Total Screened | 8 | 10.1 | 10 | 13.2 | -3.0 | 12 | 16.2 | -6.1 |

Figure 2-80: Sample Report, Controlling High Blood Pressure

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

| Controlling High Blood Pressure: List of patients with hypertension and BP value, if any. | | | | | |
|---|--------|------------------------|-----|-----|--|
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT1, STELLA LYNN | 000001 | COMMUNITY #1 | F | 46 | |
| HTN PT | | 156/82 STG 1 HTN | | | |
| PATIENT2, TARA | 000002 | COMMUNITY #1 | F | 51 | |
| HTN PT | | 201/87 STG 2 HTN | | | |
| PATIENT3, BOBBIE | 000003 | COMMUNITY #1 | F | 52 | |
| HTN PT | | 3074F/ | | | |
| PATIENT4, DARLENE | 000004 | COMMUNITY #1 | F | 54 | |
| HTN PT | | 139/73 PRE HTN 2 | | | |
| PATIENT5, NADINE | 000005 | COMMUNITY #1 | F | 61 | |
| HTN PT | | 159/86 STG 1 HTN | | | |

Figure 2-81: Sample Patient List, Controlling High Blood Pressure

2.8.9 Comprehensive CVD-Related Assessment

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 40.6% for the proportion of at-risk patients who have a comprehensive assessment.

Denominators

Active IHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with IHD prior to the Report Period, *and* at least two visits during the Report Period, *and* two IHD-related visits ever. (GPRA Denominator)

- Active IHD patients* ages 22 and older who are not Active Diabetic
- Active IHD patients* ages 22 and older who are Active Diabetic

Numerators

BP Assessed: Patients with Blood Pressure value documented at least twice in prior two years.

LDL Assessed: Patients with LDL completed in past five years, regardless of result.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Current Report period.

BMI Available: Patients for whom a BMI could be calculated.

Note: This numerator does *not* include refusals.

Lifestyle Counseling: Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education during the Report Period.

Patients with *comprehensive CVD assessment*, defined as having BP, LDL, and tobacco use assessed, BMI calculated, and lifestyle counseling.

Note: This does *not* include depression screening and *does not* include refusals of BMI. (GPRA Numerator)

Refusal of BMI: Patients who refused a height or weight measurement and for whom a BMI could not be calculated.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

Note: This numerator does *not* include refusals.

Logic Description

Age of the patient is calculated at beginning of the Report Period.

Diabetes defined as: Diagnosed with diabetes (first POV in V POV with 250.00 through 250.93) prior to the Current Report Period, *and* at least two visits during the Current Report Period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

IHD diagnosis defined as: 410.0 through 412.*, 414.0 through 414.9, 428.* or 429.2 recorded in the V POV file.

Blood pressure definition: Having a minimum of two BPs documented on non-ER visits during the Report Period in past two years. If CRS does not find two BPs, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on non-ER visit during the past two years.

LDL definition: Finds the most recent test done in the last five years, regardless of the results of the measurement.

BMI definition: CRS calculates when the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years; not required to be recorded on same day.

BMI Refusal definition: Refusals of a height and/or weight measurement include REF, NMI, and UAS and must be documented during the past year. For ages 19 and older, the height and the weight must be refused during the past year and are not required to be on the same visit.

CRS uses the following codes and taxonomies to define the numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|---|--|-------------|------------------------------|
| LDL - Finds the most recent test done in the last 5 years, regardless of the results of the measurement. | 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F | | Yes | DM AUDIT LDL CHOLESTEROL TAX |
| Tobacco Screening | D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code) or G8453 (old code) | Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE) (see table on next page) V POV or current Active Problem List: 305.1, 305.1* (old codes), 649.00-649.04, V15.82 Patient education codes: containing “TO-”, “-TO”, “-SHS”, 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code) or G8453 (old code) Dental code: 1320 | | |
| Medical Nutrition Therapy | 97802-97804, G0270, G0271 | Primary or secondary provider codes: 07, 29, 97, 99 Clinic codes: 67 (dietary) or 36 (WIC) | | |
| Nutrition Education | | V POV: V65.3 dietary surveillance and counseling Patient education codes: ending “-N” (nutrition) or “-MNT” (medical nutrition therapy) (or old code “-DT” (diet)) or containing V65.3. | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|-----------|--|-------------|----------|
| Exercise Education | | V POV: V65.41 exercise counseling Patient education codes: ending “-EX” (exercise) or containing V65.41. | | |
| Related Exercise and Nutrition Education | | Patient education codes: ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01. | | |
| Depression Screening | | V Exam: Exam Code 36 V POV: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) V Measurement in PCC or BH: PHQ2 or PHQ9 | | |
| Mood Disorders | | At least 2 visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS (see codes below). V POV: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 BHS POV: 14, 15 | | |

All existing national Tobacco Health Factors listed below are counted as tobacco screening.

| Health Factor |
|--------------------------------|
| Ceremonial |
| Cessation-Smokeless |
| Cessation-Smoker |
| Current Smokeless |
| Current Smoker |
| Current Smoker, status unknown |
| Current smoker, every day |
| Current smoker, some day |

| Health Factor |
|---|
| Non-Tobacco User |
| Previous Smokeless |
| Previous (Former) Smokeless |
| Previous Smoker |
| Previous (Former) Smoker |
| Smoke Free Home |
| Smoker In Home |
| Current Smoker & Smokeless |
| Exposure To Environmental Tobacco Smoke |

Key Logic Changes from CRS Version 12.0

Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.

Patient List Description

List of patients with assessments received, if any.

Measure Source

Not Available

Measure Past Performance Long-Term Targets

| Performance | Percent |
|--|----------------|
| IHS FY 2011 Performance (Comprehensive CVD Assessment) | 39.8% |
| IHS FY 2010 Performance (Comprehensive CVD Assessment) | 35.0% |
| IHS FY 2009 Performance (Comprehensive CVD Assessment) | 32.0% |
| IHS FY 2008 Performance (Comprehensive CVD Assessment) | 30.0% |
| IHS FY 2007 Performance (Comprehensive CVD Assessment) | 30.0% |
| IHS FY 2011 Performance (BP Assessed) | 97.2% |
| IHS FY 2010 Performance (BP Assessed) | 98.0% |
| IHS FY 2009 Performance (BP Assessed) | 97.0% |
| IHS FY 2008 Performance (BP Assessed) | 98.0% |
| IHS FY 2011 Performance (LDL Assessed) | 92.9% |
| IHS FY 2010 Performance (LDL Assessed) | 92.0% |
| IHS FY 2009 Performance (LDL Assessed) | 91.0% |
| IHS FY 2008 Performance (LDL Assessed) | 90.0% |
| IHS FY 2011 Performance (Tobacco Assessed) | 84.2% |
| IHS FY 2010 Performance (Tobacco Assessed) | 84.0% |

| Performance | Percent |
|---|---------|
| IHS FY 2009 Performance (Tobacco Assessed) | 83.0% |
| IHS FY 2008 Performance (Tobacco Assessed) | 79.0% |
| IHS FY 2011 Performance (BMI Assessed) | 97.2% |
| IHS FY 2010 Performance (BMI Assessed) | 98.0% |
| IHS FY 2008 Performance (BMI Assessed or Refused) | 85.0% |
| IHS FY 2011 Performance (Lifestyle Counseling) | 45.3% |
| IHS FY 2010 Performance (Lifestyle Counseling) | 41.0% |
| IHS FY 2009 Performance (Lifestyle Counseling) | 39.0% |
| IHS FY 2008 Performance (Lifestyle Counseling) | 38.0% |
| IHS FY 2011 Performance (Depression Screen) | 75.7% |
| IHS FY 2010 Performance (Depression Screen) | 72.0% |
| IHS FY 2009 Performance (Depression Screen) | 62.0% |
| IHS FY 2008 Performance (Depression Screen) | 53.0% |

| | | | | | | | | |
|--|-------------------|------|---------|-------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 207 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Comprehensive CVD-Related Assessment | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active IHD Pts 22+ (GPRA) | 77 | | 45 | | | 36 | | |
| # w/ BPs documented w/in 2 yrs | 72 | 93.5 | 45 | 100.0 | -6.5 | 36 | 100.0 | -6.5 |
| # w/ LDL done in past 5 yrs | 60 | 77.9 | 38 | 84.4 | -6.5 | 30 | 83.3 | -5.4 |
| # w/Tobacco Screening w/in 1 yr | 66 | 85.7 | 38 | 84.4 | +1.3 | 27 | 75.0 | +10.7 |
| # w/BMI calculated -No Refusals | 72 | 93.5 | 44 | 97.8 | -4.3 | 35 | 97.2 | -3.7 |
| # w/ lifestyle educ w/in 1 yr | 43 | 55.8 | 22 | 48.9 | +7.0 | 22 | 61.1 | -5.3 |
| # w/ BP, LDL, tobacco, BMI and life counseling -No Refusals (GPRA) | 35 | 45.5 | 19 | 42.2 | +3.2 | 14 | 38.9 | +6.6 |
| # w/BMI refusal (No BMI) | 2 | 2.6 | 0 | 0.0 | +2.6 | 0 | 0.0 | +2.6 |
| # w/ Depression screening or Mood Disorder DX -No Refusals | 20 | 26.0 | 4 | 8.9 | +17.1 | 2 | 5.6 | +20.4 |
| A. Active IHD Pts 22+ and are NOT Active | | | | | | | | |

| | | | | | | | |
|--|----|------|----|-------|-------|----|-------------|
| Diabetic | 41 | | 20 | | 17 | | |
| # w/ BPs documented | | | | | | | |
| w/in 2 yrs | 36 | 87.8 | 20 | 100.0 | -12.2 | 17 | 100.0 -12.2 |
| # w/LDL done | | | | | | | |
| in past 5 yrs | 28 | 68.3 | 17 | 85.0 | -16.7 | 13 | 76.5 -8.2 |
| # w/Tobacco Screening | | | | | | | |
| w/in 1 yr | 33 | 80.5 | 15 | 75.0 | +5.5 | 13 | 76.5 +4.0 |
| # w/BMI calculated | | | | | | | |
| -No Refusals | 38 | 92.7 | 20 | 100.0 | -7.3 | 16 | 94.1 -1.4 |
| # w/ lifestyle | | | | | | | |
| educ w/in 1 yr | 24 | 58.5 | 7 | 35.0 | +23.5 | 7 | 41.2 +17.4 |
| # w/ BP, LDL, tobacco, BMI and life counseling | | | | | | | |
| -No Refusals | 19 | 46.3 | 6 | 30.0 | +16.3 | 4 | 23.5 +22.8 |
| # w/BMI refusal (No BMI) | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 +0.0 |
| # w/ Depression screening, or Mood Disorder DX | | | | | | | |
| -No Refusals | 13 | 31.7 | 1 | 5.0 | +26.7 | 1 | 5.9 +25.8 |

Figure 2-82: Sample Report, Comprehensive CVD-Related Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Comprehensive CVD-Related Assessment: List of patients with assessments received, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|--|-----|-----|
| PATIENT1,CAITLYN | 000001 | COMMUNITY #1 | F | 22 |
| IHD | | ALL: BP: 131/67 PRE STG 1; LDL: 06/08/12; TOB: 07/25/12 NEVER SMOKED; BMI: 25.4; LIFE: 08/15/012 UTI-N SN; DEP: 05/03/12 Meas PHQ9 | | |
| PATIENT2,CARLA | 000002 | COMMUNITY #1 | F | 40 |
| IHD | | BP: 112/66 NORMAL; TOB: 08/26/12 NEVER SMOKED; BMI: 33.7 | | |
| PATIENT3,JENNY | 000003 | COMMUNITY #1 | F | 47 |
| IHD | | BP: 3074F/; TOB: 11/01/12 D1320; BMI: 39.5; LIFE: 03/03/12 Prv 97; DEP: 11/01/12 CPT 1220F | | |
| PATIENT4,SHERRY | 000004 | COMMUNITY #1 | F | 68 |
| IHD,AD | | ALL: BP: 150/82 STG 1 HTN; LDL: 09/13/12; TOB: 12/30/12 NEVER SMOKED; BMI: 26.8; LIFE: 10/19/12 PM-LA | | |
| PATIENT5,PAULINE | 000005 | COMMUNITY #1 | F | 70 |
| IHD,AD | | BP: 149/72 STG 1 HTN; LDL: 10/24/12; TOB: 10/24/12 CURRENT SMOKER, STATUS UNKNOWN; BMI: 37.5 | | |
| PATIENT6,TINA MARIE | 000006 | COMMUNITY #1 | F | 78 |
| IHD,AD | | BP: 3077F/; TOB: 01/27/12 G8402; BMI: 43.4; DEP: 09/11/12 Meas PHQ2 | | |

Figure 2-83: Sample Patient List: Comprehensive CVD-Related Assessment

2.8.10 Appropriate Medication Therapy after a Heart Attack

Denominator

Active Clinical patients aged 35 and older discharged for an AMI during the first 51 weeks of the Report Period and were not readmitted for any diagnosis within seven days of discharge. Broken down by gender.

Numerators

Patients with active prescription for or who have a contraindication/previous adverse reaction to *beta-blockers*.

Note: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/previous adverse reaction to *ASA (aspirin) or other anti-platelet agent*.

Note: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *ACEIs/ARBs*.

Note: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *statins*.

Note: This numerator does *not* include refusals.

Also included for the numerators above are subnumerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with documented refusal of the specified medication

Patients with active prescriptions for *all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin), and/or who have a contraindication/previous adverse reaction.

Note: This numerator does *not* include refusals.

Logic Description

Age is calculated at the beginning of the Report Period.

Acute Myocardial Infarction (AMI) definition: POV 410.*1 (i.e., first eligible episode of an AMI) with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.

Denominator Exclusions

Patients meeting any of the following conditions will be excluded from the denominator.

1. Patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death."
2. Patients readmitted for any diagnosis within seven days of discharge.
3. Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
4. Patients with a Provider Narrative beginning with "Consider"; "Doubtful"; "Maybe"; "Possible"; "Perhaps"; "Rule Out"; "R/O"; "Probable"; "Resolved"; "Suspect"; "Suspicious"; or "Status Post."

Numerator Logic

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the three conditions below:

1. An active prescription (not discontinued as of [discharge date plus (+) 7 days] and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within seven days after discharge. "Active" prescription defined as: Days Prescribed greater then (>) ((Discharge Date plus (+) 7 days) - Order Date); *or*
2. A refusal of the medication at least once during hospital stay through seven days after discharge date; *or...*
3. Have a contraindication/previous adverse reaction to the indicated medication.

Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/allergy will be counted in subnumerators B–C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A–C may not add up the to the numerator total.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Beta-Blocker Numerator Logic

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.)

Refusal of beta-blocker: REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during hospital stay through seven days after discharge date.

CRS uses the following codes to define contraindications to beta-blockers.

| Contraindication to Beta-Blockers (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|---|---|
| Asthma | | POV: 2 diagnoses of 493* on different visit dates |
| Hypotension | | POV: 1 diagnosis of 458* |
| Heart Block greater than (>)1 Degree | | POV: 1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7 |
| Sinus Bradycardia | | POV: 1 diagnosis of 427.81 |
| COPD | | POV: 2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496 |
| NMI Refusal | G8011 (old code) at least once during hospital stay through 7 days after discharge date | Refusal: NMI (not medically indicated) refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

Adverse Drug Reaction/Allergy to Beta-Blockers

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E942.0 |
| Entry in ART (Patient Allergies File): "beta block*" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "beta block*", "bblock*" or "b block*" |

ASA (aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated DM AUDIT ANTI-PLATELET DRUGS taxonomy.

Refusal of ASA/other anti-platelet: REF refusal of any ASA or anti-platelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during hospital stay through seven days after discharge date.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

| Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|---|--|
| Active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge | | Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS |
| Hemorrhage | | POV: 459.0 |
| NMI Refusal | G8008 (old code) at least once during hospital stay through 7 days after discharge date | Refusal: NMI (not medically indicated) refusal for any aspirin at least once during hospital stay through 7 days after discharge date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E935.3 |
| Entry in ART (Patient Allergies File): "aspirin" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "ASA" or "aspirin" |

ACEI/ARB Numerator Logic

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

Refusal of ACEI: REF refusal of any ACE inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during hospital stay through seven days after discharge date.

CRS uses the following codes to define contraindications to ACE inhibitors.

| Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|------------------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI (not medically indicated) refusal for any ACE inhibitor at least once during hospital stay through 7 days after discharge date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

Adverse Drug Reaction/ Allergy to ACE Inhibitors

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): “ace inhibitor” or “ACEI” |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: “ace i*” or “ACEI” |

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-Amlodipine-hydrochlorothiazide, Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

Refusal of ARB: REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during hospital stay through seven days after discharge date.

CRS uses the following codes to define contraindications to ARBs.

| Contraindication to ARBs (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|------------------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI refusal for any ARB at least once during hospital stay through 7 days after discharge date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ARBs.

Adverse Drug Reaction/Allergy to ARBs

| ICD and Other Codes |
|---|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "Angiotensin Receptor Blocker" or "ARB" |

Statins Numerator Logic

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Advicor, Caduet, PraviGard Pac, Vytorin.

Refusal of Statin: REF refusal of any statin medication in site-populated medication taxonomy BGP PQA STATIN MEDS at least once during hospital stay through seven days after discharge date.

CRS uses the following codes to define contraindications to statins.

| Contraindication to Statins (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|-----------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Acute Alcoholic Hepatitis | | POV: 571.1 during the Report Period |
| NMI Refusal | | Refusal: NMI refusal for any statin at least once during hospital stay through 7 days after discharge date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

Adverse Drug Reaction/Allergy to Statins

| ICD and Other Codes |
|---|
| Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period |
| Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period |
| POV: Myopathy/Myalgia, defined as any of the following during the Report Period: 359.0-359.9, 729.1, 710.5, or 074.1 |
| POV: 995.0-995.3 AND E942.9 |
| Entry in ART (Patient Allergies File): "statin" or "statins" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "Statin" or "Statins" |

| Subject Defined | ICD and CPT Codes |
|--------------------|---|
| Pregnancy | <p>POV or Problem List: At least two visits during the Report Period with 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53, 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09, where the primary provider is not a CHR (Provider code 53), and with no documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period.</p> |
| Abortion | <p>CPTs: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p>POVs: 635*, 636*, or 637*</p> <p>Procedures: 69.01, 69.51, 74.91, 96.49</p> |
| Miscarriage | <p>CPTs: 59812, 59820, 59821, 59830</p> <p>POVs: 630, 631, 632, 633*, or 634*</p> |

All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

Key Logic Changes from CRS Version 12.0

1. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
2. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).
3. Added code 48134-1 to LOINC taxonomy for ALT.
4. Added codes 12187-1, 12189-7, 13969-1, 15048-2, 15049-0, 20569-0, 2152-7, 2154-3, 2155-0, 2158-4, 32673-6, 33547-1, 38482-6, 49129-0, 49136-5, 49551-5, 50757-4, 9642-0, 9643-8 to LOINC taxonomy for Creatine Kinase.
5. Replaced BGP HEDIS STATIN MEDS with BGP PQA STATIN MEDS.
6. Updated BGP HEDIS ARB MEDS medications to include Azilsartan, Aliskiren-Amlodipine-hydrochlorothiazide, Amlodipine-hydrochlorothiazide-olmesartan, and Amlodipine-Telmisartan.
7. Updated BGP PQA STATIN MEDS medications to include Altoprev and Pitavastatin.

Patient List Description

List of patients with AMI, with appropriate medication therapy, if any.

Measure Source

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

Measure Past Performance and Long-Term Targets

None

| | | | | | | |
|--|-------------------|---|---------|---|------------------|-----------------|
| DU | November 25, 2012 | | | | | Page 216 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | |
| ----- | | | | | | |
| Appropriate Medication Therapy after a Heart Attack | | | | | | |
| | REPORT | % | PREV YR | % | CHG from BASE | % |
| | PERIOD | | PERIOD | | PREV YR % PERIOD | CHG from BASE % |
| Active Clinical Pts 35+ | | | | | | |
| hospitalized for AMI | 71 | | 0 | | 0 | |

| | | | | | | | | |
|--|----|------|---|-----|-------|---|-----|-------|
| # w/beta-blocker Rx/contra/ADR | | | | | | | | |
| -No Refusals | 27 | 38.0 | 0 | 0.0 | +38.0 | 0 | 0.0 | +38.0 |
| A. # w/beta-blocker Rx w/ % of Total | 5 | 18.5 | 0 | 0.0 | +18.5 | 0 | 0.0 | +18.5 |
| B. # w/contra/ADR w/ % of Total | 22 | 81.5 | 0 | 0.0 | +81.5 | 0 | 0.0 | +81.5 |
| # w/ beta-blocker refusal | 2 | 2.8 | 0 | 0.0 | +2.8 | 0 | 0.0 | +2.8 |
| # w/ASA Rx/contra/ADR | | | | | | | | |
| -No Refusals | 9 | 12.7 | 0 | 0.0 | +12.7 | 0 | 0.0 | +12.7 |
| A. # w/ASA Rx w/% of Total | 3 | 33.3 | 0 | 0.0 | +33.3 | 0 | 0.0 | +33.3 |
| B. # w/contra/ADR w/ % of Total | 6 | 66.7 | 0 | 0.0 | +66.7 | 0 | 0.0 | +66.7 |
| # w/ ASA refusal | 3 | 4.2 | 0 | 0.0 | +4.2 | 0 | 0.0 | +4.2 |
| # w/ACEI/ARB Rx/contra/ADR | | | | | | | | |
| -No Refusals | 19 | 26.8 | 0 | 0.0 | +26.8 | 0 | 0.0 | +26.8 |
| A. # w/ACEI/ARB Rx w/% of Total | 4 | 21.1 | 0 | 0.0 | +21.1 | 0 | 0.0 | +21.1 |
| B. # w/contra/ADR w/ % of Total | 15 | 78.9 | 0 | 0.0 | +78.9 | 0 | 0.0 | +78.9 |
| # w/ ACEI/ARB refusal | 2 | 2.8 | 0 | 0.0 | +2.8 | 0 | 0.0 | +2.8 |
| # w/statin Rx/contra/ADR | | | | | | | | |
| -No Refusals | 17 | 23.9 | 0 | 0.0 | +23.9 | 0 | 0.0 | +23.9 |
| A. # w/statin Rx w/% of Total | 5 | 29.4 | 0 | 0.0 | +29.4 | 0 | 0.0 | +29.4 |
| B. # w/contra/ADR w/ % of Total | 12 | 70.6 | 0 | 0.0 | +70.6 | 0 | 0.0 | +70.6 |
| # w/ Statin Refusal | 2 | 2.8 | 0 | 0.0 | +2.8 | 0 | 0.0 | +2.8 |
| # w/Rx/contra/ADR of ALL meds-No Refusals | 4 | 5.6 | 0 | 0.0 | +5.6 | 0 | 0.0 | +5.6 |

Figure 2-84: Sample Report, Appropriate Medication Therapy after a Heart Attack

| | | | | |
|--|--------|------------------------|-----------|---------------------------|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Appropriate Medication Therapy after a Heart Attack: List of patients with AMI, with appropriate medication therapy, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,CECELIA | 000001 | COMMUNITY #1 | F | 37 |
| AC | | BETA: 06/30/12 | Contra | 2/3 heart block POV 426.3 |
| PATIENT2,KATHLEEN | 000002 | COMMUNITY #1 | F | 38 |
| AC | | ACEI/ARB: Contra | pregnant; | STATIN: Contra pregnant |

```

PATIENT3,KIMBERLY A      000003 COMMUNITY #1    F   49
AC                        ASA: 12/16/11 CLOPIDOGREL BISULFATE 75MG TAB;
ACEI/ARB: 01/14/12 Contra BF-HC; STATIN: 01/14/12 Contra BF-HC
PATIENT4,TIMOTHY JOHN    000004 COMMUNITY #1    M   57
AC                        ACEI/ARB: 06/01/12 Contra NMI CAPTOPRIL 25MG TABS
PATIENT5,FELIPE         000005 COMMUNITY #1    M   57
AC
PATIENT6,JAMES DALTON    000006 COMMUNITY #1    M   77
AC                        ALL MEDS:  BETA: 07/23/12 Contra CPT G8011; ASA:
07/23/12 Contra CPT G8008; ACEI/ARB: 07/27/10 Contra POV 396.0; STATIN: 06/05/12
SIMVASTATIN 40MG TAB

```

Figure 2-85: Sample Patient List: Appropriate Medication Therapy after a Heart Attack

2.8.11 Persistence of Appropriate Medication Therapy after a Heart Attack

Denominator

Active Clinical patients 35 and older diagnosed with an AMI six months prior to the Report Period through the first six months of the Report Period. Broken down by gender.

Numerators

Patients with a *135-day course of treatment with beta-blockers*, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

Note: This numerator does *not* include refusals.

Patients with a *135-day course of treatment with ASA (aspirin) or other anti-platelet agent* or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

Note: This numerator does *not* include refusals.

Patients with a *135-day course of treatment with ACEIs/ARBs* or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

Note: This numerator does *not* include refusals.

Patients with a *135-day course of treatment with statins* or who have a contraindication/previous adverse reaction to statin therapy.

Note: This numerator does *not* include refusals.

Also included for the numerators above are subnumerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with documented refusal of the specified medication

Patients with a *135-day course of treatment for all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, *and* statin) following first discharge date or visit date, including previous active prescriptions; and/or who have a contraindication/previous adverse reaction.

| |
|---|
| Note: This numerator does <i>not</i> include refusals. |
|---|

Logic Description

Age is calculated at the beginning of the Report Period.

Acute Myocardial Infarction (AMI) definition: POV 410.0* through 410.9* or 412. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between six months prior to beginning of Report Period through first six months of the Report Period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.

Denominator Exclusions

Patients meeting any of the following conditions will be excluded from the denominator.

- If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death.”
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
- Patients with a Provider Narrative beginning with “Consider,” “Doubtful,” “Maybe,” “Possible,” “Perhaps,” “Rule Out,” “R/O,” “Probable,” “Resolved,” “Suspect,” “Suspicious,” or “Status Post.”

Numerator Logic

In the logic below, “ever” is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the three conditions below.

1. A total days' supply greater than or equal to (\geq) 135 days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Medications must not have a comment of RETURNED TO STOCK. Prior active prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent prescription (see codes below) prior to admission/visit date with the number of days supply equal to or greater than the discharge/visit date minus the prescription date; *or*
2. A refusal of the medication at least once at time of diagnosis through the 180 days after AMI; *or*
3. Have a contraindication/previous adverse reaction to the indicated medication.
4. Refusals and contraindications/previous ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/allergy will be counted in subnumerators B–C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the sub-numerator totals of A–C may not add up to the numerator total.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator who has prior active prescription:

- Admission Date: 2/1/2012, Discharge Date: 2/15/2012
- Must have 135 days prescribed by 8/13/2012 (Discharge Date+180)
- Prior Beta-Blocker Rx Date: 1/15/2012
- # Days Prescribed: 60 (treats patient through 3/15/2012)
- Discharge Date minus Rx Date: 2/15/2012 through 1/15/2012 = 31, 60 is greater than or equal to (\geq) 31, prescription is considered Prior Active Rx
- 3/15/2012 is between 2/15 and 8/13/2012, thus remainder of Prior Active Rx can be counted toward 180-day treatment period

- # Remaining Days Prescribed from Prior Active Rx:
- $(60 - (\text{Discharge Date} - \text{Prior Rx Date})) = 60 - (2/15/2012 - 1/15/2012) = 60 - 31 = 29$
- Rx #2: 4/1/2012, # Days Prescribed: 90
- Rx #3: 7/10/2012, #Days Prescribed: 90
- Total Days Supply Prescribed between 2/15 and 8/13/2012: $29 + 90 + 90 = 209$

Beta-Blocker Numerator Logic

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol and Hydrochlorothiazide-propranolol.)

Refusal of beta-blocker: REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

CRS uses the following codes to define contraindications to beta-blockers.

| Contraindication to Beta-Blockers (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|---|---|
| Asthma | | POV: 2 diagnoses of 493* on different visit dates |
| Hypotension | | POV: 1 diagnosis of 458* |
| Heart Block >1 Degree | | POV: 1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7 |
| Sinus Bradycardia | | POV: 1 diagnosis of 427.81 |
| COPD | | POV: 2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496 |
| NMI Refusal | G8011 (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date | Refusal: NMI refusal for any beta-blocker at least once during the period admission/visit date through the 180 days after discharge/visit date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

Adverse Drug Reaction/Allergy to Beta-Blockers

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E942.0 |
| Entry in ART (Patient Allergies File): "beta block*" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "beta block*", "bblock*" or "b block*" |

ASA (Aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

Refusal of ASA/other anti-platelet: REF refusal of any ASA or anti-platelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or DM AUDIT ANTI-PLATELET DRUGS at least once during the period admission/visit date through the 180 days after discharge/visit date.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

| Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|---|--|
| Active prescription for Warfarin/Coumadin during the period admission/visit date through the 180 days after discharge/visit date | | Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS |
| Hemorrhage | | POV: 459.0 |
| NMI Refusal | G8008 (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date | Refusal: NMI (not medically indicated) refusal for any aspirin/other anti-platelet at least once during the period admission/visit date through the 180 days after discharge/visit date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E935.3 |
| Entry in ART (Patient Allergies File): "aspirin" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "ASA" or "aspirin" |

ACEI/ARB Numerator Logic

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

Refusal of ACEI: REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

CRS uses the following codes to define contraindications to ACE inhibitors.

| Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|------------------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the period admission/visit date through the 180 days after discharge/visit date Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI refusal for any ACE inhibitor at least once during the period admission/visit date through the 180 days after discharge/visit date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

Adverse Drug Reaction/Allergy to ACE Inhibitors

| ICD and Other Codes |
|---|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): "ace inhibitor" or "ACEI" |
| Contained within or Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "ace i*" or "ACEI" |

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.).

Antihypertensive Combinations (Aliskiren-Amlodipine-hydrochlorothiazide, Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

Refusal of ARB: REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

CRS uses the following codes to define contraindications to ARBs.

| Contraindication to ARBs (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|-----------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the period admission/visit date through the 180 days after discharge/visit date Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |

| Contraindication to ARBs (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|-----------|--|
| NMI Refusal | | Refusal: NMI refusal for any ARB at least once during the period admission/visit date through the 180 days after discharge/visit date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ARBs.

Adverse Drug Reaction/Allergy to ARBs

| ICD and Other Codes |
|---|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "Angiotensin Receptor Blocker" or "ARB" |

Statins Numerator Logic

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Advicor, Caduet, PraviGard Pac, Vytorin.

Refusal of Statin: REF refusal of any statin medication in site-populated medication taxonomy BGP PQA STATIN MEDS at least once during admission/visit date through the 180 days after discharge/visit date.

CRS uses the following codes to define contraindications to statins.

| Contraindication to Statins (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|-----------|--------------------------|
| Pregnancy | | See below for definition |

| Contraindication to Statins (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|------------------|--|
| Breastfeeding | | POV: V24.1 during the period admission/visit date through the 180 days after discharge/visit date Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date |
| Acute Alcoholic Hepatitis | | POV: 571.1 during the period admission/visit date through the 180 days after discharge/visit date |
| NMI Refusal | | Refusal: NMI refusal for any statin at least once during the period admission/visit date through the 180 days after discharge/visit date |

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

Adverse Drug Reaction/Allergy to Statins

| ICD and Other Codes |
|--|
| Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the period admission/visit date through the 180 days after discharge/visit date |
| Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the period admission/visit date through the 180 days after discharge/visit date |
| POV: Myopathy/Myalgia, defined as any of the following during the period admission/visit date through the 180 days after discharge/visit date: 359.0–359.9, 729.1, 710.5, or 074.1 |
| POV: 995.0–995.3 AND E942.9 |
| Entry in ART (Patient Allergies File): “statin” or “statins” |
| Entry in Problem List or in Provider Narrative for any POV 995.0–995.3 or V14.8: “Statin” or “Statins” |

| Subject Defined | ICD and CPT Codes |
|--------------------|---|
| Pregnancy | <p>POV or Problem List: At least two visits during the Report Period with 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53, 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09, where the primary provider is not a CHR (Provider code 53), and with no documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period.</p> |
| Abortion | <p>CPTs: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p>POVs: 635*, 636*, or 637*</p> <p>Procedures: 69.01, 69.51, 74.91, 96.49</p> |
| Miscarriage | <p>CPTs: 59812, 59820, 59821, 59830</p> <p>POVs: 630, 631, 632, 633*, or 634*</p> |

All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

Key Logic Changes from CRS Version 12.0

1. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
2. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).
3. Added code 48134-1 to LOINC taxonomy for ALT.
4. Added codes 12187-1, 12189-7, 13969-1, 15048-2, 15049-0, 20569-0, 2152-7, 2154-3, 2155-0, 2158-4, 32673-6, 33547-1, 38482-6, 49129-0, 49136-5, 49551-5, 50757-4, 9642-0, 9643-8 to LOINC taxonomy for Creatine Kinase.
5. Replaced BGP HEDIS STATIN MEDS with BGP PQA STATIN MEDS.
6. Updated BGP HEDIS ARB MEDS medications to include Azilsartan, Aliskiren-Amlodipine-hydrochlorothiazide, Amlodipine-hydrochlorothiazide-olmesartan, and Amlodipine-Telmisartan.
7. Updated BGP PQA STATIN MEDS medications to include Altoprev and Pitavastatin.

Patient List Description

List of patients with AMI, with persistent medication therapy, if any.

Measure Source

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

Measure Past Performance and Long-Term Targets

None

| | | | | | | |
|--|-------------------|---|---------|---|------------------|----------|
| DU | November 25, 2012 | | | | | Page 228 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | |
| ----- | | | | | | |
| Persistence of Appropriate Medication Therapy after a Heart Attack | | | | | | |
| | REPORT | % | PREV YR | % | CHG from BASE | % |
| | PERIOD | | PERIOD | | PREV YR % PERIOD | BASE % |
| Active Clinical Pts 35+ | | | | | | |
| w/ AMI DX | 61 | | 4 | | 4 | |

| | | | | | | | | |
|-----------------------------|----|------|---|-------|-------|---|-------|-------|
| # w/135-day beta-blocker | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 23 | 37.7 | 2 | 50.0 | -12.3 | 3 | 75.0 | -37.3 |
| A. # w/135-day beta blocker | | | | | | | | |
| Rx w/ % of Total | 3 | 13.0 | 2 | 100.0 | -87.0 | 2 | 66.7 | -53.6 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 20 | 87.0 | 0 | 0.0 | +87.0 | 1 | 33.3 | +53.6 |
| # w/ beta-blocker refusal | | | | | | | | |
| | 1 | 1.6 | 0 | 0.0 | +1.6 | 0 | 0.0 | +1.6 |
| # w/135-day ASA | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 5 | 8.2 | 0 | 0.0 | +8.2 | 2 | 50.0 | -41.8 |
| A. # w/135-day ASA | | | | | | | | |
| Rx w/% of Total | 1 | 20.0 | 0 | 0.0 | +20.0 | 2 | 100.0 | -80.0 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 4 | 80.0 | 0 | 0.0 | +80.0 | 0 | 0.0 | +80.0 |
| # w/ ASA refusal | | | | | | | | |
| | 2 | 3.3 | 0 | 0.0 | +3.3 | 0 | 0.0 | +3.3 |
| # w/135-day ACEI/ARB | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 13 | 21.3 | 1 | 25.0 | -3.7 | 1 | 25.0 | -3.7 |
| A. # w/135-day ACEI/ARB | | | | | | | | |
| Rx w/% of Total | 1 | 7.7 | 1 | 100.0 | -92.3 | 1 | 100.0 | -92.3 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 12 | 92.3 | 0 | 0.0 | +92.3 | 0 | 0.0 | +92.3 |
| # w/ ACEI/ARB refusal | | | | | | | | |
| | 1 | 1.6 | 0 | 0.0 | +1.6 | 0 | 0.0 | +1.6 |
| # w/135-day statin | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 6 | 9.8 | 2 | 50.0 | -40.2 | 2 | 50.0 | -40.2 |
| A. # w/135-day statin | | | | | | | | |
| Rx w/% of Total | 2 | 33.3 | 2 | 100.0 | -66.7 | 2 | 100.0 | -66.7 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 4 | 66.7 | 0 | 0.0 | +66.7 | 0 | 0.0 | +66.7 |
| # w/ Statin refusal | | | | | | | | |
| | 2 | 3.3 | 0 | 0.0 | +3.3 | 0 | 0.0 | +3.3 |
| # w/Rx/contra/ADR of ALL | | | | | | | | |
| meds-No Refusals | 2 | 3.3 | 0 | 0.0 | +3.3 | 1 | 25.0 | -21.7 |

Figure 2-86: Sample Report, Persistence of Appropriate Medication Therapy after a Heart Attack

| | | | | |
|--|-----------|--------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Persistence of Appropriate Medication Therapy after a Heart Attack: List of patients with AMI, with persistent medication therapy, if any | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
| DENOMINATOR | NUMERATOR | | | |
| ----- | | | | |
| PATIENT1,RHONDA | 000001 | COMMUNITY #1 | F | 35 |
| AC ALL MEDS: BETA: 03/07/10 03/13/10 Contra 2 POV asthma; | | | | |
| ASA: 05/23/12 Contra NMI ASPIRIN 325MG CAP; ACEI/ARB: 07/01/12 ADR Problem List | | | | |
| 995.0 ACEI; STATIN: 07/01/12 ADR creat kinase of 5000 | | | | |

| | | | | |
|----------------------------|--------|-------------------------|------------|-----------------------------|
| PATIENT2,KATHLEEN | 000002 | COMMUNITY #1 | F | 38 |
| AC | | BETA: 06/02/12 | ADR | POV V14.8 |
| PATIENT3,KIMBERLY A | 000003 | COMMUNITY #1 | F | 49 |
| AC | | BETA: 03/01/12 | Contra 2/3 | heart block POV 426.12; |
| ACEI/ARB: Contra pregnant; | | STATIN: Contra pregnant | | |
| PATIENT4,TIMOTHY | 000004 | COMMUNITY #1 | M | 57 |
| AC | | ACEI/ARB: 06/15/12 | Contra | POV V24.1; STATIN: 06/15/12 |
| Contra POV V24.1 | | | | |
| PATIENT5,JOSHUA | 000005 | COMMUNITY #1 | M | 63 |
| AC | | ACEI/ARB: 02/03/12 | Contra | Aortic POV 395.0 |

Figure 2-87: Sample Patient List: Persistence of Appropriate Medication Therapy after a Heart Attack

2.8.12 Appropriate Medication Therapy in High Risk Patients

Denominators

Active IHD patients ages 22 and older; defined as all Active Clinical patients diagnosed with IHD prior to the Report Period, *and* at least two visits during the Report Period, *and* two IHD-related visits ever.

- *Active IHD patients* ages 22 and older who are not Active Diabetic.
- *Active IHD patients* ages 22 and older who are Active Diabetic

Numerators

Patients with a 180-day course of treatment with *beta-blockers* during the Report Period, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

Note: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *ASA (aspirin)* or *other anti-platelet agent* during the Report Period, or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

Note: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *ACEIs/ARBs* during the Report Period, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

Note: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *statins* during the Report Period, or who have a contraindication/previous adverse reaction to statin therapy.

Note: This numerator does *not* include refusals.

Also included for the numerators above are subnumerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with documented refusal of the specified medication

Patients with a 180-day course of treatment for *all medications* (i.e., beta-blocker, aspirin/anti-platelet, ACEI/ARB, *and* statin) during the Report Period, and/or who have a contraindication/previous adverse reaction.

| |
|---|
| Note: This numerator does <i>not</i> include refusals. |
|---|

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

IHD diagnosis defined as: 410.0 through 412.*, 414.0 through 414.9, or 429.2 recorded in the V POV file.

Diabetes defined as: Diagnosed with diabetes (first POV in V POV with 250.00 through 250.93) prior to the Current Report Period, *and* at least two visits during the Current Report period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

Numerator Logic

In the logic below, “ever” is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the three conditions below:

1. Prescription(s) for the indicated medication with a total days supply of 180 days or more during the Report Period. Medications must not have a comment of RETURNED TO STOCK; *or*
2. A refusal of the medication during the Report Period; *or*
3. Have a contraindication/previous adverse reaction to the indicated medication

Refusals and contraindications/previous ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/ allergy will be counted in sub-numerators B–C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the sub-numerator totals of A–C may not add up to the numerator total.

For prescriptions, the days supply requirement may be met with a single prescription or from a combination of prescriptions for the indicated medication that were filled during the Report Period and prescriptions filled prior to the Report Period but which are still active (i.e., prior active prescription). Prior active prescriptions can be included if the treatment days fall within the Report Period. Prior active prescription defined as most recent prescription for the indicated medication (see codes below) prior to Report Period Start Date with the number of days supply equal to or greater than the Report Period Start Date minus the prescription date.

Note: If a prescription for a medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator with prior active prescription:

- Report Period: 07/01/2011 through 06/30/2012
- Must have 180 days supply of indicated medication 6/30/2012 (end of Report Period)
- Prior Beta-Blocker Rx Date: 06/01/2011
- # Days Prescribed: 60 (treats patient through 07/31/2011)
- Report Period Start Date minus Rx Date: $07/01/2011 - 06/01/2011 = 30$; 60 (#Days Prescribed) is greater than or equal to (\geq) 30, prescription is considered Prior Active Rx
- 07/31/2011 is between the Report Period of 07/01/2011 and 06/30/2012, thus remainder of Prior Active Rx can be counted toward 180-days supply
- # Remaining Days Prescribed from Prior Active Rx:
- $(\# \text{ Days Prescribed} - (\text{Report Period Start Date} - \text{Prior Rx Date})) = 60 - (07/01/2011 - 06/01/2011) = 60 - 30 = 30$
- Rx #2: 08/05/2011, # Days Prescribed: 90
- Rx #3: 11/10/2011, #Days Prescribed: 90
- Total Days Supply Prescribed between 07/01/2011 and 06/30/2012, including prior active prescription: $30 + 90 + 90 = 210$

Beta-Blocker Numerator Logic

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. Medications are: Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.

Refusal of beta-blocker: REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the Report Period.

CRS uses the following codes to define contraindications to beta-blockers.

| Contraindication to Beta-Blockers (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|---|---|
| Asthma | | POV: 2 diagnoses of 493* on different visit dates |
| Hypotension | | POV: 1 diagnosis of 458* |
| Heart Block >1 Degree | | POV: 1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7 |
| Sinus Bradycardia | | POV: 1 diagnosis of 427.81 |
| COPD | | POV: 2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496 |
| NMI Refusal | G8011 (old code) at least once during the Report Period | Refusal: NMI refusal for any beta-blocker at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

Adverse Drug Reaction/Allergy to Beta-Blockers

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E942.0 |
| Entry in ART (Patient Allergies File): "beta block*" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "beta block*", "bblock*" or "b block*" |

ASA (aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

Refusal of ASA/other anti-platelet: REF refusal of any ASA or anti-platelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during the Report Period.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

| Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|---|--|
| 180-day course of treatment for Warfarin/Coumadin during the Report Period | | Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS |
| Hemorrhage | | POV: 459.0 |
| NMI Refusal | G8008 (old code) at least once during the Report Period | Refusal: NMI (not medically indicated) refusal for any aspirin at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E935.3 |
| Entry in ART (Patient Allergies File): "aspirin" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "ASA" or "aspirin" |

ACEI/ARB Numerator Logic

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril.)

Antihypertensive Combinations: (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil.)

Refusal of ACEI: REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least during the Report Period.

CRS uses the following codes to define contraindications to ACE inhibitors.

| Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|--|------------------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI refusal for any ACE inhibitor at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

Adverse Drug Reaction/Allergy to ACE Inhibitors

| ICD and Other Codes |
|--|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): "ace inhibitor" or "ACEI" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "ace i*" or "ACEI" |

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-Amlodipine-hydrochlorothiazide, Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

Refusal of ARB: REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the Report Period.

CRS uses the following codes to define contraindications to ARBs.

| Contraindication to ARBs (any of the codes occurring ever unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|-----------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Moderate or Severe Aortic Stenosis | | POV: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22 |
| NMI Refusal | | Refusal: NMI (not medically indicated) refusal for any ARB at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documented allergies to ARBs.

Adverse Drug Reaction/Allergy to ARBs

| ICD and Other Codes |
|---|
| POV: 995.0-995.3 AND E942.6 |
| Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "Angiotensin Receptor Blocker" or "ARB" |

Statins Numerator Logic

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications are: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altacor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Advicor, Caduet, PraviGard Pac, Vytori.

Refusal of Statin: REF refusal of any statin medication in site-populated medication taxonomy BGP PQA STATIN MEDS at least once during the Report Period.

CRS uses the following codes to define contraindications to statins.

| Contraindication to ACE Inhibitors (any of the codes occurring ever, unless otherwise noted) | CPT Codes | ICD and Other Codes |
|---|------------------|--|
| Pregnancy | | See below for definition |
| Breastfeeding | | POV: V24.1 during the Report Period Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period |
| Acute Alcoholic Hepatitis | | POV: 571.1 during the Report Period |
| NMI Refusal | | Refusal: NMI refusal for any statin at least once during the Report Period |

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

Adverse Drug Reaction/Allergy to Statins

| ICD and Other Codes |
|--|
| Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period |
| Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period |
| POV: Myopathy/Myalgia, defined as any of the following during the Report Period: 359.0-359.9, 729.1, 710.5, or 074.1 |
| POV: 995.0-995.3 AND E942.9 |
| Entry in ART (Patient Allergies File): "statin" or "statins" |
| Entry in Problem List or in Provider Narrative for any POV 995.0-995.3 or V14.8: "Statin" or "Statins" |

| Subject Defined | ICD and CPT Codes |
|--------------------|---|
| Pregnancy | <p>POV or Problem List: At least two visits during the Report Period with 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53, 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09, where the primary provider is not a CHR (Provider code 53), and with no documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period.</p> |
| Abortion | <p>CPTs: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p>POVs: 635*, 636*, or 637*</p> <p>Procedures: 69.01, 69.51, 74.91, 96.49</p> |
| Miscarriage | <p>CPTs: 59812, 59820, 59821, 59830</p> <p>POVs: 630, 631, 632, 633*, or 634*</p> |

All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

Key Logic Changes from CRS Version 12.0

1. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
2. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).
3. Added code 48134-1 to LOINC taxonomy for ALT.
4. Added codes 12187-1, 12189-7, 13969-1, 15048-2, 15049-0, 20569-0, 2152-7, 2154-3, 2155-0, 2158-4, 32673-6, 33547-1, 38482-6, 49129-0, 49136-5, 49551-5, 50757-4, 9642-0, 9643-8 to LOINC taxonomy for Creatine Kinase.
5. Replaced BGP HEDIS STATIN MEDS with BGP PQA STATIN MEDS.
6. Updated BGP HEDIS ARB MEDS medications to include Azilsartan, Aliskiren-Amlodipine-hydrochlorothiazide, Amlodipine-hydrochlorothiazide-olmesartan, and Amlodipine-Telmisartan.
7. Updated BGP PQA STATIN MEDS medications to include Altoprev and Pitavastatin.

Patient List Description

List of IHD patients 22 plus (+) with 180-day medication therapy during the Report Period, if any.

Measure Source

American Heart Association/American College of Cardiology Guidelines

Measure Past Performance and Long-Term Targets

None

| | | | | | | | |
|--|-------------------|---|---------|---|-----------|--------|----------|
| DU | November 25, 2012 | | | | | | Page 241 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Appropriate Medication Therapy in High Risk Patients | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | BASE % |
| Active IHD pts 22+ | 59 | | 38 | | | 30 | |
| # w/180 day beta-blocker | | | | | | | |

| | | | | | | | | |
|---|----|------|----|------|-------|----|-------|-------|
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 32 | 54.2 | 22 | 57.9 | -3.7 | 14 | 46.7 | +7.6 |
| A. # w/180 day beta-blocker | | | | | | | | |
| Rx w/% of Total | 18 | 56.3 | 14 | 63.6 | -7.4 | 11 | 78.6 | -22.3 |
| B: # w/contra/ADR | | | | | | | | |
| w/ % of Total | 14 | 43.8 | 8 | 36.4 | +7.4 | 3 | 21.4 | +22.3 |
| # w/ beta-blocker refusal | 1 | 1.7 | 0 | 0.0 | +1.7 | 0 | 0.0 | +1.7 |
| # w/180 day ASA | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 22 | 37.3 | 21 | 55.3 | -18.0 | 23 | 76.7 | -39.4 |
| A. # w/180 day ASA | | | | | | | | |
| Rx w/% of Total | 17 | 77.3 | 18 | 85.7 | -8.4 | 18 | 78.3 | -1.0 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 5 | 22.7 | 3 | 14.3 | +8.4 | 5 | 21.7 | +1.0 |
| # w/ ASA refusal | 1 | 1.7 | 0 | 0.0 | +1.7 | 0 | 0.0 | +1.7 |
| # w/180 day ACEI/ARB | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 29 | 49.2 | 15 | 39.5 | +9.7 | 18 | 60.0 | -10.8 |
| A. # w/180 day ACEI/ARB | | | | | | | | |
| Rx w/% of Total | 26 | 89.7 | 14 | 93.3 | -3.7 | 17 | 94.4 | -4.8 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 3 | 10.3 | 1 | 6.7 | +3.7 | 1 | 5.6 | +4.8 |
| # w/ ACEI/ARB refusal | 1 | 1.7 | 0 | 0.0 | +1.7 | 0 | 0.0 | +1.7 |
| # w/180 day statin | | | | | | | | |
| Rx/contra/ADR | | | | | | | | |
| -No Refusals | 30 | 50.8 | 22 | 57.9 | -7.0 | 14 | 46.7 | +4.2 |
| A. # w/180 day statin | | | | | | | | |
| Rx w/% of Total | 26 | 86.7 | 20 | 90.9 | -4.2 | 14 | 100.0 | -13.3 |
| B. # w/contra/ADR | | | | | | | | |
| w/ % of Total | 4 | 13.3 | 2 | 9.1 | +4.2 | 0 | 0.0 | +13.3 |
| # w/ Statin refusal | 1 | 1.7 | 0 | 0.0 | +1.7 | 0 | 0.0 | +1.7 |
| # w/180 day Rx/contra/ADR/ of ALL meds | | | | | | | | |
| -No Refusals | 16 | 27.1 | 8 | 21.1 | +6.1 | 6 | 20.0 | +7.1 |

Figure 2-88: Sample Report, Appropriate Medication Therapy in High Risk Patients

| | | | | |
|--|--------|--|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Appropriate Medication Therapy in High Risk Patients: List of IHD patients 22+ with 180-day medication therapy during the Report Period, if any. | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
| DENOMINATOR | | NUMERATOR | | |
| ----- | | | | |
| PATIENT1,CAITLYN | 000001 | COMMUNITY #1 | F | 22 |
| IHD | | BETA: 09/11/12 Refused METOPROLOL TARTRATE 50MG TAB; | | |
| ASA: 09/11/12 Refused ASPIRIN 325MG E.C. TAB; | | ACEI/ARB: 09/11/12 Refused CAPTOPRIL | | |
| 25MG TABS; STATIN: 09/11/12 Refused ATORVASTATIN 10MG TAB (ICP) | | | | |
| PATIENT2,CARLA | 000002 | COMMUNITY #1 | F | 40 |

| | | | | | |
|---------------------------|----------------|-----------------------------------|--------------------------|-----------------------------|--------------------------|
| IHD | | | | | |
| PATIENT3, GENEVA | 000003 | COMMUNITY #1 | F | 47 | |
| JACKSON, SHERRY LADAWN | 100939 | BRAGGS | F | 68 | |
| IHD, AD | | ACEI/ARB: (268 TOTAL DAYS); | STATIN: (319 TOTAL DAYS) | | |
| PATIENT4, SHERRY LISA | 000004 | COMMUNITY #1 | F | 68 | |
| IHD | | BETA: 09/12/12 Contra hypotension | POV 458.9; ASA: | | |
| aspirin Contra total days | WARFARIN: 372; | STATIN: (328 TOTAL DAYS) | | | |
| PATIENT5, PAULINE | 000005 | COMMUNITY #1 | F | 70 | |
| IHD, AD | | ALL MEDS; BETA: (305 TOTAL DAYS); | ASA: (291 TOTAL DAYS); | ACEI/ARB: (405 TOTAL DAYS); | STATIN: (305 TOTAL DAYS) |

Figure 2-89: Sample Patient List: Appropriate Medication Therapy in High Risk Patients

2.8.13 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

Denominator

Number of visits for *User Population patients* ages 18 and older who were hospitalized during the Report Period with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

Numerators

Number of visits where patients received a prescription for anticoagulant at discharge

Number of visits where patients refused anticoagulant therapy

Number of visits where patients did not receive anticoagulation therapy

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes to define ischemic stroke or transient ischemic attack with atrial fibrillation.

| Subject Defined | ICD and Other Codes |
|--|--|
| Ischemic Stroke or TIA with Atrial Fibrillation (Non-CHS inpatient visit - Type not equal to C and Service Category=H) The patient must be admitted to the hospital during the report period with a condition described here but the discharge may occur after the report period. | V POV: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, or 435.9 AND 427.31 (atrial fibrillation) |

Anticoagulant Therapy: Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

1. Active prescription for Warfarin, aspirin, or other anti-platelet as of discharge date. "Active" prescription defined as:

Rx Days Supply greater than or equal to (\geq) (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.

2. Prescription for Warfarin, aspirin, or other anti-platelet on discharge date.

Warfarin Medication: Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

Aspirin Medication: Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

Other Anti-Platelet/Anticoagulant Medication: Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

Refusal of Anticoagulant Therapy: Refusal of any of the following documented on discharge date:

1. Any medication in site-populated taxonomies BGP CMS WARFARIN MEDS, DM AUDIT ASPIRIN DRUGS, or BGP ANTI-PLATELET DRUGS; or
2. Any medication with VA Drug Class BL700.

No Anticoagulant Therapy: Patients who did not have an active prescription for anticoagulant therapy at time of discharge and did not receive or refuse anticoagulant therapy at discharge.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

DU

November 25, 2012

Page 248

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Stroke and Stroke Rehabilitation:

Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|--|---------------|------|----------------|-----|--------------------|-------------|-----|-----------------|
| # Stroke/TIA w/ Atrial Fib Visits for User Pop Pts 18+ | 17 | | 0 | | | 0 | | |
| # Visits w/ Anticoagulant Rx | 5 | 29.4 | 0 | 0.0 | +29.4 | 0 | 0.0 | +29.4 |
| # Visits w/ Refusal | 1 | 5.9 | 0 | 0.0 | +5.9 | 0 | 0.0 | +5.9 |
| # Visits w/ No Anticoagulant Therapy | 11 | 64.7 | 0 | 0.0 | +64.7 | 0 | 0.0 | +64.7 |

Figure 2-90: Sample Report, Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge: List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
|--|---|------------------------|-----|-----|--|
| ----- | | | | | |
| PATIENT1,SHERRY | 000001 | COMMUNITY #1 | F | 38 | |
| UP | Visit: 1) 04/01/12 POV 433.81 + POV 427.31 THERAPY: | | | | |
| NOT MET: NO THERAPY | | | | | |
| PATIENT2,CODY JACK | 000002 | COMMUNITY #1 | M | 31 | |
| UP | Visit: 1) 05/01/12 POV 433.81 + POV 427.31 THERAPY: | | | | |
| 05/01/12 MET: WARF; 2) 09/01/12 POV 433.21 + POV 427.31 THERAPY: NOT MET: NO | | | | | |
| THERAPY; 3) 10/15/12 POV 434.01 + POV 427.31 THERAPY: 10/15/12 MET: ASA | | | | | |
| PATIENT3,TIMOTHY ALLEN | 000003 | COMMUNITY #1 | M | 33 | |
| UP | Visit: 1) 04/01/12 POV 433.21 + POV 427.31 THERAPY: | | | | |
| NOT MET: NO THERAPY | | | | | |
| PATIENT4,TRACE | 000004 | COMMUNITY #1 | M | 37 | |
| UP | Visit: 1) 06/01/12 POV 434.01 + POV 427.31 THERAPY: | | | | |
| NOT MET: NO THERAPY | | | | | |

Figure 2-91: Sample Patient List: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

2.8.14 Cholesterol Management for Patients with Cardiovascular Conditions

Denominators

Active Clinical patients ages 18 to 75 who, during the first ten months of the year prior to the beginning of the Report Period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI) *or* who were diagnosed with IVD during the Report Period and the year prior to the Report Period. Broken down by gender.

User Population patients ages 18 to 75 who, during the first 10 months of the year prior to the beginning of the Report period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI) *or* who were diagnosed with IVD during the Report Period and the year prior to the Report Period. Broken down by gender.

Numerators

Patients with LDL completed during the Report Period, regardless of result.

- a. Patients with LDL less than or equal to (\leq)100, completed during the Report Period.
- b. Patients with LDL 101 through 130, completed during the Report Period.
- c. Patients with LDL greater than ($>$)130, completed during the Report Period.

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result. For numerator LDL equal to or less than (\leq)100, CPT 3048F will count as meeting the measure.

CRS uses the following codes to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|-----------|-----------------------|-------------|----------|
| AMI | | V POV: 410.*0, 410.*1 | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|--|---|-------------|------------------------------|
| PCI | 92980, 92982, 92995, G0290 | V Procedure: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), or 36.06-36.07 | | |
| CABG | 33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209 | V POV: V45.81 V Procedure: 36.1*, 36.2 | | |
| IVD | | V POV: 411.*, 413.*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, or 445.* | | |
| LDL | 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F | | Yes | DM AUDIT LDL CHOLESTEROL TAX |

Key Logic Changes from CRS Version 12.0

Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.

Patient List Description

List of patients with AMI, CABG, PCI, or IVD w/LDL value, if any.

Measure Source

HEDIS

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|---------|---|-----------|----------|---|----------|--|
| DU | November 25, 2012 | | | | Page 250 | | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Cholesterol Management for Patients with Cardiovascular Conditions | | | | | | | | |
| REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |

| | | | | | | | | |
|---|----|------|----|------|-------|----|------|-------|
| Active Clinical pts 18-75 with DX of AMI, CABG, PCI, or IVD | | | | | | | | |
| | 42 | | 28 | | | 18 | | |
| # w/LDL done | 38 | 90.5 | 21 | 75.0 | +15.5 | 9 | 50.0 | +40.5 |
| A. # w/LDL <=100 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 14 | 36.8 | 12 | 57.1 | -20.3 | 3 | 33.3 | +3.5 |
| B. # w/LDL 101-130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 5 | 13.2 | 3 | 14.3 | -1.1 | 2 | 22.2 | -9.1 |
| C. # w/LDL >130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 5 | 13.2 | 4 | 19.0 | -5.9 | 4 | 44.4 | -31.3 |
| Male Active Clinical pts 18-75 with DX of AMI, CABG PCI, or IVD | | | | | | | | |
| | 22 | | 16 | | | 10 | | |
| # w/LDL done | 20 | 90.9 | 11 | 68.8 | +22.2 | 4 | 40.0 | +50.9 |
| A. # w/LDL <=100 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 5 | 25.0 | 4 | 36.4 | -11.4 | 1 | 25.0 | +0.0 |
| B. # w/LDL 101-130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 2 | 10.0 | 3 | 27.3 | -17.3 | 1 | 25.0 | -15.0 |
| C. # w/LDL >130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 4 | 20.0 | 2 | 18.2 | +1.8 | 2 | 50.0 | -30.0 |
| Female Active Clinical pts 18-75 with DX of AMI, CABG PCI, or IVD | | | | | | | | |
| | 20 | | 12 | | | 8 | | |
| # w/LDL done | 18 | 90.0 | 10 | 83.3 | +6.7 | 5 | 62.5 | +27.5 |
| A. # w/LDL <=100 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 9 | 50.0 | 8 | 80.0 | -30.0 | 2 | 40.0 | +10.0 |
| B. # w/LDL 101-130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 3 | 16.7 | 0 | 0.0 | +16.7 | 1 | 20.0 | -3.3 |
| C. # w/LDL >130 | | | | | | | | |
| w/% of Total | | | | | | | | |
| Screened | 1 | 5.6 | 2 | 20.0 | -14.4 | 2 | 40.0 | -34.4 |

Figure 2-92: Sample Report, Cholesterol Management for Patients with Cardiovascular Conditions

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Cholesterol Management for Patients with Cardiovascular Conditions: List of
 patients with AMI, CABG, PCI, or IVD w/LDL value, if any.

| | | | |
|--------------|-----|-----------|---------|
| PATIENT NAME | HRN | COMMUNITY | SEX AGE |
| DENOMINATOR | | NUMERATOR | |

| | | | | |
|-------------------------|--------|-------------------------|---|----|
| PATIENT1, SHERRY | 000001 | COMMUNITY #1 | F | 68 |
| UP, AC | | 07/15/12 LDL: CPT 3048F | | |
| PATIENT2, CODY JACK | 000002 | COMMUNITY #1 | M | 41 |
| UP, AC | | | | |
| PATIENT3, TIMOTHY ALLEN | 000003 | COMMUNITY #1 | M | 43 |
| UP, AC | | 10/17/12 LDL: 136 | | |
| PATIENT4, TRACE | 000004 | COMMUNITY #1 | M | 47 |
| UP | | | | |
| PATIENT5, KENNETH | 000005 | COMMUNITY #1 | M | 60 |
| UP, AC | | 08/06/12 LDL: 108 | | |

Figure 2-93: Sample Patient List: Cholesterol Management for Patients with Cardiovascular Conditions

2.8.15 Heart Failure and Evaluation of LVS Function

Denominator

Active Clinical patients ages 18 or older discharged with heart failure during the Report Period.

Numerators

Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.

Logic Description

Age of the patient is calculated as of the hospital admission date.

Denominator exclusions are defined as any of the following:

1. Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).
2. Patients with a Discharge Type of Transferred or Irregular or containing “Death.”
3. Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

CRS uses the following codes to define the denominator and numerators.

Denominator Exclusions

| Subject Defined | CPT Codes | ICD and Other Codes |
|-----------------------|-----------|--|
| Comfort Measures | | V POV: V66.7 (Encounter for palliative care) documented during hospital stay |
| LVAD/Heart Transplant | | V Procedure: 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68 documented during hospital stay |

Denominator Definition

| Subject Defined | CPT Codes | ICD and Other Codes |
|-----------------|-----------|---|
| Heart Failure | | V POV (Primary Diagnosis only): 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, or 997.1 <i>and</i> with Service Category H (hospitalization). NOTE: If a patient has multiple admissions matching these criteria during the Report Period, the earliest admission will be used. |

Numerator Definition (Evaluation of LVS Function): Any of the codes listed below

| Subject Defined | CPT Codes | ICD and Other Codes |
|---|---|--|
| Ejection Fraction (ordered or documented anytime one year prior to discharge date) | 78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314–93318, 93350, 93543, 93555 | V Measurement: "CEF" V Procedure: 88.53, 88.54 |
| RCIS Order for Cardiovascular Disorders Referral (ordered during the hospital stay but no later than the hospital discharge date) | | ICD Diagnostic Category: "Cardiovascular Disorders" AND one of the following: CPT Categories: "Evaluation and/or Management," "Non-surgical Procedures" or "Diagnostic Imaging" |
| Other Procedures (documented anytime one year prior to discharge date) | | Echocardiogram: V Procedure 88.72, 37.28, 00.24; Nuclear Medicine Test: V Procedure 92.2*; Cardiac Catheterization with a Left Ventriculogram: V Procedure 37.22, 37.23, 88.53, 88.54 |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of Active Clinical heart failure patients 18 plus (+) who received evaluation of LVS function, if any.

Measure Source

CMS HF-2

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|------|---------|-----|----------|----------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 255 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Heart Failure and Evaluation of LVS Function | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR | % PERIOD | | BASE % |
| AC 18+ w/Heart | | | | | | | | |
| Failure Dx | 44 | | 2 | | | 1 | | |
| Patients w/Eval | | | | | | | | |
| of LVS Function | 14 | 31.8 | 0 | 0.0 | +31.8 | 0 | 0.0 | +31.8 |

Figure 2-94: Sample Report, Heart Failure and Evaluation of LVS Function

| | | | | |
|--|--------|------------------------|---------------------------|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Heart Failure and Evaluation of LVS Function: List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,JOAN AC | 000164 | COMMUNITY #1 | F | 36 |
| | | Admission: 06/01/12 | LVS: NOT DOCUMENTED | |
| PATIENT2,SARAH AC | 000127 | COMMUNITY #1 | F | 35 |
| | | Admission: 06/01/12 | LVS: 06/03/11 Proc 88.72 | |
| PATIENT3,JOHN AC | 000151 | COMMUNITY #1 | M | 36 |
| | | Admission: 05/01/12 | LVS: 05/01/12 Meas CEF 40 | |
| PATIENT4,ROGER AC | 000125 | COMMUNITY #1 | M | 47 |
| | | Admission: 06/01/12 | LVS: NOT DOCUMENTED | |
| PATIENT5,DANIEL AC | 000129 | COMMUNITY #1 | M | 57 |
| | | Admission: 06/01/12 | LVS: 06/01/12 CPT 78468 | |

Figure 2-95: Sample Patient List: Heart Failure and Evaluation of LVS Function

2.9 STD-Related Measure Topics

2.9.1 HIV Screening

GPRA Measure Description

During FY 2012, achieve the tentative target rate of 81.8% for the proportion of pregnant patients who are screened for HIV.

Denominators

All pregnant Active Clinical female User Population patients with no documented miscarriage or abortion and with no recorded HIV diagnosis ever (GPRA Denominator).

User Population patients ages 13 through 64 with no recorded HIV diagnosis prior to the Report Period. (GPRA Developmental Denominator).

Numerators

Patients who were screened for HIV during the past 20 months.

Note: This numerator does *not* include refusals. (GPRA Numerator).

Patients with documented HIV screening refusal during the past 20 months.

Patients who were screened for HIV during the Report Period.

Note: This numerator does *not* include refusals. (GPRA Developmental Numerator)

Patients with documented HIV screening refusal during the Report Period.

No denominator. This measure is a total count only, not a percentage. Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen.

Note: This numerator does not include refusals. (GPRA Developmental Numerator)

Logic Description

Age of the patient is calculated at the beginning of the Report period.

Pregnancy definition: At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

HIV Screening definition: For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

Note 1: The time frame for both screening and refusals for the pregnant patients denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the Report Period.

Note 2: Refusals are allowed during the past 20 months for pregnant patients (vs. only during the Report Period) in the event the patient is at the end of her pregnancy at the beginning of the Report Period and refused the HIV test earlier in her pregnancy during the previous year

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|---|-----------|--|-------------|----------|
| Pregnancy (at least 2 visits in past 20 months with 1 during the Report Period) | | V POV: 640.03, 640.83, 640.93, 641.03, 641.13, 641.23, 641.33, 641.83, 641.93, 642.03, 642.13, 642.23, 642.33, 642.43, 642.53 642.63, 642.73, 642.93, 643.03, 643.13, 643.23, 643.83, 643.93, 644.03, 644.13, 645.13, 645.23, 646.03, 646.13, 646.23, 646.33, 646.43, 646.53, 646.63, 646.73, 646.83, 646.93, 647.03, 647.13, 647.23, 647.33, 647.43, 647.53, 647.63, 647.83, 647.93, 648.03, 648.13, 648.23, 648.33, 648.43, 648.53, 648.63, 648.73, 648.83, 648.93, 649.03, 649.13, 649.23, 649.33, 649.43, 649.53, 649.63, 649.73, 651.03, 651.13, 651.23, 651.33, 651.43, 651.53, 651.63, 651.73, 651.83, 651.93, 652.03, 652.13, 652.23, 652.33, 652.43, 652.53, 652.63, 652.73, 652.83, 652.93, 653.03, 653.13, 653.23, 653.33, 653.43, 653.53, 653.63, 653.73, 653.83, 653.93, 654.03, 654.13, 654.23, 654.33, 654.43, 654.53, 654.63, 654.73, 654.83, 654.93, 655.03, 655.13, 655.23, 655.33, 655.43, 655.53, 655.63, 655.73, 655.83, 655.93, 656.03, 656.13, 656.23, 656.33, 656.43, 656.53, 656.63, 656.73, 656.83, 656.93, 657.03, 658.03, 658.13, 658.23, 658.33, 658.43, 658.83, 658.93, 659.03, 659.13, 659.23, 659.33, 659.43, 659.53, 659.63, 659.73, 659.83, 659.93, 660.03, 660.13, 660.23, 660.33, 660.43, 660.53, 660.63, 660.73, 660.83, 660.93, 661.03, 661.13, 661.23, 661.33, 661.43, 661.93, 662.03, 662.13, 662.23, 662.33, 663.03, 663.13, 663.23, 663.33, 663.43, 663.53, 663.63, 663.83, 663.93, 665.03, 665.83, 665.93, 668.03, 668.13, 668.23, 668.83, 668.93, 669.03, 669.13, 669.23, 669.43, 669.83, 669.93, 671.03, 671.13, 671.23, 671.33, 671.53, 671.83, 671.93, 673.03, 673.13, 673.23, 673.33, 673.83, 674.03, 674.53, 675.03, 675.13, 675.23, 675.83, 675.93, 676.03, 676.13, 676.23, 676.33, 676.43, 676.53, 676.63, 676.83, 676.93, 678.03, 678.13, 679.03, 679.13, V22.0 – V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09 | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|---|---|--|-------------|------------------|
| Miscarriage (after second pregnancy POV in past 20 months) | 59812, 59820, 59821, 59830 | V POV: 630, 631, 632, 633*, 634* | | |
| Abortion (after second pregnancy POV in past 20 months) | 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267 | V POV: 635*, 636*, 637* V Procedure: 69.01, 69.51, 74.91, 96.49. | | |
| HIV Diagnosis (documented anytime prior to the end of the Report Period) | | V POV or Problem List: 042, 042.0–044.9 (old codes), 079.53, V08, or 795.71 | | |
| HIV Screening | 86689, 86701–86703, 87390, 87391, 87534–87539 | | Yes | BGP HIV TEST TAX |
| Refusal of HIV lab test in past 20 months | | | | BGP HIV TEST TAX |

Key Logic Changes from CRS Version 12.0

1. Updated POV codes for pregnancy definition to only include antepartum pregnancy codes.
2. Updated pregnancy definition to exclude visits where the primary provider is a CHR (Provider code 53).
3. Added codes 49580-4, 49718-0, 49890-7, 49905-3, 50624-6, 50790-5, 53379-4, 53825-6, 53923-9, 54086-4, 57182-8, 57974-8, 57975-5, 58900-2, 59052-1, 59419-2, 62456-9, 62469-2, 68961-2, 69353-1, 69354-9 to LOINC taxonomy for HIV Screening.

Patient List Description

List of pregnant patients or User Population patients with documented HIV test or refusal, if any.

Measure Source

HP 2020 HIV-14.3

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|-------------------------|--------------|
| IHS FY 2011 Performance | 80.0% |
| IHS FY 2010 Performance | 78.0% |
| IHS FY 2009 Performance | 76.0% |
| IHS FY 2008 Performance | 75.0% |
| IHS FY 2007 Performance | 74.0% |
| IHS FY 2006 Performance | 65.0% |
| IHS FY 2005 Performance | 54.0% |
| <i>HP 2020 Goal</i> | <i>74.1%</i> |

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 256 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| HIV Screening | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Pregnant AC Pts w/ no HIV ever (GPRA) | 39 | | 38 | | | 32 | | |
| # w/HIV screening -No Refusals (GPRA) | 15 | 38.5 | 6 | 15.8 | +22.7 | 0 | 0.0 | +38.5 |
| # w/HIV screening refusal | 1 | 2.6 | 0 | 0.0 | +2.6 | 0 | 0.0 | +2.6 |
| User Pop Pts 13-64 w/ no HIV (GPRA Dev.) | 2,024 | | 1,663 | | | 1,519 | | |
| # w/HIV screening -No Refusals (GPRA Dev.) | 46 | 2.3 | 21 | 1.3 | +1.0 | 0 | 0.0 | +2.3 |
| # w/HIV screening refusal | 4 | 0.2 | 0 | 0.0 | +0.2 | 0 | 0.0 | +0.2 |
| # HIV screens for User Pop Pts w/ no prior HIV-No Refusals (GPRA Dev.) | 51 | | 21 | | +30 | 0 | | +51 |

Figure 2-96: Sample Report, HIV Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

| HIV Screening: List of pregnant patients or User Population patients with documented HIV test or refusal, if any. | | | | |
|---|--------|---|-----|-----|
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| PATIENT1, HELEN MARY UP | 000001 | COMMUNITY #1 03/31/12 Lab; Screen Count: 1 | F | 12 |
| PATIENT2, CECELIA UP | 000002 | COMMUNITY #1 | F | 19 |
| PATIENT15, BRENDA G UP | 000015 | COMMUNITY #2 03/14/12 CPT 87534; 02/14/12 CPT 86689; Screen Count: 2 | F | 30 |
| PATIENT16, ALYSHA UP, AC PREG | 000016 | COMMUNITY #2 08/25/12 Lab; Screen Count: 1 | F | 33 |

Figure 2-97: Sample Patient List, HIV Screening

2.9.2 HIV Quality of Care

Denominator

All *User Population patients* ages 13 and older with at least two direct care visits (i.e., not Contract/CHS) with HIV diagnosis during the Report Period, including one HIV diagnosis in last six months.

Numerators

Patients who received CD4 test only (without HIV viral load) during the Report Period

Patients who received HIV viral load only (without CD4) during the Report Period

Patients who received both CD4 and HIV viral load during the Report Period

Total patients receiving any test

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|-----------|---|-------------|----------|
| HIV | | 042, 042.0-044.9 (old codes), 079.53, V08, 795.71 | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|-----------------------|---------------------|-------------|------------------------|
| CD4 | 86359, 86360 86361 | | Yes | BGP CD4 TAX |
| HIV Viral Load | 87536, 87539 | | Yes | BGP HIV VIRAL LOAD TAX |

Key Logic Changes from CRS Version 12.0

- Added codes 40898-9, 40900-3, 43946-3, 43947-1, 43953-9, 43955-4, 43963-8, 43965-3, 43970-3, 44057-8, 44059-4, 47016-1, 51300-2, 51302-8, 51303-6, 51307-7, 51308-5, 51312-7, 51313-5, 63450-1, 51304-4, 58920-0, 60457-9 to LOINC taxonomy for CD4.
- Deleted codes 51866-2, 53379-4, 54086-4, 55277-8, 56888-1, 57974-8, 57975-5, 57976-3, 57977-1, 57978-9 and added codes 41143-9, 22356-0, 16976-3, 16978-9, 16979-7, 9665-1, 22357-8, 43008-2, 48346-1, 22358-6 to LOINC taxonomy for Viral Load.

Patient List Description

List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

Measure Source

HP 2010 developmental measure 13–13a Viral Load Testing

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|---|--------------------|
| <i>IHS 2020 goal for viral load testing</i> | <i>Nearly 100%</i> |
| <i>IHS 2020 baseline for CD4 testing</i> | <i>Nearly 100%</i> |

| | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 258 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| HIV Quality of Care | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| User Pop Pts >13 w/ HIV Dx | 6 | | 1 | | | 2 | | |
| # w/CD4 only | 1 | 16.7 | 0 | 0.0 | +16.7 | 0 | 0.0 | +16.7 |
| # w/viral load only | 1 | 16.7 | 0 | 0.0 | +16.7 | 0 | 0.0 | +16.7 |

| | | | | | | | | |
|-------------------------|---|------|---|-------|-------|---|-------|-------|
| # w/both | 1 | 16.7 | 1 | 100.0 | -83.3 | 2 | 100.0 | -83.3 |
| TOTAL # w/ any tests | 3 | 50.0 | 1 | 100.0 | -50.0 | 2 | 100.0 | -50.0 |

Figure 2-98: Sample Report HIV Quality of Care

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|------------------------|-----------------------------|-------|--|
| HIV Quality of Care: List of patients 13 and older diagnosed with HIV, with CD4 test, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1,MARY | 000001 | COMMUNITY #1 | F | 19 | |
| UP | | CD4: 02/01/12 | 86359 | | |
| PATIENT2,TANYA | 000002 | COMMUNITY #1 | F | 37 | |
| UP | | | | | |
| PATIENT15,JOHN | 000015 | COMMUNITY #2 | M | 18 | |
| UP | | Viral Load: 05/01/12 | 87539 | | |
| PATIENT16,HAROLD | 000016 | COMMUNITY #2 | M | 20 | |
| UP | | CD4: 03/01/12 | 86360; Viral Load: 03/01/12 | 87536 | |

Figure 2-99: Sample Patient List, HIV Quality of Care

2.9.3 Hepatitis C Screening

Denominator

User Population patients born between 1945 and 1965 with no recorded Hep C diagnosis. Broken down by gender.

Numerators

Patients screened for Hepatitis C ever.

Logic Description

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|-----------|---|-------------|----------|
| Hepatitis C diagnosis (documented anytime prior to the end of the Report Period) | | V POV or Problem List: 070.41, 070.44, 070.51, 070.54, 070.70-070.71 | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------------|-----------|---------------------|-------------|--------------------|
| Hepatitis C Screening | 86803 | | Yes | BGP HEP C TEST TAX |

Key Logic Changes from CRS Version 12.0

New topic.

Patient List Description

List of patients with documented Hepatitis C screening ever, if any.

| | | | | | | | | |
|--|-------------------|-----|----------------|-----|--------------------|-------------|----------|-----------------|
| DU | November 25, 2012 | | | | | | Page 258 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Hepatitis C Screening | | | | | | | | |
| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
| User Pop Pts w/ no Hep C | 790 | | 628 | | | 551 | | |
| # w/Hep C Screening | 48 | 6.1 | 33 | 5.3 | +0.8 | 22 | 4.0 | +2.1 |
| Male User Pop Pts w/no Hep C | 371 | | 292 | | | 253 | | |
| # w/Hep C Screening | 24 | 6.5 | 17 | 5.8 | +0.6 | 11 | 4.3 | +2.1 |
| Female User Pop Pts w/ no Hep C | 419 | | 336 | | | 298 | | |
| # w/Hep C screening | 24 | 5.7 | 16 | 4.8 | +1.0 | 11 | 3.7 | +2.0 |

Figure 2-100: Sample Report Hepatitis C Screening

| | | | | |
|--|-----|-----------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Hepatitis C Screening: List of patients with documented Hepatitis C screening ever, if any. | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE |
| DENOMINATOR | | NUMERATOR | | |

| | | | | |
|------------------|--------|--------------|-----------|----|
| PATIENT1,MARY | 000001 | COMMUNITY #1 | F | 50 |
| UP | | 08/17/01 | Lab Test | |
| PATIENT2,TANYA | 000002 | COMMUNITY #1 | F | 52 |
| UP | | | | |
| PATIENT15,JOHN | 000015 | COMMUNITY #2 | M | 65 |
| UP | | 02/03/99 | CPT 86803 | |
| PATIENT16,HAROLD | 000016 | COMMUNITY #2 | M | 66 |
| UP | | 08/20/11 | Lab Test | |

Figure 2-101: Sample Patient List, Hepatitis C Screening

2.9.4 Chlamydia Screening

Denominators

Female Active Clinical patients ages 16 through 25.

- Female Active Clinical 16 through 20.
- Female Active Clinical 21 through 25.

Female User Population patients ages 16 through 25.

- Female User Population 16 through 20.
- Female User Population 21 through 25.

Numerator

Patients tested for Chlamydia during the Report Period.

Logic Description

Age is calculated at beginning of the Report Period. The following codes are used to determine a test for Chlamydia.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-----------------|---|-----------------------|-------------|-------------------------|
| Chlamydia Test | 86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F | V POV: V73.88, V73.98 | Yes | BGP CHLAMYDIA TESTS TAX |

Key Logic Changes from CRS Version 12.0

Deleted codes 16602-5, 45079-1, 45082-5, 45083-3, 45106-2, 45107-0, 45108-8, 45112-0, 45113-8, 45114-6, 45115-3, 56909-5, 56910-3, 56911-1, 57287-5, 57679-3, 57680-1, and added codes 560-3, 4993-2, 6349-5, 6354-5, 6355-2, 21613-5, 31777-6, 36902-5, 36903-3, 43304-5, 43404-3, 45076-7, 47211-8, 47212-6, 49096-1 to LOINC taxonomy for Chlamydia Test.

Patient List Description

List of patients with documented Chlamydia screening, if any.

Measure Source

HP 2020 STD-4, annual screening for genital Chlamydia–females enrolled in commercial MCOs (aged 25 years and under); STD-3, annual screening for genital Chlamydia–females enrolled in Medicaid MCOs (aged 25 years and under).

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|---|---------|
| HP 2020 goal for Females 16 through 20 with Medicaid (STD-3.1) | 57.9% |
| HP 2020 goal for Females 21 through 24 with Medicaid (STD-3.2) | 65.3% |
| HP 2020 goal for Females 16 through 20 with Commercial Health Insurance (STD-4.1) | 44.1% |
| HP 2020 goal for Females 21 through 24 with Commercial Health Insurance (STD-4.2) | 47.9% |

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|------|----------|--|
| DU | November 25, 2012 | | | | | | | Page 260 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Chlamydia Testing | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Female Active Clinical | | | | | | | | | |
| 16-25 | 166 | | 143 | | | 128 | | | |
| # w/Chlamydia Screen | 53 | 31.9 | 49 | 34.3 | -2.3 | 43 | 33.6 | -1.7 | |
| A. Female Active Clinical | | | | | | | | | |
| 16-20 | 70 | | 55 | | | 57 | | | |
| # w/Chlamydia Screen | 24 | 34.3 | 16 | 29.1 | +5.2 | 23 | 40.4 | -6.1 | |
| B. Female Active Clinical | | | | | | | | | |
| 21-25 | 96 | | 88 | | | 71 | | | |
| # w/Chlamydia Screen | 29 | 30.2 | 33 | 37.5 | -7.3 | 20 | 28.2 | +2.0 | |
| Female User Population | | | | | | | | | |
| 16-25 | 287 | | 255 | | | 239 | | | |
| # w/Chlamydia Screen | 69 | 24.0 | 58 | 22.7 | +1.3 | 51 | 21.3 | +2.7 | |

| | | | | | | | | |
|---------------------------|-----|------|-----|------|------|-----|------|------|
| A. Female User Population | | | | | | | | |
| 16-20 | 139 | | 118 | | | 119 | | |
| # w/Chlamydia Screen | 32 | 23.0 | 19 | 16.1 | +6.9 | 25 | 21.0 | +2.0 |
| B. Female User Population | | | | | | | | |
| 21-25 | 148 | | 137 | | | 120 | | |
| # w/Chlamydia Screen | 37 | 25.0 | 39 | 28.5 | -3.5 | 26 | 21.7 | +3.3 |

Figure 2-102: Sample Report Chlamydia Testing

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|------------------------|-----|-----|--|
| Chlamydia Testing: List of patients with documented Chlamydia screening, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT1,MELISSA ANNE | 000001 | COMMUNITY #1 | F | 16 | |
| UP,AC | | | | | |
| PATIENT2,LISA MARIE | 000002 | COMMUNITY #1 | F | 16 | |
| UP,AC | | 04/04/12 Lab test | | | |
| PATIENT3,CRYSTAL LEE | 000003 | COMMUNITY #1 | F | 17 | |
| UP,AC | | 07/25/12 Lab test | | | |
| PATIENT4,DANIELLE | 000004 | COMMUNITY #1 | F | 18 | |
| UP,AC | | 06/01/12 CPT 87490 | | | |
| PATIENT5,KELLYE | 000005 | COMMUNITY #1 | F | 19 | |
| UP,AC | | | | | |

Figure 2-103: Sample Patient List, Chlamydia Testing

2.9.5 Sexually Transmitted Infection Screening

Denominators

Number of key sexually transmitted infections (STI) incidents for Active Clinical patients that occurred during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. Key STIs defined as Chlamydia, Gonorrhea, HIV/AIDS, and Syphilis. Two or more key STIs on the same visit will be counted once. Broken down by gender.

Chlamydia screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

Gonorrhea screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

HIV/AIDS screenings needed for key STI incidents for *Active Clinical patients* that occurred during the defined period. Broken down by gender.

Syphilis screenings needed for key STI incidents for *Active Clinical patients* that occurred during the defined period. Broken down by gender.

Number of key sexually transmitted infections (STI) incidents for User Population patients that occurred during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. Key STIs defined as Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Two or more key STIs on the same visit will be counted once. Broken down by gender.

Chlamydia screenings needed for key STI incidents for *User Population patients* that occurred during the defined period. Broken down by gender.

Gonorrhea screenings needed for key STI incidents for *User Population patients* that occurred during the defined period. Broken down by gender.

HIV/AIDS screenings needed for key STI incidents for *User Population patients* that occurred during the defined period. Broken down by gender.

Syphilis screenings needed for key STI incidents for *User Population patients* that occurred during the defined period. Broken down by gender.

Numerators

No denominator; count only. The total count of *Active Clinical patients* who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

No denominator; count only. The total count of separate *key STI incidents for Active Clinical patients* during the defined period. Broken down by gender.

Number of complete screenings, defined as all screenings necessary for a specific STI incident(s), performed from one month prior to the date of relevant STI incident through two months after.

Note: This numerator does *not* include refusals.

Number of documented screening refusals.

Number of needed Chlamydia screenings performed from one month prior to the date of first STI diagnosis of each incident through two months after.

Note: This numerator does *not* include refusals.

Number of documented screening refusals.

Number of needed Gonorrhea screenings performed from one month prior to the date of first STI diagnosis of each incident through two months after.

Note: This numerator does *not* include refusals.

Number of documented screening refusals.

Number of needed HIV/AIDS screenings performed from one month prior to the date of first STI diagnosis of each incident through two months after.

Note: This numerator does *not* include refusals.

Number of documented screening refusals.

Number of needed Syphilis screenings performed from one month prior to the date of first STI diagnosis of each incident through two months after.

Note: This numerator does *not* include refusals.

Number of documented screening refusals.

No denominator; count only. Total count of *User Population patients* who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

No denominator; count only. Total count only of *separate key STI incidents for User Population patients* during the defined period. Broken down by gender.

Logic Description

Key STIs are Chlamydia, Gonorrhea, HIV/AIDS, and Syphilis. Key STI diagnoses are defined with the following codes.

| STI | ICD and Other Codes |
|-----------|---|
| Chlamydia | V POV: 079.88, 079.98, 099.41, 099.50-099.59 |
| Gonorrhea | V POV: 098.0-098.89 |
| HIV/AIDS | V POV: 042, 042.0-044.9, 079.53, 795.71, V08 |
| Syphilis | V POV: 090.0-093.9, 094.1-097.9 |

Logic for Identifying Patients Diagnosed with Key STI:

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

Logic for Identifying Separate Incidents of Key STIs:

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs two months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

Example of Patient with Multiple Incidents of Single STI:

| Visit | Total Incidents |
|--|-----------------|
| 08/01/10: Patient screened for Chlamydia | 0 |
| 08/08/10: Patient diagnosed with Chlamydia | 1 |
| 10/15/10: Patient diagnosed with Chlamydia | 2 |
| 10/25/10: Follow-up for Chlamydia | 2 |
| 11/15/0: Patient diagnosed with Chlamydia | 2 |
| 03/01/11: Patient diagnosed with Chlamydia | 3 |

Denominator Logic for Needed Screenings:

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed screening tests denominator, the count will be derived from the number of separate STI incidents and the type(s) of screenings recommended for each incident. The recommended screenings for each key STI are listed below.

| STI | Screenings Needed |
|-----------|--------------------------------|
| Chlamydia | Gonorrhea, HIV/AIDS, Syphilis |
| Gonorrhea | Chlamydia, HIV/AIDS, Syphilis |
| HIV/AIDS | Chlamydia, Gonorrhea, Syphilis |
| Syphilis | Chlamydia, Gonorrhea, HIV/AIDS |

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

1. The patient has a documented STI diagnosis corresponding to the screening type in the same time period. For example, a patient with both a Chlamydia and a gonorrhea diagnosis on the same visit does not need the recommended Chlamydia screening based on the gonorrhea diagnosis.
2. Only one screening for each type of STI is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening each is needed for HIV/AIDS and Syphilis.
3. A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

Numerator Logic:

To be counted in the numerator, each needed screening in the denominator must have a corresponding laboratory test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through two months after the STI incident.

Key STI screenings are defined with the following codes.

| STI | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--------------------------|--|---------------------|-------------|--|
| Chlamydia | 86631–86632, 87110, 87270, 87320, 87490–87492, 87810, 3511F | POV: V73.88, V73.98 | Yes | BGP CHLAMYDIA TESTS TAX |
| Gonorrhea | 87590–87592, 87850, 3511F | | Yes | BKM GONORRHEA TEST TAX |
| HIV/AIDS | 86689, 86701–86703, 87390–87391, 87534–87539 | | Yes | BGP HIV TEST TAX |
| Syphilis | 86592–86593, 86781, 87285, 3512F | | Yes | BKM FTA-ABS TESTS TAX or BKM RPR TESTS TAX |
| Refusal of any screening | Any refusal type (REF, NMI, etc.) for any of the four screening tests as defined above during the specified time period. | | | |

Logic Examples

Example of Patient with Single Diagnosis of Single STI:

| | |
|-----------|--|
| 08/01/10: | Patient screened for Chlamydia |
| 08/08/10: | Patient diagnosed with Chlamydia–3 screens needed: Gonorrhea, HIV/AIDS, Syphilis |
| 08/13/10: | Patient screened for Gonorrhea, HIV/AIDS, Syphilis |
| | |
| Result: | Result: Denominator: 1 key STI incident, Numerator: 1 complete screening. |

Example of Patient with Multiple Diagnoses of Single STI:

| | |
|-----------|---|
| 08/01/10: | Patient screened for Chlamydia |
| 08/08/10: | Patient diagnosed with Chlamydia (Incident #1)–3 screens needed: Gonorrhea, HIV/AIDS, Syphilis |
| 12/01/10: | Patient screened for Chlamydia |
| 12/08/10: | Patient diagnosed with Chlamydia (Incident #2) –3 screens needed: Gonorrhea, HIV/AIDS, Syphilis |
| | |
| Result: | Result: Denominator: 2 key STI incidents, Numerator: 1 complete screening (1 each of 3 types) |

Example of Patient with Single Diagnosis of Multiple STIs:

| | |
|-----------|--|
| 10/15/10: | Patient screened for Chlamydia, Gonorrhea, HIV/AIDS, Syphilis |
| 10/18/10: | Patient diagnosed with Chlamydia–3 screens needed: Gonorrhea, HIV/AIDS, Syphilis |
| 10/20/10: | Patient diagnosed with Syphilis–removes needed screen for Syphilis (see above) |
| | |
| Result: | Result: Denominator: 2 key STI incidents, Numerator: 1 complete screening (prior to triggering diagnoses but within timeframe) |

Example of Patient with Multiple Diagnoses of Multiple STIs:

| | |
|-----------|--|
| 06/15/05: | Patient diagnosed with HIV/AIDS |
| 08/01/10: | Patient screened for Chlamydia and Gonorrhea |
| 08/08/10: | Patient diagnosed with Chlamydia and Gonorrhea (Incident #1)–1 screen needed: Syphilis (HIV/AIDS not needed since prior diagnosis) |
| 08/08/10: | Patient screened for HIV/AIDS and Syphilis–since only the Syphilis screen is needed, the HIV/AIDS screen is not counted at all |
| 12/01/10: | Patient screened for Chlamydia |
| 12/08/10: | Patient diagnosed with Chlamydia (Incident #2) –2 screens needed: Gonorrhea and Syphilis |
| 12/10/10: | Patient screened for Syphilis |
| | |

| | |
|---------|---|
| Result: | Result: Denominator: 2 key STI incidents, Numerator: 1 complete screening |
|---------|---|

Key Logic Changes from CRS Version 12.0

1. Added codes 49580-4, 49718-0, 49890-7, 49905-3, 50624-6, 50790-5, 53379-4, 53825-6, 53923-9, 54086-4, 57182-8, 57974-8, 57975-5, 58900-2, 59052-1, 59419-2, 62456-9, 62469-2, 68961-2, 69353-1, 69354-9 to LOINC taxonomy for HIV Screening.
2. Deleted codes 16602-5, 45079-1, 45082-5, 45083-3, 45106-2, 45107-0, 45108-8, 45112-0, 45113-8, 45114-6, 45115-3, 56909-5, 56910-3, 56911-1, 57287-5, 57679-3, 57680-1, and added codes 560-3, 4993-2, 6349-5, 6354-5, 6355-2, 21613-5, 31777-6, 36902-5, 36903-3, 43304-5, 43404-3, 45076-7, 47211-8, 47212-6, 49096-1 to LOINC taxonomy for Chlamydia Test.

Patient List Description

List of patients diagnosed with one or more STIs during the defined time period with related screenings.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | |
|--|-------------------|-------------------|---------------------|----------------|------------------|
| DU | November 25, 2012 | | | | Page 266 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | |
| DEMO INDIAN HOSPITAL | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | |
| ----- | | | | | |
| Sexually Transmitted Infection (STI) Screening (con't) | | | | | |
| | REPORT PERIOD | PREV YR PERIOD | CHG from PREV YR | BASE PERIOD | CHG from BASE |
| Active Clinical Pts w/ Key STI Dx | 41 | 13 | +28 | 10 | +31 |
| Male Active Clinical Pts w/ Key STI Dx | 10 | 7 | +3 | 8 | +2 |
| Female Active Clinical Pts w/ Key STI Dx | 31 | 6 | +25 | 2 | +29 |
| Total # Key STI Incidents for Active Clinical Pts | 44 | 13 | +31 | 10 | +34 |

| | | | | | |
|--|----|------|-----|-----|-------|
| Total # Male AC Key STI Incidents | 10 | 7 | +3 | 8 | +2 |
| Total # Female AC Key STI Incidents | 34 | 6 | +28 | 2 | +32 |
| # Key STI Incidents for AC Pts | 43 | 13 | | 10 | |
| # Complete Screens Performed-No Refusals | 7 | 16.3 | 0 | 0.0 | +16.3 |
| # Documented Refusals | 3 | 7.0 | 0 | 0.0 | +7.0 |
| # Key STI Incidents for Male AC Pts | 10 | 7 | | 8 | |
| # Complete Screens Performed-No Refusals | 1 | 10.0 | 0 | 0.0 | +10.0 |
| # Documented Refusals | 0 | 0.0 | 0 | 0.0 | +0.0 |

Figure 2-104: Sample Report Sexually Transmitted Infection (STI) Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Sexually Transmitted Infection (STI) Screening: List of patients diagnosed with one or more STIs during the defined time period with related screenings.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|--|--------|------------------------|-----|-----|
| PATIENT1,DIANE | 000001 | COMMUNITY #1 | F | 15 |
| UP;AC Visit 1) 02/12/12 POV: HIV 042. 1) CHL-N, GC-N, SYP-N | | | | |
| PATIENT2,LEIGHANN | 000002 | COMMUNITY #1 | F | 18 |
| UP;AC Visit 1) 11/02/11 POV: GC 098.89 1) CHL-N, HIV-Y 12/02/11 CPT [87390], SYP-N | | | | |
| PATIENT3,WHITNEY | 000003 | COMMUNITY #1 | F | 25 |
| UP;AC Visit 1) 06/17/12 POV: CHL 078.89 1) GC-Y 06/17/12 Lab [HGB], HIV-N, SYP-N | | | | |
| PATIENT4,NANCY | 000004 | COMMUNITY #1 | F | 29 |
| UP;AC Visit 1) 03/01/12 POV: CHL 079.88 1) GC-Y 02/15/12 CPT [87592], HIV-Contraind Prior DX 04/11/07 POV: HIV [079.53], SYP-Y 04/01/12 CPT [87285] | | | | |
| PATIENT5,JOHN | 000005 | COMMUNITY #1 | M | 40 |
| UP;AC Visit 1) 06/15/12 POV: GC 098.89; 2) 07/15/12 POV: HIV 042. 1) CHL-N, HIV-N, SYP-N; 2) CHL-N, GC-N, SYP-N | | | | |
| PATIENT6,NORMAN | 000006 | COMMUNITY #1 | M | 42 |
| UP;AC Visit 1) 10/11/12 POV: CHL 079.98, 10/11/12 POV: GC 098.891) HIV-N, SYP-N | | | | |

Figure 2-105: Sample Patient List, Sexually Transmitted Infection (STI) Screening

2.10 Other Clinical Measures Topics

2.10.1 Osteoporosis Management

Denominators

Female Active Clinical patients ages 67 and older who had a new fracture occurring six months (182 days) prior to the Report Period through the first six months of the Report Period with no osteoporosis screening or treatment in year prior to the fracture.

Female User Population patients ages 67 and older who had a new fracture occurring 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period with no osteoporosis screening or treatment in year prior to the fracture.

Numerator

Patients treated or tested for osteoporosis after the fracture.

Logic Description

Age is calculated at the beginning of the Report Period. Fractures do not include fractures of finger, toe, face, or skull. CRS will search for the first (i.e., earliest) fracture during the period six months (182) days prior to the beginning of the Report Period and the first six months of the Report Period. If multiple fractures are present, only the first fracture will be used.

Index Episode Start Date definition: The Index Episode Start Date is the date the fracture was diagnosed. If the fracture was diagnosed at an outpatient visit (Service Category A, S, or O), the Index Episode Start Date is equal to the Visit Date. If diagnosed at an inpatient visit (Service Category H), the Index Episode Start Date is equal to the Discharge Date.

Denominator Exclusions

1. Patients receiving osteoporosis screening or treatment in the year (365 days) prior to the Index Episode Start Date. Osteoporosis screening or treatment is defined as a Bone Mineral Density (BMD) test (see below for codes) or receiving any osteoporosis therapy medication (see below for codes).
2. Patients with a fracture diagnosed at an outpatient visit, which also had a fracture within 60 days prior to the Index Episode Start Date.
3. Patients with a fracture diagnosed at an inpatient visit, which also had a fracture within 60 days prior to the ADMISSION DATE.

Osteoporosis Treatment and Testing definition: (1) For fractures diagnosed at an outpatient visit: a nondiscontinued prescription within 6 months (182 days) of the Index Episode Start Date (i.e., visit date) or B) a BMD test within 6 months of the Index Episode Start Date. (2) For fractures diagnosed at an inpatient visit, a BMD test performed during the inpatient stay.

CRS uses the following codes to define fracture and BMD test.

| Subject Defined | CPT Codes | ICD and Other Codes |
|-----------------------|---|---|
| Fracture Codes | 21800 through 21825, 22305 through 22314, 22316 through 22324, 22520, 22521, 22523, 22524, 23500 through 23515, 23570 through 23630, 23665 through 23680, 24500 through 24585, 24620, 24635, 24650 through 24685, 25500–25609, 25611 (old code), 25620 (old code), 25622–25652, 25680, 25685, 27193 through 27248, 27254, 27500 through 27514, 27520 through 27540, 27750 through 27828, S2360, S2362 | V POV: 733.1*, 805*–806*, 807.0*–807.4, 808*–815*, 818*–825*, 827*, 828* V Procedure: 79.01–79.03, 79.05–79.07, 79.11–79.13, 79.15–79.17, 79.21–79.23, 79.25–79.27, 79.31–79.33, 79.35–79.37, 79.61–79.63, 79.65–79.67, 81.65–81.66. |
| BMD Test Codes | 77078, 76070 (old code), 77079, 76071 (old code), 77080, 76075 (old code), 77081, 76076 (old code), 77083, 76078 (old code), 76977, 78350, 78351, G0130 | V POV: V82.81 V Procedure: 88.98 |

Treatment medication codes are defined with medication taxonomy BGP HEDIS OSTEOPOROSIS MEDS. (Medications are: Alendronate, Alendronate-Cholecalciferol (Fosomax Plus D), Calcium carbonate-risedronate, Ibandronate (Boniva), Risedronate, Zoledronic acid, Calcitonin, Denosumab, Raloxifene, Estrogen, Injectable Estrogens, and Teriparatide.) Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

1. Updated 6 months to be 182 days.
2. Updated BGP HEDIS OSTEOPOROSIS DRUGS medications to include Calcium carbonate-risedronate, Zoledronic acid, and Denosumab.

Patient List Description

List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

Measure Source

HEDIS

Measure Past Performance and Long-Term Targets

None

DU

November 25, 2012

Page 277

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Osteoporosis Management

| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
|----------------------------|--------|------|---------|-----|-----------|--------|-----|----------|
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Female Active Clinical Pts | | | | | | | | |
| 67 and older | | | | | | | | |
| w/fracture | 8 | | 0 | | | 0 | | |
| # w/osteoporosis treatment | | | | | | | | |
| or testing | 3 | 37.5 | 0 | 0.0 | +37.5 | 0 | 0.0 | +37.5 |
| Female User Pop Pts | | | | | | | | |
| 67 and older | | | | | | | | |
| w/fracture | 9 | | 0 | | | 0 | | |
| # w/osteoporosis treatment | | | | | | | | |
| or testing | 4 | 44.4 | 0 | 0.0 | +44.4 | 0 | 0.0 | +44.4 |

Figure 2-106: Sample Report Osteoporosis Management

| | | | | | |
|--|--------|---|-----|-----|--|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
| Osteoporosis Management: List of female patients with new fracture who have had osteoporosis treatment or testing, if any. | | | | | |
| PATIENT NAME | HRN | COMMUNITY | SEX | AGE | |
| DENOMINATOR | | NUMERATOR | | | |
| ----- | | | | | |
| PATIENT1,ALWENA | 000001 | COMMUNITY #1 | F | 68 | |
| UP,AC | | FX: 01/01/12 CPT 22524 | | | |
| PATIENT2,SYBIL | 000002 | COMMUNITY #1 | F | 69 | |
| UP,AC | | FX: 02/10/12 CPT 22524 TX: 02/10/12 CPT G0130 | | | |
| PATIENT3,ELIZABETH | 000003 | COMMUNITY #1 | F | 78 | |
| UP,AC | | FX: 02/15/12 CPT S2362 | | | |
| PATIENT4,KATIE | 000004 | COMMUNITY #1 | F | 80 | |
| UP,AC | | FX: 02/05/12 PROC 81.66 | | | |
| PATIENT5,LINDSAY | 000005 | COMMUNITY #1 | F | 81 | |
| UP | | FX: 02/01/12 DX 733.13 TX: 02/15/12 CPT 77081 | | | |

| | |
|-------------------------------|---|
| PATIENT6, ELIZABETH UP, AC | 000006 COMMUNITY #1 F 86 FX: 01/15/11 DX 733.13 TX: 01/31/12 CPT 77081 |
|-------------------------------|---|

Figure 2-107: Sample Patient List, Osteoporosis Management

2.10.2 Osteoporosis Screening in Women

Denominators

Female Active Clinical patients ages 65 and older without a documented history of osteoporosis.

Female User Population patients ages 65 and older without a documented history of osteoporosis.

Numerators

Patients who had osteoporosis screening documented in the past two years.

Note: This numerator does *not* include refusals.

Patients with documented refusal in past year.

Logic Description

Age is calculated at the beginning of the Report Period.

Osteoporosis definition: No osteoporosis diagnosis ever (POV 733.*).

CRS uses the following codes to define osteoporosis screening.

| Subject Defined | V Radiology or CPT Codes | ICD and Other Codes |
|--|---|--|
| Osteoporosis Screening (any test documented in the past two years) | Central DEXA: 77080, 76075 (old code) Peripheral DEXA: 77081, 76076 (old code) SEXA: G0130 Central CT: 77078, 76070 (old code) Peripheral CT: 77079, 76071 (old code) US Bone Density: 76977 | V Procedure: 88.98 (Quantitative CT) V POV: V82.81 Special screening for other conditions, Osteoporosis |

| Subject Defined | V Radiology or CPT Codes | ICD and Other Codes |
|--------------------------------|--|---------------------|
| Osteoporosis Screening Refusal | Refusal (in past year): CPT or V Radiology: Central DEXA: 77080 or 76075 (old code); Peripheral DEXA: 77081 or 76076 (old code); SEXA: G0130; Central CT: 77078 or 76070 (old code); Peripheral CT: 77079 or 76071 (old code); US Bone Density: 76977 | |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of female patients ages 65 and older with osteoporosis screening, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|------|----------------|-----|--------------------|-------------|----------|-----------------|
| DU | November 25, 2012 | | | | | | Page 279 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Osteoporosis Screening in Women | | | | | | | | |
| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
| Female Active Clinical Pts =>65 | 54 | | 29 | | | 29 | | |
| # w/osteoporosis screening in past 2 years | | | | | | | | |
| -No Refusals | 6 | 11.1 | 0 | 0.0 | +11.1 | 0 | 0.0 | +11.1 |
| # w/ Osteoporosis Screening Refusal | | | | | | | | |
| | 2 | 3.7 | 0 | 0.0 | +3.7 | 0 | 0.0 | +3.7 |
| Female User Pop | | | | | | | | |
| Pts =>65 | 111 | | 79 | | | 80 | | |
| # w/osteoporosis screening in past 2 years | | | | | | | | |

| | | | | | | | | |
|-----------------------------|---|-----|---|-----|------|---|-----|------|
| -No Refusals | 6 | 5.4 | 0 | 0.0 | +5.4 | 0 | 0.0 | +5.4 |
| # w/ Osteoporosis Screening | | | | | | | | |
| Refusals | 2 | 1.8 | 0 | 0.0 | +1.8 | 0 | 0.0 | +1.8 |

Figure 2-108: Sample Report, Osteoporosis Screening in Women

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|---|-----|-------|--|
| Osteoporosis Screening in Women: List of female patients ages 65 and older with osteoporosis screening or refusal, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT1,SHERRY | 000001 | COMMUNITY #1 | F | 68 | |
| UP,AC | | 05/15/12 Refused Proc | | 88.98 | |
| PATIENT2,APRIL | 000002 | COMMUNITY #1 | F | 68 | |
| UP,AC | | 04/01/12 CPT G0130 | | | |
| PATIENT3,JACKIE | 000003 | COMMUNITY #1 | F | 69 | |
| UP,AC | | 08/21/12 RAD CT,BONE MIN DENSITY,1/+,APPEND | | | |
| PATIENT4,PAULINE | 000004 | COMMUNITY #1 | F | 70 | |
| UP,AC | | | | | |
| PATIENT5,SHANNON | 000005 | COMMUNITY #1 | F | 72 | |
| UP,AC | | | | | |
| PATIENT6,TINA MARIE | 000006 | COMMUNITY #1 | F | 78 | |
| UP,AC | | 04/15/12 CPT 77081 | | | |

Figure 2-109: Sample Patient List, Osteoporosis Screening in Women

2.10.3 Rheumatoid Arthritis Medication Monitoring

Denominator

Active Clinical patients ages 16 and older diagnosed with *rheumatoid arthritis (RA)* prior to the Report Period and with at least two RA-related visits any time during the Report Period who were prescribed maintenance therapy medication chronically during the Report Period.

Numerator

Patients who received appropriate monitoring of chronic medication during the Report Period.

Logic Description

Age is calculated at the beginning of the Report Period.

RA defined as diagnosis (POV or Problem List) 714.* prior to the Report Period, and at least two RA POVs during the Report Period.

For all maintenance therapy medications *except* intramuscular gold, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply equal to or greater than (\geq)348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. *All* medications must not have a comment of RETURNED TO STOCK.

Example of Patient Not on Chronic Medication (not included in Denominator):

Report Period: January 1 through December 31, 2012

Medication Period: 465 days from end of Report Period (December 31, 2012):
September 22, 2011 through December 31, 2012

Medication Prescribed:

Diclofenac: 1st Rx: Oct 15, 2011, Days Supply=90; 2nd Rx: Jan 01, 2012:
Days Supply=90; 3rd Rx: Mar 15, 2012: Days Supply=90.

Total Days Supply=270. 270 is not greater than ($>$)348. Patient is not considered on chronic medication and is not included in the denominator.

Example of Patient on Chronic Medication (included in Denominator):

Report Period: January 1 through December 31, 2012

Medication Period: 465 days from end of Report Period (December 31, 2012):
September 22, 2011 through December 31, 2012

Medications Prescribed:

Sulfasalazine: 1st Rx: Sep 30, 2011, Days Supply=90; 2nd Rx: December 30,
2011, Days Supply=90; 3rd Rx: March 15, 2012 Days Supply=180.

Total Days Supply=360. 360 is greater than ($>$)348. Patient is considered on chronic medication and is included in denominator.

The days' supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report period.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

For intramuscular gold, the patient must have 12 or more prescriptions during the Report Period.

Appropriate monitoring of rheumatoid arthritis medications is defined with lab tests and varies by medication, as shown in the table below. If patient is prescribed two or more types of medications, patient must meet criteria for all of the medications.

Maintenance Therapy Medications Definition

- **Medications shown in table below.** *Except* for Gold, Intramuscular, all medications requiring more than one of each type of test during the Report Period, there must be a minimum of ten days between tests. For example, if a Sulfasalazine test was performed on March 1, March 7, and March 21, 2012, the March 7 test will not be counted since it was performed only six days after the March 1 test.

| Medication | Required Monitoring Tests |
|-------------------------------|--|
| Gold, Intramuscular | CBC and urine Protein on same day as each injection during Report Period |
| Azathioprine or Sulfasalazine | 4 CBCs during the Report Period |
| Leflunomide or Methotrexate | 6 each of CBC, Serum Creatinine, and Liver Function Tests during the Report Period |
| Cyclosporin | CBC, Liver Function Tests, and Potassium within past 180 days from Report Period end date 12 Serum Creatinine tests during the Report Period |
| Gold, Oral or Penicillamine | 4 each of CBC and Urine Protein during the Report Period |
| Mycophenolate | CBC within past 180 days from Report Period end date |

The medications in the above table are defined with medication taxonomies: BGP RA IM GOLD MEDS, BGP RA AZATHIOPRINE MEDS, BGP RA LEFLUNOMIDE MEDS, BGP RA METHOTREXATE MEDS, BGP RA CYCLOSPORINE MEDS, BGP RA ORAL GOLD MEDS, BGP RA MYCOPHENOLATE MEDS, BGP RA PENICILLAMINE MEDS, BGP RA SULFASALAZINE MEDS.

1. **NSAID Medications:** All of the following medications must have Creatinine, Liver Function Tests, and CBC during the Report Period: Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefenamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celcoxib. All of these medications *except* aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

2. **Glucocorticoid Medications:** Dexamethasone, Methylprednisolone, Prednisone, Hydrocortisone, Betamethasone, Prednisolone, Triamcinolone. These medications defined with medication taxonomy BGP RA GLUCOCORTICIDS MEDS. Glucocorticoids must have a glucose test, which must be performed during the Report Period.

Example of Patient Not Included in Numerator:

Medications Prescribed and Required Monitoring:

- Gold, Oral, last Rx June 15, 2012. Requires CBC and Urine Protein within past 90 days of Report Period end date.
- CBC performed on December 1, 2012, which is within past 90 days of Report Period end date of December 31, 2012. No Urine Protein performed during that period. Patient is not in numerator.

Example of Patient Included in Numerator:

Medications Prescribed and Required Monitoring:

- Diclofenac, last Rx Sep 1, 2012. Requires LFT and CBC during Report Period.
- Mycophenolate, last Rx March 10, 2012. Requires CBC within past 180 days from Report Period end date.
- LFT and CBC performed during Report Period. CBC performed November 1, 2012, which is within past 180 days of Report Period end date of December 31, 2012. Patient is in numerator.

| Monitoring Test | CPT Codes | LOINC Codes | Taxonomy |
|--------------------------|--|-------------|----------------------------|
| CBC | 85025, 85027 | Yes | BGP CBC TESTS |
| Urine Protein | | Yes | DM AUDIT URINE PROTEIN TAX |
| Serum Creatinine | 82540, 82565-75 | Yes | DM AUDIT CREATININE TAX |
| Liver Function Tests-ALT | 84460 | Yes | DM AUDIT ALT TAX |
| Liver Function Tests-AST | 84450 | Yes | DM AUDIT AST TAX |
| Liver Function | 80076 | Yes | BGP LIVER FUNCTION TESTS |
| Glucose | 82947, 82948, 82950, 82951, 82952, 82962 | Yes | DM AUDIT GLUCOSE TESTS TAX |
| Potassium | 84132 | Yes | BGP POTASSIUM TESTS |

Key Logic Changes from CRS Version 12.0

1. Added code 48134-1 to LOINC taxonomy for ALT.
2. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.

3. Deleted codes 55394-1, 55479-0, 55480-8, 55481-6, 55482-4, 55483-2, 55484-0, 55485-7, 55486-5, 55487-3, 55492-3, 55493-1, 55494-9, 55495-6, 55496-4, 55497-2, 55498-0, 55499-8, 55505-2, 55507-8, 55508-6, 55510-2 and added codes 21004-7, 49688-5, 49689-3, 50608-9, 50667-5, 51596-5, 53928-8, 53929-6, 56751-1, 57350-1, 57971-4, 57972-2, 59157-8, 59791-4, 59792-2, 59793-0, 59794-8, 59795-5, 59796-3, 59797-1, 59812-8, 59813-6, 59814-4, 59815-1 to LOINC taxonomy for Glucose.
4. Added codes 13874-3, 13875-0, 14630-8, 15015-1, 15348-6, 15349-4, 1779-8, 17858-2, 1971-1, 2322-6, 2323-4, 2324-2, 27403-5, 33898-8, 33899-6, 44786-2, 48134-1, 48136-6, 53432-1, 54500-4, 58768-3 to LOINC taxonomy for Liver Function.
5. Added LOINC codes 12812-4, 12813-2, 22760-3, 51618-7, 59010-9 to LOINC taxonomy for Potassium.
6. Added codes 16285-9, 21028-6, 29899-2, 29951-1, 34183-4, 34184-2, 35560-2, 35561-0, 38528-6, 40857-5, 49002-9, 50209-6, 50749-1, 53121-0, 53229-1, 58431-8, 58447-4, 58992-9, 60678-0, 66481-3, 6889-0, 6890-8, 9405-2, 9406-0, 9829-3, 9831-9 to LOINC taxonomy for Urine Protein.

Patient List Description

List of RA patients age 16 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO The chronic medications and all laboratory tests the patient *did* have are displayed.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|---|---------|---|-----------|--------|----------|--|
| DU | November 25, 2012 | | | | | | Page 284 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Rheumatoid Arthritis Medication Monitoring | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | BASE % | |

| | | | | | | | | |
|------------------------------------|---|------|---|-----|-------|---|-----|-------|
| Active Clinical Pts =>16 | | | | | | | | |
| w/RA DX and maintenance therapy RX | 3 | | 0 | | | 0 | | |
| # w/RA chronic med monitoring | 2 | 66.7 | 0 | 0.0 | +66.7 | 0 | 0.0 | +66.7 |

Figure 2-110: Sample Report, Rheumatoid Arthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
CHD=Active Coronary Heart Disease; HR=High Risk Patient

Rheumatoid Arthritis Medication Monitoring: List of RA patients 16 and older prescribed maintenance therapy medication with monitoring lab tests, if any. The numerator values for patients who meet the measure are prefixed with "YES:" and patients who did not meet the measure are prefixed with "NO:". The chronic medications and all lab tests the patient DID have are displayed.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
|-----------------------------|--------|--|-----|-----|--|
| ----- | | | | | |
| PATIENT1,RUTH AC | 000001 | COMMUNITY #1 YES: NSAID: 10/21/12 CREAT, 09/22/12 CBC, 05/21/12 LFT | F | 64 | |
| PATIENT2,SHANNON AC | 000002 | COMMUNITY #1 YES: Glucocorticoids: 12/02/12 Glucose | F | 72 | |
| PATIENT34,CATHERINE AC | 000034 | COMMUNITY #3 NO: Glucocorticoids: does not have Glucose | F | 50 | |

Figure 2-111: Sample Patient List, Rheumatoid Arthritis Medication Monitoring

2.10.4 Osteoarthritis Medication Monitoring

Denominator

Active Clinical patients ages 40 and older diagnosed with *osteoarthritis (OA)* prior to the Report Period and with at least two OA-related visits any time during the Report Period and prescribed maintenance therapy medication chronically during the Report Period.

Numerator

Patients who received appropriate monitoring of chronic medication during the Report Period.

Logic Description

Age is calculated at the beginning of the Report Period.

OA defined as diagnosis (POV or Problem List) 715.* prior to the Report period, and at least two OA POVs during the Report Period.

For all maintenance therapy medications, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply equal to or greater than (\geq)348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. Medications must not have a comment of RETURNED TO STOCK.

Example of Patient Not on Chronic Medication (not included in Denominator):

- Report Period: January 1 through December 31, 2012
- Medication Period: 465 days from end of Report Period (December 31, 2012): September 22, 2011 through December 31, 2012
- Medication Prescribed:
 - Diclofenac: 1st Rx: October 15, 2011, Days Supply=90; 2nd Rx: January 1, 2012: Days Supply=90; 3rd Rx: March 15, 2012: Days Supply=90.
 - Total Days Supply=270. 270 is not greater than ($>$)348. Patient is not considered on chronic medication and is not included in the denominator.

Example of Patient on Chronic Medication (included in Denominator):

- Report Period: January 1 through December 31, 2012
- Medication Period: 465 days from end of Report Period (December 31, 2012): September 22, 2011 through December 31, 2012
- Medication Prescribed:
 - Etodolac: 1st Rx: September 30, 2011, Days Supply=90; 2nd Rx: December 30, 2011, Days Supply=90; 3rd Rx: March 15, 2012: Days Supply =180.
 - Total Days Supply=360. 360 is greater than ($>$)348. Patient is considered on chronic medication and is included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report Period.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Appropriate monitoring of OA medications is defined with laboratory tests and varies by medication, as shown below.

Maintenance Therapy Medications Defined with the Following NSAID Medications:

Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefenamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celocoxib. All of these medications, *except* aspirin, are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

All NSAID medications must have Creatinine, Liver Function Tests and CBC during the Report Period.

Example of Patient Not Included in Numerator:

- Medication Prescribed and Required Monitoring:
 - Diclofenac, last Rx June 15, 2012. Requires Creatinine, LFT and CBC during Report Period. Only the LFT was performed during Report Period. Patient is not in numerator.

Example of Patient Included in Numerator:

- Medications Prescribed and Required Monitoring:
 - Diclofenac, last Rx September 1, 2012. Requires Creatinine, LFT and CBC during Report Period. Creatinine, LFT, and CBC performed during Report Period. Patient is in numerator.

CRS uses the following codes to define the monitoring tests.

| Monitoring Test | CPT Codes | LOINC Codes | Taxonomy |
|--------------------------|--------------------|-------------|--------------------------|
| Serum Creatinine | 82540, 82565-82575 | Yes | DM AUDIT CREATININE TAX |
| CBC | 85025, 85027 | Yes | BGP CBC TESTS |
| Liver Function Tests-ALT | 84460 | Yes | DM AUDIT ALT TAX |
| Liver Function Tests-AST | 84450 | Yes | DM AUDIT AST TAX |
| Liver Function | 80076 | Yes | BGP LIVER FUNCTION TESTS |

Key Logic Changes from CRS Version 12.0

1. Added code 48134-1 to LOINC taxonomy for ALT.
2. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.
3. Added codes 13874-3, 13875-0, 14630-8, 15015-1, 15348-6, 15349-4, 1779-8, 17858-2, 1971-1, 2322-6, 2323-4, 2324-2, 27403-5, 33898-8, 33899-6, 44786-2, 48134-1, 48136-6, 53432-1, 54500-4, 58768-3 to LOINC taxonomy for Liver Function.

Patient List Description

List of OA patients 40 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO. All laboratory tests the patient did have are displayed.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

DU

November 25, 2012

Page 287

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Osteoarthritis Medication Monitoring

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR | BASE % PERIOD | % | CHG from BASE % |
|---------------------------------------|------------------|------|-------------------|------|---------------------|------------------|------|--------------------|
| Active Clinical Pts =>40 | | | | | | | | |
| w/OA DX and maintenance therapy RX | 3 | | 6 | | | 4 | | |
| # w/OA chronic med monitoring | 2 | 66.7 | 3 | 50.0 | +16.7 | 2 | 50.0 | +16.7 |

Figure 2-112: Sample Report, Osteoarthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Osteoarthritis Medication Monitoring: List of OA patients 40 and older

prescribed maintenance therapy medication with monitoring lab tests, if any. The numerator values for patients who meet the measure are prefixed with "YES:" and patients who did not meet the measure are prefixed with "NO:". All lab tests the patient DID have are displayed.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------|-----------------|-------------------|
| ----- | | | | |
| PATIENT1,RUTH | 000001 | COMMUNITY #1 | F | 64 |
| AC 451 days of NSAID | | YES: 10/21/12 | CREAT, 09/22/12 | CBC, 05/21/12 LFT |
| PATIENT2,JACKIE | 000002 | COMMUNITY #1 | F | 69 |
| AC 472 days of NSAID | | YES: 10/30/12 | CREAT, 08/06/12 | CBC, 10/30/12 LFT |
| PATIENT15,RAYMOND | 000015 | COMMUNITY #2 | M | 84 |
| AC 804 days of NSAID | | NO: 09/12/12 | CREAT | |

Figure 2-113: Sample Patient List, Osteoarthritis Medication Monitoring

2.10.5 Asthma

Denominators

All Active Clinical patients. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

Patients who have had two asthma-related visits during the Report Period or with persistent asthma. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

Numerators

Patients who have had two asthma-related visits during the Report Period or with persistent asthma.

Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the Report Period.

Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period.

Patients from Numerator 1 who have a Severity of 1.

Patients from Numerator 1 who have a Severity of 2.

Patients from Numerator 1 who have a Severity of 3.

Patients from Numerator 1 who have a Severity of 4.

Patients from Numerator 1 who have no documented Severity.

Logic Description

Age is calculated at beginning of Report Period.

Asthma visits definition: Diagnosis (POV) 493.*.

Persistent asthma definition: Any of the following:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at *any* time before the end of the Report Period, *or*
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented *any* time before the end of the Report Period.

Severity definition: Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for 493.* or in V Asthma.

Hospitalizations definition: Service Category H with primary POV 493.*.

ER and Urgent Care definition: Clinic codes 30 or 80 with primary POV 493.*.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients diagnosed with asthma and any asthma-related hospitalizations.

Measure Source

HP 2020 RD-2

Measure Past Performance and Long-Term Targets

| Measure | Target |
|---|------------------------|
| HP1998 baseline for hospitalizations for asthma: | |
| Under 5 | 45.6 per 10,000 |
| 5-64 | 12.5 per 10,000 |
| 65 and older | 17.7 per 10,000 |
| HP 2020 goal for hospitalizations for asthma: | |
| <i>Under 5</i> | <i>18.1 per 10,000</i> |
| <i>5-64</i> | <i>8.6 per 10,000</i> |
| <i>65 and older</i> | <i>20.3 per 10,000</i> |

| | | | | | | | |
|--|-------------------|---|---------|---|-----------|--------|----------|
| DU | November 25, 2012 | | | | | | Page 289 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Asthma (con't) | REPORT | % | PREV YR | % | CHG from | BASE | % |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | BASE % |

| | | | |
|--------------------------------|---------|---------------|----------------|
| Total Active Clinical Patients | 1,646 | 1,224 | 1,101 |
| # w/asthma | 58 3.5 | 42 3.4 +0.1 | 25 2.3 +1.3 |
| A. Under 15 | 28 48.3 | 22 52.4 -4.1 | 17 68.0 -19.7 |
| B. 15-34 | 7 12.1 | 7 16.7 -4.6 | 3 12.0 +0.1 |
| C. 35-64 | 15 25.9 | 8 19.0 +6.8 | 3 12.0 +13.9 |
| D. 65 and older | 8 13.8 | 5 11.9 +1.9 | 2 8.0 +5.8 |
| # w/asthma | 58 | 42 | 25 |
| # w/asthma hospitalization | 2 3.4 | 2 4.8 -1.3 | 2 8.0 -4.6 |
| A. Under 15 | 1 50.0 | 0 0.0 +50.0 | 1 50.0 +0.0 |
| B. 15-34 | 0 0.0 | 1 50.0 -50.0 | 0 0.0 +0.0 |
| C. 35-64 | 0 0.0 | 0 0.0 +0.0 | 1 50.0 -50.0 |
| D. 65 and older | 1 50.0 | 1 50.0 +0.0 | 0 0.0 +50.0 |
| # w/ ER/UC visit | 6 10.3 | 6 14.3 -3.9 | 9 36.0 -25.7 |
| A. Under 15 | 2 33.3 | 3 50.0 -16.7 | 7 77.8 -44.4 |
| B. 15-34 | 0 0.0 | 2 33.3 -33.3 | 1 11.1 -11.1 |
| C. 35-64 | 2 33.3 | 0 0.0 +33.3 | 1 11.1 +22.2 |
| D. 65 and older | 2 33.3 | 1 16.7 +16.7 | 0 0.0 +33.3 |
| # w/ Severity 1 | 3 5.2 | 0 0.0 +5.2 | 0 0.0 +5.2 |
| # w/ Severity 2 | 7 12.1 | 3 7.1 +4.9 | 0 0.0 +12.1 |
| # w/ Severity 3 | 4 6.9 | 0 0.0 +6.9 | 0 0.0 +6.9 |
| # w/ Severity 4 | 6 10.3 | 2 4.8 +5.6 | 0 0.0 +10.3 |
| # w/ No Severity | 38 65.5 | 37 88.1 -22.6 | 25 100.0 -34.5 |

Figure 2-114: Sample Report, Asthma

| | | | | |
|--|--------|---|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Asthma: List of patients diagnosed with asthma and any asthma-related hospitalizations/ER/Urgent Care visits. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,GENEVA AC | 000001 | COMMUNITY #1 Severity 4 on visit 02/02/11; ER/UC: 11/02/12; | F | 47 |
| Severity: 4 | | | | |
| PATIENT2,JACKIE AC | 000002 | COMMUNITY #1 Severity 2 on PL; Severity: 2 | F | 69 |
| PATIENT3,PAULINE AC | 000003 | COMMUNITY #1 2 Dx PCC: 03/01/12, 03/03/12; ER/UC: 10/01/12; | F | 70 |
| Severity: 1 | | | | |
| PATIENT4,WILLIAM R AC | 000004 | COMMUNITY #1 2 Dx PCC: 05/05/12, 06/06/12; Hospital: 05/05/12; | M | 7 |
| ER/UC: 06/06/12 | | | | |
| PATIENT5,ZACHARY AC | 000005 | COMMUNITY #1 2 Dx PCC: 03/20/12, 08/08/12 | M | 11 |
| PATIENT42,JOSEPHINE | 000042 | COMMUNITY #2 | F | 4 |

| | |
|----|---|
| AC | 2 Dx PCC: 07/01/12, 09/19/12; Severity: 2 |
|----|---|

Figure 2-115: Sample Patient List, Asthma

2.10.6 Asthma Assessments

Denominators

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>)65).

Numerator

Patients with asthma management plan during the Report Period.

Patients with severity documented at any time before the end of the Report Period.

Patients with control documented during the Report Period.

Patients who were assessed for number of symptom free days during the Report Period.

Patients with number of symptom free days score of 0 through 5.

Patients with number of symptom free days score of 6 through 12.

Patients with number of symptom free days score of 13 through 14.

Patients who were assessed for number of school/work days missed during the Report Period.

Patients with number of school/work days missed score of 0 through 2.

Patients with number of school/work days missed score of 3 through 7.

Patients with number of school/work days missed score of 8 through 14.

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV codes: 492.*, 506.4, 518.1, 518.2.

COPD definition: Any visit at any time on or before the end of the Report Period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

Persistent asthma definition:

1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
 - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis 493* (asthma)
 - b. At least one acute inpatient discharge with Primary Diagnosis 493.*. Acute inpatient discharge defined as Service Category of H
 - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* *and* at least two asthma medication dispensing events (see definition below)
 - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
2. Meeting any of the following criteria below:
 - a. Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
 - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ($100/30 = 3.33$, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Indacaterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Asthma management plan definition: Patient Education code ASM-SMP.

Severity documented definition:

Meeting any of the following criteria below:

1. Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at ANY time before the end of the Report Period or
2. Most recent visit-related asthma entry (i.e. V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the Report Period.

Control documented definition: POV 493.* with Asthma Control recorded in the V Asthma file.

Number of symptom free days definition: The most recent V Measurement documented during the Report Period.

Number of school/work days missed definition: The most recent V Measurement documented during the Report Period.

Key Logic Changes from CRS Version 12.0

1. Updated medications to add Formoterol-Mometasone to Inhaled Steroid Combinations.
2. Updated medications to add Ciclesonide CFC Free to Inhaled Corticosteroids.
3. Updated medications to add Indacaterol to Long-Acting, Inhaled Beta-2 Agonists.

Patient List Description

List of asthmatic patients with assessments, if any.

Measure Source

None

Measure Past Performance and Long-term Targets

None

| | | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|--|
| DU | November 25, 2012 | | | | | | Page 295 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Asthma Assessments | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical | | | | | | | | | |
| Pts =>5 w/ persistent asthma | 29 | | 11 | | | 5 | | | |
| # w/management plan | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |
| # w/severity documented | 17 | 58.6 | 5 | 45.5 | +13.2 | 1 | 20.0 | +38.6 | |
| # w/control documented | 3 | 10.3 | 0 | 0.0 | +10.3 | 0 | 0.0 | +10.3 | |
| # w/# symptom free days | 3 | 10.3 | 0 | 0.0 | +10.3 | 0 | 0.0 | +10.3 | |
| # w/# symptom free days 0-5 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |
| # w/# symptom free days 6-12 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |
| # w/# symptom free days 13-14 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |
| # w/# school/work days missed | 3 | 10.3 | 0 | 0.0 | +10.3 | 0 | 0.0 | +10.3 | |
| # w/# school/work days missed 0-2 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |
| # w/# school/work days missed3-7 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 | |

| | | | | | | | | |
|------------------------------------|---|-----|---|-----|------|---|-----|------|
| # w/# school/work days missed 8-14 | 1 | 3.4 | 0 | 0.0 | +3.4 | 0 | 0.0 | +3.4 |
|------------------------------------|---|-----|---|-----|------|---|-----|------|

Figure 2-116: Sample Report, Asthma Assessments

| | | | | | |
|--|---|-------|-------|------|---------|
| DU | November 25, 2012 | | | | Page 95 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | |
| DEMO INDIAN HOSPITAL | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | |
| ----- | | | | | |
| Asthma Assessments (con't) | | | | | |
| | Active Clinical Pts =>5 w/Persistent Asthma | | | | |
| | 5-14 | 15-34 | 35-64 | 65+ | |
| CURRENT REPORT PERIOD | | | | | |
| Active Clinical Pts =>5 | | | | | |
| w/persistent asthma | 11 | 6 | 6 | 6 | |
| # w/management plan | 1 | 0 | 0 | 0 | |
| % w/managment plan | 9.1 | 0.0 | 0.0 | 0.0 | |
| # w/severity documented | 7 | 3 | 6 | 1 | |
| % w/severity documented | 63.6 | 50.0 | 100.0 | 16.7 | |
| % w/control documented | 0 | 1 | 1 | 1 | |
| % w/control documented | 0.0 | 16.7 | 16.7 | 16.7 | |
| # w/# symptom free days | 1 | 0 | 0 | 2 | |
| % w/# symptom free days | 9.1 | 0.0 | 0.0 | 33.3 | |
| # w/# symptom free days 0-5 | 0 | 0 | 0 | 1 | |
| % w/# symptom free days 0-5 | 0.0 | 0.0 | 0.0 | 16.7 | |
| # w/# symptom free days 6-12 | 1 | 0 | 0 | 0 | |
| % w/# symptom free days 6-12 | 9.1 | 0.0 | 0.0 | 0.0 | |
| # w/# symptom free days 13-14 | 0 | 0 | 0 | 1 | |
| % w/# symptom free days 13-14 | 0.0 | 0.0 | 0.0 | 16.7 | |
| # w/# school/work days missed | 1 | 0 | 0 | 2 | |
| % w/# school/work days missed | 9.1 | 0.0 | 0.0 | 33.3 | |
| # w/# school/work days missed 0-2 | 1 | 0 | 0 | 0 | |
| % w/# school/work days missed 0-2 | 9.1 | 0.0 | 0.0 | 0.0 | |
| # w/# school/work days missed 3-7 | 0 | 0 | 0 | 1 | |
| % w/# school/work days missed 3-7 | 0.0 | 0.0 | 0.0 | 16.7 | |
| # w/# school/work days missed 8-14 | 0 | 0 | 0 | 1 | |

| | | | | |
|------------------------------------|-----|-----|-----|------|
| % w/# school/work days missed 8-14 | 0.0 | 0.0 | 0.0 | 16.7 |
|------------------------------------|-----|-----|-----|------|

Figure 2-117: Sample Age Breakdown Report, Asthma Assessments

| | | | | |
|--|--------|------------------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Asthma Assessments: List of asthmatic patients with assessments, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,GENEVA | 000001 | COMMUNITY #1 | F | 47 |
| UP,AC Severity 4 in V Asthma 02/02/11 Severity: 4; Symptom Free Days: 03/01/12 [12]; Days Missed: 03/01/12 [0] | | | | |
| PATIENT2,JACKIE | 000002 | COMMUNITY #1 | F | 69 |
| UP,AC Severity >1 on PL for 493.00 Severity: 2 | | | | |
| PATIENT3,PAULINE | 000003 | COMMUNITY #1 | F | 70 |
| UP,AC Severity >1 on PL for 493.00 Mgmt Plan: 06/01/12; Severity: 3 | | | | |
| PATIENT4,WILLIAM R | 000004 | COMMUNITY #1 | M | 7 |
| UP,AC 4 meds | | | | |
| PATIENT5,ZACHARY | 000005 | COMMUNITY #1 | M | 11 |
| AC Severity 4 in V Asthma 04/04/12 Severity: 4; Control: 05/06/12 | | | | |
| PATIENT42,JOSEPHINE | 000042 | COMMUNITY #2 | F | 4 |
| AC DX ON HOSP/OR ER ON 05/05/11 DX ON HOSP/OR ER ON 06/03/12 Control: 10/03/12; Symptom Free Days: 07/01/12 [3]; Days Missed: 07/01/12 [3] | | | | |

Figure 2-118: Sample Patient List, Asthma Assessments

2.10.7 Asthma Quality of Care

Denominators

Active Clinical patients ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

User Population patients ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema and chronic COPD. Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

Numerator

Patients who had at least one dispensed prescription for preferred asthma therapy medication during the Report Period.

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV codes: 492.*, 506.4, 518.1, 518.2.

COPD definition: Any visit at any time on or before the end of the Report Period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

Persistent asthma definition:

4. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
 - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis 493* (asthma)
 - b. At least one acute inpatient discharge with Primary Diagnosis 493.*. Acute inpatient discharge defined as Service Category of H
 - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* *and* at least two asthma medication dispensing events (see definition below)
 - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
5. Meeting any of the following criteria below:
 - a. Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
 - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ($100/30 = 3.33$, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Indacaterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, patient must have a non-discontinued prescription for preferred asthma therapy (see list of medications below) during the Report Period.

Preferred asthma therapy medication codes for numerator defined with medication taxonomy: BGP HEDIS PRIMARY ASTHMA MEDS Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline). Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

1. Updated medications to add Formoterol-Mometasone to Inhaled Steroid Combinations.
2. Updated medications to add Ciclesonide CFC Free to Inhaled Corticosteroids.
3. Updated medications to add Indacaterol to Long-Acting, Inhaled Beta-2 Agonists.

4. Updated BGP HEDIS PRIMARY ASTHMA MEDS medications to add Formoterol-Mometasone to Inhaled Steroid Combinations and Ciclesonide CFC Free to Inhaled Corticosteroids.

Patient List Description

List of asthmatic patients with preferred asthma therapy medications, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|-------|---------|-------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 292 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Asthma Quality of Care (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts 5-56 | | | | | | | | |
| w/persistent | | | | | | | | |
| asthma | 21 | | 10 | | | 5 | | |
| # w/ preferred asthma | | | | | | | | |
| control med | 7 | 33.3 | 5 | 50.0 | -16.7 | 3 | 60.0 | -26.7 |
| A. Active Clinical | | | | | | | | |
| ages 5-9 | 11 | | 3 | | | 1 | | |
| # w/ preferred asthma | | | | | | | | |
| control med | 3 | 27.3 | 1 | 33.3 | -6.1 | 1 | 100.0 | -72.7 |
| B. Active Clinical | | | | | | | | |
| ages 10-17 | 2 | | 2 | | | 1 | | |
| # w/ preferred asthma | | | | | | | | |
| control med | 2 | 100.0 | 2 | 100.0 | +0.0 | 0 | 0.0 | +100.0 |
| C. Active Clinical | | | | | | | | |
| ages 18-56 | 8 | | 5 | | | 3 | | |
| # w/ preferred asthma | | | | | | | | |
| control med | 2 | 25.0 | 2 | 40.0 | -15.0 | 2 | 66.7 | -41.7 |
| User Pop Pts 5-56 | | | | | | | | |
| w/persistent | | | | | | | | |

| | | | | | | | | |
|-----------------------------------|----|-------|----|-------|-------|---|-------|--------|
| asthma | 21 | | 11 | | | 6 | | |
| # w/ preferred asthma control med | 7 | 33.3 | 5 | 45.5 | -12.1 | 3 | 50.0 | -16.7 |
| A. User Pop ages 5-9 | 11 | | 4 | | | 1 | | |
| # w/ preferred asthma control med | 3 | 27.3 | 1 | 25.0 | +2.3 | 1 | 100.0 | -72.7 |
| B. User Pop ages 10-17 | 2 | | 2 | | | 1 | | |
| # w/ preferred asthma control med | 2 | 100.0 | 2 | 100.0 | +0.0 | 0 | 0.0 | +100.0 |
| C. User Pop ages 18-56 | 8 | | 5 | | | 4 | | |
| # w/ preferred asthma control med | 2 | 25.0 | 2 | 40.0 | -15.0 | 2 | 50.0 | -25.0 |

Figure 2-119: Sample Report, Asthma Quality of Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Asthma Quality of Care: List of asthmatic patients with preferred asthma therapy medications, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|--|--------|------------------------|-----|-----|
| PATIENT1,ZACHARY | 000011 | COMMUNITY | F | 5 |
| UP,AC,Severity 4 in V Asthma 02/02/11 | | | | |
| PATIENT12,TINA DANIELLE | 000012 | COMMUNITY | F | 6 |
| UP,AC,Severity >1 on PL for 493.00,NUM: 06/01/12, MOMETASONE/FORMOTEROL 100/5MCG INH | | | | |
| PATIENT13,THERESA LYNN | 000013 | COMMUNITY | M | 47 |
| UP,AC,Severity 2 in V Asthma 03/03/12,NUM: 06/01/12, FLUTICASONE PROPIONATE 110MCG INHALER | | | | |
| PATIENT36,NATHAN BRADLEY | 000014 | COMMUNITY | M | 16 |
| UP,AC,DX ON HOSP/OR ER ON 09/26/11,4 POVS AND 2 MEDSNUM: 09/19/12, FLUTICASONE PROPIONATE 110MCG INHALER | | | | |
| PATIENT37,JANELLE MARIE | 000015 | COMMUNITY | F | 50 |
| UP,AC,Severity 2 in V Asthma 09/04/11 | | | | |
| PATIENT38,THOMAS ELLIS | 000016 | COMMUNITY | M | 6 |
| UP,AC,4 meds | | | | |

Figure 2-120: Sample Patient List, Asthma Quality of Care

2.10.8 Medication Therapy for Persons with Asthma

Denominators

Active Clinical patients ages 5-50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

Active Clinical patients ages five and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) who had 2 or more prescriptions for a LABA during the Report Period. Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

Numerators

Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting beta2 agonist inhaler during the same 90-day period during the Report Period.

Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

Patients who were prescribed two or more controller therapy medications during the Report Period.

Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period.

Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period.

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV codes: 492.*, 506.4, 518.1, 518.2.

COPD definition: Any visit at any time on or before the end of the Report Period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

Persistent asthma definition:

5. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
 - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis 493* (asthma)
 - b. At least one acute inpatient discharge with Primary Diagnosis 493.*. Acute inpatient discharge defined as Service Category of H
 - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* *and* at least two asthma medication dispensing events (see definition below)
 - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
6. Meeting any of the following criteria below:
 - a. Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
 - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ($100/30 = 3.33$, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Beclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Indacaterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

To be included in the Suboptimal Control and Absence of Controller Therapy numerators, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totaling at least four canisters in one 90 day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Controller Therapy definition:

At least one non-discontinued prescription of controller therapy medications during the same 90 day period.

Controller therapy medications defined with medication taxonomy BGP PQA CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide, Budesonide-Formoterol, Ciclesonide, Cromolyn, Flunisolide, Fluticasone, Fluticasone-Salmeterol, Formoterol, Mometasone, Mometasone-Formoterol, Montelukast, Nedocromil, Salmeterol, Theophylline, Triamcinolone, Zafirlukast, Zileuton). Medications must not have a comment of RETURNED TO STOCK.

Inhaled corticosteroid medications defined with medication taxonomy BGP ASTHMA INHALED STEROIDS. (Medications are: Mometasone (Asmanex), Beclovent, Qvar, Vancenase, Vanceril, Vanceril DS, Bitolerol (Tornalate), Pulmicort, Pulmicort Respules, Pulmicort Turbohaler, Salmeterol/fluticasone (Advair), Triamcinolone (Azmacort), Fluticasone (Flovent), Budesonide-Formoterol (Symbicort).) Medications must not have a comment of RETURNED TO STOCK.

Long-Acting Beta-2 Agonist (LABA) medications defined with medication taxonomy BGP ASTHMA LABA MEDS. (Medications are: Aformoterol, Formoterol, Salmeterol.) Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

1. Updated medications to add Formoterol-Mometasone to Inhaled Steroid Combinations.
2. Updated medications to add Ciclesonide CFC Free to Inhaled Corticosteroids.
3. Updated medications to add Indacaterol to Long-Acting, Inhaled Beta-2 Agonists.

Patient List Description

List of patients with asthma with suboptimal control and controller therapy, if any.

Measure Source

PQA (Pharmacy Quality Alliance)

Measure Past Performance and Long-term Targets

None

| | | | | | | | | |
|--|-------------------|-------|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 299 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Medication Therapy for Persons with Asthma | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical ages | | | | | | | | |
| 5-50 w/ asthma | 19 | | 8 | | | 5 | | |
| # w/ Suboptimal | | | | | | | | |
| Control | 1 | 5.3 | 0 | 0.0 | +5.3 | 0 | 0.0 | +5.3 |
| # w/ Absence of Controller | | | | | | | | |
| Therapy | 1 | 100.0 | 0 | 0.0 | +100.0 | 0 | 0.0 | +100.0 |

| | | | | | | | | |
|---|----|------|----|------|-------|---|------|-------|
| Active Clinical Pts =>5 w/persistent asthma | 29 | | 11 | | | 5 | | |
| # w/ 2 or more controller Rx | 10 | 34.5 | 5 | 45.5 | -11.0 | 3 | 60.0 | -25.5 |
| # w/ 2 or more inhaled steroid Rx | 3 | 10.3 | 3 | 27.3 | -16.9 | 0 | 0.0 | +10.3 |
| Active Clinical =>5 w/persistent asthma and LABA Rx | 4 | | 0 | | | 0 | | |
| # w/o 2 or more inhaled steroid Rx | 3 | 75.0 | 0 | 0.0 | +75.0 | 0 | 0.0 | +75.0 |

Figure 2-121: Sample Report, Medication Therapy for Persons with Asthma

| | | | | | |
|--|--|-------|-------|-------|---------|
| DU | November 25, 2012 | | | | Page 95 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | |
| DEMO INDIAN HOSPITAL | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | |
| ----- | | | | | |
| Medication Therapy for Persons with Asthma (con't) | | | | | |
| | Active Clinical Pts =>5 w/persistent asthma | | | | |
| | 5-14 | 15-34 | 35-64 | 65+ | |
| CURRENT REPORT PERIOD | | | | | |
| Active Clinical Pts =>5 w/persistent asthma | 11 | 6 | 6 | 6 | |
| # w/ 2 or more controller Rx | 6 | 2 | 1 | 1 | |
| % w/ 2 or more controller Rx | 54.5 | 33.3 | 16.7 | 16.7 | |
| # w/ 2 or more inhaled steroid Rx | 3 | 0 | 0 | 0 | |
| % w/ 2 or more inhaled steroid Rx | 27.3 | 0.0 | 0.0 | 0.0 | |
| PREVIOUS REPORT PERIOD | | | | | |
| Active Clinical Pts =>5 w/persistent asthma | 4 | 2 | 3 | 1 | |
| # w/ 2 or more controller Rx | 2 | 1 | 1 | 0 | |
| % w/ 2 or more controller Rx | 50.0 | 50.0 | 33.3 | 0.0 | |
| # w/ 2 or more inhaled steroid Rx | 1 | 1 | 1 | 0 | |
| % w/ 2 or more inhaled steroid Rx | 25.0 | 50.0 | 33.3 | 0.0 | |
| CHANGE FROM PREVIOUS YR % | | | | | |
| # w/ 2 or more controller Rx | +4.5 | -16.7 | -16.7 | +16.7 | |
| # w/ 2 or more inhaled steroid Rx | -22.7 | -50.0 | -33.3 | +0.0 | |

| | | | | |
|-----------------------------------|-------|-------|--------|-------|
| BASELINE REPORT PERIOD | | | | |
| Active Clinical Pts =>5 | | | | |
| w/persistent asthma | 2 | 2 | 1 | 0 |
| # w/ 2 or more controller Rx | 1 | 1 | 1 | 0 |
| % w/ 2 or more controller Rx | 50.0 | 50.0 | 100.0 | 0.0 |
| # w/ 2 or more inhaled steroid Rx | 0 | 0 | 0 | 0 |
| % w/ 2 or more inhaled steroid Rx | 0.0 | 0.0 | 0.0 | 0.0 |
| CHANGE FROM BASELINE YR % | | | | |
| # w/ 2 or more controller Rx | +4.5 | -16.7 | -83.3 | +16.7 |
| # w/ 2 or more inhaled steroid Rx | -22.7 | -50.0 | -100.0 | +0.0 |

Figure 2-122: Sample Age Breakdown Report, Medication Therapy for Persons with Asthma

| | | | | |
|--|------------------|--------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Medication Therapy for Persons with Asthma: List of patients with asthma with asthma medications, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN NUMERATOR | COMMUNITY | SEX | AGE |
| ----- | | | | |
| PATIENT1,GWEN | 000001 | COMMUNITY #1 | F | 5 |
| AC,Severity 4 in V Asthma 02/02/11 | | | | |
| PATIENT2,ALICE | 000002 | COMMUNITY #1 | F | 6 |
| AC,Severity >1 on PL for 493.00 SABA: 06/15/12 ALBUTEROL 90MCG/INHALATION MDI(4) | | | | |
| PATIENT3,GENEVA | 000003 | COMMUNITY #1 | F | 47 |
| AC,Severity 2 in V Asthma 03/03/12 2+ CONT: 06/01/12 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/12 FLUTICASONE PROPIONATE 110MCG INHALER; 2+ STEROID: 06/01/12 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/12 FLUTICASONE PROPIONATE 110MCG INHALER | | | | |
| PATIENT22,MELANIE | 000022 | COMMUNITY #1 | F | 47 |
| AC,Severity >1 on PL for 493.00 | | | | |
| PATIENT27,RANDALL | 000027 | COMMUNITY #1 | M | 6 |
| AC,Severity >1 on PL for 493.00 LABA2+ CONT: 03/03/12 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/12 MOMETASONE/FORMOTEROL 100/5MCG INH; 2+ STEROID: 03/03/12 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/12 MOMETASONE/FORMOTEROL 100/5MCG INH | | | | |

Figure 2-123: Sample Patient List, Medication Therapy for Persons with Asthma

2.10.9 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation

Denominator

Number of visits for User Population patients ages 18 and older diagnosed with community-acquired bacterial pneumonia at an outpatient visit during the Report Period.

Numerators

Number of visits where patients had *oxygen saturation documented* and reviewed.

Number of visits where patients *refused oxygen saturation assessment*.

Number of visits where patients *did not have their oxygen saturation documented* and reviewed.

Logic Description

Age of the patient is calculated at the beginning of the report period.

If a patient has more than one visit for community-acquired bacterial pneumonia during the report period, each visit will be counted as long as it has been more than 45 days since the date of the prior visit. For example, a patient was diagnosed on January 1, 2012 and 35 days later he was diagnosed again with pneumonia. That second diagnosis does not count as a separate visit. However, if the patient were diagnosed again on February 16, 2012 (46 days after onset), that diagnosis counts as a separate visit. Because RPMS does not store the date of onset, visit date will be used as a surrogate for onset date.

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | ICD and Other Codes |
|---|--|
| Community-Acquired Bacterial Pneumonia (Non-CHS outpatient visit, defined as visit type not equal to "C" and service category of "A" for Ambulatory, "S" for Day Surgery, or "O" for Observation) | V POV: 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39, 482.40, 482.41, 482.42, 482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 483.0, 483.1, 483.8, 485, 486, 487.0 |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|---|---|------------------------------|-------------|-------------------|
| Oxygen Saturation Assessment (any of the arterial blood gas (ABG) or pulse oximetry tests performed at the visit) | 94760-94762, 82803, 82805, 82810, or 3028F or 3028F, where 3028F has no modifier of 1P, 2P, 3P, or 8P | V Measurement: O2 Saturation | Yes | BGP CMS ABG TESTS |

Refusal of Oxygen Saturation Assessment definition: Patients whose oxygen saturation was not assessed due to a patient refusal of assessment on visit date. Refusal is defined as refusal of any of the tests listed above.

No Assessment definition: Patients whose oxygen saturation was not assessed or refused.

Key Logic Changes from CRS Version 12.0

Added codes 19224-5, 20081-6, 20564-1, 24339-4, 24340-2, 24344-4, 2708-6, 2709-4, 2710-2, 2711-0, 28643-5, 44612-0, 44613-8, 44614-6, 44616-1, 51972-8, 51973-6, 51974-4, 59405-1, 59406-9, 59407-7, 59408-5, 59409-3, 59410-1, 59411-9, 59412-7, 59413-5, 59414-3, 59415-0, 59416-8, 59417-6, 59418-4, 68363-1, 8839-3 to LOINC taxonomy for Arterial Blood Gas.

Patient List Description

List of patients with community-acquired bacterial pneumonia, with oxygen saturation assessment or documented reason for no assessment, if any.

Measure Source

CMS PQRI Measure #57

Measure Past Performance and Long-Term Targets

None

| | | | | | | | |
|---|-------------------|---|---------|---|------------------|-----------------|--|
| DU | November 25, 2012 | | | | | Page 301 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation (con't) | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from BASE | % | |
| | PERIOD | | PERIOD | | PREV YR % PERIOD | CHG from BASE % | |
| # Pneumonia Visits for | | | | | | | |

| | | | |
|-----------------------------|---------|---------------|--------------|
| User Pop Pts 18+ | 53 | 12 | 8 |
| # Visits w/ O2 Sat Assmt | 23 43.4 | 1 8.3 +35.1 | 2 25.0 +18.4 |
| # Visits w/ Refusal | 4 7.5 | 0 0.0 +7.5 | 0 0.0 +7.5 |
| # Visits w/ No O2 Sat Assmt | 26 49.1 | 11 91.7 -42.6 | 6 75.0 -25.9 |

Figure 2-124: Sample Report, Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation: List of patients with community-acquired bacterial pneumonia, with oxygen saturation assessment or documented reason for no assessment, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX AGE |
|---|--------|--|---------|
| PATIENT1,GENEVA | 000001 | COMMUNITY #1 | F 27 |
| UP,1) 11/25/12 482.81 | | 1) 11/25/12 O2 SAT: CPT 3028F | |
| PATIENT2,JACKIE | 000002 | COMMUNITY #1 | F 29 |
| UP,1) 06/15/12 482.89 | | 1) 06/15/12 O2 SAT: LAB BLOOD GASES | |
| PATIENT3,PAULINE | 000003 | COMMUNITY #1 | F 38 |
| UP,1) 05/31/12 482.0 | | 1) 05/31/12 None | |
| PATIENT4,WILLIAM | 000004 | COMMUNITY #1 | M 38 |
| UP,1) 05/31/12 482.0; 2) 08/01/12 482.49; 3) 09/17/12 487.0 | | 1) 05/31/12 None; 2) 08/01/12 O2 SAT: CPT 82805; 3) 09/17/12 O2 SAT: CPT 82810 | |
| PATIENT5,ZACHARY LEE | 000005 | COMMUNITY #1 | M 36 |
| UP,1) 09/01/12 482.83; 2) 12/01/12 482.83 | | 1) 09/01/12 Refused CPT 94761; 2) 12/01/12 Refused O2 SAT MEAS | |

Figure 2-125: Sample Patient List, Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation

2.10.10 Chronic Kidney Disease Assessment

Denominators

Active Clinical patients ages 18 and older with serum creatinine test during the Report Period.

User Population patients ages 18 and older with serum creatinine test during the Report Period.

Numerators

Patients with Estimated GFR.

- Patients with GFR less than ($<$) 60.
- Patients with normal GFR (i.e., greater than or equal to (\geq) 60).

Logic Description

Age is calculated at beginning of the Report Period.

For the GFR less than (<) 60 numerator, CRS will include GFR results containing a numeric value less than 60 or with a text value of “less than (<) 60”. For the normal GFR (greater than or equal to (>=) 60) numerator, CRS will include GFR results containing a numeric value equal to or greater than 60 or with a text value of “60”

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--------------------|-----------------|---------------------|-------------|-------------------------------|
| Creatinine test | 82540, 82565-75 | | Yes | DM AUDIT CREATININE TAX |
| Estimated GFR test | | | Yes | BGP GPRA ESTIMATED GFR TAX |

Key Logic Changes from CRS Version 12.0

1. Added codes 59826-8 and 62425-4 to LOINC taxonomy for Creatinine.
2. Added codes 50384-7 and 69405-9 to LOINC taxonomy for Estimated GFR.

Patient List Description

List of patients with Creatinine test, with GFR and value, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | |
|--|-------------------|---|---------|---|------------------|----------|--|
| DU | November 25, 2012 | | | | | Page 303 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | |
| ----- | | | | | | | |
| Chronic Kidney Disease Assessment (con't) | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from BASE | % | |
| | PERIOD | | PERIOD | | PREV YR % PERIOD | BASE % | |
| Active Clinical Pts | | | | | | | |

| | | | | | | | | |
|---|-----|------|-----|------|-------|-----|-----|-------|
| => 18 with Serum Creatinine test | 271 | | 258 | | | 221 | | |
| w/Est GFR | 189 | 69.7 | 33 | 12.8 | +57.0 | 16 | 7.2 | +62.5 |
| A. # w/ GFR <60 | 52 | 19.2 | 30 | 11.6 | +7.6 | 15 | 6.8 | +12.4 |
| B. # w/Normal GFR (>=60) | 137 | 50.6 | 2 | 0.8 | +49.8 | 0 | 0.0 | +50.6 |
| User Pop Pts =>18 with Serum Creatinine | 331 | | 311 | | | 262 | | |
| # w/ Est GFR | 221 | 66.8 | 33 | 10.6 | +56.2 | 16 | 6.1 | +60.7 |
| A. # w/GFR <60 | 55 | 16.6 | 30 | 9.6 | +7.0 | 15 | 5.7 | +10.9 |
| B. # w/Normal GFR (>=60) | 165 | 49.8 | 2 | 0.6 | +49.2 | 0 | 0.0 | +49.8 |

Figure 2-126: Sample Report, Chronic Kidney Disease Assessment

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|------------------------|-----|-----|--|
| Chronic Kidney Disease Assessment: List of patients with Creatinine test, with GFR and value, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1, SHERISA | 000001 | COMMUNITY #1 | F | 18 | |
| UP, AC | | 08/16/12 GFR: 78 | | | |
| PATIENT2, CAITLYN | 000002 | COMMUNITY #1 | F | 22 | |
| UP, AC | | | | | |
| PATIENT3, HALEY DEBRA | 000003 | COMMUNITY #1 | F | 25 | |
| UP, AC | | 07/09/12 GFR: >60 | | | |
| PATIENT4, HELENE MARIE | 000004 | COMMUNITY #1 | F | 29 | |
| UP, AC | | 11/20/12 GFR: 114 | | | |
| PATIENT5, MARTHA | 000005 | COMMUNITY #1 | F | 30 | |
| UP | | | | | |

Figure 2-127: Sample Patient List, Chronic Kidney Disease Assessment

2.10.11 Prediabetes/Metabolic Syndrome

Denominators

Active Clinical patients ages 18 and older diagnosed with prediabetes/metabolic syndrome without a documented history of diabetes.

User Population patients ages 18 and older diagnosed with prediabetes/metabolic syndrome without a documented history of diabetes.

Numerators

All Screenings: Patients with all screenings (BP, LDL, fasting glucose or A1c, tobacco screening, BMI, lifestyle counseling, and depression screening).

BP Assessed: Patients with Blood Pressure documented at least twice during the Report Period.

LDL Assessed: Patients with LDL completed, regardless of result, during the Report Period.

Fasting Glucose or A1c Assessed: Patients with fasting glucose test or A1c assessed, regardless of result, during the Report Period.

Patients with A1c less than ($<$) 5.7.

Patients with A1c equal to or greater than (\geq) 5.7 and less than ($<$) 6.5.

Patients with A1c equal to or greater than (\geq) 6.5.

Patients with no A1c during the Report Period.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report Period.

BMI Available: Patients for whom a BMI could be calculated.

Note: This numerator does *not* include refusals.

Lifestyle Counseling: Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education during the Report Period.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report period, including documented refusals in past year.

Logic Description

Age is calculated at beginning of the Report Period.

Prediabetes/Metabolic Syndrome defined as:

1. Diagnosis of prediabetes/metabolic syndrome, defined as: Two visits during the Report Period with POV 277.7, *or*
2. One each of at least three different conditions listed below, occurring during the Report Period except as otherwise noted:

- BMI equal to or greater than (\geq) 30 *or* Waist Circumference greater than ($>$)40 inches for men or greater than ($>$)35 inches for women
- Triglyceride value greater than or equal to (\geq) 150
- HDL value less than ($<$) 40 for men or less than ($<$) 50 for women
- Patient diagnosed with hypertension *or* mean BP value equal to or greater than (\geq) 130/85 where systolic is equal to or greater than (\geq) 130 *or* diastolic is equal to or greater than (\geq) 85
- Fasting Glucose value equal to or greater than (\geq) 100 *and* less than ($<$) 126

Note: Waist circumference and fasting glucose values will be checked last.

Definition for patients without diabetes: No diabetes diagnosis ever (POV 250.00–250.93).

BMI definition: CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day.

Hemoglobin A1c definition: Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result. Without result is defined as A1c documented but with no value.

BP definition: CRS uses mean of last three BPs documented on non-ER visits during the Report Period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two).

For the BP documented numerator, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV V81.1 documented on non-ER visit during the Report Period.

Hypertension: Diagnosis of (POV or problem list) 401.* occurring prior to the Report Period, and at least one hypertension POV during the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|--|--|----------------------|-------------|--------------------------------|
| Triglyceride (requires a non-null, numeric result) | | | Yes | DM AUDIT TRIGLYCERIDE TAX |
| HDL (requires a non-null, numeric result) | | | Yes | DM AUDIT HDL TAX |
| Fasting Glucose- <i>Denominator Definition</i> (requires a non-null, numeric result) | | | Yes | DM AUDIT FASTING GLUCOSE TESTS |
| Fasting Glucose- <i>Numerator Definition</i> | | V POV: 790.21 | Yes | DM AUDIT FASTING GLUCOSE TESTS |
| Hemoglobin A1c | 83036, 83037, 3044F-3046F, 3047F (old code) | | Yes | DM AUDIT HGB A1C TAX |
| LDL | 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F | | Yes | DM AUDIT LDL CHOLESTEROL TAX |
| Estimated GFR | | | Yes | BGP GPRA ESTIMATED GFR TAX |
| Quantitative Urinary Protein Assessment | 82042, 82043, or 84156 | | Yes | BGP QUANT URINE PROTEIN |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|-------------------------|---|--|-------------|----------|
| End Stage Renal Disease | 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), or S9339 | V POV: 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.* V Procedure: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6* | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|---|--|--|-------------|----------|
| Tobacco Screening | D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code) or G8453 (old code) | Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO V POV or current Active Problem List: 305.1, 305.1* (old codes), 649.00-649.04, V15.82 Patient education codes: containing "TO-" or "-TO" or "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code) or G8453 (old code) Dental code: 1320 | | |
| Lifestyle Counseling – Medical Nutrition Counseling | 97802-97804, G0270, G0271 | Primary or secondary provider codes: 07, 29 Clinic codes: 67 (dietary) or 36 (WIC) | | |
| Lifestyle Counseling – Nutrition Education | | V POV: V65.3 dietary surveillance and counseling <i>or</i> Patient education codes: ending "-N" (nutrition) or "-MNT" (medical nutrition therapy) (or old code "-DT" (diet)) or containing V65.3, 97802-97804, G0270, or G0271. | | |

| Subject Defined | CPT Codes | ICD and Other Codes | LOINC Codes | Taxonomy |
|---|-----------|---|-------------|----------|
| Lifestyle Counseling – Exercise Education | | V POV: V65.41 exercise counseling <i>or</i> Patient education codes: ending “-EX” (exercise) or containing V65.41. | | |
| Lifestyle Counseling – Related Exercise and Nutrition Education | | Patient education codes: ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01. | | |
| Depression Screening | | V Exam: Exam Code 36 V POV: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) V Measurement in PCC or BHS: PHQ2 or PHQ9 Refusals: Exam Code 36 | | |
| Mood Disorders | | At least two visits in PCC or BHS during Report Period for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS (see codes below). V POV: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 BHS POV: 14, 15 | | |

Key Logic Changes from CRS Version 12.0

- Added codes 11054-4, 12771-2, 16616-5, 2095-8, 26015-8, 26016-6, 26017-4, 27340-9, 32309-7, 44733-4, 44915-7, 47220-9, 47221-7, 48090-5, 50409-2, 55607-6, 9322-9, 9830-1, 9832-7, 9833-5 to LOINC taxonomy for HDL.
- Added codes 11054-4, 13459-3, 14155-6, 16615-7, 16616-5, 43394-6, 44711-0, 44915-7, 50193-2, 53133-5, 56036-7 to LOINC taxonomy for LDL.

Patient List Description

List of patients age 18 and older with Prediabetes/Metabolic Syndrome with assessments received, if any. The denominator column displays the condition the patient met, either the diagnosis of 277.7 or the three conditions the patient met (e.g. BMI=35,TG=155,HDL=35).

Measure Source

“IHS Guidelines for Care of Adults with Prediabetes and/or the Metabolic Syndrome in Clinical Settings (April 2005)”

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|-------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 309 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Prediabetes/Metabolic Syndrome | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts =>18 | | | | | | | | |
| w/PreDiabetes/ | | | | | | | | |
| Met Syn | 51 | | 40 | | | 29 | | |
| # w/ All screenings | 1 | 2.0 | 0 | 0.0 | +2.0 | 0 | 0.0 | +2.0 |
| # w/ BP documented | 51 | 100.0 | 34 | 85.0 | +15.0 | 27 | 93.1 | +6.9 |
| # w/LDL done | 34 | 66.7 | 27 | 67.5 | -0.8 | 18 | 62.1 | +4.6 |
| # w/ fasting | | | | | | | | |
| glucose or Alc | 12 | 23.5 | 8 | 20.0 | +3.5 | 2 | 6.9 | +16.6 |
| # w/Alc <5.7 | 4 | 7.8 | 6 | 15.0 | -7.2 | 1 | 3.4 | +4.4 |
| # w/Alc =>5.7 | | | | | | | | |
| and <6.5 | 5 | 9.8 | 1 | 2.5 | +7.3 | 0 | 0.0 | +9.8 |
| # w/ Alc =>6.5 | 2 | 3.9 | 0 | 0.0 | +3.9 | 1 | 3.4 | +0.5 |
| # w/no Alc | 40 | 78.4 | 33 | 82.5 | -4.1 | 27 | 93.1 | -14.7 |
| # w/Tobacco Screening | | | | | | | | |
| w/in 1 yr | 48 | 94.1 | 33 | 82.5 | +11.6 | 21 | 72.4 | +21.7 |
| # w/BMI calculated | | | | | | | | |

| | | | | | | | | |
|--|----|------|----|-------|-------|----|-------|-------|
| -No Refusals | 48 | 94.1 | 40 | 100.0 | -5.9 | 29 | 100.0 | -5.9 |
| # w/lifestyle adaptation counseling | 24 | 47.1 | 15 | 37.5 | +9.6 | 8 | 27.6 | +19.5 |
| # w/Depression screening, DX, or refusal | 10 | 19.6 | 1 | 2.5 | +17.1 | 1 | 3.4 | +16.2 |

Figure 2-128: Sample Report, Prediabetes/Metabolic Syndrome

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Prediabetes/Metabolic Syndrome: List of patients 18 and older with
 Prediabetes/Metabolic Syndrome with assessments received, if any.

| PATIENT NAME DENOMINATOR | HRN NUMERATOR | COMMUNITY | SEX | AGE |
|---|------------------|--------------|-----|-----|
| ----- | | | | |
| PATIENT1,HALEY DEBRA | 000001 | COMMUNITY #1 | F | 25 |
| UP,AC,BMI=33.64; TRIG=271; HDL=45.4; HTN DX: 01/13/12 2 BPs; TOB: 01/13/12 305.1-DP; BMI: 33.64; LIFE: 12/12/12 97804-HM; | | | | |
| PATIENT2,CYNTHIA | 000002 | COMMUNITY #1 | F | 36 |
| UP,AC,TRIG=166; HDL=38.7; BP=131/80 2 BPs; LDL: 11/21/12 125; TOB: 07/09/12 NEVER SMOKED; BMI: 28.35; | | | | |
| PATIENT3,ABIGAIL | 000003 | COMMUNITY #1 | F | 39 |
| UP,BMI=34.97; TRIG=194; BP=149/84 2 BPs; LDL: 06/12/12 CPT 83704; TOB: 05/14/12 CURRENT SMOKER, STATUS UNKNOWN; BMI: 34.97; DEPR: 11/03/12 POV 296.7 + 11/30/12 POV 296.7 | | | | |
| PATIENT4,ANNA LINDA | 000004 | COMMUNITY #1 | F | 44 |
| UP,AC,277.7 on 03/15/12; 04/15/12 2 BPs; | | | | |
| PATIENT5,DARLENE T | 000005 | COMMUNITY #1 | F | 54 |
| UP,AC,BMI=35.37; TRIG=276; HDL=35.6 (ALL:) 2 BPs; LDL: 10/03/12 106; A1C: 5.2; TOB: 10/03/12 NEVER SMOKED; BMI: 35.37; LIFE: 06/06/12 Prv 29; DEPR: DEP SCRIN 05/03/12 | | | | |

Figure 2-129: Sample Patient List, Prediabetes/Metabolic Syndrome

2.10.12 Proportion of Days Covered by Medication Therapy

Denominators

Active Clinical patients ages 18 and older who had two or more prescriptions for *beta-blockers* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *RAS Antagonists* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *calcium channel blockers (CCB)* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *biguanides* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *sulfonylureas* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *thiazolidinediones* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *statins* during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for *antiretroviral agents* during the Report Period.

Numerators

Patients with proportion of days covered (PDC) greater than or equal to (\geq)80% during the Report Period.

Patients with a gap in medication therapy greater than or equal to (\geq)30 days.

Patients with proportion of days covered (PDC) greater than or equal to (\geq)90% during the Report Period.

Logic Description

Age is calculated at the beginning of the report period.

To be included in the denominator, patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

The Index Prescription Start Date is the date when the medication was first dispensed within the Report Period. This date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

The medications in the measures are defined with medication taxonomies: BGP PQA BETA BLOCKER MEDS, BGP PQA RASA MEDS, BGP PQA CCB MEDS, BGP PQA BIGUANIDE MEDS, BGP PQA SULFONYLUREA MEDS, BGP PQA THIAZOLIDINEDIONE MEDS, BGP PQA STATIN MEDS, BGP PQA ANTIRETROVIRAL MEDS.

For each PDC numerator:

Proportion of days covered = # of days the patient was covered by at least one drug in the class / # of days in the patient's measurement period.

Measurement Period definition:

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4.

Example of Proportion of Days Covered:

- Report Period: January 1 through December 31, 2012
- 1st Rx is Index Rx Start Date: 3/1/12, Days Supply=90
- Rx covers patient through 5/29/12
- 2nd Rx: 5/26/12, Days Supply=90
- Rx covers patient through 8/27/12
- 3rd Rx: 9/11/12, Days Supply=180
- Gap = (9/11/12 - 8/27/12) = 15 days
- Rx covers patient through 3/8/13
- Patient's measurement period: 3/1/12 through 12/31/12 = 306 Days
- Days patient was covered: 3/1/12 through 8/27/12 + 9/11/12 through 12/31/12 = 292 Days
- $PDC = 292 / 306 = 95\%$

For each Gap numerator:

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days supply between consecutive medication fills.

Example of Medication Gap >=30 Days:

- Report Period: January 1 through December 31, 2012
- 1st Rx: 4/1/12, Days Supply=30

- Rx covers patient through 4/30/12
- 2nd Rx: 7/1/12, Days Supply=90
- Gap #1 = (7/1/12 - 4/30/12) = 61 days
- Rx covers patient through 9/28/12
- 3rd Rx: 10/1/12, Days Supply=90
- Gap #2 = (10/1/12 - 9/28/12) = 2 days
- Rx covers patient through 12/29/12
- Gap #1 greater than or equal to (\geq)30 days, therefore patient will be included in the numerator for that medication.

Key Logic Changes from CRS Version 12.0

1. Renamed BGP PQA ACEI ARB MEDS to BGP PQA RASA MEDS.
2. Changed ACEI/ARB to RAS Antagonists.

Patient List Description

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

Measure Source

PQA (Pharmacy Quality Alliance)

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 314 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Proportion of Days Covered by Medication Therapy | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts | | | | | | | | |
| w/beta-blockers | 53 | | 44 | | | 37 | | |
| # w/ PDC >=80% | 31 | 58.5 | 24 | 54.5 | +3.9 | 22 | 59.5 | -1.0 |
| # w/ gap >=30 days | 27 | 50.9 | 23 | 52.3 | -1.3 | 15 | 40.5 | +10.4 |
| Active Clinical Pts | | | | | | | | |

| | | | | | | | | |
|--|----|------|----|------|-------|----|------|-------|
| w/ RAS Antagonists | 97 | | 80 | | | 74 | | |
| # w/ PDC >=80% | 60 | 61.9 | 55 | 68.8 | -6.9 | 39 | 52.7 | +9.2 |
| # w/ gap >=30 days | 45 | 46.4 | 32 | 40.0 | +6.4 | 42 | 56.8 | -10.4 |
| Active Clinical Pts w/ CCBs | 56 | | 48 | | | 55 | | |
| # w/ PDC >=80% | 34 | 60.7 | 30 | 62.5 | -1.8 | 37 | 67.3 | -6.6 |
| # w/ gap >=30 days | 30 | 53.6 | 20 | 41.7 | +11.9 | 22 | 40.0 | +13.6 |
| Active Clinical Pts w/ biguanides | 30 | | 26 | | | 11 | | |
| # w/ PDC >=80% | 12 | 40.0 | 18 | 69.2 | -29.2 | 3 | 27.3 | +12.7 |
| # w/ gap >=30 days | 19 | 63.3 | 10 | 38.5 | +24.9 | 8 | 72.7 | -9.4 |
| Active Clinical Pts w/ sulfonylureas | 7 | | 6 | | | 7 | | |
| # w/ PDC >=80% | 3 | 42.9 | 1 | 16.7 | +26.2 | 4 | 57.1 | -14.3 |
| # w/ gap >=30 days | 5 | 71.4 | 5 | 83.3 | -11.9 | 3 | 42.9 | +28.6 |
| Active Clinical Pts w/ thiazolidinediones | 20 | | 15 | | | 4 | | |
| # w/ PDC >=80% | 13 | 65.0 | 10 | 66.7 | -1.7 | 2 | 50.0 | +15.0 |
| # w/ gap >=30 days | 8 | 40.0 | 7 | 46.7 | -6.7 | 1 | 25.0 | +15.0 |
| Active Clinical Pts w/ statins | 60 | | 49 | | | 37 | | |
| # w/ PDC >=80% | 43 | 71.7 | 33 | 67.3 | +4.3 | 25 | 67.6 | +4.1 |
| # w/ gap >=30 days | 24 | 40.0 | 19 | 38.8 | +1.2 | 16 | 43.2 | -3.2 |
| Active Clinical Pts w/ antiretroviral agents | 2 | | 0 | | | 1 | | |
| # w/ PDC >=90% | 1 | 50.0 | 0 | 0.0 | +50.0 | 0 | 0.0 | +50.0 |

Figure 2-130: Sample Report, Proportion of Days Covered by Medication Therapy

| | | | | | |
|--|--------|---|-----|-----|---------------------|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
| Proportion of Days Covered by Medication Therapy: List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| Patient75,PAULA KAY AC | 000075 | COMMUNITY #1 CCB: IXRD: 03/24/12 [282] | F | 34 | Days=228 >80 GAP=52 |
| Patient76,CRSCT AC | 000076 | COMMUNITY #1 CCB: IXRD: 06/01/12 [213] | F | 36 | Days=180 >80 GAP=31 |
| Patient77,CRSAC | 000077 | COMMUNITY #1 | F | 44 | |

```

AC                      RASA: IXRD: 06/05/12 [209] Days=60 <80 GAP=118
Patient78,DEBORA ELLEN  000078 COMMUNITY #1    F   45
AC                      BB: IXRD: 07/23/12 [161] Days=126 <80; RASA: IXRD:
01/29/12 [336] Days=267 <80 GAP=31; BIG: IXRD: 01/29/12 [336] Days=272 >80
Patient79,STELLA LYNN  000079 COMMUNITY #1    F   46
AC                      BB: IXRD: 01/21/12 [344] Days=299 >80 GAP=38; CCB:
IXRD: 01/21/12 [344] Days=299 >80 GAP=38
Patient80,TARA MARIE   000080 COMMUNITY #1    F   51
AC                      BB: IXRD: 08/25/12 [128] Days=56 <80 GAP=70; RASA:
IXRD: 01/15/12 [350] Days=314 >80; CCB: IXRD: 01/15/12 [350] Days=218 <80 GAP=103
Patient81,CRSNK        000081 COMMUNITY #1    F   51
AC                      SULF: IXRD: 09/01/12 [121] Days=120 >80

```

Figure 2-131: Sample Patient List, Proportion of Days Covered by Medication Therapy

2.10.13 Medications Education

Denominators

Active Clinical patients with medications dispensed at their facility during the Report Period.

All User Population patients with medications dispensed at their facility during the Report Period.

Numerator

Patients who were provided patient education about their medications in any location.

Patients who refused patient education about their medications in any location.

Logic Description

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility. The purpose of this definition is to ensure that sites are not being held responsible for educating patients about medications received elsewhere that may be recorded in RPMS. CRS assumes that the appropriate facility is the one the user has logged onto to run the report.

Note: If a site's system identifier, i.e., ASUFAC code, has changed during the period between the Baseline start date and the Current Year end date, due to compacting/contracting or other reasons, your report may display zeros (0s) or very low counts for some time periods.

CRS uses the following patient education codes to define the numerator:

| | |
|----------------------|--|
| Medication Education | Any Patient Education code containing "M-" or "-M" (medication) or DMC-IN (Diabetes Medicine–Insulin) FP-DPO (Family Planning–Depot Medroxyprogesterone Injections) FP-OC (Family Planning–Oral Contraceptives) FP-TD (Family Planning–Transdermal (Patch)) *-NEB (*Nebulizer) *-MDI (*Metered Dose Inhalers) |
| Refusal | Any refusal in the past year with Patient Education codes containing "M-" or "-M" or PFE codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, or FP-TD In the past year, any Patient Education code containing "M-" or "-M" or PFE codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, or FP-TD with a level of understanding of "refused". |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients receiving medications with med education, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

| Measure | Target |
|----------------------|--------|
| <i>IHS 2020 Goal</i> | 75.0% |

| | | | | | | | | |
|--|-------------------|------|---------|------|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 316 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Medications Education (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts receiving medications | 757 | | 631 | | | 592 | | |
| # receiving medication educ | 490 | 64.7 | 268 | 42.5 | +22.3 | 81 | 13.7 | +51.0 |
| # refusals | 3 | 0.4 | 0 | 0.0 | +0.4 | 0 | 0.0 | +0.4 |

| | | | | | | | | |
|------------------------------------|-----|------|-----|------|-------|-----|------|-------|
| User Pop Pts receiving medications | 981 | | 800 | | | 753 | | |
| # receiving medication educ | 599 | 61.1 | 306 | 38.3 | +22.8 | 87 | 11.6 | +49.5 |
| # refusals | 3 | 0.3 | 0 | 0.0 | +0.3 | 0 | 0.0 | +0.3 |

Figure 2-132: Sample Report, Medications Education

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|---------------------------------------|-----|-----|--|
| Medications Education: List of patients receiving medications with med education or refusal, if any | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1, ANDREA MARY UP, AC | 000001 | COMMUNITY #1 | F | 0 | |
| PATIENT2, VIRGINIA A UP | 000002 | COMMUNITY #1 08/06/11 HTN-M | F | 0 | |
| PATIENT3, MICHAELA UP | 000003 | COMMUNITY #1 03/10/11 M-I | F | 0 | |
| PATIENT4, MISTY UP, AC | 000004 | COMMUNITY #1 05/16/11 M-DI | F | 5 | |
| PATIENT5, RITA ANN UP, AC | 000005 | COMMUNITY #1 07/05/11 M-I | F | 15 | |
| PATIENT6, DIANE LOUISE UP | 000006 | COMMUNITY #1 08/21/11 M-I | F | 15 | |
| PATIENT7, ALICIA UP, AC | 000007 | COMMUNITY #1 | F | 15 | |
| PATIENT8, ALYSHA UP, AC | 000008 | COMMUNITY #1 02/15/11 Refused M-DI | F | 16 | |
| PATIENT9, SHELLY UP, AC | 000009 | COMMUNITY #1 03/12/11 PP-M | F | 18 | |

Figure 2-133: Sample Patient List, Medications Education

2.10.14 Medication Therapy Management Services

Denominators

Active Clinical patients equal to or greater than (>=)18 with medications dispensed at their facility during the Report Period.

Numerator

Patients who received medication therapy management (MTM) during the Report Period.

Logic Description

Age is calculated at the beginning of the report period.

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility.

Medication Therapy Management (MTM) definition: 1) CPT codes 99605-99607 or 2) Clinic codes: D1, D2.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients greater than or equal to (\geq) 18 receiving medications with medication therapy management, if any.

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|-----|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 316 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Medications Therapy Management Services (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts | | | | | | | | |
| =>18 receiving | | | | | | | | |
| medications | | | | | | | | |
| | 594 | | 472 | | | 424 | | |
| # w/MTM | 5 | 0.8 | 0 | 0.0 | +0.8 | 0 | 0.0 | +0.8 |

Figure 2-134: Sample Report, Medications Therapy Management Services

| |
|--|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient |
| Medications Education: List of patients receiving medications with med education or refusal, if any (con't) |

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|------------------------------------|-----|-----|
| PATIENT5,RITA ANN AC | 000005 | COMMUNITY #1 06/01/12 CPT 99607 | F | 18 |
| PATIENT6,DIANE LOUISE AC | 000006 | COMMUNITY #1 07/28/12 CPT 99606 | F | 20 |
| PATIENT7,ALICIA AC | 000007 | COMMUNITY #1 | F | 21 |
| PATIENT8,ALYSHA AC | 000008 | COMMUNITY #1 04/01/12 C1 D1 | F | 25 |
| PATIENT9,SHELLY AC | 000009 | COMMUNITY #1 07/01/12 C1 D2 | F | 52 |

Figure 2-135: Sample Patient List, Medications Therapy Management Services

2.10.15 Self Management (Confidence)

Denominators

Active Clinical patients assessed for confidence in managing their health problems during the Report Period.

Numerator

Patients who are very confident in managing their health problems during the Report Period.

Logic Description

Confidence in managing health problems definition: Any health factor for category CONFIDENCE IN MANAGING HEALTH PROBLEMS.

Very confident definition: The most recent health factor in the CONFIDENCE IN MANAGING HEALTH PROBLEMS category of VERY SURE.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients who are confident in managing their health problems.

Measure Source

None

Measure Past Performance and Long-Term Targets

| Measure | Target |
|---------------|--------|
| IHS 2020 Goal | 75.0% |

| | | | | | | | | |
|--|-------------------|------|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 316 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Self Management (Confidence) (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| Active Clinical Pts assessed for confidence | 8 | | 1 | | | 0 | | |
| # very confident | 4 | 50.0 | 0 | 0.0 | +50.0 | 0 | 0.0 | +50.0 |

Figure 2-136: Sample Report, Medications Education

| | | | | | |
|--|--------|--------------------------|-----|-----|--|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
| Self Management (Confidence): List of patients who are confident in managing their health problems. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| ----- | | | | | |
| PATIENT5,RITA ANN AC | 000005 | COMMUNITY #1 06/01/12 | F | 18 | |
| PATIENT6,DIANE LOUISE AC | 000006 | COMMUNITY #1 07/28/12 | F | 20 | |
| PATIENT7,ALICIA AC | 000007 | COMMUNITY #1 | F | 21 | |
| PATIENT8,ALYSHA AC | 000008 | COMMUNITY #1 | F | 25 | |

Figure 2-137: Sample Patient List, Medications Education

2.10.16 Public Health Nursing**Patient-Related Measures****Denominator***All User Population patients.*

Numerators

For User Population only, the number of patients in the denominator served by Public Health Nurses (PHNs) in any setting, including Home.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting.

For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME Setting.

Visit-Related Measures**Denominators**

Number of visits to User Population patients by PHNs in any setting, including Home

- Number of visits to patients ages 0 to 28 days (Neonate) in any setting.
- Number of visits to patients ages 29 days tp12 months (infants) in any setting.
- Number of visits to patients ages 1 through 64 years in any setting
- Number of visits to patients ages 65 and older (Elders) in any setting
- Number of PHN driver/interpreter (Provider Code 91) visits

Number of visits to User Population patients by PHNs in Home setting

- Number of Home visits to patients age 0 to 28 days (Neonate)
- Number of Home visits to patients age 29 days to 12 months (Infants)
- Number of Home visits to patients ages 1 through 64 years
- Number of Home visits to patients aged 65 and over (Elders).
- Number of PHN driver/interpreter (Provider Code 91) visits in a HOME setting.

Numerator

No numerator: count of visits only

Logic Description

PHN visit is defined as any visit with primary or Secondary Provider Code 13 or 91. Home visit defined as: (1) Clinic 11 and a primary or Secondary Provider Code 13 or 91 or (2) Location Home (as defined in Site Parameters) and a primary or Secondary Provider Code 13 or 91.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients with PHN visits documented.

Numerator codes in patient list: All PHN = Number of PHN visits in any setting;
 Home = Number of PHN visits in home setting; Driver All = Number of PHN
 driver/interpreter visits in any setting; Driver Home = Number of PHN
 driver/interpreter visits in home setting.

Measure Source

None

Measure Past Performance and Long-Term Targets

| Performance | All PHN visits | PHN Home Visits |
|-------------------------|----------------|-----------------|
| IHS FY 2005 Performance | 438,376 | Not Reported |
| IHS FY 2004 Performance | 423,379 | 192,121 |
| IHS FY 2003 Performance | 359,089 | 160,650 |
| IHS FY 2002 Performance | 343,874 | 156,263 |

| | | | | | | | | |
|--|-------------------|-----|---------|-----|-----------|--------|----------|----------|
| DU | November 25, 2012 | | | | | | Page 317 | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Public Health Nursing (con't) | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % |
| All User Population | | | | | | | | |
| patients | 2,896 | | 2,456 | | | 2,346 | | |
| # served by PHNs in | | | | | | | | |
| any Setting | 13 | 0.4 | 13 | 0.5 | -0.1 | 13 | 0.6 | -0.1 |
| # served by PHN drivers/ | | | | | | | | |
| interpreter - in | | | | | | | | |
| any Setting | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # served by PHNs in | | | | | | | | |
| a Home Setting | 1 | 0.0 | 1 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| # served by PHN | | | | | | | | |
| drivers/interpreters | | | | | | | | |
| in Home Setting | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| Total # PHN Visits - | | | | | | | | |

| | | | | | |
|---|----|----|----|----|----|
| Any Setting | 18 | 16 | +2 | 19 | -1 |
| A. Ages 0-28 days | 0 | 0 | +0 | 0 | +0 |
| B. Ages 29 days - 12 months | 1 | 3 | -2 | 0 | +1 |
| C. Ages 1-64 years | 16 | 13 | +3 | 19 | -3 |
| D. Ages 65+ | 1 | 0 | +1 | 0 | +1 |
| E. Driver/Interpreter visits - any setting | 0 | 0 | +0 | 0 | +0 |
| Total # PHN Visits - Home Setting | 3 | 1 | +2 | 0 | +3 |
| A. Ages 0-28 days | 0 | 0 | +0 | 0 | +0 |
| B. Ages 29 days- 12 months | 0 | 1 | -1 | 0 | +0 |
| C. Ages 1-64 years | 3 | 0 | +3 | 0 | +3 |
| D. Ages 65+ | 0 | 0 | +0 | 0 | +0 |
| E. Driver/interpreter visits - Home Setting | 0 | 0 | +0 | 0 | +0 |

Figure 2-138: Sample Report, Public Health Nursing

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Public Health Nursing: List of patients with PHN visits documented

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|--|-----|-----|
| PATIENT1,HELENE MARIE | 000001 | COMMUNITY #1 | F | 29 |
| UP | | 2 all PHN; 0 home; 0 driver all; 0 driver home | | |
| PATIENT2,KATHLEEN | 000002 | COMMUNITY #1 | F | 38 |
| UP | | 3 all PHN; 3 home; 0 driver all; 0 driver home | | |
| PATIENT40,ERIKA SUE | 000040 | COMMUNITY #2 | F | 37 |
| UP | | 1 all PHN; 0 home; 0 driver all; 0 driver home | | |
| PATIENT41,DANIEL RAY | 000041 | COMMUNITY #2 | M | 0 |
| UP | | 1 all PHN; 0 home; 0 driver all; 0 driver home | | |

Figure 2-139: Sample Patient List, Public Health Nursing

2.10.17 Breastfeeding Rates

Denominators

Active Clinical patients who are 30 to 394 days old

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of *two months* (45 to 89 days) (PART Denominator)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of *six months* (165 to 209 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of *nine months* (255 to 299 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of *one year* (350 to 394 days)

Numerators

Patients who were screened for infant feeding choice *at least once*

Patients who were screened for infant feeding choice at the age of *two months* (45 to 89 days)

Patients who were screened for infant feeding choice at the age of *six months* (165 to 209 days)

Patients who were screened for infant feeding choice at the age of *nine months* (255 to 299 days)

Patients who were screened for infant feeding choice at the age of *one year* (350 to 394 days)

Patients who, at the age of *two months* (45 to 89 days), were either exclusively or mostly breastfed (PART Numerator)

Patients who, at the age of *six months* (165 to 209 days), were either exclusively or mostly breastfed

Patients who, at the age of *nine months* (255–299 days), were either exclusively or mostly breastfed

Patients who, at the age of *one year* (350 to 394 days), were either exclusively or mostly breastfed

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Infant feeding choice definition: The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as half breastfed and half formula and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of two months (i.e., 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days value of mostly breastfed will be used. The other exact ages are 180 days for six months, 270 days for nine months, and 365 days for one year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at six months and was exclusively breastfeeding but was not screened at two months, then the patient will only be counted in the six months numerator.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients 30 to 394 days old, with infant feeding choice value, if any.

Note: “DO” represents “Days Old.”

Measure Source

HP 2020, MICH-21.4 Exclusive breastfeeding-through three months, MICH-21.5 Exclusive breastfeeding-through six months.

Measure Past Performance and Long-Term Targets

| Performance | Percent |
|---|--------------|
| IHS FY 2011 Performance | 26.7% |
| IHS FY 2010 Performance | 33% |
| IHS FY 2008 Performance | 28% |
| <i>HP 2020 goal for breastfeeding through 3 months of age</i> | <i>44.3%</i> |
| <i>HP 2020 goal for breastfeeding through 6 months of age</i> | <i>23.7%</i> |

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 321 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |

| | | | | | | | | | |
|--|--------|-------|---------|-----|-----------|--------|-------|----------|--|
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Breastfeeding Rates | | | | | | | | | |
| | REPORT | % | PREV YR | % | CHG from | BASE | % | CHG from | |
| | PERIOD | | PERIOD | | PREV YR % | PERIOD | | BASE % | |
| Active Clinical Pts | | | | | | | | | |
| 30-394 days | 46 | | 30 | | | 34 | | | |
| # w/infant feeding | | | | | | | | | |
| choice screening | 11 | 23.9 | 0 | 0.0 | +23.9 | 1 | 2.9 | +21.0 | |
| # w/screening @ | | | | | | | | | |
| 2 mos | 4 | 8.7 | 0 | 0.0 | +8.7 | 1 | 2.9 | +5.8 | |
| # w/screening @ | | | | | | | | | |
| 6 mos | 3 | 6.5 | 0 | 0.0 | +6.5 | 0 | 0.0 | +6.5 | |
| # w/screening @ | | | | | | | | | |
| 9 mos | 4 | 8.7 | 0 | 0.0 | +8.7 | 0 | 0.0 | +8.7 | |
| # w/screening @ | | | | | | | | | |
| 1 yr | 3 | 6.5 | 0 | 0.0 | +6.5 | 0 | 0.0 | +6.5 | |
| AC Pts 30-394 days | | | | | | | | | |
| screened @ 2 mos | | | | | | | | | |
| (PART) | 4 | | 0 | | | 1 | | | |
| # @ 2 mos exclusive/ | | | | | | | | | |
| mostly breastfed | | | | | | | | | |
| (PART) | 4 | 100.0 | 0 | 0.0 | +100.0 | 1 | 100.0 | +0.0 | |
| AC Pts 30-394 days | | | | | | | | | |
| screened @ 6 mos | 3 | | 0 | | | 0 | | | |
| # @ 6 mos | | | | | | | | | |
| exclusive/mostly | | | | | | | | | |
| breastfed | 2 | 66.7 | 0 | 0.0 | +66.7 | 0 | 0.0 | +66.7 | |
| AC Pts 30-394 days | | | | | | | | | |
| screened at 9 mos | 4 | | 0 | | | 0 | | | |
| # @ 9 mos | | | | | | | | | |
| exclusive/mostly | | | | | | | | | |
| breastfed | 3 | 75.0 | 0 | 0.0 | +75.0 | 0 | 0.0 | +75.0 | |
| AC Pts 30-394 days | | | | | | | | | |
| screened @ 1 yr | 3 | | 0 | | | 0 | | | |
| # @ 1 year | | | | | | | | | |
| exclusive/mostly | | | | | | | | | |
| breastfed | 2 | 66.7 | 0 | 0.0 | +66.7 | 0 | 0.0 | +66.7 | |

Figure 2-140: Sample Report, Breastfeeding Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Breastfeeding Rates: List of patients 30-394 days old, with infant feeding choice value, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-----------------------------|--------|---|-----|-----|
| PATIENT1,AMANDA DEBRA AC | 000001 | COMMUNITY #1 Scrn: 33 DO, 02/09/11 MOSTLY BREASTFEEDING | F | 0 |
| PATIENT2,LEROY JAMES AC | 000002 | COMMUNITY #1 Scrn: 2 MOS: 48 DO, 01/20/11 EXCLUSIVE BREASTFEEDING; 6 MOS: 178 DO, 05/30/11 EXCLUSIVE BREASTFEEDING; 9 MOS: 276 DO, 09/05/11 EXCLUSIVE BREASTFEEDING; 1 YR: 382 DO, 12/20/11 MOSTLY BREASTFEEDING | M | 1 |
| PATIENT3,TERRY SCOTT AC | 000003 | COMMUNITY #1 | M | 0 |
| PATIENT4,ROBERT AC | 000004 | COMMUNITY #1 Scrn: 6 MOS: 187 DO, 08/11/11 EXCLUSIVE BREASTFEEDING | M | 0 |
| PATIENT11,STEVEN CODY AC | 000011 | COMMUNITY #2 Scrn: 2 MOS: 60 DO, 11/03/11 MOSTLY BREASTFEEDING | M | 0 |

Figure 2-141: Sample Patient List, Breastfeeding Rates

2.10.18 Use of High-Risk Medications in the Elderly

Denominators

Active Clinical patients ages 65 and older. Broken down by gender and age groups (65 through 74, 75 through 84, greater than (>) 85).

User Population patients ages 65 and older. Broken down by gender.

Numerators

Patients who received at least one high-risk medication for the elderly during the Report Period. (GPRA Developmental Numerator)

Patients who received at least two different high-risk medications for the elderly during the Report Period. (GPRA Developmental Numerator)

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Medication definitions: High-risk medications for the elderly (i.e., potentially harmful drugs) defined with medication taxonomies:

- BGP HEDIS ANTIANXIETY MEDS (Includes combination drugs) (Aspirin-Meprobamate, Meprobamate)
- BGP HEDIS ANTIEMETIC MEDS ((Scopolamine, Trimethobenzamide)
- BGP HEDIS ANALGESIC MEDS (Includes combination drugs) (Ketorolac)

- BGP HEDIS ANTIHISTAMINE MEDS (Includes combination drugs)
(APAP/dextromethorphan/diphenhydramine,
APAP/diphenhydramine/phenylephrine,
APAP/diphenhydramine/pseudoephedrine, Acetaminophen-diphenhydramine,
Carbetapentane/diphenhydramine/phenylephrine,
Codeine/phenylephrine/promethazine, Codeine-promethazine, Cyproheptadine,
Dexchlorpheniramine, Dexchlorpheniramine/dextromethorphan/PSE,
Dexchlorpheniramine/guaifenesin/PSE,
Dexchlorpheniramine/hydrocodone/phenylephrine,
Dexchlorpheniramine/methscopolamine/PSE, Dexchlorpheniramine-
pseudoephedrine, Dextromethorphan-promethazine, Diphenhydramine,
Diphenhydramine/hydrocodone/phenylephrine, Diphenhydramine-magnesium
salicylate, Diphenhydramine-phenylephrine, Diphenhydramine-pseudoephedrine,
Hydroxyzine hydrochloride, Hydroxyzine pamoate, Phenylephrine-promethazine,
Promethazine)
- BGP HEDIS ANTIPSYCHOTIC MEDS (Thioridazine)
- BGP HEDIS AMPHETAMINE MEDS (Amphetamine-dextroamphetamine,
Benzphetamine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion,
Methamphetamine, Methylphenidate, Phendimetrazine, Phenteramine)
- BGP HEDIS BARBITURATE MEDS (Butabarbital, Mephobarbital,
Pentobarbital, Phenobarbital, Secobarbital)
- BGP HEDIS BENZODIAZEPINE MEDS (Includes combination drugs)
(Amitriptyline-Chlordiazepoxide, Chlordiazepoxide, Chlordiazepoxide-clidinium,
Diazepam, Flurazepam)
- BGP HEDIS CALCIUM CHANNEL MEDS (Nifedipine - short acting only)
- BGP HEDIS GASTRO ANTISPASM MED (Dicyclomine, Propantheline)
- BGP HEDIS BELLADONNA ALKA MEDS (Includes combination drugs)
(Atropine, Atropine/CPM/hyoscyamine/PE/scopolamine,
Atropine/hyoscyamine/PB/scopolamine, Atropine-difenoxin, Atropine-
diphenoxylate, Atropine-edrophonium, Belladonna,
Belladonna/ergotamine/phenobarbital,
Butabarbital/hyoscyamine/phenazopyridine, Hyoscyamine,
Hyoscyamine/methenam/m-blue/phenyl salicyl)
- BGP HEDIS SKL MUSCLE RELAX MED (Includes combination drugs)
(ASA/cafeine/orphenadrine, ASA/carisoprodol/codeine, Aspirin-carisoprodol,
Aspirin-methocarbamol, Carisoprodol, Chlorzoxazone, Cyclobenzaprine,
Metaxalone, Methocarbamol, Orphenadrine)

- BGP HEDIS ORAL ESTROGEN MEDS (Includes combination drugs) (Conjugated estrogen, Conjugated estrogen-medroxyprogesterone, Esterified estrogen, Esterified estrogen-methyltestosterone, Estropipate)
- BGP HEDIS ORAL HYPOGLYCEMIC RX (Chlorpropamide)
- BGP HEDIS NARCOTIC MEDS (Includes combination drugs) (ASA/caffeine/propoxyphene, Acetaminophen-pentazocine, Acetaminophen-propoxyphene, Belladonna-opium, Meperidine, Meperidine-promethazine, Naloxone-pentazocine, Pentazocine, Propoxyphene hydrochloride, Propoxyphene napsylate)
- BGP HEDIS VASODILATOR MEDS (Dipyridamole-short acting only, Ergot mesyloid, Isoxsuprine)
- BGP HEDIS OTHER MEDS AVOID ELD (Includes androgens and anabolic steroids, thyroid drugs, and urinary anti-infectives) (Methyltestosterone, Nitrofurantoin, Nitrofurantoin macrocrystals, Nitrofurantoin macrocrystals-monohydrate, Thyroid desiccated).

Note: For each medication, the days supply must be >0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2012, Discontinued Date=11/19/2012, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

Key Logic Changes from CRS Version 12.0

1. Updated BGP HEDIS AMPHETAMINE MEDS medications to remove Pemoline.
2. Updated BGP HEDIS ANALGESIC MEDS medications to remove Acetaminophen-diphenhydramine and diphenhydramine-magnesium salicylate.
3. Updated BGP HEDIS ANTIHISTAMINE MEDS medications to remove Atropine/CPM/hyoscyamine/PE/PPA/scopolamine and Tripeleminine.
4. Updated BGP HEDIS ANTIPSYCHOTIC MEDS medications to remove Mesoridazine.
5. Updated BGP HEDIS BARBITURATE MEDS medications to remove Amobarbital

6. Updated BGP HEDIS BELLADONNA ALKA MEDS medications to remove Belladonna/cafeine/ergotamine/pentobarbital, Digestive enzymes/hyoscyamine/phenyltoloxamine, and Hyoscyamine-phenobarbital.
7. Updated BGP HEDIS SKL MUSCLE RELAX MED medications to remove Aspirin-meprobamate.
8. Updated BGP HEDIS VASODILATOR MEDS medications to remove Cyclandelate.

Patient List Description

List of patients 65 and older with at least one prescription for a potentially harmful drug.

Measure Source

HEDIS

Measure Past Performance and Long-Term Targets

None

DU

November 25, 2012

Page 324

*** IHS 2012 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2012 to Dec 31, 2012

Previous Year Period: Jan 01, 2011 to Dec 31, 2011

Baseline Period: Jan 01, 2000 to Dec 31, 2000

Use of High-Risk Medications in the Elderly

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR | BASE % PERIOD | % | CHG from BASE % |
|--|------------------|------|-------------------|------|---------------------|------------------|------|--------------------|
| Active Clinical Pts =>65 | 116 | | 64 | | | 65 | | |
| # w/exposure to at least 1 high-risk med (GPRA Dev.) | 23 | 19.8 | 12 | 18.8 | +1.1 | 18 | 27.7 | -7.9 |
| # w/exposure to multiple high-risk meds (GPRA Dev.) | 11 | 9.5 | 1 | 1.6 | +7.9 | 8 | 12.3 | -2.8 |
| Male Active Clinical =>65 | 53 | | 28 | | | 27 | | |
| # w/exposure to at least 1 high-risk med (GPRA Dev.) | 10 | 18.9 | 4 | 14.3 | +4.6 | 6 | 22.2 | -3.4 |
| # w/exposure to multiple high-risk | | | | | | | | |

| | | | | | | | | |
|--|-----|------|-----|------|------|-----|------|-------|
| meds (GPRA Dev.) | 4 | 7.5 | 0 | 0.0 | +7.5 | 2 | 7.4 | +0.1 |
| Female Active Clinical =>65 | 63 | | 36 | | | 38 | | |
| # w/exposure to at least 1 high-risk med (GPRA Dev.) | 13 | 20.6 | 8 | 22.2 | -1.6 | 12 | 31.6 | -10.9 |
| # w/exposure to multiple high-risk meds (GPRA Dev.) | 7 | 11.1 | 1 | 2.8 | +8.3 | 6 | 15.8 | -4.7 |
| User Pop Pts =>65 | 222 | | 149 | | | 143 | | |
| # w/exposure to at least 1 high-risk med | 25 | 11.3 | 13 | 8.7 | +2.5 | 18 | 12.6 | -1.3 |
| # w/exposure to multiple high-risk meds | 11 | 5.0 | 2 | 1.3 | +3.6 | 8 | 5.6 | -0.6 |

Figure 2-142: Sample Report, Drugs to be Avoided in the Elderly

| | | | | |
|--|-------------------|-------|------|----------|
| DU | November 25, 2012 | | | Page 326 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | |
| DEMO INDIAN HOSPITAL | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | |
| ----- | | | | |
| Use of High-Risk Medications in the Elderly (con't) | | | | |
| ACTIVE CLINICAL PATIENTS 65+ | | | | |
| | Age Distribution | | | |
| | 65-74 | 75-84 | 85+ | |
| CURRENT REPORT PERIOD | | | | |
| AC Patients 65+ | 70 | 36 | 10 | |
| # w/exposure to at least 1 high-risk med | 15 | 6 | 2 | |
| % w/exposure to at least 1 high-risk med | 21.4 | 16.7 | 20.0 | |
| # w/exposure to multiple high-risk meds | 8 | 2 | 1 | |
| % w/exposure to multiple high-risk meds | 11.4 | 5.6 | 10.0 | |
| PREVIOUS YEAR PERIOD | | | | |
| AC Patients 65+ | 39 | 19 | 6 | |
| # w/exposure to at least 1 high risk med | 7 | 4 | 1 | |
| % w/exposure to at least 1 high-risk med | 17.9 | 21.1 | 16.7 | |

| | | | |
|---|------|------|-------|
| # w/exposure to multiple high-risk meds | 1 | 0 | 0 |
| % w/exposure to multiple high-risk meds | 2.6 | 0.0 | 0.0 |
| CHANGE FROM PREV YR % | | | |
| w/exposure to at least 1 high risk med | +3.5 | -4.4 | +3.3 |
| w/exposure to multiple high-risk meds | +8.9 | +5.6 | +10.0 |

Figure 2-143: Sample Report, Drugs to be Avoided in the Elderly

| | | | | |
|--|------------------|--------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Use of High Risk Medications in the Elderly: List of patients 65 and older with at least one high-risk medication. | | | | |
| PATIENT NAME DENOMINATOR | HRN NUMERATOR | COMMUNITY | SEX | AGE |
| ----- | | | | |
| PATIENT1,JONELLE | 000001 | COMMUNITY #1 | F | 69 |
| UP,AC 2 drugs: 08/04/12 ESTERIFIED ESTROGENS 0.625MG TAB (ORAL ESTROGEN); 08/04/12 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) | | | | |
| PATIENT2,PAULINE | 000002 | COMMUNITY #1 | F | 70 |
| UP,AC 1 drug:11/02/12 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) | | | | |
| PATIENT3,NADINE | 000003 | COMMUNITY #1 | F | 82 |
| UP,AC 2 drugs: 09/25/12 DIAZEPAM 5MG TAB (BENZODIAZEPINE); 09/25/12 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) | | | | |
| PATIENT4,JESSE NATHAN | 000004 | COMMUNITY #1 | M | 77 |
| UP,AC 1 drug:08/27/122 CYCLOBENZAPRINE HCL 10MG TAB (SKL MUSCLE) | | | | |

Figure 2-144: Sample Patient List, Drugs to be Avoided in the Elderly

2.10.19 Functional Status Assessment in Elders

Denominator

Active Clinical patients ages 55 and older. Broken down by gender.

Numerator

Patients screened for functional status at any time during the Report Period.

Logic Description

Age is calculated at the beginning of the Report Period.

Functional status screening definition: Any non-null values in V Elder Care for (1) at least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence *and* (2) at least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the Report Period.

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients equal to or greater than (\geq) 55 with functional status codes, if any. The following are the abbreviations used in the Numerator column:

- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER–Transfers
- FEED–Feeding
- CONT–Continence
- FIN–Finances
- COOK–Cooking
- SHOP–Shopping
- HSWK–Housework/Chores
- MEDS–Medications
- TRNS–Transportation

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 328 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | |
| ----- | | |
| Functional Status Assessment in Elders | | |

| | REPORT PERIOD | % | PREV YR PERIOD | % | CHG from PREV YR % | BASE PERIOD | % | CHG from BASE % |
|------------------------------------|------------------|-----|-------------------|-----|-----------------------|----------------|-----|--------------------|
| Active Clinical Pts =>55 | 271 | | 162 | | | 127 | | |
| # w/functional status screening | 2 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| Male Active Clinical =>55 | 135 | | 77 | | | 60 | | |
| # w/functional status screening | 1 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |
| Female Active Clinical =>55 | 136 | | 85 | | | 67 | | |
| # w/functional status screening | 1 | 0.7 | 0 | 0.0 | +0.7 | 0 | 0.0 | +0.7 |

Figure 2-145: Sample Report, Functional Status Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

Functional Status Assessment in Elders: List of patients => 55 with functional status codes, if any.

| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
|-------------------------------|--------|---|-----|-----|
| PATIENT1, GLENDA JOYCE AC | 000001 | COMMUNITY #1 | F | 57 |
| PATIENT2, NADINE AC | 000002 | COMMUNITY #1 | F | 61 |
| PATIENT3, CHARLOTTE MAE AC | 000003 | COMMUNITY #1 YES: 02/24/12 BATH, CONT, COOK, DRES, FEED, FIN, HSWK, MEDS, SHOP, TLT, TRNS, XFER | F | 64 |
| PATIENT4, KATHERINE ANN AC | 000004 | COMMUNITY #1 YES: 07/11/12 BATH, FIN | F | 66 |
| PATIENT5, ANNA MARIE AC | 000005 | COMMUNITY #1 | F | 66 |
| PATIENT6, DIANA AC | 000006 | COMMUNITY #1 | F | 67 |
| PATIENT7, PEGGY ANN AC | 000007 | COMMUNITY #1 NO: 05/20/12 FIN | F | 70 |

Figure 2-146: Sample Patient List, Functional Status Assessment in Elders

2.10.20 Fall Risk Assessment in Elders

Denominators

Active Clinical patients ages 65 and older. Broken down by gender.

User Population patients ages 65 and older. Broken down by gender.

Numerators

Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.

Note: This numerator does *not* include refusals.

- a. Patients who have been screened for fall risk in the past year
- b. Patients with a documented history of falling in the past year
- c. Patients with a fall-related injury diagnosis in the past year
- d. Patients with abnormality of gait/balance or mobility diagnosis in the past year

Patients with a documented refusal of fall risk screening exam in the past year

Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Fall risk screening/fall related diagnosis is defined as any of the codes in the table below.

| Subject Defined | ICD and Other Codes | Exam Code | E Codes (Injury) |
|---|---|------------------------|--|
| Fall Risk Exam | CPT: 1100F, 1101F, 3288F | V Exam: 37 (Fall Risk) | |
| History of Falling | V POV: V15.88 (Personal History of Fall) | | |
| Fall-related Injury | | | V POV (Cause Codes #1-3): E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.* |
| Abnormality of Gait/Balance or Mobility | V POV: 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9 | | |
| Refusal | | V Exam: 37 (Fall Risk) | |

Key Logic Changes from CRS Version 12.0

None

Patient List Description

List of patients 65 years or older with fall risk assessment, if any.

Measure Source

HP 2010 15–28 Reduce hip fractures among older adults.

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | | |
|--|-------------------|------|----|------|------|---|----------|------|--|
| DU | November 25, 2012 | | | | | | Page 331 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Fall Risk Assessment in Elders (con't) | | | | | | | | | |
| Active Clinical Pts | | | | | | | | | |
| 65+ | 116 | | 64 | | 65 | | | | |
| # w/ fall risk screen/ Dx-No Refusals | 14 | 12.1 | 8 | 12.5 | -0.4 | 8 | 12.3 | -0.2 | |
| A. # w/ fall risk screen | 5 | 4.3 | 0 | 0.0 | +4.3 | 0 | 0.0 | +4.3 | |
| B. # w/ history of fall | 1 | 0.9 | 0 | 0.0 | +0.9 | 0 | 0.0 | +0.9 | |
| C. # w/ fall injury | 2 | 1.7 | 1 | 1.6 | +0.2 | 3 | 4.6 | -2.9 | |
| D. # w/ abnormal gait | 6 | 5.2 | 7 | 10.9 | -5.8 | 5 | 7.7 | -2.5 | |
| # w/ refusal | 3 | 2.6 | 0 | 0.0 | +2.6 | 0 | 0.0 | +2.6 | |
| Male Active Clinical | | | | | | | | | |
| 65+ | 53 | | 28 | | 27 | | | | |
| # w/ fall risk screen/ Dx-No Refusals | 6 | 11.3 | 3 | 10.7 | +0.6 | 2 | 7.4 | +3.9 | |
| A. # w/ fall risk screen | 2 | 3.8 | 0 | 0.0 | +3.8 | 0 | 0.0 | +3.8 | |
| B. # w/ history of fall | 1 | 1.9 | 0 | 0.0 | +1.9 | 0 | 0.0 | +1.9 | |
| C. # w/ fall injury | 0 | 0.0 | 0 | 0.0 | +0.0 | 1 | 3.7 | -3.7 | |
| D. # w/ abnormal gait | 3 | 5.7 | 3 | 10.7 | -5.1 | 1 | 3.7 | +2.0 | |
| # w/ refusal | 1 | 1.9 | 0 | 0.0 | +1.9 | 0 | 0.0 | +1.9 | |
| Female Active Clinical | | | | | | | | | |
| 65+ | 63 | | 36 | | 38 | | | | |
| # w/ fall risk screen/ | | | | | | | | | |

| | | | | | | | | |
|--------------------------|---|------|---|------|------|---|------|------|
| Dx-No Refusals | 8 | 12.7 | 5 | 13.9 | -1.2 | 6 | 15.8 | -3.1 |
| A. # w/ fall risk screen | 3 | 4.8 | 0 | 0.0 | +4.8 | 0 | 0.0 | +4.8 |
| B. # w/ history of fall | 0 | 0.0 | 0 | 0.0 | +0.0 | 0 | 0.0 | +0.0 |
| C. # w/ fall injury | 2 | 3.2 | 1 | 2.8 | +0.4 | 2 | 5.3 | -2.1 |
| D. # w/ abnormal gait | 3 | 4.8 | 4 | 11.1 | -6.3 | 4 | 10.5 | -5.8 |
| # w/ refusal | 2 | 3.2 | 0 | 0.0 | +3.2 | 0 | 0.0 | +3.2 |

Figure 2-147: Sample Report, Fall Risk Assessment in Elders

| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | | |
|--|--------|-------------------------------------|-----|-----|--|
| Fall Risk Assessment in Elders: List of patients 65 years or older with fall risk assessment, if any. | | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE | |
| PATIENT1,SHERRY | 000001 | COMMUNITY #1 | F | 68 | |
| UP,AC | | | | | |
| PATIENT2,LORETTA LYNN | 000002 | COMMUNITY #1 | F | 78 | |
| UP,AC | | Refused 03/03/12 Ex 37 | | | |
| PATIENT17,NICOLE | 000017 | COMMUNITY #2 | F | 71 | |
| UP,AC | | Abnormal Gait: 11/25/12 POV 443.9 | | | |
| PATIENT18,VERONICA | 000018 | COMMUNITY #2 | F | 72 | |
| UP | | Screen: 03/03/12 CPT 1100F | | | |
| PATIENT19,STEPHANIE | 000019 | COMMUNITY #2 | F | 76 | |
| UP,AC | | Fall Injury: 11/10/12 E-CODE E883.9 | | | |

Figure 2-148: Sample Patient List, Fall Risk Assessment in Elders

2.10.21 Palliative Care

Denominators

Active Clinical patients ages 18 and older with two or more types of cancer documented during the Report Period. Broken down by gender and age groups (18-54, greater than (>)55).

Numerators

No denominator; count only. The total number of *Active Clinical patients* with at least one palliative care visit during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

No denominator; count only. The total number of palliative care visits for *Active Clinical patients* during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

Patients with at least two palliative care visits during the Report Period.

Logic Description

Age is calculated at the beginning of the Report Period.

Palliative care visit definition: POV V66.7.

Cancer Types:

| Cancer Type | ICD Codes |
|------------------------------|--|
| Melanoma | V POV: 172* |
| Breast | V POV: 174*, 175*, 239.3 |
| Colon | V POV: 153*, 154*, 235.2 |
| Gyn | V POV: 180*, 182*, 183*, 184*, 236.1, 236.2 |
| Prostate | V POV: 185* 236.5 |
| Testes/Male GU | V POV: 186*, 187.3, 187.4, 187.9, 236.4, 236.6 |
| Head and Neck | V POV: 140–149.9, 160*, 161*, 162*, 195.0 |
| Urinary Tract | V POV: 188*, 189*, 236.7, 236.91, 239.4, 239.5 |
| Non-melanomatous skin cancer | V POV: 173*, 238.2 |
| Non-colon GI | V POV: 150–152.9, 155–159.9, 235*, 239.0 |
| Lung | V POV: 162*, 235.9, 239.1 |
| Brain | V POV: 190–192.9, 237.5, 237.6, 239.6 |
| Bones/soft tissue | V POV: 170*, 171*, 238.1, 238.2 |
| Endocrine | V POV: 193, 194*, 237.0, 237.4, 239.7 |
| Pleura/mediastinum | V POV: 163*, 164* |
| Non-specific site | V POV: 195*, 199*, 238.8, 238.9, 239.8, 239.9 |
| Lymph node spread | V POV: 196* |
| Secondary cancer | V POV: 196*, 197* |

Patient List Description

List of patients with a palliative care visit.

Key Logic Changes from CRS Version 12.0

None

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | | | | | | | |
|--|-------------------|------|---------|-----|----------|----------|-----|----------|
| DU | November 25, 2012 | | | | | Page 334 | | |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | | | | | | | |
| DEMO INDIAN HOSPITAL | | | | | | | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | |
| ----- | | | | | | | | |
| Palliative Care | | | | | | | | |
| | REPORT | | PREV YR | | CHG from | BASE | | CHG from |
| | PERIOD | | PERIOD | | PREV YR | PERIOD | | BASE |
| Total # of Patients | | | | | | | | |
| w/At Least 1 Palliative | | | | | | | | |
| Care Visit | 40 | | 0 | | +40 | 0 | | +40 |
| A. Total # of Patients | | | | | | | | |
| <18 w/At Least 1 Palliative | | | | | | | | |
| Care Visit | 1 | | 0 | | +1 | 0 | | +1 |
| B. Total # of Patients 18-54 | | | | | | | | |
| w/At Least 1 Palliative | | | | | | | | |
| Care Visit | 25 | | 0 | | +25 | 0 | | +25 |
| C. Total # of Patients 55+ | | | | | | | | |
| w/At Least 1 Palliative | | | | | | | | |
| Care Visit | 14 | | 0 | | +14 | 0 | | +14 |
| Total # of Palliative | | | | | | | | |
| Care Visits | 62 | | 0 | | +62 | 0 | | +62 |
| A. Total # of Palliative | | | | | | | | |
| Care Visits-Pts | | | | | | | | |
| <18 | 2 | | 0 | | +2 | 0 | | +2 |
| B. Total # of Palliative | | | | | | | | |
| Care Visits-Pts | | | | | | | | |
| 18-54 | 38 | | 0 | | +38 | 0 | | +38 |
| C. Total # of Palliative | | | | | | | | |
| Care Visits-Pts | | | | | | | | |
| 55+ | 22 | | 0 | | +22 | 0 | | +22 |
| Active Clinical Pts 18+ | | | | | | | | |
| w/ 2+ types of | | | | | | | | |
| cancer | 28 | | 3 | | | 3 | | |
| # w/ 2+ Palliative | | | | | | | | |
| Care Visits | 14 | 50.0 | 0 | 0.0 | +50.0 | 0 | 0.0 | +50.0 |

Figure 2-149: Sample Report, Palliative Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease;
 CHD=Active Coronary Heart Disease; HR=High Risk Patient

| Palliative Care: List of patients with a palliative care visit, if any. | | | | |
|---|--------|--|-----|-----|
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| PATIENT1,JOHN | 000012 | Community #1 | M | 57 |
| AC | | 1 visit: 05/01/12 | | |
| PATIENT2,ROBERT | 000013 | Community #1 | M | 59 |
| AC,CAN | | 2 visits: 01/25/12, 05/10/12 | | |
| PATIENT3,JAMES | 000014 | Community #2 | M | 67 |
| AC,CAN | | 0 visits: | | |
| PATIENT4,TONYA | 000015 | Community #3 | F | 78 |
| AC | | 1 visit: 06/01/12 | | |
| PATIENT5,RITA ANN | 000016 | Community #3 | F | 96 |
| AC | | 2 visits: 06/01/12; 06/07/12 | | |
| PATIENT6,Clifford | 000017 | Community #3 | M | 24 |
| AC,CAN | | 3 visits: 01/25/12, 05/10/12, 08/01/12 | | |

Figure 2-150: Sample Patient List, Palliative Care

2.10.22 Annual Wellness Visit

Denominators

Active Clinical patients ages 65 and older. Broken down by gender.

Numerators

Patients with at least one Annual Wellness Exam in the past 15 months.

Logic Description

Age is calculated at the beginning of the Report Period.

Annual Wellness Exam: CPT G0438, G0439, G0402.

Patient List Description

List of patients with an annual wellness visit in the past 15 months.

Key Logic Changes from CRS Version 12.0

None

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| DEMO INDIAN HOSPITAL | | | | | | | | | |
|--|---------------|-----|----------------|-----|------------------|--|-------------|-----|---------------|
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | | | | | | | | |
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Annual Wellness Visit | | | | | | | | | |
| | REPORT PERIOD | | PREV YR PERIOD | | CHG from PREV YR | | BASE PERIOD | | CHG from BASE |
| Active Clinical Pts 65+ | 116 | | 64 | | | | 65 | | |
| # w/ Annual Wellness Exam | 2 | 1.7 | 0 | 0.0 | +1.7 | | 0 | 0.0 | +1.7 |
| Male Active Clinical Pts 65+ | 53 | | 28 | | | | 27 | | |
| # w/ Annual Wellness Exam | 0 | 0.0 | 0 | 0.0 | +0.0 | | 0 | 0.0 | +0.0 |
| Female Active Clinical Pts 65+ | 63 | | 36 | | | | 38 | | |
| # w/ Annual Wellness Exam | 2 | 3.2 | 0 | 0.0 | +3.2 | | 0 | 0.0 | +3.2 |

Figure 2-151: Sample Report, Annual Wellness Visit

| | | | | |
|--|--------|--------------------------------|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Annual Wellness Visit: List of patients with an annual wellness visit in the past 15 months, if any. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| Patient1,DENISE AC | 000001 | Community #1 12/31/11 G0402 | F | 65 |
| Patient2,MELISSA GAYLE AC | 000002 | Community #1 | F | 66 |
| Patient3,JESSICA DAWN AC | 000003 | Community #1 02/22/12 G0438 | F | 67 |
| Patient4,RUTH ALICE AC | 000004 | Community #1 | F | 69 |
| Patient5,BRYSON DEWAY AC | 000005 | Community #1 | F | 72 |
| Patient6,BRITTNEY ANN AC | 000006 | Community #1 05/31/12 G0439 | F | 73 |
| Patient7,MARK AC | 000007 | Community #1 | M | 67 |
| Patient8,HOWIE AC | 000008 | Community #1 10/01/11 G0402 | M | 72 |

Figure 2-152: Sample Patient List, Annual Wellness Visit

2.10.23 Goal Setting

Denominators

User Population patients who received patient education during the report period.

Numerators

Number of patients who set at least one goal during the Report Period.

Number of patients who met at least one goal during the Report Period.

Logic Description

Patient education codes must be the standard national patient education codes, which are included in the Patient and Family Education Protocols and Codes (PEPC) manual published each year. If codes are found that are not in the table, they will not be reported on (i.e. locally-developed codes).

Numerator Logic:

For Goal Set, the patient education code must have a "GS" value documented during the Report Period.

For Goal Met, the patient education code must have a "GM" value documented during the Report Period but the patient is not required to have set a goal during the Report Period.

Patient List Description

List of User Population patients who received patient education during the Report Period with goal setting information.

Key Logic Changes from CRS Version 12.0

None

Measure Source

None

Measure Past Performance and Long-Term Targets

None

| | | |
|--|-------------------|----------|
| DU | November 25, 2012 | Page 338 |
| *** IHS 2012 Selected Measures with Community Specified Report *** | | |
| DEMO INDIAN HOSPITAL | | |
| Report Period: Jan 01, 2012 to Dec 31, 2012 | | |

| | | | | | | | | | |
|--|---------------|-----|----------------|-----|------------------|--|-------------|-----|---------------|
| Previous Year Period: Jan 01, 2011 to Dec 31, 2011 | | | | | | | | | |
| Baseline Period: Jan 01, 2000 to Dec 31, 2000 | | | | | | | | | |
| ----- | | | | | | | | | |
| Goal Setting | | | | | | | | | |
| | REPORT PERIOD | | PREV YR PERIOD | | CHG from PREV YR | | BASE PERIOD | | CHG from BASE |
| # User Pop w/ Pat Ed | 1,024 | | 858 | | | | 644 | | |
| # w/ goal set | 8 | 0.8 | 0 | 0.0 | +0.8 | | 0 | 0.0 | +0.8 |
| # w/ goal met | 6 | 0.6 | 0 | 0.0 | +0.6 | | 0 | 0.0 | +0.6 |

Figure 2-153: Sample Report, Goal Setting

| | | | | |
|--|--------|--|-----|-----|
| UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; IHD=Active Ischemic Heart Disease; CHD=Active Coronary Heart Disease; HR=High Risk Patient | | | | |
| Goal Setting: List of User Population patients who received patient education during the Report Period with goal setting information. | | | | |
| PATIENT NAME DENOMINATOR | HRN | COMMUNITY NUMERATOR | SEX | AGE |
| ----- | | | | |
| Patient1,Paula UP | 000001 | Community #1 GS: 11/17/12 | F | 34 |
| Patient2,PENNY UP | 000002 | Community #1 | F | 43 |
| Patient3,RITA UP | 000003 | Community #1 GS: 04/15/12, GM: 06/15/12 | F | 64 |
| Patient4,HARRY UP | 000004 | Community #1 GM: 10/30/12 | M | 50 |
| Patient5,ROSS UP | 000005 | Community #1 | M | 55 |
| Patient6,FELIPE UP | 000006 | Community #1 GS: 09/10/12 | M | 57 |
| Patient7,MARK UP | 000007 | Community #1 | M | 67 |
| Patient8,CATHERINE UP | 000008 | Community #2 GM: 07/30/12 | F | 72 |

Figure 2-154: Sample Patient List, Goal Setting

Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

Phone: (505) 248-4371 or (888) 830-7280 (toll free)

Fax: (505) 248-4363

Web: <http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm>

Email: support@ihs.gov